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Abstract 
The first stage of atherosclerosis is endothelial dysfunction (ED) which occurs at sites where 
the endothelial cell layer is exposed to injury or stress. Nitric oxide (NO) is an important 
signaling molecule secreted by the endothelium which regulates function of this vascular 
barrier. Reduced NO availability is a hallmark of ED. In contrast, inorganic nitrate and vitamin 
C may boost NO availability.  
Data synthesis from 14 randomised controlled trials (RCTs) demonstrated that supplementation 
with inorganic nitrate or beetroot (a rich source of nitrate) improved flow mediated dilation 
(FMD) significantly. However, the improvement in FMD tended to be smaller in older, 
overweight/obese participants and in those with underlying cardio-metabolic disease. An 
umbrella review of 10 meta-analyses revealed weak evidence for an overall effect of vitamin C 
supplementation on biomarkers of cardiovascular disease (CVD) risk but subgroup and meta-
regression analyses indicated significant benefits in participants with advanced age, higher 
BMI, lower vitamin C intake and higher CVD risk. 
In the first crossover RCT, I tested the effects of a single dose of inorganic nitrate on markers 
of vascular function (skin microvascular blood flow and circulatory biomarkers) in younger and 
older obese individuals subjected to acute hyperglycaemia. Inorganic nitrate supplementation 
produced greater improvements in biomarkers of inflammation (interleukin-6) and oxidative 
stress (3-nitrotyrosine) in older compared with younger participants. Conversely, greater 
improvement in biomarkers of endothelial function (P- and E-selectin) was observed in younger 
rather than older participants.  
In the second RCT, younger and older non-obese participants were supplemented with 
inorganic nitrate and vitamin C in a 2x2 factorial design. I found that the administration of 
inorganic nitrate and vitamin C, individually or combined, significantly improved blood 
pressure (BP), arterial stiffness and heart rate variability (HRV) indices in older participants. 
Moreover, inorganic nitrate significantly modified the effects of vitamin C on diastolic BP and 
HRV in younger participants. Finally, inorganic nitrate and vitamin C co-supplementation 
yielded synergistic effects on arterial stiffness, HRV indices and circulatory biomarkers. 
In conclusion, age, obesity and metabolic disorders modify the cardiovascular effects of 
inorganic nitrate and vitamin C.  
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Structure of the thesis  
The first chapter of this thesis introduces endothelial function (EF) and its relevance to the 
incidence and progression of cardiovascular diseases. I discuss the role of nitric oxide (NO) in 
maintaining vascular health and introduce the concept that oral inorganic nitrate and vitamin C 
supplementations may boost NO availability.  
In the second chapter, I present a systematic review and meta-analysis of randomised controlled 
clinical trials which investigated the effects of inorganic nitrate and beetroot (a rich source of 
nitrate) supplementation on physiological measures of EF (flow mediated dilatation, forearm 
blood flow, skin microvascular blood flow, pulse wave velocity and augmentation index).  
In the third chapter, I conducted an umbrella review of meta-analysis studies which have 
investigated the effects of vitamin C supplementation on biomarkers of cardiovascular disease 
risk (arterial stiffness, blood pressure, EF, glycaemic control and lipid profile).  
In Chapter 4, I report the results of a randomised controlled crossover study which tested the 
effects of a single dose of inorganic nitrate on markers of vascular function (skin microvascular 
blood flow and circulatory biomarkers) in young and older obese individuals subjected to acute 
hyperglycaemia.  
In the fifth chapter, I report the results from a second randomised controlled crossover study, 
also carried out in younger and older, but non-obese, participants. In this study, I investigated 
the effects of single doses of inorganic nitrate and vitamin C supplementations (alone or in 
combination) on blood pressure and vascular function (skin microvascular blood flow and pulse 
wave velocity).  
In the final chapter I provide a synthesis of my findings, highlight the strengths and limitations 
of the current work and make recommendations for future research. 
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Chapter 1. Introduction  
1.1 Cardiovascular diseases 
1.1.1 Definitions 
Cardiovascular diseases (CVD) are characterised by a multifactorial pathogenesis. They can be 
divided according to the location of the main insult in the vascular bed. Insults affecting blood 
supply to the heart are referred to as coronary heart diseases (CHD). Pathologies affecting brain 
vessels are known as cerebrovascular diseases (CRB), whereas disorders of the peripheral 
arteries are termed as peripheral arterial diseases (PAD) (Frayn and Stanner, 2005). 
The clinical outcomes of CHD, CRB, and PAD are largely attributed to a reduction in the blood 
supply to associated organs and tissues. This occurs secondary to thickening in the walls and 
functional obstruction of the arteries. The process of thickening is called atherosclerosis and 
the lesion formed is called plaque. The plaque may obstruct blood supply to the tissue partially 
causing ischemia (e.g. angina when it affects the heart muscle). Occasionally, the plaque may 
rupture and thrombosis may ensue leading to complete blockage of blood supply to, and death 
of, the tissue (e.g. myocardial infarction) (Gaziano, 2007).     
1.1.2 Epidemiology 
Cardiovascular diseases are the leading cause of death worldwide, accounting for around one 
third of all-cause mortality each year. Cardiovascular mortality varies between countries; 
relatively low mortality rates are observed in Japan and Mediterranean countries such as France, 
Spain and Portugal. Eastern European countries such as Ukraine, Russia and Latvia experience 
high CVD prevalence. Globally, around 45% of CVD deaths are due to CHD (WHO, 2013).  
In the UK, cardiovascular mortality is amongst the highest in the world. It accounts for 19 and 
28% of premature deaths among women and men, respectively. CHD is the most common cause 
of death in the UK with one in five men and one in ten women dying from CHD each year. 
Furthermore, CVD is also a major cause of morbidity and disability. It has been estimated that 
1.5 million of the UK population have survived heart attack and 2.6 million have CHD (BHF, 
2012). However, recently, the death rates from CHD have been falling across all age groups 
with faster rates observed in those aged over 55 years (43% reduction in men aged 55-64 in 
comparison with only 21% reduction observed in those aged 35-44 years) (BHF, 2012).   
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1.1.3 Risk Factors for CVD 
The risk factors for CVD may be divided into modifiable and non-modifiable risk factors. The 
non-modifiable risk factors include age, sex and family history of cardiovascular illnesses 
(Mosca et al., 2004). On the other hand, the modifiable risk factors are the major contributors 
to cardiovascular morbidity and mortality and account for > 90% of all myocardial infarctions 
(Dahlof, 2010). Importantly, manipulation of these  modifiable factors changes CVD incidence 
(Ritz, 2007) (see Table 1.1).    
Table 1.1: Risk factors for Coronary heart diseases  (George and Lyon, 2010) 
Modifiable factors Non-modifiable 
factors 
Lifestyle Biochemical and physiological Personal factors 
 Cigarette smoking 
 Diet rich in saturated fats 
and energy with low 
intake of fruits and 
vegetables. 
 Physical inactivity  
 Excess alcohol intake  
 Psychosocial stress 
 Obesity  
 Dyslipidaemias (high plasma 
cholesterol, low plasma HDL, 
high triglycerides) 
 High blood pressure (BP) 
 Diabetes mellitus  
 Thrombotic factors 
 Age  
 Gender  
 Family history  
 Genetics  
1.2  Atherosclerosis  
1.2.1 Definition 
Atherosclerosis is a multifactorial, progressive lesion of the arterial wall characterised by a soft 
atheros (lipid core) and surrounded by hard, collagenous fibrous tissue (sclerosis) (Channon, 
2006). The atherosclerotic process may commence silently in late adolescence with the clinical 
manifestation usually becoming obvious after the age of 45 years (Wilson, 2004).   
1.2.2 Pathogenesis 
 Atherosclerosis affects primarily the inner layer (intima) of blood vessels. It can affect arteries 
of different sizes from the aorta down to the small tertiary branches of the coronary arteries 
(Hansson, 2005). Historically, there were two major theories to explain the mechanism of 
atherosclerosis. The cellular theory proposes that the atherosclerotic lesion occurs secondarily 
to changes within the arterial wall. This theory called the response-to-injury hypothesis was 
proposed first by Rudolf Virchow in 1856 (Cullen et al., 2005). The second theory is the 
humoral theory which stresses that changes in the environment surrounding the artery cause the 
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developing atherosclerotic plaque (Cullen et al., 2005). Currently, atherosclerosis is described 
as a chronic inflammatory process of the arterial wall that occurs at sites exposed to continuous 
trauma due to turbulent blood flow.  Consequently, both cellular and humoral factors contribute 
to the progression of atherosclerotic lesions (Stylianou et al., 2012). 
1.2.3 Stages of Atherosclerosis 
The first stage of atherosclerosis is endothelial dysfunction (ED) which occurs at sites where 
the endothelial cell layer is exposed to injury or stress. It has been suggested that reduction of 
nitric oxide (NO) availability is the hallmark of ED (Yetik-Anacak and Catravas, 2006). This 
is followed by structural alterations, including disruption of the luminal layer with the exposure 
of the underlying proteoglycan. The exposed proteoglycan permits sub-endothelial 
accumulation of LDL and its subsequent oxidative modifications by free radicals in the vascular 
wall (Weber and Noels, 2011).  
The development of a fatty streak is the next stage in the process of atherosclerosis. This 
commences when the oxidised LDL triggers an inflammatory reaction in the endothelium which 
secretes cytokines in response. These cytokines will further attract T cells and leukocytes to the 
site of injury. The fatty streak lesion occurs when monocytes and macrophages engulf oxidised 
LDL forming lipid-laden foam cells (Rosenfeld, 2013). Lastly, successive accumulation of 
macrophage foam cells and extracellular lipid droplets form a core region surrounded by fibrous 
tissue composed of collagen and smooth muscle cells. This is called a fibroatheromatous plaque 
(Hansson et al., 2006).    
1.2.4 Risk Factors 
The coexistence of one or more of the risk factors (hyperlipidaemia, hyperglycaemias, obesity, 
hypertension, smoking, or family history of cardio-metabolic disorders) with local 
haemodynamic factors could contribute to initiation and progression of atherosclerosis (Figure 
1.1) (Rodrigues et al., 2012). 
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Figure 1.1: Risk factors for the development of atherosclerosis 
1.2.5 Clinical assessment of atherosclerosis 
The clinical assessment of atherosclerosis and differentiation of the various stages is important 
to evaluate individual risk for CVDs as well as for monitoring the effectiveness of clinical 
treatments. Various methods are used which differ in characteristics including equipment, cost, 
expertise, invasiveness, technical assumptions, rapidity, accuracy and precision. The most 
commonly applied methods are: 1) Carotid Intima Media Thickness (CIMT): a widely used and 
well-known marker of systemic atherosclerosis. A previous meta-analysis demonstrated that 
baseline CIMT predicts future CVD risk (Lorenz et al., 2007); 2) Pulse Wave Analysis (PWA): 
commonly measured at the right radial artery. This approach measures the speed of conduction 
of heart waves across the arterial tree, the shorter the time of travel, the stiffer the arteries due 
to atherosclerosis (Holewijn et al., 2010); 3) Intravascular Ultrasound (IVUS): This involves 
invasive catheter-based technology that allows the visualisation of all three layers of arterial 
wall (Klingenberg et al., 2012); 4) Optical Coherence Tomography (OCT): This is a novel 
technology which uses a catheter-based light-source with a better resolution and lower 
penetration than IVUS (Klingenberg et al., 2012).    
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1.3 The Endothelium 
1.3.1 Definition  
The endothelium is a monolayer of cells separating the vascular lumen from the rest of the 
blood vessel. It can be represented as one of the major organs of the human body with a surface 
area extending over 700 m2 (Lehr et al., 2006). The endothelium had been regarded as an inert 
physical barrier between the circulating blood and the underlying tissue. It is now recognised 
that the endothelium has vital paracrine, endocrine and autocrine functions (Sena et al., 2013). 
Therefore, in addition to helping maintain blood flow, the main function of the endothelium is 
to serve as an endocrine organ (Michiels, 2003).  
1.3.2 Functions of the endothelium 
The endothelium generates several extracellular messengers that mediate multiple functions 
including preserving haemostatic balance. In addition to insulating the thrombogenic sub-
endothelial layers, the endothelium secretes factors that inhibit the inappropriate formation of 
thrombus, e.g. NO, prostacyclin I2 (PGI2), tissue plasminogen activator (tPA) and protein 
C/protein S. However, in case of vessel damage and exposure to certain pro-inflammatory 
substances, the balance is shifted towards a procoagulant/prothrombotic state. This stimulates 
the endothelium to secrete agents that help with platelet aggregation and clot formation 
including platelet activating factor, von Willebrand factor, and thromboxane A2 (Sumpio et al., 
2002). Furthermore, NO secreted by the normal endothelium prevents an inflammatory 
response in the vascular wall following local injury. In contrast, a dysfunctional endothelium 
secretes adhesion molecules and chemokines that attract inflammatory cells to the site of injury 
(van Hinsbergh, 2012).  
Normal vascular endothelium has anti-proliferative and anti-apoptotic properties that are 
mediated through the activity of NO, PGI2 and C-type natriuretic peptide. Moreover, endothelial 
cells secrete factors that promote proliferation of smooth muscle cells and the formation of new 
blood vessels, e.g. vascular endothelial growth factor (VEGF), angiopoietins and adropins 
(Mensah, 2007). Dysfunction in the endothelium is characterized by: disturbed vasodilator and 
anticoagulant function, increased adhesiveness of the vessel wall for platelets and leukocytes 
(inflammation), reduced fibrinolytic activity and breakdown of barrier function causing leakage 
and oedema formation (Vanhoutte et al., 2009).  
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1.4 Factors affecting endothelial function (EF) 
1.4.1 Nitric oxide  
NO is a free radical gas molecule which is involved in many physiological processes and 
reduced availability of NO contributes to many pathological conditions (Yetik-Anacak and 
Catravas, 2006). NO is regarded as one of the most important molecules secreted by the 
endothelium. It is a highly diffusible molecule with a very short half-life (<1 sec) (Channon, 
2006). The production of NO is catalysed by the nitric oxide synthase enzyme (NOS). There 
are three isoforms of this enzyme, endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) 
(Lei et al., 2013). eNOS is a homodimeric enzyme expressed constitutively in endothelial cells 
where it facilitates the conversion of the amino acid L-arginine into L-citrulline and NO 
(Michiels, 2003). This process requires molecular oxygen and reduced nicotinamide-adenine-
dinucleotide phosphate (NADPH) as co-substrates, as well as the following cofactors: flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), tetrahydrobiopterin (BH4), heme 
and calcium-calmodulin (Figure 1.2) (Forstermann and Sessa, 2012). 
 
Figure 1.2: Mechanisms of activation of endothelial nitric oxide synthase (eNOS) and 
the release of nitric oxide (NO).  FAD, flavin adenine dinucleotide; FMN, flavin 
mononucleotide; BH4, tetrahydrobiopterin; sGC, soluble guanylyl cyclase 
 
The trigger for NO synthesis and release is either mechanical stretching of the vessel wall or 
receptor-mediated agonists such as bradykinin, acetylcholine or histamine (Khazaei et al., 
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2008). These signals lead to an increase in intracellular calcium concentration. Intracellular 
Ca2+ binds to calmodulin to form Ca2+-calmodulin complex that mobilises eNOS from its 
binding to Caveolin, so allowing the activated (eNOS) to catalyse synthesis of NO from L-
arginine (Khazaei et al., 2008). Because of the gaseous nature of NO, it diffuses from where it 
is synthesised in the endothelium to the vascular smooth muscle where it activates soluble 
guanylate cyclase leading to increasing intracellular cyclic guanosine monophosphate (cGMP). 
The cGMP causes smooth muscle relaxation and, eventually, arterial dilation (Forstermann, 
2010).  
In addition to arterial dilation, NO has many other vital protective functions in blood vessels. 
These protective functions include decreasing: 1) smooth muscle proliferation; 2) platelet 
aggregation; 3) endothelin production; 4) monocyte and platelet adhesion; 5) expression of 
adhesion molecules and 6) oxidation of LDL (Vanhoutte et al., 2009). Because of the vital role 
of NO, researchers have suggested that reduced NO availability is the major cause of ED. This 
deficiency activates atherogenic processes in the vessel wall which include vasoconstriction, 
monocyte activation and adherence to vascular endothelium, proliferation of smooth muscle 
cells, thrombosis and impaired coagulation and, eventually, atherosclerosis (Versari et al., 
2009).  
Many factors modulate NO synthesis and degradation and, therefore, affect EF. Asymmetric 
dimethyl L-arginine (ADMA), is a product of protein metabolism formed secondarily to 
methylation of L-arginine (Giles, 2006). ADMA decreases the synthesis of NO by reducing the 
expression and/or activity of eNOS. ADMA is increased in many pathological conditions such 
as hypercholesterolaemia, atherosclerosis, hypertension, chronic heart failure, diabetes mellitus 
and chronic renal failure (North and Sinclair, 2012). Furthermore, uncoupling of eNOS as a 
result of the oxidation of BH4 or depletion of L-arginine and the accumulation of endogenous 
methylarginines may lead to reduced formation of NO, i.e. the eNOS enzyme is converted from 
a NO-producing enzyme to a superoxide-producing enzyme (Schmidt and Alp, 2007). 
Overproduction of reactive oxygen species (ROS) is the major cause of reduced NO availability 
in CVD. NO reacts with the superoxide anion with high affinity forming the harmful free radical 
peroxynitrite (ONOO−) (Sena et al., 2013). Lipid peroxyl radicals and oxidised LDL react with 
endothelial NO before it reaches the vascular smooth muscle cells and, therefore, inhibit NO 
from dilating blood vessels (Sena et al., 2013).  
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1.4.2 Oxidative stress 
Oxidative stress is the condition of excessive production of ROS beyond the neutralising 
capacity of the endogenous antioxidant defence mechanism. ROS, or free radicals, are atoms 
or group of atoms with one or more electrons missing. The missing electrons make these 
molecules highly reactive as they try to capture electron from other compounds to gain stability.  
Raised concentrations of free radicals have detrimental effect on cellular function because ROS 
interact with and damage membranes, enzymes and nucleic acids (Packer, 2005). 
Sources of ROS in CVD include the following: 1) mitochondrial respiratory chain: the 
mitochondria are a well-known source of ROS. About 1% of the O2 consumed by the 
mitochondrion is reduced by single electrons to form the free radical superoxide O2¯ (Murphy, 
2009); 2) NADPH oxidases: these are a family of multiple-subunit enzymes located in the 
membranes of various cells e.g. endothelial cells, smooth muscle cells and fibroblasts.  NADPH 
oxidases generate superoxide via one electron reduction of oxygen using NADPH as an electron 
source. These enzymes are upregulated in disorders including hypertension, diabetes and 
hypercholesterolaemia (Munzel et al., 2010); 3) xanthine oxidase: this enzyme is highly 
expressed in capillary endothelium and readily donates electrons to molecular oxygen thereby 
generating the superoxide free radical. Additionally, the xanthine oxidase can reduce nitrate 
(𝑁𝑂3
−) to nitrite (𝑁𝑂2
−) to facilitate the production of nitric oxide (Munzel et al., 2010); 4) 
lipoxygenases: these enzymes catalyse the incorporation of oxygen into polyunsaturated fatty 
acids. Some lipoxygenase isoforms promote atherosclerosis by generating ROS and causing 
oxidative modification of LDL (Sugamura and Keaney, 2011); 5) nitric oxide synthases: eNOS 
may become uncoupled which leads to a reduction of molecular oxygen rather than a transfer 
of electrons to L-arginine, therefore generating superoxide instead of NO (Sugamura and 
Keaney, 2011).  
On the other hand, the antioxidant mechanisms of the human body include: 1) superoxide 
dismutase (SOD): SOD catalyses the dismutation of O2¯ into oxygen and hydrogen peroxide. 
A variant of this enzyme (SOD3) is associated with high risk of CHD (Forstermann, 2010); 2) 
catalase: this enzyme catalyses the decomposition of hydrogen peroxide to water and oxygen 
(Forstermann, 2010); 3) glutathione peroxidase (GPx): GPx reduces free hydrogen peroxide to 
water and lipid hydropreoxides to their corresponding alcohols (Forstermann, 2010); 4) heme 
oxygenase: the cardiovascular protective effect of this enzyme is through its ability to degrade 
the pro-oxidative heme to biliverdin. Biliverdin is subsequently changed to bilirubin, which has 
antioxidant effects (Forstermann, 2010); 5) thioredoxin: thioredoxins are a class of small redox 
proteins, present in the endothelium and smooth muscle cells, which have the ability to 
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scavenge hydrogen peroxide and peroxynitrite (Sugamura and Keaney, 2011); 6) paraxonase: 
this family of enzymes, which are synthesised in the liver and circulate in plasma, have the 
ability to reduce the peroxidation of HDL and LDL (Sugamura and Keaney, 2011).   
Several biomarkers in the blood can be used to estimate the degree of oxidative stress. In healthy 
individuals, the circulating concentration of oxidised low density lipoprotein (oxLDL) is an 
independent risk factor for CHD (Forstermann, 2010). Plasma F2-isoprostanes are considered a 
valid measure of oxidative stress and increased urinary output of isoprostanes is regarded as an 
independent risk factor for CVD (Forstermann, 2010).  
1.4.3 Health status  
The ability of the endothelium to maintain the integrity of the vessel wall can be affected by the 
biochemical and pathophysiological state of the rest of the human body. For example, chronic 
smoking deteriorates EF by decreasing NO production and enhancing its degradation via the 
generation of oxygen free radicals (Toda and Toda, 2010). Furthermore, hypercholesterolemia 
and high homocysteinaemia may reduce the availability of NO secondary to oxidative stress 
(Dayal and Lentz, 2005; Sibal et al., 2010).  
ED has been demonstrated both in resistance and conduit arteries of several animal models of 
hypertension (Tang and Vanhoutte, 2010). Moreover, reduced forearm blood flow responses to 
endothelium-dependent vasodilator agonists, such as acetylcholine and bradykinin (Linder et 
al., 1990; Panza et al., 1990) and increased vasoconstrictor responses to locally administered 
NOS inhibitors (Panza et al., 1993) were observed in hypertensive patients. In their prospective 
cohort study, Rossi et al. (2004) revealed that a 1 unit reduction in flow mediated dilatation 
(FMD) is associated with a 16% increase in the risk of hypertension in postmenopausal women, 
independent of age and baseline blood pressure. The cause of ED associated with hypertension 
is speculated to be reduction in NO bioavailability (increased degradation by oxidative stress, 
reduced production by eNOS inactivation) and abundance of vasoconstrictor agents in the 
circulation such as angiotensin II and prostaglandins (Tang and Vanhoutte, 2010).  
1.4.4 Obesity, hyperglycaemia and ED  
The prevalence of obesity has dramatically increased worldwide and nowadays, obesity 
considered as a global epidemic (Ng et al., 2014). Obesity is a major risk factor for numerous 
diseases and conditions including CVD, type 2 diabetes, hypertension, cancer and sleep apnoea 
(Bastien et al., 2014). In the context of the present project, obesity is an independent risk factor 
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for atherosclerosis (Al Suwaidi et al., 2001) and significant EF deterioration was observed in a 
cohort of severely obese children (Tounian et al., 2001). Moreover, Arcaro et al. (1999) 
demonstrated that the visceral/subcutaneous adipose tissue ratio significantly predicts ED in 
obese individuals (r = 0.624, P = 0.0058). NO is reduced in obesity either because of enhanced 
degradation (oxidative stress) or decreased formation (eNOS inactivation) (Toda and Okamura, 
2013). 
Adipose tissue produces several molecules that influence EF including leptin, resistin, tumor 
necrosis factor alpha (TNF-α), interleukin (IL) 6, monocyte chemoattractant protein (MCP)-1, 
plasminogen activator inhibitor (PAI)-1, adiponectin and the proteins of the renin–angiotensin 
system (Avogaro and de Kreutzenberg, 2005).  
Leptin affects EF by stimulating sympathetic activity (vasoconstriction), increasing oxidative 
stress and inflammatory markers. On the other hand, resistin increases the production of 
endothelin-1 and vascular adhesion molecules (Singhal, 2005). Moreover, the secretion of the 
other inflammatory mediators by the adipose tissue contributes to a chronic inflammatory state 
in the vascular wall and the subsequent ED (Avogaro and de Kreutzenberg, 2005).  
Chronic hyperglycaemia (e.g. diabetes) is associated with greater CVD risk (Bakker et al., 
2009). Besides, evidence from epidemiological studies demonstrated that postprandial 
hyperglycaemia is a better predictor for cardiovascular mortality and morbidity than sustained 
hyperglycaemia (Mah and Bruno, 2012). Transient and prolonged hyperglycaemia impairs EF 
in animals (Bitar et al., 2005) and humans (Ceriello et al., 2002). 
In a prospective population-based cohort (n=445, median follow-up of 7.6 years), reduced flow-
mediated dilatation was associated with a higher rate of cardiovascular events in type 2 diabetes 
mellitus patients. The authors concluded that ED and type 2 diabetes mellitus act synergistically 
to increase cardiovascular event risk (van Sloten et al., 2014). Hyperglycaemia is associated 
with increased oxidative stress, uncoupling of eNOS, LDL oxidation, and increased 
concentrations of vasoconstrictor mediators, e.g. endothelins, angiotensins, and prostanoids 
(Sena et al., 2013).   
1.5 Assessment of EF  
 Since ED precedes atherosclerosis and its degree of impairment reflects the severity of 
atherosclerosis (Harris et al., 2010), the assessment of EF has important diagnostic, therapeutic 
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and prognostic value for atherosclerotic vascular diseases. The following methods can be used 
to assess EF: 
1.5.1 Invasive methods  
a. Intracoronary infusions of vasoactive agents: Infusion of vasoactive agents directly into the 
coronary arteries combined with quantitative angiography is the method of choice for direct 
quantification of coronary endothelial function (Higashi, 2015). It allows both the 
evaluation of dose-response relations of endothelial agonists and antagonists, as well as 
assessment of the basal EF by the infusion of NOS inhibitors (Tousoulis et al., 2005). 
Although intracoronary studies are the gold standard for early detection of ED in the 
coronary arteries, they have the disadvantage of being invasive and expensive, with the risks 
of coronary catheterisation, and cannot be used as a screening test in the general population 
(Tousoulis et al., 2005).  
b. Intrabrachial infusion of vasoactive agents: Endothelial function in the coronary arteries is 
closely related to endothelial function in peripheral arteries such as the brachial artery 
(Tousoulis et al., 1997). Therefore, to avoid intracoronary invasiveness, vasoactive 
substances can be injected into the brachial arteries to assess EF and the resulting measure 
of brachial artery EF reflects the health status of the coronary arteries (Tousoulis et al., 
2005). 
1.5.2 Non-invasive methods   
a. FMD: Many blood vessels respond to increased blood flow (shear stress) by NO-dependent 
dilation of that vessel. Estimating the degree of dilatation of the vessel by Ultrasound is 
called FMD (Corretti et al., 2002). The principle of FMD is to occlude the forearm blood 
flow for 5 minutes with blood pressure cuff inflated to supra-systolic levels. Subsequent 
release of the cuff leads to increased shear stress stimuli, NO production and vasodilation. 
Assessment of the degree of vasodilation with high resolution ultrasound is the FMD 
(Charakida et al., 2010). Advantages of FMD are that it is a safe, non-invasive, fast method 
and results for FMD relate closely to EF in the coronary arteries, however FMD 
measurement varies between assessors i.e. it is observer-dependent (Tousoulis et al., 2005). 
b. Venous occlusion plethysmography (VOP): Forearm blood flow (FBF) can be measured 
with VOP. The principle of this method is that occlusion of venous blood flow with a 
pressure cuff placed on the forearm leads to continuous flow of the arterial blood and linear 
increase in forearm volume over time (Wilkinson and Webb, 2001). The changes in FBF 
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during acetylcholine or nitroprusside infusions represent indices of endothelium dependent 
and endothelium independent dilation, respectively (Tousoulis et al., 2005). A disadvantage 
of VOP is its semi-invasiveness (requires intra-arterial cannulation) but this technique is 
less observer-dependent than FMD (Tousoulis et al., 2005). 
c. Cutaneous microvascular blood flow: One of the major drawbacks of VOP and FMD is the 
assessment of total limb flow without distinguishing between the muscle and skin 
circulation, which have different functions (Newton et al., 2001). The microcirculation 
refers to arteries, arterioles, capillaries, and venules with the smallest resistance and less 
than 150 µm in diameter (Roustit and Cracowski, 2013). Skin microcirculation is important 
because it is the place where fine control of the blood supply takes place; tissue ischemia is 
highly dependent on microvascular flow in most circumstances (Newton et al., 2001). 
Patients with impaired coronary microvascular function also have evidence of impaired 
peripheral microvascular function, suggesting a generalized disorder in the regulation of the 
microvasculature (Roustit and Cracowski, 2012). Similarly, correlated abnormalities 
between cutaneous and retinal microcirculation in diabetic patients have been reported 
(Roustit and Cracowski, 2012). 
Recently, the skin microcirculation has emerged as an accessible and potentially 
representative vascular bed to examine the mechanisms of microcirculatory function and 
dysfunction (Holowatz et al., 2008). Minimally invasive skin-specific methodologies make 
the skin microcirculation a useful translational model for investigating mechanisms of 
vascular disease and providing preclinical data about the state of microcirculatory function 
in high-risk populations (Roustit and Cracowski, 2012). To date, the skin has been used as a 
circulation model to investigate vascular mechanisms in a variety of disease states, including 
hypertension, Type II diabetes, hypercholesterolemia, renal disease, PAD, atherosclerotic 
CAD, heart failure and ageing (Holowatz et al., 2008).  
Laser Doppler flowmetry measures skin microvascular EF. Laser Doppler is based on the 
reflection of a beam of laser light. Light undergoes changes in wavelength (Doppler shift) 
when it hits moving blood cells. The magnitude and frequency distribution of these changes 
in wavelength are related to the number and velocity of blood cells. Several different 
signals can be recorded but the red blood cell flux (i.e. the product of the velocity and 
concentration of moving blood cells within the measured volume) is used most often 
(Roustit and Cracowski, 2013).  
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NO secretion and its accompanied vasodilatation in the microcirculation can be enhanced 
either with the application of post-reactive hyperaemia in the forearm or through the 
introduction of acetylcholine through the skin (iontophoresis) (Roustit and Cracowski, 
2013). Iontophoresis delivers charged pharmacological agents in a vehicle solution to a 
localized area of skin using opposing electrical current (Holowatz et al., 2008). There are 
significant correlations between Laser Doppler flowmetry and plasma NO and endothelin-
1 (Turner et al., 2008). Additionally, a preliminary study showed a correlation between 
skin and coronary microvascular function (Turner et al., 2008). The major advantage of 
this technique is its sensitivity at detecting and quantifying relative changes in skin blood 
flow in response to a given stimulus (Cracowski et al., 2006). A disadvantage of Laser 
Doppler is the contribution of prostaglandins, in addition to NO, to the vasodilator response 
(Turner et al., 2008). Reproducibility is a major issue of Laser Doppler flowmetry but this 
variation can be minimised if the recording site is standardised (Cracowski et al., 2006).      
d. Pulse wave analysis (PWA) and velocity (PWV): contraction of the left ventricle during 
systole generates a pressure wave that travels across the aortic wall and the highly 
conductive arteries. This pressure wave confronts impedance at the junction of the large 
conduit artery and high-resistance arterioles, blocking its entry into the arterioles so that it 
is reflected backwards towards the heart (Safar et al., 2011). The contribution of the 
reflected wave to the aortic pressure can be estimated by calculating the augmentation index 
(AIx). The speed of travel of the heart wave between two arterial points is called pulse wave 
velocity (e.g. carotid-femoral PWV) and can be detected by using pressure transducers 
(Shirwany and Zou, 2010). PWV reflects structural changes in the vessel walls (arterial 
stiffness) and such structural and functional changes in the vessel wall contribute to the 
onset and progression of arterial stiffness (Zieman et al., 2005). 
Structural changes include the replacement of elastin with collagen and smooth muscle 
proliferation (Correia and Haynes, 2007). Oxidative stress and inflammation contribute 
significantly to this structural remodelling (Patel et al., 2011) through the process of smooth 
muscle proliferation and collagen deposition (Park and Lakatta, 2012) which increase the 
rigidity of vascular conduits and modifies arterial compliance. Functional deterioration 
involves reduced NO bioavailability and the onset of endothelial dysfunction. Arterial 
stiffening is a hallmark of ageing and is closely associated with many pathological conditions 
including atherosclerosis, dyslipidaemia, diabetes and chronic kidney diseases (Shirwany 
and Zou, 2010). Arterial stiffness is a precursor of CVD and is a marker for increased CVD 
risk and all-cause mortality (Ben-Shlomo et al., 2014).   
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1.5.3 Biochemical markers 
Circulating markers of EF which are secreted from the endothelium in response to inflammation 
or injury include E- and P-selectin, vascular cell adhesion molecules, and intercellular adhesion 
molecules (Deanfield et al., 2007). Additionally, many direct and indirect methods have been 
used to assess the production of NO. In vivo NO production may reflect the underlying EF in 
health and disease (Siervo et al., 2011b). Blood biomarkers can provide important information 
regarding mechanisms and severity of endothelial dysfunction in the population (Higashi, 
2015). However, due to the biological variability, difficulty, expense and limited assay 
availability, these biomarkers currently have only a very limited role in the assessment of 
individual patients (Deanfield et al., 2007). 
Circulating levels of  𝑁𝑂2
− and nitrosylated proteins partially reflect endothelial generation of 
NO, but are difficult to measure and may not always represent endothelial NO production. 
Measurements of  𝑁𝑂2
− and 3-nitrotyrosine (3-NT) may be confounded by the formation of 
adducts from other nitrogen-containing species, other sources of NO, and wide variation in 
dietary NO (Deanfield et al., 2007). 3-NT is the result of a post-translational modification in 
proteins carried by reactive nitrogen species such as peroxynitrite and nitrogen dioxide radicals 
(Teixeira et al., 2016).  It is formed after the substitution of a hydrogen by a nitro group (𝑁𝑂2
−) 
in the ortho position of the phenolic ring of the tyrosine residues (Teixeira et al., 2016). 
Moreover, tyrosine can be nitrated by peroxidase (or haemoprotein)-catalysed, hydrogen 
peroxide-dependent oxidation of nitrite to form  𝑁𝑂2
− (Bryan and Grisham, 2007).  
Activated endothelial cells secrete a cascade of inflammatory cytokines (including E-selectin, 
vascular cell adhesion molecule 1, intercellular adhesion molecule 1 and P-selectin) that trigger 
leukocyte attraction, adhesion and migration into the sub-endothelial space. These molecules 
are fundamental to the initiation, progression and destabilization of the atherosclerotic lesion 
and can be measured in the circulation with commercial immunoassays (Constans and Conri, 
2006). E-selectin is probably the most specific for endothelial cell activation. Studies showed 
that E-selectin increases in association with cardiovascular risk factors and such increases are 
associated with structural and functional measures of atherosclerotic disease, as well as with 
adverse cardiovascular prognosis (Deanfield et al., 2007).  
1.6 Nutritional interventions in cardiovascular diseases 
Dietary habits are strongly associated with CVD incidence and progression (Verschuren, 2012). 
It has been speculated that most of the risk factors of atherosclerosis are influenced by diet (De 
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Caterina et al., 2006; Rosenfeld, 2013) and, for example, there is considerable  evidence for 
adverse effects of nutrients such as saturated and trans-fatty acids on EF (Hennig and Toborek, 
2001).      
1.7 Dietary modulation of EF 
1.7.1 Dietary patterns  
a. Positive energy balance and obesity are strongly associated with insulin resistance and 
chronic inflammation (secretion of pro-inflammatory cytokines). Insulin resistance and 
inflammatory cytokines are pro-atherogenic through mechanisms linked to ED (Hamdy et 
al., 2003). Six weeks exposure to a very-low-calorie diet (daily energy: 580 kcal/2.3 MJ) 
improved FMD by 60% (Raitakari et al., 2004). Moreover, 6-years caloric restriction in 
healthy individuals reduced CIMT by 40% in comparison with a control group (Fontana et 
al., 2004). 
b. The Mediterranean diet is characterised by high content of monounsaturated fats, fruits and 
vegetables, legumes, high-fibre cereals and antioxidants and low intakes of animal-derived 
foods apart from fish. Feeding the Mediterranean diet for 2 months to obese people was 
found to significantly improve EF (2.05%; 95% CI: 0.97, 3.13%) (Rallidis et al., 2009). 
Furthermore, the Mediterranean diet was found to be anti-atherogenic and significantly 
reduce the incidence of cerebro- and cardiovascular diseases (Martínez-González et al., 
2011; Estruch et al., 2013). The Mediterranean dietary intervention halts atherosclerosis 
through modulating the pro-inflammatory processes that initiate and disseminate ED, 
plaque formation and rupture (De Caterina et al., 2006).  
c. The Dietary Approaches to Stop Hypertension (DASH) diet is a widely-used life style 
intervention to reduce CVD risk. A recently published study showed that a four week DASH 
diet-intervention enhanced EF by 68% in middle-aged hypertensive patients (Jablonski et 
al., 2013). The proposed mechanism is reduction of oxidative stress and enhancement of 
eNOS expression (Jablonski et al., 2013).   
1.7.2 Macronutrients  
a. Dietary fats: Eating meals rich with saturated fat significantly deteriorates EF in healthy 
volunteers (FMD: -2.2 ± 0.9%; p < 0.05). Moreover, high-fat meals deteriorate the anti-
inflammatory properties of HDL in terms of their ability to inhibit expression of 
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1) (Aromataris et al., 2015). Epidemiological studies revealed an inverse 
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relationship between the dietary consumption of fish and mortality from coronary heart 
diseases (Kris-Etherton et al., 2002). Moreover, a recently published meta-analysis 
demonstrated beneficial effects of fish oil on EF (FMD: 1.49%; 95% CI 0.48% to 2.50%) 
(Xin et al., 2012) and the authors speculate that these beneficial effects were due to the 
antioxidant and anti-inflammatory properties of the fish oils (Xin et al., 2012). 
b. Carbohydrates: In contrast with high-fat, low-carbohydrate, acute ingestion of a low-fat, 
high carbohydrate meal did not deteriorate EF significantly (Ong et al., 1999). However a 
recently published meta-analysis revealed that meal ingestion (irrespective of carbohydrate 
content) significantly reduces FMD (-2.03; 95% CI: -2.28, -1.77) (Thom et al., 2016).  
c. Proteins: Studies in mice have shown that a high-protein intake is associated with 
endothelial dysfunction and progression of atherosclerosis (Foo et al., 2009; Namikoshi et 
al., 2009). Moreover, 1 year follow-up of 26 patients on high-protein diet showed 
significant deterioration in coronary blood flow and circulatory inflammatory biomarkers 
(Fleming, 2000). 
1.7.3 Micronutrients  
a. Observational studies have provided strong evidence of an inverse correlation between 
dietary intake of antioxidant vitamins and risk of cardiovascular morbidity and mortality 
(Rimm et al., 1993; Yochum et al., 2000). However, randomised controlled trials (RCTs) 
testing the effects of antioxidant supplements on similar outcomes has not reported 
significant protective effects. In the study by (Sesso et al., 2008), neither vitamin C nor 
vitamin E supplementation for 8 years to male physicians reduced the risk of major 
cardiovascular events. Lack of beneficial effects was also observed in post-menopausal 
women given antioxidant vitamins (Waters et al., 2002). Further evidence regarding the 
effects of vitamin C on cardiovascular risk biomarkers will be discussed in Chapter three 
of this thesis.      
b. Because the semi-essential amino acid L-arginine is of vital importance for endogenous 
NO synthesis, there has been speculation that it has important protective effects on EF 
(Gornik and Creager, 2004). Data synthesis of 11 RCTs (387 participants) demonstrated 
that compared with placebo, L-arginine intervention significantly lowered systolic BP by 
5.39 mmHg (95% CI −8.54 to −2.25, P = .001) and diastolic BP by 2.66 mmHg (95% CI 
−3.77 to −1.54, P < .001) (Dong et al., 2011). Another meta-analysis (12 studies, 492 
participants) revealed that L-arginine supplementation significantly enhanced EF (FMD: 
1.98%; 95% CI: 0.47, 3.48) (Bai et al., 2009).  
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c. Omega-3 fatty acids may improve EF by reducing inflammatory cytokines and enhancing 
the release of NO. Recently, a meta-analysis study (16 eligible studies involving 901 
participants) showed that omega-3 fatty acids, at doses ranging from 0.45 to 4.5 g/d over 
a median of 56 days, significantly improved EF (FMD: 2.30%; 95% CI: 0.89–3.72%) 
(Wang et al., 2012).  
d. Data from several studies have shown that eating diets rich in polyphenols is associated 
with better cardiovascular prognosis (Stoclet et al., 2004). The observed improvement was 
suggested to be secondary to improvement in EF. Polyphenols may enhance EF by several 
mechanisms, e.g. reducing oxidative stress and enhancing NO production (Schini-Kerth 
et al., 2010). Dietary flavonoids (which are examples of polyphenolic compounds) that 
occur naturally in plant foods increased FMD after acute (3.99%; 95% CI: 2.86, 5.12; 6 
studies) and chronic (1.45%; 0.62, 2.28; 2 studies) intake (Hooper et al., 2008).         
e. Poor vitamin D status is associated increased risk of cardiovascular events and mortality 
(Pludowski et al., 2013). Furthermore, both observational and interventional studies have 
established an association of low vitamin D concentration with ED (Caprio et al., 2012). 
However, pooling data from 16 clinical trials showed no significant effect of vitamin D 
on EF overall (standardised mean difference [SMD]: 0.08, 95% CI: -0.06, 0.22, P=0.28). 
However, subgroup analysis showed a significant improvement of EF in diabetic subjects 
(SMD: 0.31, 95% CI: 0.05, 0.57, P=0.02). Meta-regression analyses demonstrated that the 
effect size was weakly associated with diastolic BP (β: 0.02; P=0.07) and body mass index 
(BMI) (β: 0.05; P=0.06) (Hussin AM et al., 2015).  
f. Folic acid and B vitamins may enhance EF through their capacity to reduce homocysteine 
concentrations (Chambers et al., 2000). A meta-analysis of RCTs showed that folic acid 
enhanced EF significantly (FMD:1.08; 95% CI: 0.57,1.59) (de Bree et al., 2007).    
1.8 Vascular ageing  
The following sections (1.8, 1.9 and 1.10) are adopted from our book chapter “Chapter 43 - 
Vitamin C, Antioxidant Status, and Cardiovascular Aging, in Mocchegiani, E. (ed.) Molecular 
Basis of Nutrition and Aging. San Diego: Academic Press, pp. 609-619”  
1.8.1 Overview of the biology of ageing 
The ageing process is characterised by a progressive decline of cellular integrity and function 
resulting from the structural modification of macromolecules including formation of oxidised 
lipid species, advanced glycated products, nitrosylated proteins and DNA mutations and 
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epimutations. Epimutation is any heritable change such as methylation that did not affect the 
actual sequence of the DNA (Dobrovic and Kristensen, 2009; Vijg and Suh, 2013). The 
accumulation of modified molecules and their incorporation into cellular components are 
responsible for the structural and functional deterioration of tissues and organs with time (Ashor 
et al., 2016b).  
Whilst the complexity of the biological mechanisms contributing to the ageing process is still 
poorly understood, a comprehensive summary of some of these mechanisms has been proposed 
recently by Lopez-Otin et al. (2013). These authors proposed the following set of hallmarks of 
ageing viz.  genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, 
deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell 
exhaustion, and altered intercellular communication which are seen across diverse species 
(Lopez-Otin et al., 2013). Many factors contribute to age-related molecular damage but it seems 
likely that much damage is due to three common stressors viz. oxidative stress/ redox changes, 
inflammation and metabolic stress (Mathers, 2015). 
The accumulation of molecular damage in stem cells which leads to cell death, senescence or 
loss of regenerative function is likely to have a particularly profound effect on ageing because 
of the role of stem cells in maintaining tissue integrity. The cumulative load of (macro) 
molecular damage, together with alterations in tissue cellularity, causes diminished functional 
capacity and increases the risk of age-related frailty, disability and disease, including CVD. In 
humans, factors such as nutrition which modulate the ageing trajectory and the risk of age-
related diseases must do so by affecting the acquisition of molecular damage with age or by 
altering the body’s ability to defend itself against that damage (Mathers, 2015). For example, 
nutrition influences DNA repair - a key cellular defence mechanism which ensures the integrity 
of the genome (Tyson and Mathers, 2007). Although the mechanisms through which dietary 
factors affect DNA repair systems are poorly understood, recent studies from the Mathers 
laboratory suggest that this may include altered expression of the genes encoding key repair 
proteins such as the base excision repair (BER) enzyme apurinic/apyrimidinic endonuclease 1 
(APE1) and that this may involve epigenetic mechanisms (Langie et al., 2014).  
1.8.2  Ageing and cardiovascular disease risk 
Cardiovascular diseases are the most common cause of death among elderly populations in the 
Western World (Virdis et al., 2010). Age-specific mortality rates from heart disease and stroke 
increase exponentially with age and account for more than 40% of all deaths among individuals 
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aged 65-74 years and almost 60% at age 85 years and older (Ungvari et al., 2010). In the UK, 
although death rates from CVD have been falling for 4 decades, ischemic heart disease is ranked 
number one for years of life lost due to premature mortality. Importantly, lifestyle factors 
including smoking, poor diet and lack of physical activity are the major causes of morbidity 
measured by disability-adjusted life years (Murray et al., 2013).     
As noted above, ageing is associated with complex structural and functional changes in all 
tissues including the vascular system and these changes increase CVD risk independent of other 
risk factors such as hypertension, diabetes or hypercholesterolemia (Jani and Rajkumar, 2006). 
These functional changes include wide-spread ED, dilation of the central arteries and increased 
arterial stiffness (Taddei et al., 2001; Mitchell et al., 2004). Development of strategies to 
attenuate ageing of the vascular system could make a substantial contribution to lowering CVD 
risk and improving the quality of life of older people (El Assar et al., 2012).  
1.8.3 Factors that impair EF with aging  
a. Oxidative stress  
The accumulation of endogenous oxygen radicals and the consequent oxidative modification 
of cellular macromolecules (lipids, proteins and nucleic acids) have been suggested to 
contribute to ageing in all organisms (Puca et al., 2013). Increased production of free radicals, 
secondary to mitochondrial dysfunction, causes oxidative damage to cells including vascular 
cells (Fusco et al., 2007). As discussed earlier (Section 1.4.2), the accumulation of free radicals 
eventually causes reduced NO bioavailability and ED (Figure 1.3).  
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Figure 1.3: Factors associated with vascular ageing and atherosclerosis.  The triad of 
oxidative stress, inflammation and endothelial cell senescence contribute to reduced 
nitric oxide (NO) availability, endothelial dysfunction and the subsequent 
atherosclerosis.  
 
b. Inflammation  
Chronic inflammation is a driver of ageing and contributes to the  pathology of many age-
related diseases including atherosclerosis (Chung et al., 2009). Observational and experimental 
studies have demonstrated the importance of inflammation as a determinant of an unhealthy 
ageing phenotype. For example, the Whitehall II study reported that a high level of interleukin 
6 almost halved the odds of successful ageing after 10 years (OR=0.53) and increased the risk 
of cardiovascular events and non-cardiovascular mortality (Akbaraly et al., 2013). In addition, 
there appears to be a synergistic interaction between DNA damage and inflammatory signals 
and, in mice, chronic inflammation aggravates telomere dysfunction and cellular senescence 
independent of genetic and environmental factors (Jurk et al., 2014).  In this recent study, 
administration of anti-inflammatory agents rescued telomere dysfunction, prevented cellular 
senescence and supported tissue regenerative potential (Jurk et al., 2014).     
Growing evidence suggests important cross-talk between oxidative stress, inflammatory 
processes and the onset of ED prior to atherosclerosis (Ungvari et al., 2010). Reactive oxygen 
species induce pro-inflammatory changes in vascular endothelium – described as “endothelial 
activation” - which involves secretion of autocrine/paracrine factors, leukocyte-endothelial 
interaction and the up-regulation of expression of cellular adhesion molecules (Herrera et al., 
2010).  
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Oxidative stress activates  redox-sensitive transcription factors including the activator protein 
(AP-1) and nuclear factor-κB (NF-κB), increasing the expression of cytokines (TNF-α, IL-1 
and IL-6), adhesion molecules (ICAM and VCAM) and pro-inflammatory enzymes (iNOS and 
cyclooxygenase-2) (El Assar et al., 2012).  
Aging is associated with higher circulating concentrations of cytokines, especially TNF-α, IL-
1β and IL-6, which mediate the acute phase protein C-reactive protein (CRP). These factors 
contribute significantly to the pro-inflammatory microenvironment and facilitate the 
development of vascular dysfunction (El Assar et al., 2012). Among middle-aged and older 
adults, the Framingham Heart Study showed that brachial FMD is inversely related to CRP, IL-
6 and ICAM inflammatory markers (Vita et al., 2004). Furthermore, inhibition of NF-κB 
signalling improved EF significantly in middle-aged and older adults (Pierce et al., 2009).  
c. Senescence 
Cellular senescence is characterized by permanent loss of mitotic capability associated with 
morphological and functional changes and impaired cellular homeostasis (Erusalimsky, 2009). 
Senescent cells are characterised by the absence of proliferative markers, by the presence of 
senescent-associated β-galactosidase activity, by increased expression of tumour suppressor 
genes and cell cycle inhibitors, by increased DNA damage markers, more nuclear foci of 
constitutive heterochromatin and prominent secretion of signalling molecules (Munoz-Espin 
and Serrano, 2014). Without functional telomeres, DNA at the ends of chromosomes would be 
eroded each time a cell divides i.e. during mitosis (Farsetti et al., 2009). In addition to  telomere 
length shortening, alterations in several signalling pathways contribute to the occurrence of 
cellular senescence (van Deursen, 2014). Most of these signalling pathways activate p53 and 
they converge in activation of the cyclin-dependent kinase (CDK) inhibitors p16, p15, p21 and 
p27 (Munoz-Espin and Serrano, 2014).  
All the risk factors for atherosclerosis including oxidative stress, inflammation, smoking, 
diabetes and hypertension have been associated with accelerated telomere shortening 
(Fyhrquist and Saijonmaa, 2012). Furthermore, clinical trials showed that the presence of 
atherosclerosis is independently associated with increased telomere shortening (Zietzer and 
Hillmeister, 2014). The induction of senescence may be related to the enhanced susceptibility 
of telomeres to oxidative damage (Kurz et al., 2004). Telomere length in endothelial cells is 
inversely proportional to patient age (Aviv et al., 2001) and this shortening is exacerbated in 
elderly patients with coronary artery disease (Ogami et al., 2004). Cross sectional studies 
demonstrate that those with increased arterial stiffness, an indicator of vascular ageing, have 
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shorter telomeres (Nawrot et al., 2010). Hypertensive patients have shorter telomeres than their 
normotensive peers and hypertensives with shorter telomeres are more likely to develop 
atherosclerosis over five years follow-up (El Assar et al., 2012). The above observations 
suggest that telomere length might be a good marker for cardiovascular ageing but several 
issues limit the interpretation of these studies. Characterisation and quantification of telomere 
length is difficult and not all methods are reliable. Second, the small sample size and 
heterogeneity of the populations included limits confidence in these studies. Lastly, the cross-
sectional design of many of these studies precludes definitive conclusions particularly in the 
context of CVD which has multiple risk factors, which influence and confound each other 
(Zietzer and Hillmeister, 2014). 
Vascular endothelial cell senescence in vivo has been observed (Minamino et al., 2002). The 
development of more senescent endothelial cells was associated with a shift from an anti-
atherosclerotic phenotype (characterised by decreased levels of NO, eNOS activity and shear 
stress-induced NO production) to a pro-atherosclerotic phenotype (indicated by increased 
reactive oxygen species, thromboxane A2 and endothelin-1). These observations implicate 
endothelial cell senescence in the initiation and progression of atherosclerosis (Minamino and 
Komuro, 2007). Nitric oxide increases telomerase activity and promotes mobilisation of 
endothelial progenitors cells (EPCs) which have the potential to delay endothelial cell ageing 
by replacing damaged endothelial cells to maintain physical and functional integrity of the 
endothelium (Farsetti et al., 2009).  
1.9 Antioxidant vitamins as a strategy to delay vascular ageing  
Antioxidants are endogenous or exogenous moieties which inhibit or delay the oxidation of 
biological macromolecules (proteins, lipids and nucleic acids). Endogenous antioxidant 
defences include both enzymatic (SOD, GPx and catalases) and non-enzymatic (uric acid, 
glutathione, thiols and albumin) components. Exogenous antioxidant defences include some 
vitamins (vitamins C and E and the pro-vitamin A molecule beta carotene) and polyphenols 
which are present in relatively high concentrations in plant-based foods including vegetables, 
fruits and wholegrain products (Fusco et al., 2007). 
Furthermore, the causal role played by oxidative stress in the pathogenesis of cardiovascular 
diseases and the, overall, positive associations between high anti-oxidant intake and lower 
incidence of cardiovascular diseases and mortality found in epidemiological studies have 
stimulated the design of large clinical trials (e.g. the Women’s Health Study and the Physicians’ 
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Health Study II) which have attempted to test the anti-oxidant hypotheses. The results of these 
seminal studies were not encouraging since they found no evidence for beneficial effects of 
supplementation with large doses of antioxidant vitamins on cardiovascular outcomes (Ridker 
et al., 2005; Sesso et al., 2008). However, follow up, secondary analyses of the same datasets 
and subsequent meta-analyses have led to a re-evaluation of the conclusions and have suggested 
that antioxidant vitamin supplementation might be beneficial only among subjects who 
experience a pro-oxidant state due to high oxidative damage and/or low antioxidant status, but 
not for the whole population (Cesari et al., 2014). In other words, the sub-group of participants 
experiencing a pro-oxidant state might be those with the potential to benefit from enhanced 
antioxidant status.  
Ageing is associated with increased risk of micronutrient deficiency and diet-related illnesses 
(Ahmed and Haboubi, 2010). In the United States, total energy intake decreases substantially 
with age: by 1000 kcal–1200 kcal in men, and by 600 kcal–800 kcal in women in the seventh 
decade (Thomas, 2006). This results in concomitant declines in intakes of most nutrients. Lower 
food intake among the elderly has been associated with lower intakes of calcium, iron, zinc, B 
vitamins and vitamin E (Thomas, 2006). In the following sections, I will focus on vitamin C as 
a prototype antioxidant vitamin, discussing in more detail the molecular mechanisms which 
may modulate the effects of vitamin C on cardiovascular ageing.  
1.10 Vitamin C (ascorbic acid) 
Ascorbic acid is a six-carbon compound which was isolated first in 1928. Its structure was 
determined in 1933 and the L-isomer is the active form. The Home sapiens is one of the few 
mammals unable to synthesise vitamin C (ascorbic acid). This inability to synthesise vitamin C 
results from the lack of the last enzyme in the pathway of vitamin C synthesis (gulonolactone 
oxidase). A classical set of symptoms called scurvy, now known to be due to inadequate vitamin 
C intake, had been known for centuries (Lykkesfeldt et al., 2014). Chemically, vitamin C is an 
electron donor, or reducing agent. Beside its ability to reduce oxidized species, electrons from 
ascorbate can reduce metals such as copper and iron leading to the formation of superoxide and 
hydrogen peroxide; these subsequently will generate reactive oxygen species (Rietjens et al., 
2002). Therefore, under certain circumstances, vitamin C becomes pro-oxidant rather than 
antioxidant (Halliwell, 1996). Ascorbic acid loses its electrons in two stages. When the first 
electron is lost, the product formed is the ascorbate radical with a short half-life (seconds to 
minutes). Dehydroascorbic acid (DHA) is formed after losing the second electron. Both DHA 
and the ascorbate radical are reversibly reduced to ascorbic acid (Padayatty and Levine, 2016).   
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1.10.1 Daily requirement, sources, dietary intakes and population status of vitamin C 
In foods, vitamin C is found mainly in fruits and vegetables with the highest concentrations in 
cantaloupe, grapefruit, kiwi, mango, orange, tangerine and strawberries. As a supplement, 
vitamin C is available in tablet or powder form and it is included in many multi-vitamin 
formulations (Padayatty et al., 2003). 
The US recommended daily allowance (RDA) for vitamin C is 75 mg for adult women and 90 
mg for men with an upper tolerable limit of 2000mg/day for both. However, recommendations 
for vitamin C intake vary between countries with lower requirements set by the UK (40mg/day) 
and higher recommendations set by Japan's National Institute of Health and Nutrition 
(100mg/day). The latter level of intake is associated with plasma concentrations of vitamin C 
of ~70 µmol/l and, with greater intakes, circulating concentrations of vitamin C will reach, or 
exceed, the renal threshold of 80 µmol/L and result in increasing urinary excretion (Frei et al., 
2012). 
Many epidemiological studies have demonstrated that a significant proportion of the Western 
population suffer from hypovitaminosis C (estimated as a plasma concentration less than 28 
µmol/l) (Lykkesfeldt and Poulsen, 2010; Frei et al., 2012). In the third National Health and 
Nutrition Examination Survey (NHANES III), about 10% of the included American population 
suffered from severe vitamin C deficiency (plasma concentration less than 11 µmol/l) (Frei et 
al., 2012). Additionally, 20% of males and 15% of females had marginal vitamin C deficiency 
(determined as plasma concentrations between 11-28 µmol/l) (Schleicher et al., 2009). The 
Low Income Diet and Nutrition Survey (2003-05) of a representative sample of the low-
income/materially deprived UK population estimated that 25% of men and 16% of women had 
deficient plasma vitamin C concentrations (Mosdol et al., 2008). In the third Glasgow 
MONICA study (Multinational Monitoring of Trends and Determinants in Cardiovascular 
Disease), 26% of men and 14% women were in the severe vitamin C category (Wrieden et al., 
2000). Moreover, in the French population, 7 to 12 % of males and 3 to 5% of females suffered 
from severe vitamin C deficiency while 10 to 46% of males and 3 to 15% of females categorised 
with marginal vitamin C deficiency (Lykkesfeldt and Poulsen, 2010).    
The age-related increase in vitamin C deficiency may be due to a decline among older people 
in the capacity to absorb vitamin C as a consequence of reduced activity of sodium-dependent 
vitamin C transporter proteins in the intestine. This reduction in vitamin C absorptive capacity 
is associated with chronic reduction in vitamin C concentration in the elderly (Visioli and 
Hagen, 2007). A meta-analysis of the relationship between vitamin C intake and plasma 
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concentration of vitamin C found that, at the same intake (60 mg/d), circulating concentrations 
were 25% less among older adults (>65 years) than in younger adults (Brubacher et al., 2000). 
The authors concluded that the elderly would require double the oral intakes of vitamin C, as 
compared with younger subjects, to maintain plasma concentration of 50 µmol/l (Brubacher et 
al., 2000; Li and Schellhorn, 2007). 
1.10.2 Cardiovascular effects of vitamin C  
An overview of the pathways linking vitamin C and cardiovascular ageing is provided in Figure 
1.4. 
a. Antioxidant effect 
Vitamin C can be oxidised by free radicals, reactive oxygen species and compounds that react 
with free radicals and which are changed to radicals themselves such as tocopheroxyl radicals 
(Duarte and Lunec, 2005). Vitamin C counteracts the potential damaging effects of oxidative 
stress through its ability to quench aqueous reactive oxygen and nitrogen species and by helping 
to regenerate the antioxidant vitamin E (Aguirre and May, 2008). In addition, vitamin C may 
mitigate the earliest stages of atherosclerosis through the following mechanisms: 1) preventing 
the oxidation of LDL and reducing uptake and modification by activated macrophages; 2) 
stimulation of endothelial cell proliferation and prevention of apoptosis; 3) decreasing 
recruitment and proliferation of vascular smooth muscle cells and 4) increasing type IV 
collagen synthesis (Aguirre and May, 2008). 
   
26 
 
 
Figure 1.4: Vitamin C enhances nitric oxide (NO) bioavailability by affecting both the internal 
(L-arginine, endothelial nitric oxide synthase [eNOS]) and external pathways ( 𝑵𝑶𝟑
−- 𝑵𝑶𝟐
−-
NO) of NO synthesis.  Dotted lines represent inhibition while continuous lines represent 
stimulation. BH4, tetrahydrobiopterin, ONOO-, peroxynitrite. 
 
b. Nitric oxide-sparing effect  
Vitamin C contributes to maintenance of the total pool of NO through several different 
mechanisms.  (The NO pool represents the released NO which come in direct contact with the 
blood and can also be transported throughout the body to function in a paracrine fashion, much 
like a hormone (Rassaf et al., 2004)). 1) Superoxide free radicals are highly reactive molecules 
which, in excess, may react with NO leading the formation of the harmful free radical 
peroxynitrite. Vitamin C inactivates the superoxide free radical leading to higher bioavailability 
of the protective NO (May, 2000). 2) Vitamin C stabilizes, and increases the synthesis of BH4, 
a cofactor which is essential for the function of eNOS. BH4 deficiency leads to eNOS 
uncoupling and the production of superoxide instead of NO (Schmidt and Alp, 2007). 3) 
Inhibition of the enzyme arginase and consequent increase in L-arginine bioavailability (May, 
2000). 4) Vitamin C may enhance the activity of eNOS by acting as a cofactor in hydroxylation 
reactions that lead to NO release. In addition, vitamin C may protect the eNOS enzyme from 
S-nitrosylation and, consequently, inactivation (Holowatz, 2011). 5) Vitamin C may enhance 
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the functional activity of NO by preserving guanylate cyclase activity and, hence, the formation 
of cGMP, the second messenger of NO production (May and Harrison, 2013). 6) Vitamin C-
induced enhanced decomposition of nitrosothiol into NO (May, 2000). 7) Enhancing the  𝑁𝑂3
−-
 𝑁𝑂2
−-NO pathway. In vitro and animal studies have shown that vitamin C may convert  𝑁𝑂2
− 
to NO in the gastrointestinal tract and plasma leading to increased availability of NO in the 
tissues (Wolff and Wasserman, 1972; Mowat and McColl, 2001).  
c. Lipid-lowering effect  
Vitamin C facilitates the conversion of cholesterol into bile acids by modifying the activity of 
the rate-limiting enzyme cholesterol 7a-hydroxylase involved in bile acid synthesis and, 
therefore, may help to lower blood cholesterol concentrations. Animals deficient in vitamin C 
exhibit hypercholesterolemia and the subsequent administration of vitamin C restores 
cholesterol concentrations to normal (Chambial et al., 2013). Furthermore, human 
observational studies showed that high plasma concentrations of vitamin C were associated 
with more favourable lipid profiles (Dobson et al., 1984; Khaw et al., 2001) but whether this is 
a causal relationship is uncertain. A meta-analysis of 13 trials which recruited participants with 
hypercholesterolemia showed that vitamin C supplementation reduced concentrations of LDL-
C (weighted mean difference [WMD]: -7.9 mg/dL; 95% CI: -12.3 to -3.5) and triglycerides 
(WMD: -20.1 mg/dL; 95%CI: -33.3 to -6.8) significantly with no significant effect on HDL-C 
(WMD: 1.1 mg/dL; 95% CI: -0.2 to 2.3) concentrations (McRae, 2008). 
d. Blood pressure-lowering effect  
A population-based cross-sectional study involving 20,926 participants with mean age of 58.5 
years demonstrated that people in the highest quartiles of plasma vitamin C concentration had 
lower clinic blood pressure (odds ratio: 0.78; 95% CI: 0.71 to 0.86) in comparison with the 
bottom quartiles after adjusting for other relevant factors (Myint et al., 2011). Block et al. 
(2001) conducted a study involved 68 men aged 30 to 59 years who had a mean systolic BP of 
122.2 mmHg and a mean diastolic BP of 73.4 mm Hg. The participants were subjected to one 
month depletion/one month repletion of vitamin C and the investigators found that individuals 
in the lowest quartile of plasma ascorbic acid had >7 mm Hg higher diastolic blood pressure 
than did those in the top quartile of the plasma ascorbate. A recently published systematic 
review and meta-analysis has shown that vitamin C can lower systolic BP and diastolic BP 
significantly. The pooled changes in systolic BP and diastolic BP were -3.84 mm Hg and -1.48 
mm Hg respectively. The proposed mechanism is the ability of vitamin C to reduce oxidative 
stress and to increase NO availability (Juraschek et al., 2012).  
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1.10.3 Prooxidant effects of vitamin C 
Vitamin C may act as prooxidant rather than as an antioxidant in high pharmacological doses, 
high oxygen tension and in the presence of metal ions (Halliwell, 1996; Rietjens et al., 2002). 
For example, intraperitoneal injection of 4 g/kg of vitamin C to mice resulted in a significant 
increase in the formation of both ascorbate radicals and H2O2 (Chen et al., 2007). In vitro, 
vitamin C can convert Fe3+ into Fe2+, which then reacts with oxygen or hydrogen peroxide 
resulting in the formation of superoxide anions and hydroxyl radicals (Rietjens et al., 2002). 
This iron/ascorbate mixture has been used as a model of lipid peroxidation stimulation. Adding 
vitamin C to purified DNA in the presence of redox active metal ions causes single-strand 
breaks and base modifications such as 8-oxo-2-deoxyguanosine (8-oxodG) (Halliwell, 1996). 
In contrast, vitamin C intake in the dose range of 150-900 mg/kg did not appear to affect lipid 
peroxidation in rats (Halliwell, 1996). In guinea pigs initially subjected to marginal vitamin C 
deficiency, optimum and mega-doses of vitamin C had no effect on the levels of 8-oxodG (Carr 
and Frei, 1999).  In healthy human volunteers aged 17 and 49 years, six weeks of 
supplementation with 500mg vitamin C per day produced a significant reduction in 8-
oxoguanine and a significant increase in 8-oxoadenine (Podmore et al., 1998). However, post 
hoc analysis of serum and urine samples from the above study demonstrated significant 
reduction in the concentration of 8-oxodG (Cooke et al., 1998). Moreover, Rehman et al. (1998) 
showed significant increase in total oxidative DNA base damage with the co-administration of 
iron and vitamin C to participants with relatively high baseline plasma concentration of vitamin 
C (> 71.9µmol/L). However, further work is needed to investigate the pro-oxidant effects of 
vitamin C supplementation in long-term clinical trials.  
1.10.4 Genetic influences on vitamin C status and impact on cardiovascular risk 
Vitamin C homeostasis is influenced by several common genetic variants (Michels et al., 2013). 
These genetic variations fall into two major categories. The first category are variants in genes 
which encode proteins responsible for vitamin C absorption and transport, the sodium-
dependent vitamin C transporters 1 and 2 (SVCT1, SVCT2) which are encoded by the 
SLC23A1 and SLC23A2 genes respectively. SVCT1 is expressed in epithelial cells, notably 
the enterocytes of the small bowel where it transports vitamin C into the body. SVCT2 is 
expressed widely throughout the body especially in metabolically active cells. The second 
category of genes are those related to the antioxidant and redox activities of vitamin C and 
include variants in genes affecting iron homeostasis and oxidative stress such as haptoglobin 
and the glutathione S-transferases (GSTs) (Michels et al., 2013). Transcriptional regulation of 
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the SLC23 genes controls the tissue distribution of vitamin C transporters (SVCTs) and is 
responsible for the maintenance of vitamin C concentrations in cells, tissues and extracellular 
fluids (Burzle and Hediger, 2012). 
1.11 Inorganic 𝑵𝑶𝟑
− and vascular ageing 
Throughout this introduction, I have emphasised the importance of NO for a healthy 
endothelium and described the pivotal role of NO in the prevention of atherosclerosis. In this 
section, I will discuss the impact of ageing on NO bioavailability and the role of inorganic  𝑁𝑂3
− 
in restoring NO sufficiency and in improving EF in advanced age groups.  
1.11.1 Ageing-associated NO insufficiency  
Vascular NO insufficiency in older people is mediated in part by decreased NO production by 
eNOS (Cau et al., 2012). There is evidence that eNOS activity is reduced with age because of 
post-translational modification such as acylation, nitrosylation, glycation or phosphorylation 
(Cau et al., 2012). Additionally, this reduction in eNOS activity might be secondary to the 
deficiency of cofactors required in the process of NO production (e.g. BH4) (Seals et al., 2014). 
The age-associated increase in arginase activity may compete with eNOS for the critical 
substrate required in NO production, L-arginine (Seals et al., 2014). Lastly, excessive 
superoxide production with age may contribute to NO insufficiency. The interaction of 
superoxide with NO produces a highly reactive nitrogen species, peroxynitrite (Sindler et al., 
2014). Due to its ability to restore reduced NO bioavailability, inorganic 𝑁𝑂3
− represents a 
potential therapeutic strategy to treat age-associated vascular dysfunction (Sindler et al., 2014).    
1.11.2 A historical perspective of the  𝑵𝑶𝟑
−-  𝑵𝑶𝟐
−- NO pathway  
Many epidemiological studies have shown apparently protective effect of higher intakes of 
fruits and vegetables against cardiovascular diseases. On the assumption that the beneficial 
effects of fruits and vegetables were due to their contents of antioxidant vitamins (Kevil et al., 
2011), many RCTs of supplemental antioxidant vitamins were launched. Unfortunately, large 
scale clinical trials of such supplementation have not revealed beneficial effects of these 
antioxidants vitamins on cardiovascular outcomes (Hord et al., 2009).  
Until that time,  𝑁𝑂3
− and  𝑁𝑂2
− contents of fruits and vegetables were thought to be inert 
substances or even harmful to the human body. Inorganic  𝑁𝑂3
− was linked to the notorious 
substances nitrosamines accused of causing cancer in animal studies and the intake of  𝑁𝑂3
− 
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was strictly regulated (Kapil et al., 2010b).  Vegetables are the dominant source of inorganic 
 𝑁𝑂3
− in diet (> 80%) and leafy green vegetables, in particular, contain a high amount of this 
anion. Furthermore, the beneficial BP lowering effect of the DASH diet may, in part, be due to 
its high contents of inorganic  𝑁𝑂3
− (Hord et al., 2009).  
It has been believed that the beneficial effect of NO disappears in a few seconds as it is 
converted to 𝑁𝑂2
− and then to 𝑁𝑂3
−.  𝑁𝑂2
− and  𝑁𝑂3
− are then excreted in urine indicating the 
end of the story for the biological effects of NO. Interestingly, in the last two decades, scientists 
discovered an alternative pathway for generating NO other than the classical L-arginine-eNOS-
NO pathway (Zweier et al., 1995). The other source of NO was found to be  𝑁𝑂2
− which can be 
converted back to NO by the action of several enzymes and molecules including 
deoxyhaemoglobin, deoxymyoglobin, xanthine oxidoreductase, protons, polyphenols and 
ascorbic acid. Of note, this pathway is more active and efficient in cases of hypoxia in which 
the level of both oxygen and NO are low (Zweier et al., 1999) (Figure 1.5).  
1.11.3 Dietary sources of inorganic  𝑵𝑶𝟑
−  
Eighty five per cent of the dietary 𝑁𝑂3
− is derived from vegetables and the remaining is mostly 
from drinking water. Our dietary intake of  𝑁𝑂2
− comes from cured meat, to which it is added 
to prevent the development of botulinum toxin. Vegetables can be categorised into three 
categories according to their  𝑁𝑂3
− content: 1) high  𝑁𝑂3
− contents, e.g. rocket, spinach, lettuce 
and beetroot (> 1000 mg/kg); 2) medium 𝑁𝑂3
− contents, e.g. turnip, cabbage, green beans, 
cucumber and carrot (100-1000 mg/kg); 3) low  𝑁𝑂3
− contents, e.g. onion and tomato (< 100 
mg/kg) (Lidder and Webb, 2013). The concertation of  𝑁𝑂3
− in drinking water varies according 
to geographical location and regional rules regarding safe levels of  𝑁𝑂3
− in tap or bottled water. 
The permissible concentration of  𝑁𝑂3
− in drinking water is 50 mg/L in Europe and 44 mg/L in 
the US according to the WHO recommendations (Bryan and Ivy, 2015).    
The acceptable daily intake for  𝑁𝑂3
− set by the European Food Safety Authority (EFSA) is 3.7 
mg/kg (0.06 mmol/kg). Those consuming a vegetarian diet have been found to ingest 4.3 mmol 
 𝑁𝑂3
− per day which is 4 times higher than the intake of omnivores and greater than the EFSA 
recommendation of ~ 1.2 mmol  𝑁𝑂3
−  per day (Lidder and Webb, 2013).  
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Figure 1.5: Exogenous and endogenous sources of nitric oxide (NO).  NO is produced 
by a family of enzymes known as NO synthases (NOS) which utilize the substrate L-
arginine. The  𝑵𝑶𝟑
−– 𝑵𝑶𝟐
−–NO pathway has been proposed as an alternative pathway 
for NO generation. ADMA: asymmetric dimethylarginine; BH4: tetrahydrobiopterin; 
cGMP: cyclic guanosine monophosphate; GTP: guanosine triphosphate; ONOO-, 
peroxynitrite; sGC: soluble guanylate cyclase.  
1.11.4 Entero-salivary circulation of  𝑵𝑶𝟑
− 
Dietary  𝑁𝑂3
− is well-absorbed in the upper gastrointestinal tract with approximately 100% 
bioavailability and plasma concentration of 𝑁𝑂3
− peaking after 1 hr (Lidder and Webb, 2013). 
About 25% of the circulating pool of  𝑁𝑂3
− is actively taken up from the blood via an anion 
exchange channel called sialin and secreted by the salivary glands into the saliva (Bailey et al., 
2014). The salivary  𝑁𝑂3
− is reduced to  𝑁𝑂2
−  by facultative anaerobic bacteria in the oral 
cavity. This  𝑁𝑂2
− and other inorganic  𝑁𝑂3
− travel to the stomach where they are converted to 
NO under the high acidity of the stomach and with the help of ascorbic acid (Hord et al., 2009). 
In this strong acidic environment of the stomach,  𝑁𝑂2
− is protonated to form nitrous acid 
(HNO2) (Bailey et al., 2014). Nitrous acid can spontaneously give rise to the generation of NO 
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through the following sequence of reactions: 2HNO2→ H2O + N2O3 and N2O3 ↔ NO + NO2 
(Butler and Feelisch, 2008). The liberated NO has been found to be protective for the gastric 
mucosa (enhances blood supply). Moreover, the remaining NO,  𝑁𝑂2
−, and  𝑁𝑂3
− diffuse to the 
general circulation and contribute to the NO pool (Lundberg et al., 2006). Stable nitrogen 
isotope tracer studies demonstrated that 60% of oral  𝑁𝑂3
− dose is excreted via the kidneys 
within 48 hours (Bailey et al., 2014).   
1.11.5 Mechanisms of 𝑵𝑶𝟐
− reduction to NO in the circulation  
In the circulation,  𝑁𝑂2
− may function as a source of NO that is activated in hypoxia and acidic 
conditions to increase blood flow and regulate blood pressure (Zweier et al., 2010; Kevil et al., 
2011). There are many mechanisms involved in the bioconversion of  𝑁𝑂2
− to NO in the blood. 
The most common is the reaction of deoxyhaemoglobin (HbFe2+) with  𝑁𝑂2
− in an acidic 
environment which will liberate NO ( 𝑁𝑂2
− + HbFe2+ +H+ →NO + HbFe3+ + OH−) (Kim-
Shapiro and Gladwin, 2014). In addition to HbFe2+, there are many enzymes and proteins that 
enhance the conversion of  𝑁𝑂2
− to NO such as myoglobin, cytochrome C oxidase, eNOS and 
xanthine oxidoreductases (Kim-Shapiro and Gladwin, 2014).  
1.11.6 Therapeutic effects of inorganic  𝑵𝑶𝟑
−  
 𝑁𝑂3
− has been used in the treatment of cardiovascular diseases (angina and digital ischemia) 
since medieval times according to the translation of Buddhist manuscripts (Butler and Feelisch, 
2008; Machha and Schechter, 2012). In the last thirty years, since the discovery of the  𝑁𝑂3
−-
 𝑁𝑂2
−-NO pathway, there has been a renewal in using 𝑁𝑂3
− and  𝑁𝑂2
− in experiments and in 
clinical trials. This discovery demonstrated the contribution of  𝑁𝑂3
−/ 𝑁𝑂2
− to the overall NO 
pool (Kapil et al., 2014).  
Larsen et al. (2006) reported a pioneer study that demonstrates the beneficial effect of inorganic 
 𝑁𝑂3
− in BP reduction. In that study, the investigators administered 0.1 mmol sodium  𝑁𝑂3
−/kg 
body weight/day to healthy participants which corresponds to an intake of 100-300 g of  𝑁𝑂3
−-
rich vegetables per day. After three days of  𝑁𝑂3
− supplementation, a 4 mmHg reduction in 
diastolic BP was observed (Larsen et al., 2006). Administration of the same dose of  𝑁𝑂3
− to a 
greater group of individuals produced significant reductions in both systolic BP and diastolic 
BP (Larsen et al., 2007). Four weeks of  𝑁𝑂3
− supplementation (9 mg/kg) to older people at 
higher CVD risk significantly lowered systolic BP by 8 mmHg in comparison with placebo 
(Rammos et al., 2014). Supplementing beetroot juice (providing a  𝑁𝑂3
− dose of 300-400 mg) 
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to older overweight, but otherwise healthy, participants for three weeks lowered daily home-
measured systolic BP by 7 mmHg (Jajja et al., 2014). In the latter study BP values returned to 
pre-intervention values, one week after stopping the beetroot supplementation.   
In contrast, studies in diabetics or treated hypertensive patients did not show significant 
improvement of BP with beetroot administration (Gilchrist et al., 2013; Bondonno et al., 
2015b). Moreover, an individual participant meta-analysis (85 participants) showed that 
beetroot supplementation lowered 24 hrs-ambulatory BP significantly in younger participants 
only (<65 years) (Siervo et al., 2015). However, data synthesis from 16 studies involving 254 
participants demonstrated a significant reduction of systolic BP (-4.4 mm Hg) with inorganic 
 𝑁𝑂3
− or beetroot consumption (Siervo et al., 2013).  
The discovery of the contribution of dietary  𝑁𝑂3
− to NO bioavailability has  provided a 
rationale for the use of  𝑁𝑂3
− to reverse ED following NO insufficiency (Machha and Schechter, 
2012). Inorganic  𝑁𝑂2
− supplementation reversed ED significantly in a murine model of 
hypercholesterolemia (Stokes et al., 2009). In addition,  𝑁𝑂2
− supplementation reversed age-
associated ED, oxidative stress and arterial stiffness in mice (Sindler et al., 2011). In humans, 
less consistent results were observed (Webb et al., 2008; Gilchrist et al., 2013). Acute ingestion 
of inorganic  𝑁𝑂3
− (8 mmol) had no significant effect on FMD three hours post-intervention in 
healthy participants (Bahra et al., 2012). Two weeks of beetroot intake by type 2 diabetics was 
ineffective on EF (macro- and microvascular function) (Gilchrist et al., 2013). Three weeks 
supplementation with beetroot juice in older overweight healthy subjects had no significant 
effect on skin microvascular blood flow (Ashor et al., 2015a). On the contrary, a recently 
conducted study in 15 young healthy participants revealed a noticeable improvement in FMD 
after acute ingestion of inorganic 𝑁𝑂3
− (Rodriguez-Mateos et al., 2015) and six weeks daily 
intake of beetroot juice improved FMD significantly in patients with hypercholesterolemia 
(Velmurugan et al., 2016).   
Inorganic  𝑁𝑂2
− reversed ageing-related arterial stiffness in older mice. In the latter study, 
Sindler et al. (2011) observed that plasma  𝑁𝑂2
− concentration was reduced in older mice and 
that this was restored to youthful concentrations with inorganic 𝑁𝑂2
− supplementation. In 
healthy humans, Bahra et al. (2012) observed a significant reduction in arterial stiffness three 
hours after  𝑁𝑂3
− ingestion. Moreover, daily consumption of  𝑁𝑂3
− (900 mg) for four weeks 
reduced pulse wave velocity in older people at increased CVD risk (Rammos et al., 2014). 
However, arterial compliance increased with no change in pulse wave velocity after 220 mg 
 𝑁𝑂3
− supplementation in 28 healthy participants (Liu et al., 2013).  
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In vitro studies have shown that inorganic  𝑁𝑂3
− prevents the oxidation of LDL and so may 
slow down the process of atherogenesis (Kapil et al., 2010b). In addition, feeding inorganic 
 𝑁𝑂3
− to mice with hypercholesterolemia reduced circulating triglyceride concentrations 
(Stokes et al., 2009). Moreover, inorganic 𝑁𝑂3
− administration inhibits platelet aggregation and, 
therefore, may reduce thrombotic events in both humans and experimental animals (Richardson 
et al., 2002; Park et al., 2013).   
The restoration of blood to a tissue after a period of ischemia is sometimes associated with 
severe tissue injury due to a high release of free radicals. Animal studies have demonstrated 
that the prior administration of inorganic  𝑁𝑂3
− reduces the infarct size in a model of ischaemic-
reperfusion injury (Lundberg et al., 2011). Moreover, low dose sodium  𝑁𝑂2
− attenuated 
myocardial ischemia and vascular reperfusion injury in a human experimental study (Ingram et 
al., 2013).   
Administration of inorganic  𝑁𝑂3
− is associated with reduced oxygen consumption during 
exercise which has been interpreted as an increase in the energetic efficiency of exercise (Jones, 
2014).  It has been proposed that NO increases the efficiency of oxidative phosphorylation by 
reducing the leak of protons from the mitochondria (Kapil et al., 2010b; Lundberg et al., 2011). 
Whilst dietary  𝑁𝑂3
− supplementation increased exercise performance in most studies with 
young healthy participants (Hoon et al., 2013), similar studies in older individuals or diseased 
patients revealed contradictory results (Kelly et al., 2013; Shepherd et al., 2015).         
Data from animal studies have shown promising results regarding the effect of dietary  𝑁𝑂3
− on 
biomarkers of metabolic diseases. Supplementation of eNOS-deficient mice suffering 
metabolic syndrome with inorganic 𝑁𝑂3
− for 10 weeks reduced visceral fat and circulating 
triglycerides concentration and reversed the pre-diabetic phenotype (Carlstrom et al., 2010). 
Furthermore, supplementing diabetic rats with sodium  𝑁𝑂3
− for two months produced 
significant improvements in glucose homeostasis, lipid profile and oxidative stress markers 
(Khalifi et al., 2015). However,  𝑁𝑂3
− supplementation in humans did not result in improvement 
in glucose and insulin homeostasis in diabetic (Gilchrist et al., 2013; Cermak et al., 2015; 
Shepherd et al., 2015) or in non-diabetic participants (Larsen et al., 2014).  
1.12 Vitamin C and inorganic 𝑵𝑶𝟑
− interaction  
Epidemiological studies have associated higher intakes of vitamin C with protective effects 
from nitrate-associated adverse events such as colorectal cancer and diabetes mellitus 
(Dellavalle et al., 2014; Bahadoran et al., 2017). The purported mechanisms of the beneficial 
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effects of vitamin C include the wash-out of  𝑁𝑂2
− by converting it into NO and, therefore, 
prevention of the formation of NOCs (Mowat et al., 1999). Vitamin C generate NO over a wide 
pH range in aqueous solution by rapid reduction of nitrous acid and production of DHA 
(Bartsch et al., 1988).  
Acidification of urine and ingestion of vitamin C has been used in the treatment and prophylaxis 
against urinary tract infection. Ingestion of 2 g of vitamin C over 2 days induced a sevenfold 
increase in NO release from nitrite-containing urine from healthy individuals (Lundberg et al., 
1997). Vitamin C may enhance the conversion of  𝑁𝑂2
− into NO in the circulation, therefore, 
further contributing to the NO pool (Lundberg et al., 2008).   
In the previous sections, we have demonstrated that both inorganic 𝑁𝑂3
− and vitamin C, 
separately, may enhance NO production and improve EF. Moreover, the co-administration of 
vitamin C with inorganic  𝑁𝑂3
− may further enhance the conversion of  𝑁𝑂2
− to NO, therefore 
an additive or synergistic effect on EF might be expected from this combination. Synergism 
means that the combined effect of both dietary agents is greater than that predicted by their 
individual potencies (Tallarida, 2011). The additive effect is the situation in which the effect 
produced by the dietary agents is the algebraic sum of their independent actions. A synergistic 
interaction allows the use of lower doses of dietary agents, a situation that may reduce adverse 
reactions (Tallarida, 2001).  
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1.13 Hypotheses, aims and objectives 
  The hypotheses for this project were: 
1. Dietary 𝑁𝑂3
− supplementation will improve EF and arterial stiffness in human adults. 
The effect on vascular function will be associated with a significant reduction in blood 
pressure. Moreover, inorganic 𝑁𝑂3
− supplementation will ameliorate the effects of 
hyperglycaemia on skin microvascular blood flow and biomarkers of EF in young and 
older obese individuals. 
2. Vitamin C supplementation will improve EF and arterial stiffness in adult humans. This 
effect will be accompanied by a reduction in blood pressure.  
3. Combined inorganic 𝑁𝑂3
− and vitamin C supplementation will have a greater effects on 
blood pressure, skin microvascular blood flow and arterial stiffness than each 
intervention alone in both young and older healthy participants.   
The aims of this thesis were to test the above hypotheses by investigating the effects of 
inorganic 𝑁𝑂3
− and vitamin C supplementation (alone or in combination) on blood pressure 
and EF. Furthermore, I investigated whether the effects of these interventions were different 
between younger and older participants.   
The specific objectives of the study included:  
1. To carry out systematic reviews and meta-analyses to examine the evidence for effects of 
inorganic  𝑁𝑂3
−/beetroot supplementation on EF. 
2. To carry out systematic reviews and meta-analyses to examine the evidence for acute and 
chronic effects of vitamin C on biomarkers of CVD. 
3. To undertake an intervention study to investigate the acute effects of inorganic 𝑁𝑂3
− on 
EF in young and older obese healthy volunteers subjected to acute hyperglycaemia. 
4. To undertake an intervention study to investigate the effects of vitamin C and of 
inorganic 𝑁𝑂3
− alone, and in combination, on blood pressure and vascular function in 
young and older healthy volunteers.   
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Chapter 2. The effects of inorganic 𝑵𝑶𝟑
− and beetroot supplementation on 
EF: An updated systematic review and meta-analysis 
2.1 Introduction  
NO is the key molecule secreted from endothelial cells which regulates vascular tone, platelet 
aggregation, thrombosis, monocytes adhesion and smooth muscle proliferation (Forstermann, 
2010). Endothelial dysfunction appears in the early stages of the pathogenesis of vascular 
disorders and it is closely related to the progression of severe clinical conditions (i.e. stroke, 
pulmonary embolism and myocardial infarction) (Pober et al., 2009). Endothelial dysfunction 
is also commonly observed in metabolic disorders associated with increased atherosclerotic risk 
such as diabetes mellitus, metabolic syndrome and hypercholesterolemia (Singhal, 2005; Tang 
and Vanhoutte, 2010; Sena et al., 2013).   
The imbalance created by over-production of pro-inflammatory free radicals and reduced bio-
availability of NO alters EF and activates mechanisms (i.e. vasoconstriction, monocyte 
activation, smooth muscle cell proliferation and hyper-coagulation) which are causally linked 
to the formation of atherosclerotic plaques (Forstermann, 2010). 
Arterial stiffening is a hallmark of ageing and is closely associated with many pathological 
conditions including atherosclerosis, dyslipidaemia, diabetes and chronic kidney diseases 
(Shirwany and Zou, 2010). Reduced arterial compliance (i.e. increased stiffness) leads to faster 
reflection of the systolic wave from the peripheral small arteries to the heart, causing 
augmentation of the central aortic pressure (Cavalcante et al., 2011). This augmentation in 
central pressure leads to increased ventricular afterload and reduced coronary perfusion 
pressure which, eventually, may cause myocardial hypertrophy, ischemia and infarction 
(Sakuragi and Abhayaratna, 2010). Thus, arterial stiffness appears to contribute to the complex 
aetiology of CVDs and is regarded as a predictor of increased CVD risk and all-cause mortality 
(Laurent and Boutouyrie, 2007). 
Numerous nutritional interventions that target the conventional NO pathway have been 
proposed to maintain or restore healthy endothelial reactivity (Bai et al., 2009; Hall, 2009; 
Hord, 2011; Lovegrove and Griffin, 2013). For example, supplementation with L-arginine, the 
substrate for constitutive NO synthase that governs tonic endothelial NO generation, has been 
assessed in healthy individuals and in multiple disease states but with mixed results and the 
long-term benefits of arginine supplementation have been questioned (Luiking et al., 2012).  
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Similarly, provision of co-factors for NOS activity, particularly tetrahydrobiopterin (Alp and 
Channon, 2004), improved EF in healthy and specific cohorts of individuals with CVD (Bendall 
et al., 2014). However, tetrahydrobiopterin demonstrated no effects on EF in patients with 
coronary artery disease (Cunnington et al., 2012; Bendall et al., 2014). 
More recently, considerable interest has focussed on elevating NO utilising pathways 
independent of the conventional L-arginine/NO synthase pathway. Dietary  𝑁𝑂3
− 
supplementation is one of these pathways that is regarded as an external source of nitric oxide 
(Lidder and Webb, 2013). Benjamin (Benjamin et al., 1994) and Lundberg  (Lundberg et al., 
1994) separately demonstrated that administration of oral  𝑁𝑂3
− to healthy volunteers resulted 
in elevations of gastric  𝑁𝑂2
− that upon entry into the low pH environment of the stomach was 
converted to NO. Later, in a double-blind crossover study, Larsen et al. reported, for the first 
time, reduction in diastolic BP (-3.7 mmHg) after sodium 𝑁𝑂3
− consumption by healthy 
volunteers (Larsen et al., 2006).  
Subsequently, studies confirmed the effects of  𝑁𝑂3
− or beetroot (juice) on blood pressure 
(Siervo et al., 2013). Moreover, inorganic  𝑁𝑂3
− or beetroot prevented endothelial dysfunction 
(measured by brachial artery FMD induced by an acute ischemic insult in the human forearm 
and significantly attenuated ex vivo platelet aggregation in response to collagen and adenosine 
diphosphate (Webb et al., 2008). Importantly, the BP-lowering and vascular effects of inorganic 
 𝑁𝑂3
− may be due to the endogenous conversion of  𝑁𝑂3
− to NO (Gladwin et al., 2005; Lundberg 
et al., 2009). 
It is plausible that the BP lowering effects of dietary inorganic  𝑁𝑂3
− intake may in part be due 
to the improvements in vascular function (Hord, 2011); however a critical analysis of the 
evidence on this subject is lacking. Here, we conducted a systematic review and meta-analysis 
of the evidence from RCTs investigating the efficacy of inorganic  𝑁𝑂3
− and beetroot 
supplementation, chosen as a rich source of inorganic  𝑁𝑂3
−, on physiological measures of EF 
including FMD, FBF, microvascular blood flow, PWV, and AIx (Tousoulis et al., 2005). We 
also investigated whether the effect of  𝑁𝑂3
− on EF was modified by the age, health status, 
baseline BMI and baseline systolic BP or diastolic BP of the included participants or modified 
by the daily dose or duration of inorganic  𝑁𝑂3
−/beetroot supplementation. 
2.2 Methods  
This systematic review was conducted according to the Cochrane guidelines and is reported 
according to PRISMA guidelines (Higgins and Green, 2008; Liberati et al., 2009).  
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2.2.1 Data sources 
This systematic review and meta-analysis is an update of a previously conducted study 
performed by our group (Lara et al., 2015). The search for relevant studies was conducted via 
electronic search of three databases (Medline, Embase and Scopus). Additionally, we searched 
for eligible studies in the reference lists of the relevant articles and reviews. The following 
keywords were used to search the above databases from January 2014 until January 2016: 
inorganic nitrate, dietary nitrate, nitrate, beetroot, endothelial function, flow mediated dilation 
(FMD), blood flow, vascular function, microvascular function, microcirculation, pulse wave, 
arterial stiffness, arterial compliance and augmentation index.  
2.2.2 Study selection 
The following criteria were applied to identify the articles to be included in this systematic 
review and meta-analysis: 1) RCTs (no exclusion criteria were applied in relation to study 
design or blinding); 2) studies involving adults aged 18 years or more and no exclusion criteria 
were applied for health status, smoking history or body size; 3) inorganic  𝑁𝑂3
− or beetroot 
administered alone i.e. not combined with other drugs or nutritional interventions; 4) studies 
were not excluded because of the dose or duration of administration of  𝑁𝑂3
−; 5) studies 
reporting changes in EF measured using ultrasound, VOP, PWV, iontophoresis, pulse 
amplitude tonometry. Two investigators independently screened the titles and abstracts of the 
articles to evaluate eligibility for inclusion. If consensus was reached, articles were either 
excluded or moved to the next stage (full-text). If consensus was not reached the article was 
moved to the full-text stage. The full-texts of the selected articles were appraised critically to 
determine eligibility for inclusion in the systematic review. Disagreements were resolved by 
discussion between the reviewers until consensus was reached.   
2.2.3 Data extraction  
The following information was extracted from the eligible articles:  
1. Authors, journal details and year of publication 
2. Participants’ characteristics (age, sex, health status, BMI, systolic BP and diastolic BP) 
3. Study characteristics (design, sample size and study quality) 
4. Inorganic  𝑁𝑂3
−or beetroot intervention (dose, duration and type of intervention) 
5. Circulating concentrations of  𝑁𝑂3
− before and after intervention. 
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2.2.4 Statistical analyses  
As stated above, several methods are used to assess EF including FMD, FBF, microvascular 
blood flow, PWV and AIx. However, we considered for meta-analysis only outcomes reported 
in ≥ 5 studies (Higgins and Green, 2008). The other outcomes of < 5 reports in the studies were 
included in the qualitative analysis only. Therefore, the outcome of the meta-analysis is the net 
difference between the intervention and control group in FMD, PWV and AIx at the end of the 
study. The FMD was calculated by subtracting the peak diameter after hyperaemia from the 
baseline diameter divided by the baseline diameter and multiplied by 100 (Tousoulis et al., 
2005). PWV is defined as the speed of travel of the pressure pulse along the arterial segment, 
is calculated as the distance/transit time ratio and is expressed as meters per second (Zoungas 
and Asmar, 2007). The AIx is defined as the proportion of central pulse pressure due to the late 
systolic peak which, in turn, is attributed to the reflected pulse wave and is expressed as 
percentage (Yasmin and Brown, 1999).  
Statistical analyses were performed using STATA 12 (StataCorp. 2011. College Station, TX, 
USA). The effect size (the magnitude of effect e.g. the difference between treatment mean and 
control mean) was estimated as weighted mean differences (WMDs) with 95% confidence 
interval. Random effect models were used to take account of between-study heterogeneity for 
participant characteristics, study design and methods used to assess endothelial function. Data 
not provided in the main text or tables were extracted from the figures. For crossover trials, we 
used the mean and SD separately for the intervention and control conditions (Elbourne et al., 
2002).  
Subgroup analyses were undertaken to investigate the role of potential factors influencing the 
effect of  𝑁𝑂3
− on EF and accounting for the heterogeneity of the models. These factors included 
participants’ characteristics such as health status, age of participants, baseline values for BMI, 
blood pressure and factors related to study characteristics including type of intervention, study 
design and study quality. Meta-regression analyses were conducted to examine possible 
relationships between the effect of  𝑁𝑂3
− supplementation on markers of EF (FMD, PWV and 
AIx) and continuous variables reported such as age, BMI, systolic BP, diastolic BP and dose 
and duration of  𝑁𝑂3
− intervention. 
2.2.5 Quality assessment    
Indices of study quality were assessed by the modified Jadad score (range 0 – 5). This score is 
based on three main features of study quality including randomisation, blinding and description 
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of dropout or withdrawals. Possible scores ranged from 0 to 5 and a score of ≤ 2 indicates high 
risk while a score of ≥ 3 indicates low risk of bias (Jadad et al., 1996).     
Publication bias was evaluated by visual inspection of the funnel plot and by Egger’s regression 
test (Egger et al., 1997). Heterogeneity between studies was evaluated using Cochrane Q 
statistics; P > 0.1 indicates significant heterogeneity. The I2 test was also used to evaluate 
consistency between studies where a value < 25% indicates low risk of heterogeneity, 25-75% 
indicates moderate risk of heterogeneity and > 75% indicates high risk of heterogeneity 
(Higgins et al., 2003). 
2.3 Results  
2.3.1 Search results 
The process followed in the selection of eligible studies is summarized in Figure 2.1. After full 
text examination, 18 RCTs were included in the systematic review.  
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Figure 2.1: Flow diagram of the process used in selection of the studies reporting 
randomised controlled trials included in this systematic review and meta-analysis 
2.3.2 Studies characteristics 
Characteristics of the studies included in the systematic review and meta-analysis are 
summarized in Table 2.1. The total number of participants was 383 with a median sample size 
of 15 participants per study (range 8 – 67). The studies included 217 males and 139 females, 
but two studies did not report the gender of their participants (Rossi et al., 2004; Bahra et al., 
2012). Participant age ranged from 22 to 67.2 years (median 42 years). The dose of inorganic 
 𝑁𝑂3
− ranged from 1.1 to 22.5 mmol/day and the median dose was 7.75 mmol/day. The duration 
of the studies ranged from 1-42 days. The study designs comprised 14 crossover (Panza et al., 
1993; Arcaro et al., 1999; Newton et al., 2001; Tounian et al., 2001; Ceriello et al., 2002; Rossi 
et al., 2004; Bitar et al., 2005; Correia and Haynes, 2007; Webb et al., 2008; Shirwany and 
Zou, 2010; Bahra et al., 2012; Roustit and Cracowski, 2013; Higashi, 2015; Lee et al., 2015) 
and 4 parallel group studies (Porter, 1993; Rammos et al., 2014; van Sloten et al., 2014; 
Velmurugan et al., 2016). 
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Table 2.1: Characteristics of studies included in the systematic review and meta-analysis 
 AIx: augmentation index, DB: double-blind, CO: crossover, FBF: forearm blood flow, FMD: flow mediated dilation, LDF: laser Doppler flow, P: parallel, PWV: pulse wave velocity, UB: non-blinded,  
Author Study 
Design 
Health Status Outcomes Age 
(years) 
Sample 
Size 
(Male) 
 𝑵𝑶𝟑
− 
Dose 
(mmol) 
Type Duration 
(days) 
Baseline 
BMI 
(kg/m2) 
Baseline 
systolic 
BP 
(mmHg) 
Baseline 
diastolic 
BP 
(mmHg) 
 𝑵𝑶𝟑
−Concentration 
before (µM/L) 
 𝑵𝑶𝟑
− 
concentration 
after (µM/L) 
Washout 
Period 
Jadad’s 
Score 
Porter (1993) UB, P Healthy LDF 62.7 21 (12) 5.6 Beetroot 21 30.5 135.1 77.5 
   
3 
Bahra et al. (2012) DB, CO Healthy FMD, 
PWV 
27.9 14 (NR) 8 Inorganic 
 𝑁𝑂3
− 
1 24.5 116.9 67.7 31.1 216 1-4 
weeks 
3 
Panza et al. (1993) DB, CO Healthy FMD 25 11 (7) 5 Beetroot 1 22 115 70 
  
24 hours 4 
Rossi et al. (2004) UB, CO Hypertension PWV 52.9 15 (NR) 3.5 Beetroot 1 26.2 139.9 86.5 46.8 156.8 
 
2 
Tounian et al. (2001) DB, CO Type 2 diabetes LDF, FMD 67.2 27 (18) 7.5 Beetroot 14 30.8 142.9 81.1 31 150 4 weeks 3 
Arcaro et al. (1999) DB, CO Healthy FMD 26 10 (5) 11.3 Inorganic 
 𝑁𝑂3
− 
1 
   
13 261 
 
4 
Ceriello et al. (2002) UB, CO Healthy LDF, 
PWV, Aix 
31 23 (23) 1.1 Beetroot 1 23.3 124 74 8.6 30.2 24 hours 2 
Bitar et al. (2005) UB, CO Healthy FMD, 
PWV 
61 20 (20) 8.1 Beetroot 1 30.1 135.2 93.2 
  
1 week 2 
van Sloten et al. (2014) DB, P Hypertension FMD, 
PWV, Aix 
57.6 64 (26) 6.4 Beetroot 28 26.8 149 88.9 
   
3 
Higashi (2015) DB, CO Healthy FMD 24.7 12 (5) 5.5 Beetroot 1 
 
104 63 34 
 
1 week 2 
Newton et al. (2001) UB, CO Peripheral arterial 
Disease 
FMD 67 8 (4) 18.2 Beetroot 1 28.6 140 76 75 475 1-2 
weeks 
2 
Roustit and Cracowski 
(2013) 
DB, CO Healthy FMD, 
PWV 
22 12 (12) 12.9 Beetroot 1 25 120 64 31 561 5 days 5 
Lee et al. (2015)  DB, CO Healthy FMD 22 14 (14) 6.4 Beetroot 15 23.4 116 77 83.8 167.6 2 weeks 4 
Rammos et al. (2014) DB, P Hypertension FMD, 
PWV, Aix 
63.7 20 (13) 11.3 Inorganic 
 𝑁𝑂3
− 
28 24 137 80 32 263 
 
3 
Shirwany and Zou (2010) DB, CO Healthy FMD 25 15 (15) 12.1 Inorganic 
 𝑁𝑂3
− 
1 24.1 119 68 
 
238 1 week 4 
Velmurugan et al. (2016) DB, P Hypercholesterolemia FMD, 
PWV, Aix 
53.3 67 (24) 6 Beetroot 42 26.8 125.2 76.3 25 200 
 
5 
Webb et al. (2008) UB, CO Healthy FMD 26.6 10 (4) 22.5 Beetroot 1 21.3 
  
25 400 1 week 2 
Correia and Haynes (2007)  DB, CO Heart Failure FBF, Aix 65.5 20 (15) 12.9 Beetroot 1 35.4 
  
10 326 10 days 3 
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Different methods were used to assess changes in EF in the trials. The most commonly used 
methods were FMD (14 trials), PWV (8 trials) and AIx (6 trials). Some trials used LDF (3 trials) 
and only one study used FBF (Table 2.1). Eleven studies investigated the effect of inorganic 
 𝑁𝑂3
− or beetroot in healthy volunteers (Panza et al., 1993; Porter, 1993; Arcaro et al., 1999; 
Ceriello et al., 2002; Bitar et al., 2005; Webb et al., 2008; Shirwany and Zou, 2010; Bahra et 
al., 2012; Roustit and Cracowski, 2013; Higashi, 2015; Lee et al., 2015). The remaining studies 
were conducted in participants with cardiovascular and metabolic conditions including 
hypertension (Rossi et al., 2004; Rammos et al., 2014; van Sloten et al., 2014), heart failure 
(Correia and Haynes, 2007), peripheral arterial disease (Newton et al., 2001), 
hypercholesterolemia (Velmurugan et al., 2016) and type 2 diabetes (Tounian et al., 2001).    
2.3.3 Qualitative analysis  
Two thirds of the studies (12 studies) included in this meta-analysis were of moderate-high 
quality on the Jadad score (≥ 3) while the rest of studies (6 studies) appeared to have a high risk 
of bias (Table 2.1). Individually, 13 studies reported that inorganic  𝑁𝑂3
− or beetroot 
supplementation improved endothelial function significantly. Six studies reported adverse 
effects including beeturia or stool discoloration (Newton et al., 2001; Tounian et al., 2001; 
Ceriello et al., 2002; Zieman et al., 2005; van Sloten et al., 2014; Velmurugan et al., 2016).  
Twelve studies reported the dropout rate during the interventions (Panza et al., 1993; Porter, 
1993; Tounian et al., 2001; Ceriello et al., 2002; Rossi et al., 2004; Bitar et al., 2005; Correia 
and Haynes, 2007; Webb et al., 2008; Shirwany and Zou, 2010; van Sloten et al., 2014; Higashi, 
2015; Velmurugan et al., 2016). The washout period used in the crossover trials varied from 1 
day to 4 weeks and two studies failed to report this information (Arcaro et al., 1999; Rossi et 
al., 2004). 
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2.3.4 The effects of inorganic  𝑵𝑶𝟑
− or beetroot on FMD 
Data synthesis revealed significant increase in FMD with inorganic  𝑁𝑂3
− or beetroot 
interventions (WMD: 1.36%, 95% CI: 0.73, 1.99, P < 0.001). However, these studies were 
characterized by significant heterogeneity (X2 = 76.8, P < 0.001, I2 = 83.1%) (Figure 2.2). 
Subgroup analyses (Table 2.2) demonstrated a significantly greater effect in healthy 
participants in comparison with those with underlying diseases (WMD: 2.25%, 95% CI: 1.35, 
3.14, P < 0.001). Likewise, inorganic  𝑁𝑂3
− or beetroot showed higher efficacy in non-obese 
participants (BMI < 25 kg/m2) (WMD: 1.49%, 95% CI: 0.74, 2.23, P < 0.001). 
  
 
Figure 2.2: Forest plot showing the effect of inorganic  𝑵𝑶𝟑
− or beetroot on flow mediated 
dilation.  Diamonds indicate the effect size of each study summarized as weighted mean 
difference (WMD). The size of the shaded squares is proportional to the percentage weight 
of each study. Horizontal lines represent the 95% confidence interval and the vertical 
broken line represents the overall effect. 
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Table 2.2: Subgroup analysis of the effect of inorganic  𝑵𝑶𝟑
− or beetroot on flow mediated 
dilation 
 
 
 
 
 
 
 
  
 No. of 
subgroups 
Effect 
size 
95% CI P Value P between 
subgroups 
I2 (%) 
Health status     0.01  
Healthy  9 2.25 1.35 to 3.14 0.001  76.6 
Disease 5 0.18 -0.07 to 0.44 0.152  0 
Age of participants (years)     0.07  
< 60 years 10 2.06 1.00 to 3.12 0.001  87.9 
≥ 60 years 4 0.69 0.36 to 1.02 0.001  0 
Body mass index (kg/m2)     0.04  
< 25  6 1.49 0.74 to 2.23 0.001  56.0 
≥ 25 6 0.45 -0.02 to 0.92 0.06  51.2 
Systolic blood pressure  (mmHg)     0.14  
< 130 7 1.79 0.55 to 3.04 0.005  88.9 
≥ 130 5 0.71 0.39 to 1.03 0.001  0 
Diastolic blood pressure (mmHg)     0.81  
< 85 10 1.15 0.33 to 1.97 0.006  83.8 
≥ 85 2 0.86 0.48 to 1.25 0.001  0 
Type of intervention      0.59  
Beetroot 10 1.13 0.44 to 1.82 0.001  77.5 
Inorganic  𝑵𝑶𝟑
− 4 1.82 0.44 to 3.19 0.009  85.1 
Study Design     0.16  
Parallel  3 0.27 -0.12 to 0.66 0.172  24.5 
Crossover 11 1.77 0.98 to 2.56 0.001  75.5 
Study Quality (Jadad Score)     0.61  
Low risk (4-6) 10 1.28 0.46 to 2.09 0.002  84.5 
High risk (2-3) 4 1.86 0.24 to 3.48 0.025  82.0 
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Meta-regression analyses (Figure 2.3) revealed significant reduction in the effects of inorganic 
 𝑁𝑂3
− or beetroot on FMD in older participants (β: -0.05, 95% CI: -0.09, 0.02, P < 0.01) and in 
those with higher baseline systolic BP (β: -0.06, 95% CI: -0.12, 0.01, P = 0.02).    
 
  
 
Figure 2.3: Associations between inorganic  𝑵𝑶𝟑
− or beetroot supplementation effects 
on flow mediated dilation and participants’ characteristics (age, baseline body mass 
index, systolic or diastolic blood pressure) or of studies characteristics (dose and 
duration of  𝑵𝑶𝟑
− intervention). Each study is depicted by a circle where the circle size 
represents the degree of weighting for the study based on participant numbers in the 
study. 
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2.3.5 The effects of inorganic  𝑵𝑶𝟑
− or beetroot on PWV 
Inorganic  𝑁𝑂3
− or beetroot supplementation had no detectable effect on PWV (WMD: -0.05 
m/s, 95% CI: -0.38, 0.28, P = 0.75) (Figure 2.4). There was no significant heterogeneity 
between trials (X2 = 11.3, P = 0.13, I2 = 38.2). Subgroup analyses of studies showed no 
significant differences between groups based on participant or study characteristics (Table 2.3). 
However, meta-regression analyses (Figure 2.5) demonstrated marginally significant 
relationship between the changes in PWV and the dose of inorganic  𝑁𝑂3
− (β: -0.09, 95% CI: -
0.18, -0.002, P = 0.05).  
 
 
Figure 2.4: Forest plot showing the effect of inorganic  𝑵𝑶𝟑
− or beetroot on pulse wave 
velocity.  Diamonds indicate the effect size of each study summarized as weighted mean 
difference (WMD). The size of the shaded squares is proportional to the percentage 
weight of each study. Horizontal lines represent the 95% confidence interval and the 
vertical broken line represents the overall effect. 
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Table 2.3: Subgroup analysis of the effect of inorganic  𝑵𝑶𝟑
− and beetroot on pulse wave 
velocity 
 
  
 No. of 
subgroups 
Effect 
size 
95% CI P Value P between 
subgroups 
I2 (%) 
Health status     0.26  
Healthy  4 0.11 -0.41 to 0.63 0.686  62.3 
Disease 4 -0.28 -0.69 to 0.14 0.194  0 
Age of participants (years)     0.87  
< 60 years 6 -0.06 -0.45 to 0.33 0.774  54.5 
≥ 60 years 2 -0.13 -1.06 to 0.81 0.786  0 
Body mass index (kg/m2)     0.18  
< 25  3 0.22 -0.51 to 0.94 0.561  70.4 
≥ 25 5 -0.26 -0.61 to 0.09 0.153  0 
Systolic blood pressure  (mmHg)     0.27  
< 130 4 0.07 -0.38 to 0.52 0.761  64.2 
≥ 130 4 -0.40 -0.97 to 0.17 0.168  0 
Diastolic blood pressure (mmHg)     0.33  
< 85 5 0.04 -0.38 to 0.47 0.837  54.5 
≥ 85 3 -0.38 -0.97 to 0.21 0.206  0 
Type of intervention      0.85  
Beetroot 6 -0.06 -0.53 to 0.41 0.798  53.4 
Inorganic  𝑵𝑶𝟑
− 2 -0.10 -0.46 to 0.27 0.602  0 
Study Design     0.46  
Parallel  3 -0.22 -0.67 to 0.22 0.319  0 
Crossover 5 0.02 -0.47 to 0.51 0.932  57.4 
Study Quality (Jadad Score)     0.08  
Low risk (4-6) 5 -0.17 -0.44 to 0.10 0.219  0 
High risk (2-3) 3 0.17 -0.68 to 1.02 0.695  60.8 
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Figure 2.5: Associations between inorganic  𝑵𝑶𝟑
− or beetroot supplementations effects 
on pulse wave velocity and characteristics of participants (age, baseline body mass 
index, systolic or diastolic blood pressure) or of studies characteristics (dose and 
duration of  𝑵𝑶𝟑
− intervention).  Each study is depicted by a circle where the circle size 
represents the degree of weighting for the study based on participant numbers in the 
study. 
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2.3.6 The effects of inorganic  𝑵𝑶𝟑
− or beetroot on AIx 
Meta-analysis revealed no effect of inorganic  𝑁𝑂3
− or beetroot supplementation on AIx (WMD: 
-1.73 %, 95% CI: -3.85, 0.40, P = 0.11) (Figure 2.6). There was no significant heterogeneity 
between trials (X2 = 2.65, P = 0.73, I2 = 0). Because of the small number of studies (6 trials), we 
could not conduct subgroup analyses. However, meta-regression analyses found no evidence 
that characteristics of participants or of studies influenced the effect of inorganic  𝑁𝑂3
− or 
beetroot on AIx (Figure 2.7).   
  
 
Figure 2.6: Forest plot showing the effect of inorganic  𝑵𝑶𝟑
− or beetroot on 
augmentation index (%).  Diamonds indicate the effect size of each study summarized 
as weighted mean difference (WMD). The size of the shaded squares is proportional to 
the percentage weight of each study. Horizontal lines represent the 95% confidence 
interval and the vertical broken line represents the overall effect. 
 
  
   
 52 
 
 
Figure 2.7: Associations between inorganic  𝑵𝑶𝟑
− or beetroot supplementations effects 
on augmentation index and characteristics of participants (age, baseline body mass 
index, systolic or diastolic blood pressure) or of studies characteristics (dose and 
duration of  𝑵𝑶𝟑
− intervention).  Each study is depicted by a circle where the circle size 
represents the degree of weighting for the study based on participant numbers in the 
study. 
2.3.7 Publication bias 
The funnel plots (Figure 2.8) showed asymmetry in the distribution of the studies included in 
the three meta-analyses (FMD, PWV and AIx) which may denote either publication bias or 
small study effect (the tendency of small studies to show higher effect sizes than larger studies). 
However, Egger’s regression test (β: 0.20, P = 0.05; β: 0. 28, P = 0. 37; β: -1.14, P = 0. 84 for 
FMD, PWV and AIx, respectively) suggest low likelihood of publication bias.   
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Figure 2.8: Funnel plot for publication bias of the effect of inorganic  𝑵𝑶𝟑
− or 
beetroot supplementations on, A) flow mediated dilation (FMD); B) pulse wave 
velocity (PWV); C) augmentation index (Aix). 
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2.4 Discussion  
Inorganic 𝑁𝑂3
− and beetroot supplementations were associated with a significant improvement 
in FMD. However, neither PWV nor AIx was improved with these interventions. Nevertheless, 
inorganic 𝑁𝑂3
− or beetroot administration in larger doses might be associated with greater 
reduction in PWV. The improvement in EF tends to be smaller in older, overweight/obese 
participants and in those with underlying cardio-metabolic disease.  
The biological mechanisms explaining the apparent influence of ageing in modifying the effect 
of inorganic  𝑁𝑂3
− on EF remain uncertain. It is possible that ageing interferes with the bio-
conversion of dietary  𝑁𝑂3
− to nitric oxide e.g. by modification of oral micro-environment 
which may influence the efficiency of bacterial reductase activity in the conversion of  𝑁𝑂3
− 
into  𝑁𝑂2
− (Percival et al., 1991). In addition, gastric acid production declines with age (Britton 
and McLaughlin, 2013) and this process may affect the formation of NO in the acid stomach 
from the acid-mediated disproportionation of  𝑁𝑂2
− (Zweier et al., 1999). Disproportionation is 
a specific type of redox reaction in which an element from a reaction undergoes both oxidation 
and reduction to form two different products. Epidemiological studies showed a 4.8% 
prevalence of atrophic gastritis (reduction in the number of acid-producing cells) in population 
aged 50-54 years; this number bounced to 8.9% in those aged > 70 years (Brownie, 2006; Weck 
et al., 2007). In the current study, we found around 70% reduction in the effect of  𝑁𝑂3
− on 
FMD in > 60 years old population (Table 2.2).    
 Hence, it is currently not known whether greater doses of inorganic  𝑁𝑂3
− are required in older 
people to account for the decline in redox potential and augment NO bioavailability. Ageing 
may also be associated with diminished sensitivity to the dilatory effects of NO, thus higher 
doses may be required (Lyons et al., 1997; Montero et al., 2015). In chapter four and five of 
this thesis, we will try to answer the question regarding the difference in absorptive capacity 
and efficacy of inorganic  𝑁𝑂3
− supplementation in two different age groups.  
Whilst the main finding from this analysis is that dietary  𝑁𝑂3
− improves FMD, it is important 
to also appreciate that the duration of the interventions was relatively short (longest duration 
was 42 days).  Furthermore, the meta-regression analysis showed a tendency of reduction in the 
effect of  𝑁𝑂3
− supplementation on FMD over time (Figure 2.3). Therefore, it is not known from 
the present meta-analysis whether the observed improvements in vascular function can be 
maintained in a relatively longer duration studies. This is a critical factor which needs to be 
evaluated to understand if  𝑁𝑂3
−/ beetroot interventions have the potential to be effective 
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strategies for the primary and/or secondary prevention of endothelial dysfunction and 
atherosclerosis.   
The pathological process behind the deterioration of PWV and AIx reflect three potential risk 
factors including systolic BP, pulse pressure and structural changes in the arterial wall (Jani and 
Rajkumar, 2006). Therefore, any interventions expected to improve PWV and AIx need to 
improve these risk factors. In contrast with the functional alteration associated with endothelial 
dysfunction (measured by FMD) (Seals et al., 2011), the structural alteration in the arterial wall 
needed a longer duration intervention to observe a clinically reasonable effect.  The current 
study revealed a non-significant effect of inorganic  𝑁𝑂3
− on PWV and AIx. This may be linked 
to the short-term duration of the studies which is unlikely to induce structural changes of the 
arterial wall and have an effect on pulse wave transit and reflection.  
This study has several potential limitations. One limitation of the present analysis is the high 
levels of heterogeneity among the FMD studies and hence our findings should be treated with 
caution. The considerable variability in the design, duration, dose of dietary  𝑁𝑂3
− and 
participant characteristics (age, sex, health status) may have contributed to the significant 
heterogeneity observed in our meta-analysis. We undertook subgroup analysis to explore a 
number of potential sources of heterogeneity; but, heterogeneity remained at moderate to high 
levels. The asymmetry observed in the funnel plot may be evidence of publication bias. 
However, the latter observation should be interpreted cautiously. Apparent asymmetry in such 
funnel plots may be due to factors other than the presence of publication bias including: 1) most 
of the included studies had small sample size (small study effect). The small study effect means 
that small trials tend to report greater treatment effect than large trials and therefore causes 
asymmetry of the funnel plot  (Nuesch et al., 2010); 2) heterogeneity in design and in outcome 
measures between studies (there is substantial clinical and methodological heterogeneity among 
the studies included in our meta-analysis), and studies involving different populations (Lau et 
al., 2006). 
The meta-analyses are based on retrospective analytical inference which may be affected by 
several factors such as inclusiveness of the search strategy to identify eligible studies, 
assumptions on consistency of methodologies applied across the different studies, inconsistency 
in reporting study results and limited accessibility to individual study data. In addition, we have 
limited our search to articles published in English. The clear delineation of a priori inclusion 
and exclusion criteria and the comprehensive search of three major electronic databases and 
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reference lists are likely to have minimized bias and increased the representativeness of the 
results.  
2.4.1 Conclusions 
This systematic review and meta-analysis revealed a significant improvement of EF after 
inorganic  𝑁𝑂3
− and beetroot juice supplementation. If such improvements were sustained in 
the long-term, these finds have potential implications for the prevention of atherosclerosis and 
cardiovascular diseases. However, before the results can be translated into new nutritional 
recommendations, the long-term effects of inorganic  𝑁𝑂3
− on endothelial function need to be 
investigated in older subjects and in patients at higher cardiovascular risk. Importantly, the 
present findings suggest that inorganic  𝑁𝑂3
− supplementation may be less effective, at least in 
the short-term, in such population groups. 
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Chapter 3. Vitamin C and biomarkers of cardiovascular diseases: An 
umbrella review  
3.1 Introduction  
Vitamin C is an essential nutrient which has antioxidant roles in the human body (Padayatty et 
al., 2003). It is regarded by some investigators as the most important antioxidant in human 
plasma (Halliwell, 1996). Ascorbic acid (the reduced form of vitamin C) scavenges 
physiologically relevant reactive oxygen and nitrogen species (Carr and Frei, 1999). Similarly, 
vitamin C can reduce non-radical species and can regenerate circulatory antioxidant molecules 
(Figure 3.1) (Carr and Frei, 1999).  
 
Figure 3.1: Antioxidant functions of vitamin C 
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Regardless of the extensive evidence of antioxidant action, studies have shown that vitamin C 
can also behave as a prooxidant in certain laboratory settings (e.g. high oxygen tension and in 
the presence of metal ions) (Padayatty and Levine, 2016). Vitamin C has been considered as a 
perplexing micronutrient “Of all the paradoxical compounds, ascorbic acid probably tops the 
list. It is truly a two-headed Janus, a Dr. Jekyll-Mr. Hyde, an oxymoron of antioxidants" (Porter, 
1993).  
Antioxidants such as vitamin C proved to be beneficial on CVD outcomes in small experimental 
and epidemiological cohort studies (Li and Schellhorn, 2007). Conversely, large RCTs did not 
establish any superior effects of supplemental vitamin C to placebos on CVD outcomes 
(Honarbakhsh and Schachter, 2009). However, there are some limitations in the design and 
conduct of these large RCTs which confounded the interpretation of the beneficial/deleterious 
effects of supplementary vitamin C (Lykkesfeldt and Poulsen, 2010; Frei et al., 2012; Michels 
and Frei, 2013). The majority of big trials used combined antioxidant vitamins so that it is 
impossible to separate the effects (or lack of effects) of vitamin C from the effects of the other 
vitamins with which it was administered (Lykkesfeldt and Poulsen, 2010). Additionally, these 
studies recruited well-nourished control and intervention groups (Padayatty and Levine, 2016). 
Pharmacokinetics studies have shown that supplementing vitamin C to well-nourished 
individuals will modestly increase plasma and tissue vitamin C concentrations (Levine et al., 
1996; Levine et al., 2001). Failure of these studies to include measures of cardiovascular 
biomarkers (e.g. BP, arterial stiffness, EF or lipid profile) throughout the study period and 
correlating them to the therapeutic interventions is considered by some investigators as a major 
drawback in these large RCTs (Pashkow, 2011). Therefore, in this overview of systematic 
reviews and meta-analyses “umbrella review”, I aimed to investigate the effects of 
supplementation of vitamin C alone on biomarkers of cardiovascular diseases. In addition, I 
aimed to evaluate the strength of evidence and the methodological qualities of these studies.       
3.2 Methods  
This umbrella review was conducted and reported according to the guidelines described by 
Aromataris et al. (2015).  
3.2.1 Data sources and search strategy  
The search for relevant systematic reviews and meta-analyses was conducted via electronic 
search of three databases (Medline, Embase and Scopus). Additionally, I searched for eligible 
studies in the reference lists of the relevant articles and reviews. The following keywords were 
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used to search the above databases from inception until November 2016: antioxidants, ascorbic 
acid, vitamin C, cardio-metabolic, cardiovascular diseases, metabolic diseases, systematic 
review and meta-analysis.  
3.2.2 Study selection 
The following criteria were applied to identify the articles to be included in this umbrella 
review: 1) systematic reviews and meta-analyses of RCTs; 2) studies involving adults aged 18 
years or more and no exclusion criteria were applied for health status; 3) vitamin C administered 
alone i.e. not combined with other drugs or nutritional interventions; 4) studies reporting 
changes in CVD biomarkers (i.e. arterial stiffness, blood pressure, endothelial function, 
glycaemic index and lipid profile). Two investigators screened the titles and abstracts of the 
articles independently to evaluate eligibility for inclusion. If consensus was reached, articles 
were either excluded or moved to the next stage (full-text). If consensus was not reached the 
article was moved to the full-text stage. The full-texts of the selected articles were critically 
appraised to determine eligibility for inclusion in the umbrella review. Disagreements were 
resolved by discussion between the reviewers until consensus was reached. 
3.2.3 Data extraction  
The following information was extracted from the eligible articles: 1) authors, journal details 
and year of publication; 2) descriptive information: databases searched, number of trials 
included, studies outcomes, total number of participants, age range; 3) data synthesis results: 
effect size, heterogeneity, subgroup analysis, meta-regression analysis and publication bias.    
3.2.4 Quality assessment    
Study quality were assessed by the modified version of the Overview of Quality Assessment 
Questionnaire (OQAQ) (Oxman and Guyatt, 1991). As used for assessment of systematic 
reviews, this tool included 9 questions: 1) were the search methods used to find evidence on the 
primary question(s) stated? 2) was the search for evidence reasonably comprehensive? 3) were 
the criteria used for deciding which studies to include in the review reported? 4) was bias in the 
selection of articles avoided? 5) were the criteria used for assessing the methodological quality 
of studies reviewed reported?; 6) were study quality assessment criteria used to inform the 
review analysis? 7) were the methods used to combine the findings of the relevant studies (to 
reach a conclusion) reported? 8)  were findings of the relevant studies combined appropriately 
relative to the primary question of the overview? 9) were the conclusions made by the author(s) 
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supported by the data and/or analysis reported in the overview? These questions were answered 
as “yes”, “no” or “partially/can’t tell” and then the answers were scored 2, 0 and 1, respectively 
(the total score ranged from 0 to 18).   
3.3 Results  
3.3.1 Search results and studies characteristics  
The process followed in the selection of eligible studies is summarized in Figure 3.2. After full 
text examination, 10 systematic reviews and meta-analyses were included in the umbrella 
review. Three studies investigated the effects of vitamin C on endothelial function (Ashor et 
al., 2014a; Montero et al., 2014; Ashor et al., 2015b), two studies lipid profile (McRae, 2008; 
Ashor et al., 2016c), two studies glycaemic index (Tabatabaei-Malazy et al., 2014; Ashor et 
al., 2017) and one study each for arterial stiffness (Ashor et al., 2014b), blood pressure 
(Juraschek et al., 2012) and insulin resistance (Khodaeian et al., 2015) (Table 3.1).  
The number of trials included in each study ranged from 3 to 44 trials, included participants 
ranged from 92 to 1981 participants per meta-analysis. The age of participants ranged from 20 
to 82 years. Two studies did not report the number and age of the included participants (Montero 
et al., 2014; Tabatabaei-Malazy et al., 2014) (Table 3.1). The OQAQ quality score of the studies 
ranged from 11 to 18 (Table 3.2). Summary of the findings from these meta-analysis studies 
are presented in (Figure 3.3) below.  
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Figure 3.2: Flow diagram of the process used in selection of the systematic reviews 
and meta-analyses studies included in this umbrella review 
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Figure 3.3: Summary of the findings from studies included in vitamin C and 
cardiovascular biomarkers umbrella review.  Each circle represents a meta-analysis 
study. Green circles denote positive effect, red circles denote absence of effect and 
circles with green and red pattern represent absence of an overall effect, however, 
subgroup and meta-regression analyses demonstrated positive effects. HbA1c: 
haemoglobin A1C; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; TG: triglycerides   
 
 
 
   
 63 
Table 3.1: Description of the 10 systematic reviews and meta-analyses of vitamin C and cardiovascular biomarkers included in this umbrella 
review   
 
 
 
 
 
 
 
NR: not reported  
  
Study  Outcome Database searched Search range (years) Number of 
trials 
Number of 
participants  
Age range 
(years) 
Ashor et al. 2014 Endothelial function PubMed, Embase, Scopus and Cochrane 
Library 
from inception to May 2013 44 1129 22-68 
Ashor et al. 2015 Endothelial function MEDLINE, Embase, Scopus and 
Cochrane Library  
from inception to May 2014 17 478 23-78 
Ashor et al. 2014 Arterial stiffness MEDLINE, Embase and Scopus from inception to December  2013 10 273 22-63.5 
Ashor et al. 2015 Lipid profile PubMed, Embase, Scopus and Cochrane 
Library 
from inception to August  2014 40 1981 20-81 
Ashor et al. 2017 Glycaemic control PubMed, Embase, Scopus, and 
Cochrane Library 
from inception until July 2015 24 998 22 – 72 
Juraschek et al. 2012 Blood pressure MEDLINE, Embase and Cochrane 
Library  
1966-2011 29 1407 22-74 
Khodaeian et al. 2015 Insulin resistance Google Scholar and PubMed from inception to January  2014 3 92 39-72+ 
McRae 2008 Lipid profile MEDLINE 1970-2007 13 549 48-82 
Montero et al. 2013 Endothelial function MEDLINE, Cochrane, Scopus and Web 
of Science 
from inception to February  2013 6 NR NR 
Tabatabaei-Malazy et al. 2014 Glycaemic control Google Scholar and PubMed, Scopus, 
IranMedex and Magiran web 
from inception to January  2013 12 NR NR 
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Table 3.2: Quality assessment of the 10 systematic reviews and meta-analyses of vitamin C and cardiovascular biomarkers included in this 
umbrella review 
 
 
Study  1. Were the 
search 
methods used 
to find 
evidence on 
the primary 
question(s) 
stated? 
2. Was the 
search for 
evidence 
reasonably 
comprehensive? 
3. Were the 
criteria used for 
deciding which 
studies to include 
in the review 
reported? 
4. Was bias in 
the selection of 
articles 
avoided? 
5. Were the 
criteria used for 
assessing the 
methodological 
quality of 
studies reviewed 
reported? 
6. Were study 
quality 
assessment 
criteria used to 
inform the 
review analysis? 
7. Were the 
methods used to 
combine the 
findings of the 
relevant studies 
(to reach a 
conclusion) 
reported? 
8. Were findings 
of the relevant 
studies combined 
appropriately 
relative to the 
primary question 
of the overview? 
9. Were the 
conclusions made 
by the author(s) 
supported by the 
data and/or 
analysis reported 
in the overview? 
Sum 
quality 
score 
Ashor et al. 2014 Yes Yes Yes Yes Yes Yes Yes Yes Yes 18/18 
Ashor et al. 2015 Yes Yes Yes Yes Yes Yes Yes Yes Yes 18/18 
Ashor et al. 2014 Yes Yes Yes Yes Yes Yes Yes Yes Yes 18/18 
Ashor et al. 2015 Yes Yes Yes Yes Yes Yes Yes Yes Yes 18/18 
Ashor et al. 2017 Yes Yes Yes Yes Yes Yes Yes Yes Yes 18/18 
Juraschek et al. 2012 Yes Partial Yes Yes Yes Partial Yes Yes Yes 16/18 
Khodaeian et al. 2015 Yes Yes Yes Partial Yes Partial Yes Yes Partial  15/18 
McRae 2008 Yes Yes Yes Partial No No Partial Yes Yes 11/18 
Montero et al. 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes 18/18 
Tabatabaei-Malazy et 
al. 2014 
Yes Partial  Yes Partial  Yes No Yes Yes Yes 14/18 
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3.3.2 Vitamin C and cardiovascular biomarkers  
a. Vitamin C and arterial stiffness: Data synthesis from 10 trials (273 participants aged 
between 22-63.5 years) revealed no significant effects of vitamin C supplementation 
on indices of arterial stiffness (PWV, AIx, compliance coefficient, distensibility 
coefficient or digital volume pulse) (SMD: -0.16; 95% CI: -0.42, 0.11) (Ashor et al., 
2014b). In addition, low heterogeneity between studies was reported (I2 = 29.2%) 
(Table 3.3).   
b. Vitamin C and blood pressure: The single systematic review and meta-analysis (29 
trials, 1407 participants aged between 22-74 years) which investigated effects on BP 
found that vitamin C supplementation  reduced both systolic (WMD: -3.84 mmHg; 
95% CI: -5.29, -2.38) and diastolic BP (WMD: -1.48 mmHg; 95% CI: -2.86, -0.10) 
(Juraschek et al., 2012). However, there was high heterogeneity between studies 
(systolic BP: I2 = 69%; diastolic BP: I2 = 81%). In subgroup analyses, the authors 
reported greater effects in younger people, in studies with larger sample size and in 
studies which reported fewer BP measurements (Table 3.3).  
c. Vitamin C and EF: In their meta-analysis of six trials (number and age of participants 
not reported), Montero et al. (2014) showed no significant effect of vitamin C 
supplementation on indices of EF (FMD, plethysmography, post-reactive 
hyperaemia [PORH], capillaroscopy) (Table 3.3). However, another two meta-
analyses (Ashor et al., 2014a; Ashor et al., 2015b) revealed that vitamin C 
supplementation improved EF significantly.  
The first study (Ashor et al., 2014a), which involved 44 trials (1129 participants aged 
22-68 years), demonstrated modest, but statistically significant, improvement in EF 
with vitamin C supplementation (SMD: 0.50, 95% CI: 0.34, 0.66). Moreover, 
subgroup analyses showed bigger effects in experimentally-induced endothelial 
dysfunction, and in patients with atherosclerosis or diabetes. Meta-regression 
analysis demonstrated significant correlation between vitamin C dose and the 
magnitude of effect on EF (Table 3.3). The second meta-analysis (Ashor et al., 
2015b) excluded studies in which vitamin C was supplemented for less than 2 weeks. 
Data synthesis of 17 trials (478 participants with age range of 23-78 years) showed 
mild improvement in EF after supplementation of vitamin C (SMD: 0.25; 95% CI: 
0.01, 0.48).  In subgroup analyses, bigger effects were observed in older people > 56 
years (Table 3.3). Furthermore, the authors reported significant positive correlation 
between age and the effect of vitamin C supplementation on EF (Beta: 0.023, 95% 
   
 66 
CI: 0.001 to 0.05). However, all the three meta-analyses were associated with high 
levels of heterogeneity between the included studies [Montero et al. (2014): I2 = 47%; 
Ashor et al. (2014a): I2 = 54%; (Ashor et al., 2015b): I2 = 40.5%). Moreover, the 
study by Ashor et al. (2014a) reported evidence for significant publication bias in 
their meta-analysis.  
3.3.3 Vitamin C and cardio-metabolic biomarkers  
a. Vitamin C and glycaemic control: Analysis of data from five clinical trials 
(Tabatabaei-Malazy et al., 2014) involving individuals with type 2 diabetes 
demonstrated significant improvement in fasting blood glucose concentration after 
vitamin C supplementation (SMD: -20.59; 95% CI: -40.77, -0.40). However, in a 
recent meta-analysis of 23 trials (998 participants with and without diabetes) (Ashor 
et al., 2017) showed no significant effects of vitamin C supplementation on glucose 
concentration (WMD: -0.09 mmol/L; 95% CI: -0.34, 0.18). Nevertheless, subgroup 
analyses (Ashor et al., 2017) revealed larger effects in diabetics (WMD: -0.44 
mmol/L; 95% CI: -0.81, -0.07) and in longer duration studies (> 30 days) (WMD: -
0.53 mmol/L; 95CI: -0.97 to -0.10). Moreover, meta-regression analyses showed 
bigger effects in longer duration studies (β: -0.01, 95% CI: -0.018 to -0.001), higher 
BMI (β: -0.05, 95% CI: -0.10, -0.01) and in studies with higher baseline plasma 
concentration of glucose (β: -0.17, 95% CI: -0.29, -0.04). 
Both Tabatabaei-Malazy et al. (2014) and Ashor et al. (2017) showed no significant 
effects of vitamin C supplementation on insulin and HbA1c concentrations (Table 
3.3). However, in a subgroup analysis, (Ashor et al., 2017) revealed significant 
improvement in fasting insulin concentration following vitamin C supplementation 
(WMD: -13.63 pmol/L; 95% CI: -22.73 to -4.54). Moreover, in meta-regression 
analyses, the observed effect size increased with age (β: -0.69, 95% CI: -1.29 to -
0.11), in those with higher BMI (β: -3.31, -6.72 to -0.10) and higher baseline plasma 
glucose concentration (β: -3.65, -7.46 to -0.15).  Using data from 3 studies, one meta-
analysis (Khodaeian et al., 2015) investigated the effect of vitamin C 
supplementation on insulin sensitivity (homoeostasis model assessment) index in 
type 2 diabetes patients and concluded that vitamin C had no effect (SMD: -0.15; 
95% CI: -0.49, 0.19).  
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Table 3.3: Summary of the results of the 10 systematic reviews and meta-analyses of vitamin C and cardiovascular biomarkers included in this 
umbrella review  
Outcome  Study Number of 
trials 
Effect size Heterogeneity Subgroup analysis Meta-regression analysis Publication 
bias 
Arterial stiffness Ashor et al. 2014 10 SMD= -0.16 (-0.42 to 0.11) I² (%)= 29.2 NR NR NR 
Blood pressure Jurascheck et al. 2012 29 Systolic BP (WMD): -3.84 (95% 
CI: -5.29 to -2.38) diastolic BP 
(WMD): -1.48 (95% CI: -2.86 to -
0.10) 
Systolic BP: I² (%) 
= 69       diastolic 
BP: I² (%) = 81 
Higher effect in < 50 years old: 
WMD: -5.07 (95% CI: -7.22 to -
2.92) higher effect in fewer BP 
measurements (1-2): WMD: -4.02 
(95% CI: -5.57 to -2.47)                          
higher effect in larger sample size 
studies: WMD: -2.69 (95% CI: -
4.49 to -0.88) 
NR No 
Endothelial 
function 
Montero et al. 2013 6 SMD= 0.28 (95% CI: -0.19 to 
0.74) 
I² (%)= 47 NR NR No 
 
Ashor et al. 2014 44 SMD= 0.50 (95% CI: 0.34 to 
0.66) 
I² (%)= 54 higher effect in experimentally-
induced endothelial dysfunction: 
SMD: 0.87 (95% CI: 0.62 to 1.13) 
atherosclerotic: SMD: 0.84 (95% 
CI: 0.41 to 1.26) diabetics: SMD: 
0.52 (95% CI: 0.21 to 0.82)  
Significant correlation between 
vitamin C dose and the magnitude of 
effect on EF (β: 0.00011, 95% CI: 
0.00001 to 0.00021) 
Yes 
 
Ashor et al. 2015 17 SMD= 0.25 (95% CI: 0.01 to 
0.48) 
I² (%)= 40.5 higher effect in older age group > 
56 years                                                            
SMD: 0.58 (95% CI: 0.16 to 0.99) 
Significant positive correlation 
between age and the effect of 
vitamin C supplementation on EF 
(β: 0.023, 95% CI: 0.001 to 0.05) 
No 
Glucose 
concentration 
Tabatabaei-Malazy et al. 
2014 
5 SMD= -20.59 (95% CI: -40.77 to -
0.4) 
Cochrane Q test (P 
= 0.69) 
NR NR No 
 
Ashor et al. 2017 23 WMD= -0.09 (mmol/L) (95% CI: 
-0.34 to 0.18) 
I² (%)= 55.6 Higher effect in diabetics: WMD= -
0.44 (mmol/L)( 95% CI: -0.81 to -
0.07) longer duration studies (> 30 
days): WMD= -0.53 (mmol/L) 
(95% CI: -0.97 to -0.10) 
Higher effect in longer duration 
studies (β: -0.01; 95% CI: -0.018 to 
-0.001)  higher BMI (β: -0.05; 95% 
CI:  -0.10 to -0.01) and higher 
baseline plasma concentration of 
glucose (β: -0.17; 95% CI: -0.29 to -
0.04)  
No 
HbA1c Tabatabaei-Malazy et al. 
2014 
5 SMD= -0.46 (95% CI: -1.75 to 
0.84) 
Cochrane Q test (P 
< 0.0001) 
NR NR Yes 
 
Ashor et al. 2017 10 WMD= -0.02 % (95% CI: -0.19 to 
0.15) 
I² (%)= 0 No effect No effect No 
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Insulin 
concentration 
Ashor et al. 2017 9 WMD= -5.92 (pmol/L) (95% CI: -
14.29 to 2.46) 
I² (%)= 27 Higher effect on fasting insulin: 
WMD= -13.63 (pmol/L) (95% CI: -
22.73 to -4.54) 
Higher effect with increased age (β: 
-0.69; 95% CI: -1.29 to -0.11)  
higher BMI (β: -3.31; 95% CI: -6.72 
to -0.10) and higher baseline plasma 
concentration of glucose (β: -3.65; 
95% CI:  -7.46 to -0.15)  
No 
Insulin resistance Khodaeian et al. 2015 3 SMD= -0.15 (95% CI: -0.49 to 
0.19) 
I² (%)= 35.4 NR NR No 
HDL-cholesterol McRae et al. 2008 12 WMD= 1.1 (mg/dL) (-0.2 to 2.3) NR NR NR Yes 
 
Ashor et al. 2016 35 WMD= 0.004 (mmol/L) (95% CI: 
-0.03 to 0.03) 
I² (%)= 45 Higher effect in diabetics: WMD: -
0.06 (95% CI: 0.02 to 0.11) 
Greater effect in those with low 
baseline plasma concentration of 
vitamin C  (β: -0.002; 95% CI: -
0.003 to -0.0001)  
No 
LDL-cholesterol  McRae et al. 2008 11 WMD= -7.9 (mg/dL) (-12.3 to -
3.5) 
NR NR NR No 
 
Ashor et al. 2016 29 WMD= -0.09 (mmol/L) (95% CI: 
-0.28 to 0.11) 
I² (%)= 85 Higher effect in healthy 
participants: WMD: -0.32 (95% CI: 
-0.57 to -0.07) 
A trend towards a larger reduction in 
LDL-C concentration following 
vitamin C supplementation in 
participants with low baseline 
plasma concentration of vitamin C 
(β: 0.01; 95% CI: -0.004 to -0.03)  
No 
Total cholesterol Ashor et al. 2016 37 WMD= -0.10 (mmol/L) (95% CI: 
-0.22 to 0.01) 
I² (%)= 57.2 Higher effect in younger 
participants (≤52 years) : WMD: -
0.26 (95% CI: -0.45 to -0.07) 
Greater effect in those with higher 
baseline plasma cholesterol 
concentration   (β: -0.24; 95% CI: -
0.36 to -0.11)  
No 
Triglycerides McRae et al. 2008 10 WMD= -20.1 (mg/dL) (95% CI: -
33.3 to -6.8) 
NR NR NR No 
 
Ashor et al. 2016 35 WMD= -0.03 (mmol/L) (95% CI: 
-0.13 to 0.08) 
I² (%)= 72.4 Higher effect in diabetics: WMD: -
0.15 (95% CI: -0.30 to -0.002) 
Greater effect in those with higher 
baseline plasma triglyceride 
concentration   (β: -0.17; 95% CI:-
0.30 to -0.05)  
No 
NR: not reported  
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b. Vitamin C and lipid profile: Two meta-analyses (McRae, 2008; Ashor et al., 2016c) 
investigated the effects of vitamin C supplementation on lipid profile (i.e. total-, LDL-, 
HDL-cholesterol and triglyceride (TG) s concentrations). Results from 13 trials (549 
participants) (McRae, 2008) demonstrated a significant reduction in LDL-cholesterol 
(LDL-C) (WMD: -7.9 mg/dL; 95% CI: -12.3, -3.5) and TG (WMD: -20.1 mg/dL; 95% CI: 
-33.3, -6.8) concentrations. The authors reported no significant effects on HDL-C (WMD: 
1.1 mg/dL; 95% CI: -0.2 to 2.3). In contrast, Ashor et al. (2016c) reported no significant 
effects on total cholesterol (WMD: -0.10 mmol/L; 95%CI: -0.22 to 0.01), LDL-C (WMD: 
-0.09 mmol/L; 95%CI: -0.28 to 0.11), HDL-C (WMD: 0.004 mmol/L; 95%CI: -0.03 to 
0.03) and TG (WMD: -0.03 mmol/L; 95%CI: -0.13 to 0.08) concentrations. However, in 
subgroup analyses, the authors revealed a significant improvement of lipid profile in 
diabetics (HDL-C and TG), healthy (LDL-C) and younger (≤ 52 years) participants (total 
cholesterol). Additionally, meta-regression analyses demonstrated significantly greater 
effects of vitamin C supplementation on lipid profile in individuals with lower baseline 
plasma concentration of vitamin C and higher baseline plasma concentrations of 
cholesterol and TG (Table 3.3).        
3.4 Discussion  
3.4.1 Summary of the findings 
Close inspection of the results from the 10 systematic reviews and meta-analyses included in 
this umbrella review revealed a weak evidence of the overall effects of vitamin C 
supplementation on biomarkers of CVD risk. Meta-analyses conducted by different groups 
often reached different conclusions. For example, two meta-analyses reported positive effects 
on EF (Ashor et al., 2014a; Ashor et al., 2015b) whereas no significant effects were found in 
another meta-analysis (Montero et al., 2014). Similar heterogeneous results were observed for 
glycaemic control and lipid profile (Table 3.3). However, subgroup and meta-regression 
analyses indicated significant benefits in participants with advanced age, higher BMI and with 
low vitamin C intakes and higher CVD risk (Table 3.3).  
3.4.2 Mechanism of action of vitamin C 
Vitamin C is an electron donor (reducing agent) whose antioxidant function derives from its 
ability to reduce oxidized species or oxidant radicals (Padayatty and Levine, 2016). However, 
vitamin C can also generate free radicals (i.e. have a pro-oxidant function) by donating electrons 
to metals such as copper or iron (Halliwell, 1996).  
   
 70 
The plasma vitamin C concentration of healthy individuals can vary over a wide range but is 
typically 30-60µM (Korantzopoulos and Galaris, 2003). Some pharmacokinetics studies have 
shown that a dose of 200mg/day is sufficient to raise the plasma level of vitamin C to 100-120 
µM (Levine et al., 1996) . However, this relationship between ingested dose of vitamin C and 
plasma vitamin C concentration is non-linear. Oral doses of vitamin C in excess of 400 mg/day 
do not result in additional increases in plasma vitamin C concentration (Levine et al., 2001). At 
plasma vitamin C concentrations of < 70µM, the kidneys reabsorb all the filtered ascorbic acid 
via SVCT transporters. However, with vitamin C concentrations in excess of 70 µM, ascorbate 
is excreted in urine in progressively greater amounts (Duconge et al., 2008).     
In vitro studies demonstrated that mM concentrations of vitamin C in plasma are required to 
prevent NO from reacting with O2.- (Frei, 1999). The rate constant for the reaction of vitamin C 
with O2.- is 2 × 105 M-1 × s-1, while the rate constant of reaction of O2.- with NO is  1.7 × 1010 
M-1 × s-1 (Jackson et al., 1998). These studies question the antioxidant capacity of the relatively 
small concentrations of vitamin C in plasma under normal physiological conditions 
(Korantzopoulos and Galaris, 2003). The counter-argument is that the relatively high 
intracellular concentrations of vitamin C (1-5 mM in leukocytes, 1-4 mM in platelets) may 
indicate its potential to act as an antioxidant (Michels et al., 2013). Moreover, the pleotropic 
action of vitamin C cannot be reduced to the mere interaction with O2.- (Korantzopoulos and 
Galaris, 2003). Vitamin C, besides being a powerful antioxidant, has a broad spectrum of  
biological functions (Lykkesfeldt et al., 2014). Vitamin C catalyses the hydroxylation of lysine 
and proline residues in procollagen chains which is regarded as the building blocks for the 
mature collagen. Moreover, vitamin C serve as an electron donor for a variety of enzymes 
involved in carnitine and norepinephrine biosynthesis, tyrosine metabolism and peptide 
hormone amidation. Moreover, the hydroxylation of hypoxia inducible factor 1α by vitamin C 
regulates the transcription of several genes involved in homeostasis, angiogenesis and cell 
proliferation (Lykkesfeldt et al., 2014).               
3.4.3 Evidence from epidemiological studies  
Epidemiological studies support the beneficial effects of vitamin C on cardiovascular outcomes 
(Moser and Chun, 2016). In the NHANES I Epidemiological Follow-Up Study cohort (11,348 
American adults aged 25-74), vitamin C intake was found to be inversely related with all 
cardiovascular diseases (males, standardized mortality ratio [SMR]: 0.58, 95% CI: 0.41, 0.78; 
females, SMR: 0.75, 95% CI: 0.55, 0.99) (Enstrom et al., 1992). Another cohort of 85,118 
female nurses followed up for 16 years for the incidence of CHD revealed a significant inverse 
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relationship between total intake of vitamin C and risk of CHD (relative risk [RR]: 0.73, 95% 
CI: 0.57, 0.94) (Osganian et al., 2003). However, a subgroup analysis showed that 
supplementation rather than intake of vitamin C from the diet was strongly associated with the 
reduction in CHD risk (supplemental vitamin C, RR: 0.72; 95% CI 0.61, 0.86; dietary vitamin 
C, RR: 0.86; 95% CI 0.59, 1.26) (Osganian et al., 2003). Further confirmation has come from 
studies measuring plasma ascorbic acid concentration (more accurate estimation of vitamin C 
intake in comparison with questionnaire-based surveys). In NHANES II, serum ascorbic acid 
was measured and participants followed up for 14-16 years (Loria et al., 2000). Men in the 
lowest (< 28.4 µmol/L) compared with the highest (≥ 73.8 µmol/L) serum ascorbate quartile 
had a 57% higher risk of dying from any cause (RR: 1.57; 95% CI: 1.21, 2.03) and a 62% higher 
risk of dying from cancer (RR: 1.62; 95% CI: 1.01, 2.59) (Loria et al., 2000). Vitamin C 
deficiency (plasma ascorbate < 11.4 μmol/l) in a random cohort of 1605 Finnish men aged 42, 
48, 54, or 60 was found to be significantly associated with increased risk of acute myocardial 
infarction (RR: 3.5; 95% CI: 1.8, 6.7) (Nyyssonen et al., 1997). 
Four years follow-up of a British cohort of men and women aged 45 to 79 years revealed an 
inverse association of plasma vitamin C concentration with cardiovascular mortality (Khaw et 
al., 2001). The investigators claimed that 20 µmol/L increases in plasma ascorbic acid were 
associated with about 20% reduction in all-cause mortality (Khaw et al., 2001). Further analyses 
from the above cohort showed a significant inverse correlation of plasma ascorbic acid with 
systolic, diastolic BP (Boekholdt et al., 2006), glucose (Sargeant et al., 2000) and C - reactive 
protein concentrations (Boekholdt et al., 2006) and positive correlation with HDL concentration 
(Boekholdt et al., 2006). Meta-analysis of 15 prospective cohort studies (374,488 participants 
with a median follow-up of approximately 10 years) showed  a significant reduction of CHD 
risk in the highest tertile for vitamin C intake (RR: 0.84; 95% CI, 0.73–0.95) (Ye and Song, 
2008). However, subgroup analyses showed a lack of effect of vitamin C supplementation on 
CHD risk (Ye and Song, 2008).  
3.4.4 Evidence from large RCTs 
RCTs of antioxidant vitamins supplementation have reported contradictory results (Cordero et 
al., 2010). A meta-analysis of 50 RCTs (294,478 participants) showed that supplementation 
with vitamins and antioxidants was not associated with lower risk for major cardiovascular 
events (RR: 1.00, 95%CI: 0.98, 1.02) (Myung et al., 2013). Moreover, subgroup analysis 
including RCTs supplementing vitamin C (7 trials) showed lack of effects on major 
cardiovascular events (RR: 0.99, 95%CI: 0.94, 1.04) (Myung et al., 2013). However, we cannot 
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rule out the effects of vitamin C supplementation, due to the fact that all of the seven trials 
included in that subgroup analysis used a combination of vitamin C and other antioxidants 
supplementation (Mark et al., 1996; Brown et al., 2001; You et al., 2001; 2002; Waters et al., 
2002; Hercberg et al., 2004; Sesso et al., 2008).  
In vitro studies have demonstrated that vitamin C can regenerate oxidized vitamin E leading to 
the restoration of its antioxidant capacity (Traber and Stevens, 2011). This potentially beneficial 
interaction between the two vitamins provides an underpinning mechanism in support of the 
design and conduct of RCTs testing the efficacy of combined vitamins C and E supplementation 
on cardiovascular and metabolic outcomes (Cook et al., 2007; Sesso et al., 2008). However, 
these studies failed to show beneficial effects of the combined supplements on the investigated 
outcomes. Recently conducted meta-analysis has showed that, in contrast with single 
supplementation, the co-administration of vitamin C and E did not improve EF (vitamin C: 
SMD: 0·25, 95% CI 0·02, 0·49; vitamin E: SMD: 0·48, 95% CI 0·23, 0·72; combined: SMD: 
0·12, 95% CI 20·18, 0·42) (Ashor et al., 2015b). Moreover, post hoc analysis of the WAVE 
study showed that combined vitamin C and E supplementation exacerbated significantly 
cardiovascular outcomes in a subpopulation with the haptoglobin 2-2 genotype.  
In transgenic animals with the haptoglobin 2-2 genotype, Asleh and Levy reported that the co-
administration of vitamin C mitigated the protective effect of vitamin E on high density 
lipoprotein (HDL) (Asleh and Levy, 2010). Human mechanistic studies have found that adding 
vitamin C to vitamin E may not cause any further reduction in oxidative stress biomarkers 
(Dietrich et al., 2002). Similarly, in vitro experimental studies demonstrated that the synergistic 
action of vitamin C and E disappeared under anaerobic conditions and may be converted to a 
pro-oxidant effect (Kadoma et al., 2006a). In these studies, monitoring the rate of alpha-
tocopheroxyl radical formation in the presence of co-antioxidants such as ascorbate revealed 
that the rate of alpha-tocopheroxyl radical formation was enhanced with higher concentrations 
of vitamin E or under anaerobic conditions (Fujisawa et al., 2006; Kadoma et al., 2006b).      
3.4.5 Beneficial effects of vitamin C in certain populations  
Subgroup and meta-regression analyses revealed beneficial effects in subpopulations with 
certain phenotypic characteristics such as younger (Juraschek et al., 2012; Ashor et al., 2016c), 
older age (Ashor et al., 2015b; Ashor et al., 2017), obese (Ashor et al., 2017), having lower 
vitamin C concentrations (Ashor et al., 2016c) or having higher risk of CVD (Ashor et al., 
2014a; Ashor et al., 2016c; Ashor et al., 2017).    
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Older people are more likely to have inadequate micronutrient intake and so may receive greater 
benefit from vitamin C supplementation (Brubacher et al., 2000). Inadequate intake may be 
exacerbated by a reduced capacity for vitamin C absorption with age (Brubacher et al., 2000; 
Visioli and Hagen, 2007). Furthermore, older people may require more vitamin C than do 
younger adults to reduce the greater oxidative stress due to age-related mitochondrial 
dysfunction (Puca et al., 2013); however, the quantitative needs for vitamin C, and for other 
micronutrients, in older populations are poorly understood. In the SU.VI.MAX Study, Hercberg 
et al. (2004) found that those with lower baseline concentrations of vitamin C and beta-carotene 
benefitted more from supplementation with antioxidant vitamins and minerals. Furthermore, 
supplementation with multivitamins for 6 years in a population with high prevalence of 
micronutrient deficiency improved cerebrovascular disease mortality significantly (Mark et al., 
1996). These studies support the concept that individual vitamin status may determine the 
magnitude of the effect of antioxidant vitamin supplementation on EF and, therefore, explain 
some of the inter-individual variation in response to such supplementation. 
Some investigators question the validity of the conclusions derived from the big RCTs 
regarding the lack of any beneficial effects of vitamin C supplementation (Lykkesfeldt and 
Poulsen, 2010; Michels and Frei, 2013). Participants involved in diet-related RCTs are usually 
healthy-motivated individuals who eat balanced diets and maintain optimal body weight. 
Therefore, these individuals have overall a lower disease risk and better nutritional status 
(Michels and Frei, 2013). Moreover, in diet-related studies of vitamin C, there no true placebo 
group. The control group (non-supplemented group) continues  to obtain vitamin C from their 
diet over the study period (Michels and Frei, 2013). Additionally, failure to measure vitamin C 
status at baseline and over the study duration may question the effectiveness of the supplements 
in these studies (Lykkesfeldt and Poulsen, 2010). In addition, there is wide inter-individual 
variation in vitamin C levels (e.g. age, smoking status, BMI, socioeconomic status and genetic 
polymorphisms), which may considerably affect plasma concentrations and, consequently, the 
physiological response to supplemental vitamin C (Frei et al., 2012; Michels and Frei, 2013; 
Michels et al., 2013). 
3.4.6 Limitations  
The main limitations of this umbrella review are related to the characteristics of the trials 
included in each meta-analysis such as small sample size, intervention of short duration, 
different recruitment strategies and measurement protocols. This large heterogeneity 
represented a serious limitation which impeded the conduction of an umbrella meta-analysis.  
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3.4.7 Conclusions 
Vitamin C seems to significantly improve cardiovascular biomarkers in selected populations 
(advanced age, obesity, vitamin C deficiency or presence of higher CVD risk). However, these 
results are still preliminary due to important limitations of the currently available evidence from 
RCTs. Future trials should take into account these limitations to achieve greater efficacy and 
sustainability of the physiological effects derived from vitamin C supplementation.  
  
   
 75 
Chapter 4. Impact of inorganic 𝑵𝑶𝟑
− on adverse cardiometabolic effects 
induced by acute hyperglycaemia in younger and older obese 
participants  
4.1 Introduction  
Post-prandial hyperglycaemia (PPH) is a major predictor of CV mortality (Mah and Bruno, 
2012). In a Japanese cohort followed up for 7 years, the presence of impaired glucose tolerance 
(IGT) was associated with a higher risk of death from CVDs (Tominaga et al., 1999). Similarly, 
in a 10-year cohort of 2620 middle-aged participants, participants with IGT had a significantly 
higher risk for CHD (hazard ratio [HR]: 1.49, 95% CI: 0.95, 2.34), CVD mortality (HR: 2.34; 
95%CI: 1.42, 3.85) and all-cause mortality (HR: 1.65; 95%CI: 1.13, 2.40) (Qiao et al., 2003). 
Heightened intracellular glucose concentration increases free radical production secondary to 
uncoupling of mitochondrial oxidative respiration (Siervo et al., 2011a). It has been postulated 
that the free radicals associated with PPH cause endothelial dysfunction by decreasing NO 
availability. These reactive oxygen species deplete arginine, oxidise BH4 and enhance ADMA, 
consequently causing eNOS uncoupling which increases free radicals and reduces NO 
availability (Mah and Bruno, 2012).  
Ageing is associated with key morphological and functional changes including increased risk 
of central obesity, insulin resistance and endothelial dysfunction (Figure 4.1) (Ahima, 2009). 
The global prevalence of obesity is rising and the consequential burden on public health may 
become unsustainable if effective lifestyle and nutritional prevention strategies are not 
developed and implemented (Nguyen and Lau, 2012; Ng et al., 2014). Obesity is a major 
determinant of numerous life-threatening co-morbidities, most notably type 2 diabetes, 
coronary heart disease and cancer (Haslam and James, 2005). In particular, excess adiposity is 
associated with increased release of inflammatory cytokines which impairs insulin signalling 
and glucose disposal as well as predisposing to vascular damage as a result of reduced anti-
oxidant capacity and NO availability (Martyn et al., 2008; Bakker et al., 2009).  
NO is a gaseous signalling molecule that plays an essential role in regulating systemic 
physiological functions (e.g. vascular tone, muscular performance, immune function, and 
neurotransmission) and NO deficiency has been associated with multiple pathological 
processes including atherosclerosis, insulin resistance and mitochondrial dysfunction (Yetik-
Anacak and Catravas, 2006). Two major pathways contribute to systemic NO formation 
(Sindler et al., 2014). The endogenous pathway produces NO from L-arginine in the presence 
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of oxygen and is catalysed by NO synthase (Sindler et al., 2014). The exogenous  𝑁𝑂3
−- 𝑁𝑂2
−-
NO pathway makes a quantitatively smaller contribution to NO formation (Lidder and Webb, 
2013). Ingested  𝑁𝑂3
− is reduced to  𝑁𝑂2
− by the commensal bacteria in the oral cavity (Govoni 
et al., 2008). Upon swallowing,  𝑁𝑂2
− is further reduced in the gastric acidic environment to 
nitrous acid, which spontaneously decomposes to NO and other bioactive nitrogen oxides 
(Lidder and Webb, 2013). Additionally, circulating 𝑁𝑂2
− may be converted to NO via numerous 
 𝑁𝑂2
− reductases such as deoxyhaemoglobin and xanthine oxidoreductase (Sibmooh et al., 
2008).  
 
Figure 4.1: The relationship of ageing, obesity and hyperglycaemia with endothelial 
dysfunction  
Recent meta-analyses have showed that supplementation with  𝑁𝑂3
−-rich beetroot juice or 
inorganic  𝑁𝑂3
− improves systolic blood pressure (BP) and endothelial function (Siervo et al., 
2013; Lara et al., 2015). Moreover, high consumption of 𝑁𝑂3
−-rich green leafy vegetables (e.g. 
rocket, broccoli, cabbage, lettuce and spinach) reduces the risk of developing type 2 diabetes 
(Carter et al., 2010). The positive effects of inorganic  𝑁𝑂3
− on metabolic functions have been 
corroborated in animal models of metabolic syndrome and type 2 diabetes and these benefits 
were linked to reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity 
   
 77 
and 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, improved 
pancreatic β-cell secretion and glucose transporter 4 (GLUT-4) translocation (Carlstrom et al., 
2010; Jiang et al., 2014; Khalifi et al., 2015; Peleli et al., 2015).  
The current study aimed to test the hypothesis that the administration of inorganic  𝑁𝑂3
− could 
ameliorate the acute adverse effects of postprandial hyperglycaemia on vascular function in 
obese participants. We also tested the hypothesis that the response to the  𝑁𝑂3
− administration 
is age-dependent with potentially greater benefits in older aged than in younger participants. 
4.2 Methods  
4.2.1 Participants  
The study group comprised 20 volunteers (13 males, 7 females) with an age range of 18-70 
years and a BMI range of 30-40 kg/m2 who were recruited in the Clinical Ageing Research Unit 
(CARU), Newcastle University from September 2013 until November 2014. The study was 
approved by the regional ethics committee of Yorkshire & the Humber - Humber Bridge (REC 
reference:  13/YH/0253, Appendix A) and was registered with Current Controlled Trials 
(ISRCTN42776917). All participants were fully informed of the nature and purpose of the study 
and provided written consent to participate.  
4.2.2 Exclusion criteria 
Participants were excluded if they had medical conditions (i.e. diabetes, cancer or systemic 
inflammatory disorders) or were taking medications (i.e. organic nitrates, corticosteroids, 
diuretics, hormonal therapies and weight loss medications) that could interfere with the 
nutritional intervention and study outcomes. In addition, individuals were excluded if they were 
smokers, vegetarian, reported alcohol intake greater than 21 U/week for men and 14 U/week 
for women, or their body weight had changed more than 3 kg within the last month. 
4.2.3 Study design and randomisation  
This was a randomised, cross-over, double-blind, placebo controlled clinical trial. The 
randomisation was conducted by an independent investigator outside the research team. The 
preparation and labelling of the two solutions (inorganic  𝑁𝑂3
− and placebo) were performed by 
the Pharmacy Department of the Newcastle upon Tyne Hospitals (Royal Victoria Infirmary). A 
member of the CARU Research Facility outside the research team was the guarantor of the 
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safety and accessibility of the randomisation codes. Inorganic  𝑁𝑂3
− and placebo solutions had 
the same organoleptic characteristics and had identical volume, colour and presentation.  
4.2.4 Study protocol  
The study was divided into three phases: screening, intervention and wash-out periods. An 
initial telephone screening interview was conducted to evaluate eligibility for the study. Eligible 
participants were invited for their first visit at the research facility early in the morning (~8.30 
am) in fasting condition (~12 h after last eating). Participants were asked to follow a 24-h run 
in period to standardise 𝑁𝑂3
− intake and to refrain from strenuous exercise, limit alcohol and 
caffeine consumption and not use mouthwash prior to each testing visit.  Body weight, height 
and waist circumference were measured according to standardised protocols. Body fat was 
assessed by bioelectrical impedance analysis (Tanita BC420 MA, Tanita Corporation, Tokyo, 
Japan). A cannula was then fitted in an ante-cubital vein while participants were supine.  
Baseline measurements were performed. Immediately following collection of the baseline 
blood sample, participants were given an oral dose of glucose (75g) and they were randomised 
to receive a weight-adjusted dose of either inorganic  𝑁𝑂3
− or placebo in a cross-over order. 
Participants were then asked to rest for the next three hours and BP was measured and blood 
samples were collected at 15, 30, 60, 90, 120, 180 minutes post-intervention. Microvascular 
function was measured at baseline and 3-hours post-intervention. A wash-out period of seven 
days was allowed before the second intervention. During the wash-out period, participants were 
asked to resume their habitual lifestyle and diet (including caffeine and alcohol consumption, 
if relevant). After the 7-day wash-out period, participants returned for the second visit having 
been asked to follow a similar 24-h run in period prior to the start of the second assessment 
visit.  Measurements were repeated in the same order and participants received the cross-over 
intervention. Each participant was asked to complete a food frequency questionnaire [FFQ] to 
assess food intake over the last month. Physical activity and  𝑁𝑂3
− intake (Appendix B) over 
the week prior to each visit were documented through additional questionnaires. A summary of 
the study protocol is provided in Figure 4.2. 
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Figure 4.2: Study protocol conducted at each study visit 
4.2.5 Nutritional supplements  
Participants were randomised to receive either 1)  𝑁𝑂3
− supplementation (oral dose of 7.0 mg 
[0.1 mmol/kg] of potassium 𝑁𝑂3
− per kilogram of body weight in sterile water) or 2) placebo 
(7.0 mg of potassium chloride per kilogram of body weight in sterile water). Participants first 
drank the glucose solution (75g anhydrous glucose dissolved in 250 ml of  𝑁𝑂3
−-free water) 
which was followed immediately by the oral administration of a solution of either inorganic 
 𝑁𝑂3
− or placebo. The  𝑁𝑂3
− dose corresponded to the amount normally found in 150–250 g of 
a  𝑁𝑂3
−-rich vegetable such as spinach, lettuce or beetroot (Larsen et al., 2007). In our trial we 
used potassium rather than sodium in the placebo and the intervention groups to avoid the 
cardiovascular adverse effects associated with increased sodium intake (Geleijnse et al., 2003).   
4.2.6 Skin microvascular blood flow  
Laser Doppler Iontophoresis (LDI, Moor Instruments, Axminster, UK) is a non-invasive 
technique used for the transdermal delivery of charged substances. We used 1% acetylcholine 
(Ach) to quantify changes in endothelial-dependent microvascular blood flow by measuring 
non-invasively the increase in erythrocyte flux after Ach application. Forearm skin erythrocyte 
flux was measured for 5 minutes prior to iontophoresis (baseline), for 5 minutes during Ach 
delivery by iontophoresis (stimulation) and for 5 minutes after the Ach delivery (recovery). All 
assessments were performed with the participant supine in a temperature-controlled room (22-
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24 °C) following an acclimatisation period of 10 minutes. LDI measurements were stored 
directly onto a PC and later analysed using MoorVMS V3.1 software. Quantification of blood 
flow was expressed in perfusion units (PU) in relation to an internal standard calibration of the 
device. The perfusion index was calculated as the ratio of the area under the curve (AUC) for 
the stimulation period relative to the AUC of the baseline period. Figure 4.3 below showed an 
example of blood flow recording from study participant.  
 
Figure 4.3: Laser Doppler Iontophoresis (LDI) recording from a participant during 
one of the study visits.     
4.2.7 Blood sample processing and biochemical assays  
Blood samples were stored on ice and processed within 30 minutes of collection. Samples were 
spun at 4000 x g for 10 minutes at 4C and serum and plasma aliquots were stored immediately 
at -80C until further analyses. These samples were used to measure glucose and insulin 
concentrations,  𝑁𝑂3
− plus  𝑁𝑂2
− concentrations (NOx) and interleukin 6 (IL-6). Plasma glucose 
was measured (in the Royal Victoria Infirmary) by standard automated enzymatic methods 
using an Olympus AU 640 analyser (Olympus, Watford, UK) and fasting insulin (in the Royal 
Victoria Infirmary) by immunoassay (ELISA; Dako UK Ltd, Ely, UK). NOx were analysed in 
the School of Agriculture, Food & Rural Development at Newcastle University using gas 
chromatography mass spectrometry (GC-MS) (Qadir et al., 2013). IL-6 was measured in 
University of Cambridge Laboratories using high-sensitivity, quantitative ELISA kits (R&D 
systems, Minneapolis, MN, USA).  
   
 81 
The following biomarkers were measured in our laboratory in the Human Nutrition Research 
Centre, Newcastle University: cGMP, 3 nitrotyrosine (3-NT) and human vascular injury 
multiplex (P- selectin, E- selectin, ICAM-3 and thrombomodulin).    
4.2.8 cGMP  
cGMP is formed by the action of the enzyme guanylate cyclase on guanosine triphosphate 
(GTP) (Murad, 1986). It acts as a second messenger for many hormones and molecules in the 
blood such as insulin, oxytocin, acetylcholine, serotonin and NO (Murad, 1986). I used cGMP 
Complete ELISA kit (ENZO Life Sciences Inc) for analysing cGMP in plasma samples. This 
is a competitive immunoassay for the quantitative determination of cGMP. The standards and 
samples were added to wells coated with goat anti-rabbit (GxR) IgG antibodies. Then we added 
a blue solution of cGMP conjugated to alkaline phosphatase. This is followed by adding a 
yellow solution of rabbit polyclonal antibodies to cGMP. During the incubation period, the 
antibodies will competitively bind to cGMP in the samples or conjugates. When the plate 
washed, only the bound cGMP remained in the wells. In the next step, we added p-nitrophenyl 
phosphate (pNpp) substrate solution. This substrate generates a yellow colour when catalysed 
by the alkaline phosphatase on the cGMP conjugate. The last step, we added the stop solution 
and read absorbance at 405nm. The amount of signal is indirectly proportional to concentration 
of cGMP in the sample. Detailed steps followed in conducting the assay are summarised in 
(Appendix C).     
4.2.9 3 nitrotyrosine  
3 nitrotyrosine considered as an index of oxidative stress (Ischiropoulos, 2009). It is formed by 
the interaction of reactive nitrogen species (peroxynitrite anion, nitrogen dioxide) with the 
tyrosine residues of proteins (Radi, 2004). This reaction is considered as a post-translational 
modification of these proteins with consequent changes in its function (Ischiropoulos, 2009). 
Moreover, 3 nitrotyrosine concentrations strongly correlated with CVD (Shishehbor et al., 
2003). Significantly higher levels of nitrotyrosine were found among patients with CAD 
(Shishehbor et al., 2003). I used ELISA kits (ab113848, Abcam, Cambridge, USA) to analyse 
3 nitrotyrosine in serum samples. This ELISA kits utilizes nitrotyrosine-coated plates and 
horseradish peroxidase (HRP)-conjugated antibodies to detect 3 nitrotyrosine in the samples. 
The detailed steps that followed in conducting the assay are summarised in (Appendix C). 
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4.2.10 Human vascular injury multiplex (P- selectin, E- selectin, intercellular adhesion 
molecule 3 [ICAM 3] and thrombomodulin) 
P-, E- selectins, ICAM-3 and thrombomodulin are adhesion molecules secreted mainly from 
the endothelium during inflammation and vascular damage (Blankenberg et al., 2003).  P-, E- 
selectins and ICAM-3 facilitate the rolling and adhesion of leukocytes to endothelial cells 
(Dong et al., 1998; Blankenberg et al., 2003). Thrombomodulin secreted from damaged 
endothelium and it facilitated thrombolysis in the vessel wall (Takano et al., 1990). All these 
molecules were found to be increased in patients with CVDs (Lind, 2003). The human vascular 
injury I kit (Meso Scale Discovery [MSD], Gaithersburg, MD, USA) biomarker assay provide 
a rapid and convenient method for measuring the levels of these biomarkers within a single, 
small volume sample. These assays are sandwich immunoassays. The plates are pre-coated with 
capture antibodies on independent and well-defined spots. Multiplex kits are provided on 4-
spot plate. Detailed steps followed in conducting the assay are summarised in (Appendix C).    
4.2.11 Statistical analysis  
All statistical analyses were completed using SPSS for Windows (version 22.0; SPSS inc, 
Chicago, IL, USA). Summary data are presented as means ± SEM. Changes were analysed 
using paired Student’s t tests or repeated-measure analysis of variance (ANOVA) with time and 
intervention as within-subject factors and age as between-subject factor. Models were checked 
for sphericity assumptions and multivariate models were applied if these assumptions were 
violated. If the model was significant, post hoc tests with Bonferroni correction to control for 
multiple comparisons were conducted. P values < 0.05 were considered to indicate statistical 
significance. 
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4.3 Results  
4.3.1 Recruitment and baseline characteristics of the participants  
A total of 20 participants were randomised to the interventions, ten younger (31.4±1.8 years) 
and ten older (64±1.3 years) participants (Figure 4.4). Laser Doppler Iontophoresis data were 
complete for all twenty volunteers but biochemical analyses data were obtained from only 
nineteen participants as we were unable to collect blood samples from one participant in the 
older group. The interventions were well-tolerated and no adverse effects were reported. 
Baseline characteristics of the participants (Table 4.1) shows that the younger and older 
participants were well-matched for anthropometric variables, dietary energy intake and physical 
activity but systolic BP was significantly higher in older participants (P = 0.01).  
 
 
Figure 4.4: Flowchart of recruitment phases 
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Table 4.1: Baseline characteristics of younger and older participants 
 
Data shown as mean±SEM. 1BP= blood pressure. 2MET= Metabolic Equivalent of Task 
4.3.2  𝑵𝑶𝟑
−/ 𝑵𝑶𝟐
− (NOx) and cGMP concentrations  
Baseline plasma concentrations of NOx were significantly higher in the younger (246±24 
µmol/l) compared with older (168±26 µmol/l) participants (P = 0.04). Plasma NOx did not 
change between baseline and 3h post-intervention when the placebo was administered (P = 
0.91) (Figure 4.5). Following the ingestion of inorganic 𝑁𝑂3
−, plasma NOx reached peak 
concentration around 2 h post-intervention (young: 798±32 µmol/l; old: 430±48 µmol/l) and 
there was a significant difference between age groups for plasma NOx concentrations with 
higher concentrations (~42%, P = 0.01) observed in the younger group. Pairwise comparison 
demonstrated that, at all times post-inorganic 𝑁𝑂3
− administration, NOx concentration was 
significantly higher in younger than in older participants.  Inorganic  𝑁𝑂3
− did not modify the 
concentration of cGMP (Figure 4.6) but it was significantly higher in younger compared with 
older participants (P < 0.01). 
4.3.3 Glucose and insulin concentrations 
At baseline, plasma glucose (Figure 4.7) and insulin (Figure 4.8) concentrations did not differ 
between placebo and inorganic  𝑁𝑂3
− treatments (P = 0.36). Peak plasma concentrations of 
 All Younger Older P value 
Number  20 10 10  
Gender, male/female 13/7 8/2 5/5  
Age, years 47.8±3.9 31.4±1.8 64±1.3 <0.01 
Height, cm 169.8±2.1 168.5±2.1 171±3.7 0.56 
Body weight, kg 98.7±3.3 95.9±3.9 101.5±5.4 0.41 
Body mass index, kg/m2 34.2±0.8 33.7±0.9 34.7±1.4 0.58 
Waist circumference cm 109.9±2.5 106.5±3.8 113.2±3 0.18 
Fat mass, kg 36.5±2.1 33±3 40.4±2.5 0.07 
Fat mass, % 37.3±1.8 34.2±2.3 40.7±2.5 0.07 
Total body water, L 45.3±1.9 46.2±2.2 44.2±3.6 0.63 
Heart rate, bpm 60.7±2.6 62.6±2.2 58.8±4.8 0.47 
Systolic BP1, mmHg 125.5±4.1 114.5±2.8 136.4±6.1 0.01 
Diastolic BP, mmHg 71.9±2.1 68.8±3.3 75.1±2.4 0.13 
Energy intake, kJ/day 11247±1303 11106±2313 11375±1473 0.92 
Physical activity, METs/wk2 2442±486 2257±440 2627±897 0.72 
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glucose and insulin were reached 60 minutes post-administration of the glucose load (P < 
0.001). 
4.3.4 Skin microvascular function (Laser Doppler iontophoresis) 
Inorganic  𝑁𝑂3
−  supplementation did not affect cutaneous microvascular blood flow in younger 
or older participants (Table 4.7). 
4.3.5 Biomarkers of endothelial function  
Inorganic  𝑁𝑂3
− supplementation reduced E- and P-selectin concentrations (P = 0.04) with 
greater decline being observed for P-selectin in the younger group (P = 0.04) (Figure 4.9, Figure 
4.10). Inorganic  𝑁𝑂3
− did not modify the concentrations of thrombomodulin, ICAM-3 (Figure 
4.11, Figure 4.12) but thrombomodulin was consistently higher in younger and ICAM-3 was 
significantly higher in older participants (P < 0.01). 
4.3.6 Biomarkers of inflammation and oxidative stress 
Acute induction of hyperglycaemia tended to increase IL-6 concentrations in older compared 
with the younger participants and this increase tended to be attenuated by inorganic  𝑁𝑂3
− (P = 
0.06; Figure 4.13). Hyperglycaemia influenced 3-NT concentrations only in older participants 
whereas concentrations were unaffected in younger participants (P = 0.08). In older participants 
inorganic  𝑁𝑂3
− significantly reduced 3-NT in comparison with placebo (P = 0.04) and a 
significant difference was reached at 180 minutes (P = 0.01) (Figure 4.14). 
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Figure 4.5: Plasma NOx in younger and older participants given a placebo or a single 
dose of inorganic  𝑵𝑶𝟑
−   (7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 
10 (young). Data were analysed with a 3-factor repeated-measures (age x time x 
treatment) ANOVA. *Different from placebo intervention within age group. *: P < 
0.05; **: P < 0.01; ***: P < 0.001. 
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Figure 4.6: Plasma cGMP in younger and older participants given a placebo or a single 
dose of inorganic  𝑵𝑶𝟑
−  (7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 
(young). Data were analysed with a 3-factor repeated-measures (age x time x 
treatment) ANOVA.  
   
 88 
 
 
  
 
Figure 4.7: Plasma glucose concentrations after a 75 g oral glucose challenge in 
younger and older participants given a placebo or a single dose of inorganic  𝑵𝑶𝟑
−   
(7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 (young). Data were 
analysed with a 3-factor repeated-measures (age x time x treatment) ANOVA. 
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Figure 4.8: Plasma insulin concentrations after a 75 g oral glucose challenge in 
younger and older participants given a placebo or a single dose of inorganic  𝑵𝑶𝟑
−   
(7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 (young). Data were 
analysed with a 3-factor repeated-measures (age x time x treatment) ANOVA.  
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Table 4.2: The effects of inorganic  𝑵𝑶𝟑− supplementation on skin microvascular blood flow in younger and older participants 
 
Values represent mean±SEM, P values represents 3-factor repeated-measures (age x time x treatment) ANOVA 
 
 
 
 All (n=20) Older (n=10) Younger (n=10)  
 Dietary  𝑁𝑂3
− Placebo Dietary  𝑁𝑂3
− Placebo Dietary  𝑁𝑂3
− Placebo  
 Before After Before After Before After Before After Before After Before After P value 
Skin microvascular blood flow  
  Baseline flow  9.4±0.9 11.1±1.3 9.8±0.8 12.7±1.6 9.8±1.5 12.1±2.4 10.8±1.2 10.1±1.9 9.1±0.8 10.1±0.9 8.7±0.9 15.2±2.4 0.47 
  Peak iontophoresis flow  71.4±6.7 56.2±5.3 61.1±7.6 73.8±18.9 82.8±8.8 61.6±9.1 65.9±8.9 49.6±7.9 59.9±9 50.8±5.4 56.2±12.5 98±36.4 0.16 
  Post-iontophoresis flow  98.9±9.6 86.6±8.6 85.6±11 94.6±21 114±12 104±14 97.1±14 73.7±12 84.3±14 69.4±7.9 74.1±16 116±41 0.12 
  Perfusion index  8.6±0.9 6±0.7 6.2±0.7 6±1 9.9±1.4 6.5±1.1 5.9±0.6 5.4±0.8 7.3±1.2 5.5±0.8 6.4±1.2 6.7±2 0.90 
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Figure 4.9: Plasma E-selectin concentration after a 75 g oral glucose challenge in 
younger and older participants given a placebo or a single dose of inorganic  𝑵𝑶𝟑
−   
(7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 (young). Data were 
analysed with a 3-factor repeated-measures (age x time x treatment) ANOVA. 
Asterisks (*) indicate significant difference from placebo intervention within age 
group. *: P < 0.05 
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Figure 4.10: Plasma P-selectin concentration after a 75 g oral glucose challenge in 
younger and older participants given a placebo or a single dose of inorganic  𝑵𝑶𝟑
−   
(7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 (young). Data were 
analysed with a 3-factor repeated-measures (age x time x treatment) ANOVA. 
Asterisks (*) indicate significant difference from placebo intervention within age 
group. **: P < 0.01. 
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Figure 4.11: Plasma thrombomodulin concentration after a 75 g oral glucose 
challenge in younger and older participants given a placebo or a single dose of 
inorganic  𝑵𝑶𝟑
−   (7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 
(young). Data were analysed with a 3-factor repeated-measures (age x time x 
treatment) ANOVA.  
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Figure 4.12: Plasma intercellular adhesion molecule-3 (ICAM-3) concentration after 
a 75 g oral glucose challenge in younger and older participants given a placebo or a 
single dose of inorganic  𝑵𝑶𝟑
−   (7 mg/kg weight). Values are means ± SEMs, n= 9 
(old) or 10 (young). Data were analysed with a 3-factor repeated-measures (age x 
time x treatment) ANOVA.  
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Figure 4.13: Plasma interleukin 6 (IL-6) concentration after a 75 g oral glucose 
challenge in younger and older participants given a placebo or a single dose of 
inorganic  𝑵𝑶𝟑
−   (7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 
(young). Data were analysed with a 3-factor repeated-measures (age x time x 
treatment) ANOVA.  
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Figure 4.14: Plasma 3-nitrotyrosine concentration after a 75 g oral glucose challenge 
in younger and older participants given a placebo or a single dose of inorganic  𝑵𝑶𝟑
− 
  (7 mg/kg weight). Values are means ± SEMs, n= 9 (old) or 10 (young). Data were 
analysed with a 3-factor repeated-measures (age x time x treatment) ANOVA. 
Asterisks (*) indicate significant difference from placebo intervention within age 
group. **: P < 0.01. 
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4.4 Discussion  
4.4.1 Summary of the findings  
This study tested the hypothesis that inorganic  𝑁𝑂3
−  would attenuate the vascular stress 
associated with acute hyperglycaemia in younger and older obese adults. Additionally, we 
hypothesized that the response to the  𝑁𝑂3
− administration is potentially of greater benefits in 
older aged than in younger participants. Inorganic 𝑁𝑂3
− supplementation significantly 
improved ED and oxidative stress associated with hyperglycaemia. Plasma NOx, cGMP, 
ICAM-3 and thrombomodulin concentrations were significantly different between age groups. 
Supplementation with inorganic  𝑁𝑂3
− produced greater improvements in biomarkers of 
inflammation (IL-6) and oxidative stress (3-NT) in older compared with young participants. 
Conversely, greater improvement in biomarkers of endothelial function (P- and E-selectin) was 
observed in younger rather than older participants. However, these changes were not mirrored 
by improvements in cutaneous microvascular blood flow in either age group.  
4.4.2 Impact of age and obesity on NO metabolites  
Ageing is associated with multiple structural and functional changes of organs and tissues 
(Mangoni and Jackson, 2004). In the current study, the lower concentration of NOx in older 
individuals may be related to the lower gastric acidity, reduced intestinal motility and changes 
in oral and intestinal microflora associated with the ageing process (Schultz et al., 1985; 
Brownie, 2006; Claesson et al., 2012; Miller et al., 2012). However, in a recently conducted 
study there were no significant differences in the concentrations of  𝑁𝑂2
− between younger and 
older non-obese healthy after consumption of 500 ml of beetroot juice which provided 
9.4 mmol of  𝑁𝑂3
− (Hughes et al., 2016). Moreover, in our study (Chapter five) we also did not 
observe a significant difference of  𝑁𝑂3
−/ 𝑁𝑂2
− between younger and older non-obese 
individuals. Therefore, we may speculate that obesity and hyperglycaemia may have significant 
impact on the concentrations of NO metabolites. However, a recent study reported non-
significant correlation between  𝑁𝑂3
−/ 𝑁𝑂2
− concentrations and BMI in men ( 𝑁𝑂3
−: r = -0.13; 
P = 0.59 and 𝑁𝑂2
−: r = -0.30; P = 0.20) and women ( 𝑁𝑂3
−:  r = -0.211; P = 0.37 and 𝑁𝑂2
− : r = 
0.34; P = 0.14) (Baiao Ddos et al., 2016). Nevertheless, the authors of that study did not report 
the BMI range of the included participants. Therefore, it might be underpowered to detect a 
statistically significant difference between obese and non-obese individuals.  
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4.4.3 Hyperglycaemia and EF 
Previous studies showed that PPH significantly deteriorates EF (Sena et al., 2013). For 
example, Mah et al. (2011) observed 40% reduction in FMD in healthy young adults subjected 
to acute hyperglycaemia. Oxidative stress secondary to mitochondrial dysfunction is the major 
culprit of hyperglycaemia-induced endothelial dysfunction (Bakker et al., 2009).  
Hyperglycaemia may exacerbate superoxide radical production in the mitochondria to levels 
that exceed the endogenous antioxidant capacity (Mah and Bruno, 2012). In addition, oxidative 
stress deteriorates EF by enhancing eNOS uncoupling through several mechanisms such as 
oxidation of BH4, arginase-mediated reduction in arginine bioavailability and increased 
concentration of ADMA (Bakker et al., 2009). eNOS uncoupling may further increase the 
generation of free radicals and contribute to the damaging effects of a hyperglycaemic state 
(Carlstrom et al., 2010; Omar et al., 2015).      
In addition to oxidative stress, hyperglycaemia is strongly associated with increased 
inflammation in the vascular wall (Mah and Bruno, 2012). Exposure of human umbilical vein 
endothelial cell (HUVEC) to 30mM glucose significantly enhanced the expression of ICAM, 
VCAM, E-selectin, and IL-6 (Piconi et al., 2004). The mechanism of hyperglycaemia-induced 
inflammation might be related to an increase in the expression of NF-κB in hyperglycaemic 
conditions (Ho et al., 2006). Furthermore, in human setting, oral glucose challenge of healthy 
and patients with diabetes revealed significant rise in inflammatory markers such as CRP, E- 
selectin, ICAM and VCAM (Festa et al., 2002; Ceriello et al., 2004; Konukoglu et al., 2008).  
4.4.4 Anti-inflammatory and antioxidant effects of inorganic 𝑵𝑶𝟑
− 
I hypothesised that supplementation with inorganic  𝑁𝑂3
−  would ameliorate some of the 
adverse effects of acute hyperglycaemia through its anti-inflammatory and antioxidant effects. 
These may involve scavenging of superoxide, enhanced mitochondrial efficiency or reduced 
generation of reactive oxygen species (ROS) by xanthine oxidase, NADPH oxidase or 
cytochrome P450 systems (Carlstrom et al., 2011; Larsen et al., 2011; Montenegro et al., 2011; 
Peleli et al., 2015; Yang et al., 2015). Treatment of Sprague-Dawley hypertensive rats for eight 
to 11 weeks with  𝑁𝑂3
− can significantly reduce biomarkers of oxidative stress such as 
malondialdehyde, F2-isoprostanes and 8-hydroxy-2-deoxyguanosine (Carlstrom et al., 2011). 
In addition,  𝑁𝑂3
− administration significantly reduced superoxide production and improved 
metabolic profile in adenosineA2B receptor knockout mice (Peleli et al., 2015). Similarly 
supplementation of  𝑁𝑂2
− to mouse model of oxidative stress (superoxide dismutase-1 
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knockouts) can significantly reduce free radical production by inhibiting NADPH oxidase (Gao 
et al., 2015).   
We observed that acute hyperglycaemia increased inflammatory (IL-6) and oxidative stress (3-
NT) biomarkers and that the co-administration of inorganic  𝑁𝑂3
− blunted the rise in these 
biomarkers in older participants. Two studies have tested the link between inorganic 
 𝑁𝑂3
−  supplementation and oxidative stress in healthy participants (Larsen et al., 2014; 
Velmurugan et al., 2016). Both studies found a non-significant effect of inorganic  𝑁𝑂3
− on 
oxidized low density lipoproteins (Velmurugan et al., 2016), total oxidative capacity (Larsen et 
al., 2014) and plasma isoprostanes (Larsen et al., 2014). Velmurugan et al. (2016)  also 
observed a non-significant effect of beetroot juice supplementation on biomarkers of 
inflammation (i.e. C reactive protein and chemokine (CXC motif) ligand 1 [CXCL1]). Several 
reasons could explain the differences across studies including use of different biomarkers, 
phenotypic characteristics of the populations under study and the nutritional strategy used to 
supplement inorganic 𝑁𝑂3
−.  Potentially important is the higher oxidative stress and 
inflammation in our obese participants which were further increased by the hyperglycaemic 
insult, and which may have made these participants more responsive to the putative anti-oxidant 
properties of inorganic  𝑁𝑂3
− . The use of healthy participants in the other two studies (Larsen 
et al., 2014; Velmurugan et al., 2016) could explain the observed lower responsiveness to the 
 𝑁𝑂3
− interventions. 
4.4.5 Inorganic 𝑵𝑶𝟑
− and cutaneous microvascular blood flow  
However, the single dose of inorganic 𝑁𝑂3
− used in the present study did not affect 
microvascular blood flow measured by Laser Doppler. The results are corroborated by the lack 
of changes in cGMP which suggest that despite the changes in  𝑁𝑂3
−, this has not led to an acute 
increased activity of the NO signalling. Studies have shown that acetylcholine-mediated 
dilatation of human skin is unchanged or only partially attenuated following endothelial NO 
synthase inhibition (Holowatz et al., 2005; Cracowski et al., 2006). Moreover, supplementing 
type 2 diabetics with beetroot juice for two weeks was ineffective in improving skin 
microvascular blood flow (Gilchrist et al., 2013). A recently published meta-analysis showed 
that the effect of inorganic  𝑁𝑂3
−  supplementation on endothelial function declined with 
advanced age (β= -0.01, P = 0.02) (Lara et al., 2015) and this may explain our finding of a 
significant improvement in endothelial function biomarkers (E- and P-selectin) in younger 
participants only.  
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4.4.6 Strength and limitations  
In this study, we investigated for the first time, the effects of a single dose of inorganic  𝑁𝑂3
−  on 
hyperglycaemia-induced ED in both younger and older participants. The study had a robust 
experimental design (randomised, double-blind and cross-over) and to avoid a carry-over effect, 
we allowed one week wash-out period between each intervention. Previous study demonstrated 
that the concentrations of NO metabolites return to baseline levels after 24 h of consumption 
(James et al., 2015).  
𝑁𝑂2
− regarded as the immediate precursor of the active molecule NO (Lundberg et al., 2008). 
Therefore, measurement of plasma  𝑁𝑂2
−  concentration is vital for studies supplementing 
inorganic 𝑁𝑂3
−. In the present study, blood samples processing was not immediately carried out 
after collection. Moreover, the solution supposed to stop the reaction of haemoglobin with  𝑁𝑂2
− 
was not added to the samples. Additionally, the GC-MS method used was not sensitive enough 
to detect low concentration of  𝑁𝑂2
−. Moreover, we did not use Sievers NO analyser which is 
regarded as the gold-standard method for measuring  𝑁𝑂2
−/ 𝑁𝑂3
− in plasma (Pelletier et al., 
2006).  
However, previous studies of inorganic 𝑁𝑂3
− supplementation showed a significant rise in 
plasma 𝑁𝑂2
− concentrations after increased plasma 𝑁𝑂3
− concentrations similar to that observed 
in this study (Webb et al., 2008; Kapil et al., 2010a). In particular, Cermak et al showed in older 
overweight and obese diabetic patients (age 66±8.2 y, BMI 29.2±3.9 kg/m2) similar acute 
changes over a 2 h period in plasma  𝑁𝑂3
− , which were mirrored by a significant increase in 
plasma  𝑁𝑂2
−  (Cermak et al., 2015).  
4.4.7 Conclusions  
Overall, our results showed possible positive effects of inorganic 𝑁𝑂3
− supplementation in 
counteracting the adverse effects of hyperglycaemia on EF. Greater improvement in biomarkers 
of EF was observed in younger participant. One the other hand, older participants showed 
greater reduction in oxidative stress and inflammatory markers. These findings may offer novel 
research questions to be investigated in future studies. Moreover, if confirmed in longer 
interventions, these findings could have important implications for the prevention and 
management of pathological processes associated with post-prandial hyperglycaemia. 
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Chapter 5. Effects of inorganic 𝑵𝑶𝟑
− and vitamin C supplementation on 
markers of cardiovascular diseases in younger and older healthy 
participants   
5.1 Introduction  
Fruits and vegetables consumption is associated with a reduction in cardiovascular mortality 
and morbidity (Joshipura et al., 2001; Crowe et al., 2011). Several bioactive components of 
fruits and vegetables are responsible for the cardio-protective effects such as flavonoid, 
antioxidant vitamins and inorganic 𝑁𝑂3
− (Hooper et al., 2008; Juraschek et al., 2012; Siervo et 
al., 2013). Antioxidant vitamins such as vitamin C play a major role in conferring beneficial 
effect by mitigating the earliest stages of atherosclerosis (Aguirre and May, 2008). Vitamin C 
may ameliorate ED by enhancing NO availability through several mechanisms (Chapter one). 
However, inconsistent results from large RCTs questioned the protective cardiovascular effects 
of antioxidant vitamins (Chapter three). Therefore, researchers suggested that inorganic 𝑁𝑂3
− 
contents have the greatest share of the protective role of fruits and vegetables (Larsen et al., 
2006; Lundberg et al., 2006). The 𝑁𝑂3
− contents of green leafy vegetables were found to be an 
important source of  𝑁𝑂2
− and NO in the circulation (Lundberg et al., 2008; Machha and 
Schechter, 2012).   
Vitamin C and inorganic 𝑁𝑂3
−, individually, proved to have beneficial effects on cardiovascular 
outcomes (Siervo et al., 2013; Ashor et al., 2014a; Ashor et al., 2015b; Lara et al., 2015) which 
are related to an enhanced NO production and subsequent improvement of endothelial function 
(Aguirre and May, 2008; Hobbs et al., 2013). Moreover, we have shown that age might modify 
the effects of vitamin C and inorganic  𝑁𝑂3
− on cardiovascular markers.  While vitamin C 
effects seemed to be greater in older participants, inorganic  𝑁𝑂3
−  effects were larger in younger 
participants (chapter two and three of this thesis).  
The possibility of a mechanistic interaction between vitamin C and  𝑁𝑂3
− and  𝑁𝑂2
−  dates back 
more than 40 years ago, when vitamin C was used to block the conversion of  𝑁𝑂3
− and  𝑁𝑂2
− 
into N-nitroso compounds (NOCs) (Wolff and Wasserman, 1972; Bednar and Kies, 1994). 
These NOCs were regarded as an important step in the initiation of gastric carcinogenesis 
(Mowat et al., 1999). The purported mechanisms of the beneficial effects of vitamin C included 
the wash-out of  𝑁𝑂2
− by converting it into NO and, therefore, preventing the formation of 
NOCs (Mowat et al., 1999).  
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Several studies reported the possibility of interaction of vitamin C with  𝑁𝑂3
−- 𝑁𝑂2
−-NO 
pathway (Scorza et al., 1997; Sibmooh et al., 2008; Garcia-Saura et al., 2012). Vitamin C may 
enhance the conversion of  𝑁𝑂2
− into NO in the circulation, therefore, further contributing to 
the NO pool (Lundberg et al., 2008). Besides the circulatory interaction, studies have shown 
the possibility of  𝑁𝑂2
−-vitamin C interaction in the oral cavity (Duncan et al., 1995; Takahama 
et al., 2008), stomach (Mowat and McColl, 2001) and kidney tubules (Carlsson et al., 2001).   
In the present study, we hypothesized that inorganic 𝑁𝑂3
− and vitamin C co-administration will 
have greater increase in NO availability than each intervention alone. Therefore, greater 
improvement in BP, skin microvascular blood flow and arterial stiffness would be expected 
from the anticipated synergistic interaction. Synergism is the situation in which the co-
administration of two agents will produce greater effect than the algebraic sum of their 
independent actions when given separately (Tallarida, 2011). Furthermore, we hypothesized 
that the effects of inorganic 𝑁𝑂3
− and vitamin C would vary in younger and older participants.      
In a 2×2 crossover RCT, we aimed to investigate the potential, additive or synergistic effects 
of vitamin C and inorganic  𝑁𝑂3
− administration on resting BP, heart rate variability (HRV) and 
vascular function. The secondary aim was to investigate whether age modifies putative 
interactions between vitamin C and inorganic 𝑁𝑂3
− on these outcomes. To understand some of 
the mechanisms of this potential interaction we measured circulatory cardiovascular markers 
such as NO metabolites (𝑁𝑂3
− and 𝑁𝑂2
−), cGMP, tetrahydrobiopterin (BH4), dehydroascorbic 
acid (DHA) and 3 nitrotyrosine (3- NT).  
5.2 Methods  
5.2.1 Participants  
The study included twenty volunteers (9 males, 11 females) with a mean age of 45.75±1.9 years 
(range: 18-70 years) and a mean body mass index (BMI) of 24.3±0.8 kg/m2 (range: 20-29.9 
kg/m2). Participants were recruited from members of staff or the general public who responded 
to our newspaper advertisement or emails targeted towards potential volunteers. All the study 
visits were conducted in the Clinical Ageing Research Unit (CARU), Newcastle University 
from November 2014 to November 2015. The trial was performed in accordance with the 
Declaration of Helsinki and the principles of the International Conference on Harmonization-
Good Clinical Practice (ICH-GCP) guidelines. The study was approved by the regional ethics 
committee of East of Scotland Research Ethics Service (EoSRES) (REC reference:  
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14/ES/0059, Appendix D) and was registered with Current Controlled Trials 
(ISRCTN98942199).  
5.2.2 Participants screening and exclusion criteria   
Participants who approached the research team with the intention to participate in the study 
received detailed information about the study. Potential eligible volunteers were then contacted 
via telephone to ensure an accurate evaluation of the inclusion and exclusion criteria including 
socio-demographic status, smoking history and confirming the participants’ commitment and 
availability to complete the study visits. If participants passed this first initial screening phase, 
they were then invited to CARU for a short screening visit to confirm their eligibility for the 
study.  
Participants were excluded if they had been diagnosed with medical conditions (i.e. diabetes, 
cancer or systemic inflammatory disorders) or had blood pressure of ≥ 180 mmHg systolic or 
≥ 110 mmHg diastolic at the screening visit. Participants were also excluded if they reported 
taking medications or nutritional supplements (i.e. organic nitrates, corticosteroids, diuretics, 
hormonal therapies or multivitamins) that could interfere with the nutritional interventions 
(inorganic 𝑁𝑂3
− and vitamin C) or study outcomes. In addition, individuals were excluded if 
they were smokers, vegetarian, reported alcohol intake greater than 21 U/week for men and 14 
U/week for women, or their body weight had changed more than 3 kg within the last 2 months. 
Participants who reported history of major surgeries or blood donations in the last 3 months 
were also excluded from the study.   
5.2.3 Study design and randomisation 
This was a Latin-square 2×2 factorial cross-over randomised, double-blind, placebo controlled 
study. The randomisation was conducted by an independent investigator outside the research 
team. The preparation and labelling of the solutions (inorganic 𝑁𝑂3
−, vitamin C and their 
placebos) were performed by the Pharmacy Department of the Newcastle upon Tyne Hospitals 
(Royal Victoria Infirmary). The safety and accessibility of the randomisation codes was 
guaranteed by a member of the CARU Research Facility outside the research team. 
Interventions (inorganic 𝑁𝑂3
−  or vitamin C) and the corresponding placebos solutions had the 
same characteristics and had identical volume, colour and presentation.  
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5.2.4 Sample size calculation  
Prior to this study, the combined effects of inorganic nitrate and vitamin C on cardio-metabolic 
outcomes had not been tested in humans and therefore experimental information was not 
available to inform our sample size calculations. In addition the influence of ageing on the 
effects of these nutritional interventions has never been assessed. Therefore we based our 
calculations on the differences that would be detected in each age group after the combined 
interventions. Our calculations are based on a minimal difference of ±3mmHg in SBP (SD = 
±3mmHg) between placebo and combined interventions. Using a matched paired design, a 
sample size of 10 subjects for each age group was required to detect a significant difference in 
SBP with a power of 80% and alpha of 0.05. Therefore, we recruited a total of 20 participants 
(10 younger and 10 older) who received all the 4 interventions in a crossover design. The sample 
size calculation was performed using G*Power 3.1 (Heinrich Heine Universität Düsseldorf, 
Germany). 
5.2.5 Nutritional supplements  
The active 𝑁𝑂3
− supplementation contained 7 mg [0.1 mmol/kg] of potassium 𝑁𝑂3
− per kg of 
body weight in sterile water while its placebo was consisted of a matched amount of potassium 
chloride (7 mg per kg of body weight). The active vitamin C supplementation contained 20 mg 
ascorbic acid per kg body weight and its placebo consisted of matched volume of Sodium 
chloride 0.9%. Participants were randomised to the following interventions: 1)  𝑁𝑂3
− 
supplementation (active) + vitamin C (active); 2)  𝑁𝑂3
− supplementation (active) + vitamin C 
(placebo); 3)  𝑁𝑂3
− supplementation (placebo) + vitamin C (active); 4)  𝑁𝑂3
− supplementation 
(placebo) + vitamin C (placebo). Each participant received all four interventions in four 
consecutive visits. As mentioned above, each visit was separated by a 7-day washout period. 
The  𝑁𝑂3
− dose corresponded to the amount normally found in 150–250 g of a  𝑁𝑂3
−-rich 
vegetable such as spinach, lettuce or beetroot (Larsen et al., 2007). The dose of vitamin C 
implemented in this study was 20 mg/kg which means 1400 mg in a 70 kg adult person. This 
dose based on our previous observation that the lowest effective dose to improve EF was around 
1000 mg per day (Ashor et al., 2014a).   
5.2.6 Study protocol  
a. Screening visit: Eligible subjects, from the initial telephone interview, were invited to the 
research unit in fasting conditions (at least 12 hours). At the screening visit, potential 
volunteers were given detailed information of the study and their BMI and blood pressure 
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were checked. Eligible subjects were, then, asked to complete a written consent to 
participate in the study. Additionally, a blood sample obtained for the assessment of plasma 
 𝑁𝑂3
− and vitamin C concentrations. At the end of that visit, participants were asked to 
follow a run-in diet (low 𝑁𝑂3
−/low vitamin C diet, Appendix E) and to avoid using 
antibacterial mouthwash and chewing-gum for two days prior to each study visit. The run-
in diet ensured a standardized  𝑁𝑂3
− and vitamin C intake among study participants. The 
mouthwash and chewing-gum restriction avoided any interference with the salivary 
conversion of  𝑁𝑂3
− into NO.  
b. Study visits (1, 2, 3 and 4): Participants arrived early in the morning (~8.00am) in fasting 
condition (~ 12 hours). Participants were then randomised to one of the four interventions 
(inorganic 𝑁𝑂3
−, vitamin C, both, or placebo). Body weight, height, waist circumference 
were measured and body composition (fat mass, fat free mass) assessed by using 
bioelectrical impedance analysis (Tanita BC420 MA, Tanita Corporation, Tokyo, Japan). 
Heart rate variability (HRV) was monitored throughout the study visit by fitting a strap 
around the participants’ chest and which was remotely connected to a wrist watch (Polar 
S810, Polar Electro). A cannula was then inserted in the ante-cubital vein while subjects 
were lying in a supine position. Blood pressure (systolic, diastolic) was measured at baseline 
(pre-dose administration) and then every 30 minutes after the administration of the dose. 
Endothelial function was assessed by post-reactive occlusion hyperaemia and pulse wave 
velocity at baseline and 180 min post-interventions. Blood samples were collected at 0, 30, 
60, 120 and 180 minutes. Participants were asked to complete a food frequency 
questionnaire to assess their typical food intake. Physical activity levels and dietary nitrate 
intake (Appendix B) over the week prior to each visit were documented by completing two 
short questionnaires. After each study session, the cannula was removed from the 
participants’ arm and a small breakfast was offered to the participant. Participants were 
asked to return to their normal eating habits during the wash-out period and to follow the 
low nitrate/low vitamin C run-in diet for 2 days prior to their next study visit. This protocol 
was repeated at the second, third and fourth (last) visit and each time the nutritional 
interventions were administered as dictated by the randomisation order. A detailed 
description of the study phases and measurement protocols conducted during the study is 
provided in Figure 5.1.  
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Figure 5.1: Study protocol and description of succession of measurements conducted at each 
study visit 
5.2.7 Blood pressure  
Baseline BP was measured five times at 1-minute intervals using a semi-automated blood 
pressure recorder (Dinamap V100; GE Medical Systems, Milwaukee, WI, USA). The mean of 
the five records was taken as the baseline values of blood pressure. Subsequently, BP was 
measured at 30, 60, 90, 120, 150, 180 minutes from the administration of the interventions. 
Measurements of BP were conducted in a rested, supine position and results were concealed 
from each participant. 
5.2.8 Cutaneous microvascular blood flow 
Cutaneous microvascular reactivity was measured during post-occlusive reactive hyperaemia 
(PORH) of the forearm using laser Doppler (Moor LDF, Moor Instruments, Axminster, UK). 
All assessments were performed in a temperature-controlled room (22-24 °C) following an 
acclimatisation period of 15 minutes. With the subject supine, the laser Doppler probe was 
attached to the right forearm. Resting cutaneous blood flow was recorded for 5 minutes 
followed by a 3-minute inflation of right upper-arm pressure cuff to 200 mmHg to occlude 
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brachial artery. The hyperaemic response was recorded for 4 minutes following the deflation of 
the pressure cuff. The mean blood flow of the selected area was determined with the help of the 
Moor VMS V3.1 software and expressed in perfusion units (PU) in relation to an internal 
standard calibration of the device. The PORH index was calculated as the ratio of the area under 
curve (AUC) one minute after the release of the cuff relative to the AUC of a one minute period 
before cuff inflation (Figure 5.2).  
 
Figure 5.2: Example of Laser Doppler blood flow recording of study participant.  
The protocol lasted for 12 minutes (5 minutes resting blood flow were recorded, 3 
minutes were pressure cuff around the arm inflated to 200mmHg and the last 4 
minutes of recording were after the release of pressure cuff). AUC: area under 
curve; BP: blood pressure; PU: perfusion unit.  
5.2.9 Pulse wave velocity  
Photoplethysmography (PPG), developed by the Medical Physics Department of Newcastle 
University, was used to measure pulse wave velocity (PWV) and the distensibility coefficient 
(DC) (Figure 5.3). The PPG probes, which included a matched infrared emitter, were used to 
quantify changes in blood volume in the index finger and earlobe. In addition, a three-electrode 
ECG signal was also recorded to provide a timing reference for the PPG pulses. The signals 
from each of the PPG probes and ECG electrodes were fed to a data capture computer (Fujitsu 
Lifebook S3020 laptop, Japan). Special software, named ARD (Analogue Recorder and 
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Display) which had been developed in the Medical Physics Department was used for the PPG 
and ECG signal acquisition, display and data storage.  
All assessments were performed in a temperature-controlled room (22-24 °C) following a 
resting period of 15 minutes. PPG probes were attached to the same side index fingertip and 
earlobe. Right, left arms and left leg ECG probes were also attached to the participant’s body. 
Once good signals from PPG probes and ECG were obtained on the computer, recording started 
and continued for 120 seconds (Figure 5.4). The distance between the fingertip to the sternal 
notch and fingertip to the earlobe was measured. This distance used to calculate the propagation 
velocity of the pulse wave across the arterial wall. DC were derived from PWV using a formula 
described by Zheng and Murray (2011).  
 
Figure 5.3: Photoplethysmography (PPG). A) Schematic diagram of the 
measurement protocol of pulse wave velocity; B) The data capture computer 
(Fujitsu Lifebook S3020 laptop, Japan) and the ARD (Analogue Recorder and 
Display) software. Adapted from Zheng and Murray (2011) 
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Figure 5.4: Example of pulse wave recording of study participant. PPG: 
photoplethysmography 
5.2.10 Heart rate variability (HRV) 
A portable, automated device was used to assess components of HRV and to provide 
information on autonomic balance (RS800; Polar Electro, Kemple, Finland). The chest strap of 
the Polar RS800 was fixed around the participant’s chest according to the manufacturer’s 
instructions. The interbeat interval (R–R series) of the Polar equipment was stored 
automatically in the watch and later transferred to a laptop computer. The R–R series data were 
analysed using Protrainer Polar 5 software (version 5.40.171, Polar Electro).  
The following indices of HRV were extracted: 1) RMSSD (milliseconds): square root of the 
mean of the squared differences of successive normal R-R intervals over a full 3hr recording. 
This measurement reflects the beat-to-beat variance in HR mediated principally by 
parasympathetic activity (Vanderlei et al., 2009); 2) pNN50 (%): the percentage of intervals 
that differ from each other by more than 50ms. This is correlated with parasympathetic activity 
(Vanderlei et al., 2009); 3) low frequency/high frequency ratio measured in milliseconds 
(LF/HF) which is an indirect measure of autonomic balance (sympathetic/parasympathetic 
balance) (Vanderlei et al., 2009); 4) SD1 (milliseconds): is an indicator of the standard 
deviation of the instantaneous RR variability and is considered a parasympathetic index of sinus 
node control (Hoshi et al., 2013); 5) SD2 (milliseconds): is an indicator of the standard 
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deviation of the continuous or long-term variability of the heart rate. SD2 is influenced by both 
parasympathetic and sympathetic tones (Hoshi et al., 2013).   
5.2.11 Blood sample processing and biochemical assays 
At each predetermined time point, blood samples were collected in 4 tubes (4mL each). Two 
tubes contained lithium heparin and one tube each contained EDTA 
(Ethylenediaminetetraacetic acid) and serum gel. Blood samples were processed immediately 
after collection. Stop solution was added to aliquots intended for measuring NO metabolites 
(0.25mL of stop solution added to 1mL of plasma).  
The purpose of stop solution is to stop the reaction of nitrite with oxy- and deoxyhaemoglobins 
(Hb) by oxidising the heme to form metHb. The stop solution consists of potassium ferricyanide 
(MW 329.24), N-ethylmaleimide (MW 125.12) and Nonidet P-40 (all from Sigma-Aldrich) 
(Pelletier et al., 2006). A new stock of stop solution was prepared fresh in every study visit day. 
1320 mg of potassium ferricyanide and 65 mg of N-ethylmaleimide were added to 4.5 mL of 
distilled water and mixed them thoroughly to remove any remaining particles. Then, 500 µL of 
Nonidet P-40 were added and the solution was mixed gently to avoid excessive foaming 
(Pelletier et al., 2006).  
Blood samples were spun at 5000x g for 5 minutes at 4C and serum and plasma aliquots were 
stored immediately at -80C until further analyses. These samples were then used to 
measure 𝑁𝑂3
−, 𝑁𝑂2
−, vitamin C, dehydroascorbic acid (DHA) cyclic guanosine monophosphate 
(cGMP), tetrahydrobiopterin (BH4) and 3-nitrotyrosine (3-NT) concentrations.  
5.2.12  𝑵𝑶𝟑
− and  𝑵𝑶𝟐
− analyses  
Plasma concentrations of  𝑁𝑂3
− and  𝑁𝑂2
− were analysed at Professor Alan Schechter’s 
laboratory of biomolecular medicine at the National Institutes of Health (NIH), Bethesda, USA 
using a Sievers gas-phase chemiluminescence nitric oxide analyser (Sievers NOA 280i, 
Analytix Ltd, Durham, UK).  
The Sievers NOA consists of two components, glass purge vessel and NO chemiluminescence 
analyser. The purge vessel contains either vanadium chloride or tri-iodide (I3) solutions. These 
solutions react with  𝑁𝑂3
− and  𝑁𝑂2
− (respectively) in the injected samples to produce NO. NO 
released from the above reactions are quantified by the chemiluminescence analyser. The 
concentrations of  𝑁𝑂3
− and  𝑁𝑂2
− were determined by plotting signal area (mV) against a 
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calibration plot of a known concentrations of  𝑁𝑂3
− and  𝑁𝑂2
− standards. To analyse data from 
the injected samples, two types of software were used: data acquisition and analysis software. 
For data acquisition the Liquid Program (version 3.21) was used and for data analysis the Origin 
software (version 10; OriginLab) was then applied to obtain the AUC (measured in mV). A 
detailed description of the protocol is provided in (Appendix F). 
5.2.13 Vitamin C analysis  
Vitamin C concentration in plasma samples was estimated using ESA CoulArray high 
performance liquid chromatography (HPLC). All samples were injected from an autosampler 
at 0-2 ºC. The column was Hypersil GOLD AX (diameter: 4.6mm; length: 250mm; particle 
size: 5µm; Thermo Fisher Scientific). The flow rate was 1.2mL/minute and the injection volume 
20µL. The mobile phase was Ammonium Acetate (100mM, pH 6.8) and acetonitrile (30:70). 
10% meta-phosphoric acid (MPA) was used to stabilise vitamin C in plasma samples.    
5.2.14 DHA analysis  
DHA is the oxidised form of vitamin C. DHA is transported intracellularly (e.g. erythrocytes) 
were it is regenerated to ascorbic acid by several intracellular mechanisms (Lykkesfeldt, 2007). 
Increased tissue DHA regarded as a sign of redox imbalance and inadequate recycling capacity 
(Lykkesfeldt, 2007). DHA Microplate Assay Kits (Cohesion Biosciences) were used to analyse 
DHA in our plasma samples. The principle of the assay is initiation of enzymatic catalysis of 
the DHA by dithiothreitol (DTT). The enzyme reaction product (ascorbic acid) then can be 
measured with colorimetric plate reader at 265nm.  
5.2.15 cGMP analysis 
Assay principles of cGMP analysis were described in section 4.2.8 of chapter four of this thesis.  
5.2.16 BH4 analysis  
Vitamin C stabilizes, and increases the synthesis, of BH4, a cofactor which is essential for the 
function of eNOS. BH4 deficiency leads to eNOS uncoupling and the production of superoxide 
instead of NO (Schmidt and Alp, 2007). We analysed plasma concentration of BH4 using 
Human Tetrahydrobiopterin Elisa Kit (MBS283103, MyBiosource, Inc. San Diego, USA). This 
is a competitive enzyme immunoassay technique.  
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5.2.17 3-NT analysis 
3-NT considered as an index of oxidative stress (Ischiropoulos, 2009). It is formed by the 
interaction of reactive nitrogen species (peroxynitrite anion, nitrogen dioxide) with the tyrosine 
residues of proteins (Radi, 2004). This reaction considered as a post-translational modification 
of these proteins with consequent changes in its function (Ischiropoulos, 2009). Moreover, 3-
NT concentrations strongly correlated with CVD (Shishehbor et al., 2003). Significantly higher 
levels of NT were found among patients with CAD (Shishehbor et al., 2003). I used ELISA kits 
(ab210603, Abcam, Cambridge, USA) to analyse 3-NT in serum samples. This ELISA kits 
utilizes nitrotyrosine-coated plates and horseradish peroxidase (HRP)-conjugated antibodies to 
detect 3-NT in the samples.  
5.2.18 Statistical analysis 
Data were checked for normality and appropriate transformations were applied for non-
normally distributed data. Summary data are presented as means ± SEM. For outcomes with 
repeated measurements over time (BP and plasma concentrations of vitamin C, 
DHA, 𝑁𝑂3
−, 𝑁𝑂2
−, cGMP, BH4 and 3-NT), we calculated the mean values of the multiple 
measurements post-intervention with an adjustment for baseline in the model and the area under 
curve (AUC) over 3 hrs using the trapezoid method (6.11Appendix G). The mean differences 
were calculated for EF outcomes (PORH index, PWV and DC) by subtracting the baseline 
measurements from the measurements at the end of the visits. Figure 5.5 illustrates the process 
followed in the statistical analysis of this study.  Linear mixed models were applied to analyse 
the data using Stata version 13 (StataCorp LP, TX, USA). 
The statistical model examined the effects of each dietary agent (inorganic 𝑁𝑂3
− or vitamin C) 
individually and for a potential interaction effect (interaction between inorganic 𝑁𝑂3
− and 
vitamin C). In addition, the possibility of age interaction examined by including age as fixed 
factor in the statistical model. The main effects of inorganic 𝑁𝑂3
− investigated by comparing 
groups who were given  𝑁𝑂3
− with groups who were not (Nitrate + vs. Nitrate -). The main 
effects of vitamin C studies by comparing groups who were given vitamin C with groups who 
were not (Vitamin C + vs. Vitamin C -). Fixed factors include inorganic 𝑁𝑂3
−, vitamin C 
(within-subject factors) and age (between-subject factor). Subjects’ identification was regarded 
as random factor. Due to the presence of significant interaction between age, inorganic 𝑁𝑂3
− 
and vitamin C, statistical analyses per group (inorganic 𝑁𝑂3
−, vitamin C and the combination 
of both interventions versus placebo) were presented. GraphPad prism version 7 (GraphPad 
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software, CA, USA) was used to construct the graphs.  P values < 0.05 were considered to 
indicate statistical significance.  
 
 
 
Figure 5.5: The statistical plan applied to analyse the study results 
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5.3 Results  
5.3.1 Recruitment and baseline characteristics of the participants 
A total of 20 participants were randomised to the interventions, ten younger (29.2±0.8 years) 
and ten older (62.3±0.6 years) participants (Figure 5.6). All participants completed all the four 
study visits. The interventions were well-tolerated and no adverse effects were reported. 
Baseline characteristics of the participants (Table 5.1) show that the younger and older 
participants were well-matched for anthropometric variables, dietary energy intake and vitamin 
C intake. However, BP was significantly higher in older participants (P < 0.01).  
 
 
Figure 5.6: Flow diagram of the study 
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Table 5.1: Baseline characteristics of younger and older participants1 
1Data shown as mean±SEM. 2MET: Metabolic Equivalent of Task, 3BH4: tetrahydrobiopterin 
 
 
 
All Younger Older P value 
Number  20 10 10 
 
Gender (male/female) 9/11 5/5 4/6 
 
Age (years) 45.8±3.9 29.2±1.7 62.3±1.3 0.0001 
Body mass index (kg/m2) 24.3±0.6 24.5±0.7 24.2±1 0.82 
Waist circumference (cm) 84.9±2.1 84.8±2.4 85.2±3.7 0.94 
Fat mass (kg) 18.6±1.1 18.4±1.4 18.9±1.6 0.83 
Systolic blood pressure (mmHg) 115.7±3.9 106 ±2.6 125±6 0.009 
Diastolic blood pressure (mmHg) 66.3±2 60.5±1.4 72±2.7 0.001 
Mean arterial pressure (mmHg) 85.2±2.7 77.6±1.6 92.8±3.8 0.002 
Energy intake (KJ/day) 12204±983 13638±1720 10769±815 0.14 
Vitamin C intake (mg/day) 170.5±20 184.5±28 156.5±28 0.48 
Nitrate intake (mg/day) 176.51±11.6 179.1±20 173.9±12 0.82 
Physical activity, METs/wk2 3440±322 3142±390 3801±533 0.31 
Plasma nitrate (µmol/L)  27.3±2 29.6±2.8 25.1±2.7 0.27 
Plasma nitrite (nmol/L) 238±24 245±43 231±23 0.78 
Plasma vitamin C (µmol/L) 56.9±4 51±7 62.4±3 0.17 
Plasma BH43 (pg/mL)  565±60 464±64 665±92 0.10 
Serum 3-nitrotyrosine (nmol/mL) 592±60 543±87 640±86 0.43 
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5.3.2  𝑵𝑶𝟑
− and  𝑵𝑶𝟐
− concentrations  
Compared with placebo, plasma  𝑁𝑂3
− was significantly increased after inorganic 𝑁𝑂3
− 
(younger: ∆ 177 µmol/L, 95% CI: 160, 195; older: ∆ 177 µmol/L, 95% CI: 160, 195) and 
inorganic 𝑁𝑂3
− + vitamin C intake (younger: ∆ 173 µmol/L, 95% CI: 155, 191; older: ∆ 196 
µmol/L, 95% CI: 178, 213) (Figure 5.7A). Similarly, relative to control, plasma  𝑁𝑂2
− was 
significantly increased after inorganic 𝑁𝑂3
− (younger: ∆ 135 nmol/L, 95% CI: 76, 194; older: 
∆ 206 nmol/L, 95% CI: 147, 265) and inorganic 𝑁𝑂3
− + vitamin C intake (younger: ∆ 125 
nmol/L, 95% CI: 66, 184; older: ∆ 184 nmol/L, 95% CI: 125, 243) (Figure 5.7B). However, no 
significant differences in plasma  𝑁𝑂3
− and  𝑁𝑂2
− were observed after vitamin C intake (Figure 
5.7). Moreover, no significant difference was reported between younger and older participants. 
Vitamin C did not significantly modify the concertation of plasma 𝑁𝑂3
− and  𝑁𝑂2
− when co-
administered with inorganic 𝑁𝑂3
−.  
5.3.3 Vitamin C and DHA concentrations  
In comparison with placebo, vitamin C concentration significantly increased after vitamin C 
(younger: ∆ 41 µmol/L, 95% CI: 32, 51; older: ∆ 45 µmol/L, 95% CI: 35, 54) and inorganic 
𝑁𝑂3
− + vitamin C intake (younger: ∆ 39 µmol/L, 95% CI: 29, 48; older: ∆ 52 µmol/L, 95% CI: 
42, 61) (Figure 5.8A). However, only older participants demonstrated a significant increase in 
DHA concentration after vitamin C supplementation (∆ 0.8 µmol/mL, 95% CI: 0.01, 1.6) 
(Figure 5.8B). Additionally, no significant differences were seen after inorganic 
𝑁𝑂3
− supplementation. Lastly, no interactions between age, inorganic 𝑁𝑂3
−  and vitamin C 
were reported.  
5.3.4 Systolic, diastolic and mean BP 
Overall, systolic, diastolic and mean arterial BP were significantly higher in older than younger 
participants (systolic: ∆ 15.6 mmHg, 95% CI: 7.1, 24; diastolic: ∆ 8.9 mmHg, 95% CI: 4.3, 
13.4; mean BP: ∆ 12 mmHg, 95% CI: 6.5, 17.4) (Figure 5.9A, Figure 5.10A and Figure 5.11A). 
In older participants, systolic BP was significantly reduced after inorganic 𝑁𝑂3
− (∆ -3.7 mmHg, 
95% CI: -6.8, -0.6) and vitamin C (∆ -3.9 mmHg, 95% CI: -6.9, -0.8) intake (Figure 5.9A). 
Likewise, single and combined supplementation of inorganic 𝑁𝑂3
− and vitamin C significantly 
reduced mean BP in older participants only (vitamin C: ∆ -2.4 mmHg, 95% CI: -4.7, -0.11; 
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inorganic 𝑁𝑂3
−: ∆ -2.7 mmHg, 95% CI: -5.0, -0.43; inorganic 𝑁𝑂3
− + vitamin C: ∆ -2.6 mmHg, 
95% CI: -4.9, -0.27) (Figure 5.11A). Moreover, age significantly modified the effects of 
vitamin C on systolic, diastolic and mean arterial BP (P < 0.05) (Figure 5.9B, Figure 5.10B 
and Figure 5.11B). Younger participants demonstrated a significant increase in diastolic BP 
after vitamin C supplementation (∆ 2.2 mmHg, 95% CI: 0.02, 4.4) (Figure 5.10A). 
Additionally, marginally significant interaction was found between inorganic 𝑁𝑂3
− and vitamin 
C for diastolic BP (P = 0.05) (Figure 5.10B).  
5.3.5 Physiological markers of EF 
Inorganic 𝑁𝑂3
− supplementation marginally improved PORH index in both younger and older 
participants (younger: ∆ 2.2 AU, 95% CI: -0.003, 4.3 [P = 0.05]; older: ∆ 2.1 AU, 95% CI: -
0.11, 4.2 [P = 0.06]) (Figure 5.12A). However, in older participants, inorganic 𝑁𝑂3
− + vitamin 
C intake produced greater improvement in arterial stiffness indices (PWV: ∆ -2 m/s, 95% CI: 
-3.61, -0.32; DC: ∆ 0.03 % per mmHg, 95% CI: 0.002, 0.06) than the sum of the effects of 
inorganic 𝑁𝑂3
− and vitamin C supplemented individually (Figure 5.12B and Figure 5.12C). 
5.3.6 Indices of HRV 
HRV indices tend to be lower in older than younger participants (RMSSD: ∆ -22 ms, 95% CI: 
-45, 1.4; pNN50: ∆ -9.4 %, 95% CI: -15, -3.7) (Figure 5.13 and Figure 5.14). Nevertheless, 
inorganic 𝑁𝑂3
−+ vitamin C intervention significantly improved RMSSD and pNN50 in older 
participants (RMSSD: ∆ 21 ms, 95% CI: 6.8, 35.8; pNN50: ∆ 3 %, 95% CI: 0.16, 5.7). 
Moreover, the effects of inorganic 𝑁𝑂3
−+ vitamin C on RMSSD and pNN50 was greater than 
the effects of both intervention supplemented separately (Figure 5.13 and Figure 5.14).  
Likewise, intervention with inorganic 𝑁𝑂3
− significantly improved SD1 and SD2 indices in 
older participants (SD1: ∆ 56.2 ms, 95% CI: 17.6, 94.8; SD2: ∆ 323 ms, 95% CI: 98, 548) 
(Figure 5.15 and Figure 5.16). In contrast, vitamin C intake significantly reduced pNN50 in 
younger participants (∆ -3.3 ms, 95% CI: -5.9, -0.57) (Figure 5.14B). However, there was a 
tendency of beneficial interaction of inorganic 𝑁𝑂3
−and vitamin C on pNN50 (P = 0.05) (Figure 
5.14C). No changes in LF/HF ratio were reported following all interventions (Figure 5.17).  
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5.3.7 Circulatory biomarkers  
Relative to placebo, vitamin C supplementation marginally increased cGMP concentration in 
older participants (∆ 5.4 pmol/mL, 95% CI: -0.46, 11.3) (Figure 5.18A). Moreover, inorganic 
+ vitamin C significantly increased BH4 concentration in the same age group (∆ 145 pg/mL, 
95% CI: 41.3, 250) (Figure 5.18B). In contrast, inorganic + vitamin C significantly reduced 3-
NT in younger participants only (∆ -93.5 nmol/mL, 95% CI: -170, -17.4) (Figure 5.18C). The 
effect of inorganic + vitamin C co-administration on BH4 and 3-NT concentrations was greater 
than the sum of the effects of both intervention given separately (Figure 5.18B and Figure 
5.18C).    
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Figure 5.7: Plasma  𝑵𝑶𝟑
− (A) and   𝑵𝑶𝟐
− (B) in younger (n= 10) and older participants 
(n= 10) given a single dose of inorganic  𝑵𝑶𝟑
−  (7 mg/kg body weight), vitamin C (20 
mg/kg) both agents combined or their placebos in a 2×2 factorial crossover design.  
Values are means ± SEMs. Data were analysed using linear mixed model. 
Unmatched letters denote significantly different from placebo (P < 0.05).  
   
120 
 
 
Figure 5.8: Plasma vitamin C (A) and dehydroascorbic acid (DHA) (B) in younger 
(n= 10) and older participants (n= 10) given a single dose of inorganic  𝑵𝑶𝟑
− (7 mg/kg 
body weight), vitamin C (20 mg/kg) both agents combined or their placebos in a 2×2 
factorial crossover design.  Values are means ± SEMs. Data were analysed using 
linear mixed model. Unmatched letters denote significantly different from placebo 
(P < 0.05). *: P < 0.05.  
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Figure 5.9: Systolic blood pressure (BP) (A) and the age × vitamin C interaction (B) in 
younger (n= 10) and older participants (n= 10) given a single dose of inorganic  𝑵𝑶𝟑
− 
(7 mg/kg body weight), vitamin C (20 mg/kg) both agents combined or their placebos 
in a 2×2 factorial crossover design. Values are means ± SEMs.  Data were analysed 
using linear mixed model. Unmatched letters denote significantly different from 
placebo (P < 0.05). **: P < 0.01. 
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Figure 5.10: Diastolic blood pressure (BP) (A), the age × vitamin C interaction (B) and 
inorganic  𝑵𝑶𝟑
− × vitamin C interaction (C) in younger (n= 10) and older participants (n= 
10) given a single dose of inorganic  𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 mg/kg) both 
agents combined or their placebos in a 2×2 factorial crossover design. Values are means ± 
SEMs. Data were analysed using linear mixed model. Unmatched letters denote 
significantly different from placebo (P < 0.05). **: P < 0.01. 
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Figure 5.11: Mean arterial blood pressure (BP) (A), the age × vitamin C interaction 
(B) in younger (n= 10) and older participants (n= 10) given a single dose of inorganic 
 𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 mg/kg) both agents combined or their 
placebos in a 2×2 factorial crossover design. Values are means ± SEMs.  Data were 
analysed using linear mixed model. Unmatched letters denote significantly different 
from placebo (P < 0.05). ***: P < 0.001.  
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Figure 5.12: Post-occlusive reactive hyperaemic blood flow (PORH) index (A) Pulse wave velocity (PWV) (B) and the 
distensibility coefficient (DC) (C) in younger (n= 10) and older participants (n= 10) given a single dose of inorganic  𝑵𝑶𝟑
− (7 
mg/kg body weight), vitamin C (20 mg/kg) both agents combined or their placebos in a 2×2 factorial crossover design.  Values 
are means ± SEMs. Data were analysed using linear mixed model. Unmatched letters denote significantly different from 
placebo (P < 0.05). m/s: meter per second.  
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Figure 5.13: Square root of the mean of the squared differences (RMSSD) of 
successive normal R-R intervals over a full 3 hours recording in younger (n= 10) and 
older participants (n= 10) given a single dose of inorganic  𝑵𝑶𝟑
− (7 mg/kg body 
weight), vitamin C (20 mg/kg) both agents combined or their placebos in a 2×2 
factorial crossover design. Values are means ± SEMs. Data were analysed using 
linear mixed model. Unmatched letters denote significantly different from placebo 
(P < 0.05). ms: millisecond.  
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Figure 5.14: The percentage of intervals that differ from each other by more than 50ms 
(pNN50) over a full 3 hours recording  (A), the age × vitamin C interaction (B) and 
inorganic  𝑵𝑶𝟑
− × vitamin C interaction (C) in younger (n= 10) and older participants 
(n= 10) given a single dose of inorganic  𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 
mg/kg) both agents combined or their placebos in a 2×2 factorial crossover design. 
Values are means ± SEMs. Data were analysed using linear mixed model. Unmatched 
letters denote significantly different from placebo (P < 0.05). **: P < 0.01 
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Figure 5.15: Standard deviation of the instantaneous RR variability (SD1) over a full 3 
hours recording in younger (n= 10) and older participants (n= 10) given a single dose 
of inorganic  𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 mg/kg) both agents combined 
or their placebos in a 2×2 factorial crossover design. Values are means ± SEMs. Data 
were analysed using linear mixed model. Unmatched letters denote significantly 
different from placebo (P < 0.05). ms: millisecond. 
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Figure 5.16: Standard deviation of the continuous variability of the heart rate (SD2) 
over a full 3 hours recording  in younger (n= 10) and older participants (n= 10) given a 
single dose of inorganic  𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 mg/kg) both agents 
combined or their placebos in a 2×2 factorial crossover design. Values are means ± 
SEMs. Data were analysed using linear mixed model. Unmatched letters denote 
significantly different from placebo (P < 0.05). ms: millisecond. 
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Figure 5.17: The low frequency/high frequency ratio (LF/HF) over a full 3 hours 
recording   in younger (n= 10) and older participants (n= 10) given a single dose of 
inorganic  𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 mg/kg) both agents combined 
or their placebos in a 2×2 factorial crossover design. Values are means ± SEMs. Data 
were analysed using linear mixed model. Unmatched letters denote significantly 
different from placebo (P < 0.05). ms: millisecond. 
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Figure 5.18: Plasma cyclic guanosine monophosphate (cGMP) (A) tetrahydrobiopterin (BH4) (B) and 3 nitrotyrosine (3-NT) (C) in 
younger (n= 10) and older participants (n= 10) given a single dose of inorganic  𝑵𝑶𝟑
− (7 mg/kg body weight), vitamin C (20 mg/kg) 
both agents combined or their placebos in a 2×2 factorial crossover design.  Values are means ± SEMs. Data were analysed using 
linear mixed model. Unmatched letters denote significantly different from placebo (P < 0.05).  
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5.4 Discussion  
5.4.1 Summary of findings  
Higher BP and lower HRV indices observed in older participants. Nevertheless, the 
administration of inorganic 𝑁𝑂3
− and vitamin C, individually or combined, significantly 
improved the above outcomes in the same age group. Moreover, inorganic 𝑁𝑂3
− significantly 
modified the effects of vitamin C on diastolic BP and pNN50 index in younger participants. 
Finally, inorganic 𝑁𝑂3
− and vitamin C co-supplementation yielded synergistic effects on arterial 
stiffness indices (PWV and DC), HRV indices (RMSSD and pNN50) and circulatory 
biomarkers (BH4 and 3-NT).    
5.4.2 Effects on plasma 𝑵𝑶𝟑
− and 𝑵𝑶𝟐
− 
The administration of inorganic 𝑁𝑂3
− to our participants was associated with a significant 
increase in the concentrations of plasma  𝑁𝑂3
− and 𝑁𝑂2
−. In contrast to our previous study 
(Chapter 4), we did not observe a significant difference in plasma 𝑁𝑂3
− between younger and 
older participants. This suggests that adiposity and hyperglycaemia modified 
plasma 𝑁𝑂3
−/ 𝑁𝑂2
− concentrations in older people. It seems that, in older obese individuals, 
hyperglycaemia may have a detrimental effect on NO metabolites. In older participants, we 
observed a significant increase in 3-NT (biomarker of oxidative stress). This rise in oxidative 
stress may enhanced the conversion of  𝑁𝑂2
− and NO to ONOO- and then eventually to 3-NT 
(Bailey et al., 2014; Teixeira et al., 2016).  
In the current study, we did not observe any modifying effects of vitamin C on plasma levels 
of  𝑁𝑂3
− and 𝑁𝑂2
−. This is in contrast with previous studies who showed a significant reduction 
in plasma S-nitrosothiols and 𝑁𝑂2
− after combined supplementation of flavonoids and inorganic 
𝑁𝑂3
− (Bondonno et al., 2012; Rodriguez-Mateos et al., 2015).  
5.4.3 Effects on plasma vitamin C and DHA 
As expected, in both younger and older participants, plasma concentrations of vitamin C 
significantly increased after vitamin C administration. However, only in older participants, 
vitamin C intake caused significantly higher concentration of DHA. DHA is an oxidised product 
of ascorbic acid, it is formed at the end of protective antioxidant process of vitamin C (Sibmooh 
et al., 2008). DHA can be regenerated back to ascorbic acid with the help of intracellular 
reducing agents such as glutathione or NADPH (Sibmooh et al., 2008). Therefore, we may 
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speculate that age-related oxidative stress might enhance the oxidation of vitamin C to DHA. 
The other possible explanation is that the capacity of vitamin C to regenerate was compromised 
in older participants. Previous study in mice showed that ascorbic acid recycling capacity 
declined with age (Lykkesfeldt et al., 1998).  
5.4.4 Effects on BP 
We observed a significant reduction of -4 mmHg in systolic BP in older participants after single 
supplementation of inorganic 𝑁𝑂3
− or vitamin C. Furthermore, single or combined 
supplementation of inorganic 𝑁𝑂3
− and vitamin C significantly reduced mean BP (~-2.5 mmHg) 
in older individuals. Our results agreed with previous meta-analyses which showed significant 
reduction in systolic BP after vitamin C (-3.84 mmHg; 95% CI: -5.29, -2.38) and inorganic 
nitrate supplementation (-4.4 mmHg, 95% CI: -5.9, -2.8) (Juraschek et al., 2012; Siervo et al., 
2013).  
However, in the meta-analysis of vitamin C and blood pressure, Juraschek et al. (2012) 
observed a significantly higher reduction in systolic blood pressure in younger (age < 50 years) 
(-5.07 mmHg, 95% CI: -7.22 to -2.92) compared with older participants (age > 60 years) (-1.85 
mmHg, 95% CI: -2.94 to -0.77). Nevertheless, nearly half of the studies included in that meta-
analysis supplemented vitamin C with other micronutrients or pharmacological agents 
(Juraschek et al., 2012). Therefore, we cannot rule out the modifying effects of age on the 
hypotensive effects of vitamin C.    
In our study, the administration of vitamin C was associated with slight increase in BP in 
younger participants. However, in those participants, vitamin C supplementation was not 
associated with increase in oxidative stress markers (DHA and 3-NT). This suggests that the 
rise in BP may not have been a result of increased oxidative stress. Similarly, Magen et al. 
(2004) showed, in comparison with placebo, a significant increase of 4.2 mmHg in diastolic BP 
in hypertensive patients treated with vitamin C (500 mg/day) for 8 weeks. Another two studies 
also reported significant increase in diastolic BP (Title et al., 2000; Ward et al., 2005) with 
vitamin C administration. However, the latter two studies used a combination of vitamin C, 
vitamin E and folic acid (Title et al., 2000) or polyphenols (Ward et al., 2005). In contrast, in 
the present study, inorganic  𝑁𝑂3
− positively modified the effect of vitamin C on diastolic BP. 
Previous observational studies showed that 5-6 mmHg reduction in diastolic BP was associated 
with a 38 and 23% reduction in risk of stroke and CHD, respectively (Collins et al., 1990).    
   
 133 
5.4.5 Effects on arterial stiffness  
Combined inorganic 𝑁𝑂3
− and vitamin C supplementation significantly improved arterial 
stiffness indices (PWV and DC) in older participants. The effects of inorganic 𝑁𝑂3
− + vitamin 
C was greater than the effects of both agents when given separately. This denote that the 
interaction of inorganic 𝑁𝑂3
− and vitamin C was synergistic. Previously conducted meta-
analyses revealed no significant effects of inorganic 𝑁𝑂3
− or vitamin C supplementation on 
arterial stiffness indices (Chapter 2 and 3). Our finding of synergistic interaction of both dietary 
agent may have important health implications. However, due to the acute nature of the current 
study, this synergistic effect need to be confirmed in longer term clinical trials.  
The mechanism of this synergism might be enhanced conversion of 𝑁𝑂2
− to NO. However, this 
synergism is not mirrored by an increase in cGMP concentration, the second messenger of NO. 
Moreover, we did not observe significant change in the concentration of 𝑁𝑂2
− after inorganic 
𝑁𝑂3
− + vitamin C co-supplementation.  
Previous inorganic 𝑁𝑂3
− studies showed conflicting results regarding cGMP concentration. For 
example, supplementing mice with inorganic 𝑁𝑂2
− was associated with increased (Bryan et al., 
2005) or no changes in cGMP concentration (Carlstrom et al., 2010). In human study, Kapil et 
al. (2010a) showed that supplementing inorganic 𝑁𝑂3
− (24 mmol) to young male and female 
adults associated with significant increase in cGMP concentration. In a similar cohort, with a 
smaller dose of inorganic 𝑁𝑂3
− (8 mmol), Velmurugan et al. (2013) demonstrated a significant 
increase in cGMP in male volunteers only. Previous studies have shown that the vascular effects 
of NO are not completely dependent on cGMP production (Bolotina et al., 1994; Jaffrey and 
Snyder, 2001). 
Nevertheless, in our study, BH4 a co-factor of endogenous NO production increased 
significantly after the combined administration of both agents in a synergistic mode as well. 
BH4 depletion causes uncoupling of eNOS enzyme with the consequent production of 
superoxide free radicals instead of NO (Schmidt and Alp, 2007). Clinical studies have shown 
that BH4 supplementation may reverse endothelial dysfunction in healthy and in patients with 
cardio-metabolic disorders (Wang et al., 2014). In vitro studies demonstrated that vitamin C 
may enhance the stability of BH4 and, therefore, maintain high BH4-to-BH2 ratio (Mortensen 
and Lykkesfeldt, 2014). The proposed mechanisms include the ability of vitamin C to reduce 
the oxidised BH3 to BH4 and/or by preventing BH4 from being oxidised, in the first place, by 
free radicals (Mortensen and Lykkesfeldt, 2014). Feeding wild-type mice diet containing 1% 
vitamin C significantly increased BH4 concentration in the aorta (d'Uscio et al., 2003).  
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In addition to vitamin C, inorganic 𝑁𝑂3
− supplementation significantly increased BH4 
concentration. Previous study in mice showed that the administration of inorganic  𝑁𝑂2
−  
significantly increased BH4 concentration and improved BH4-to-BH2 ratio (Stokes et al., 
2009). The proposed mechanism might be linked to the antioxidant effects of inorganic 𝑁𝑂3
−, 
therefore protecting BH4 from being oxidised or regenerating it from the oxidised form (BH2) 
(Stokes et al., 2009). Therefore, besides being an external source of NO, our study showed the 
ability of inorganic 𝑁𝑂3
− to contribute to the endogenous NO production by increasing the 
concentration of BH4. 
In our study, combined inorganic 𝑁𝑂3
− and vitamin C administration significantly reduced 3-
NT concentration in younger participants. Like BH4, the combined supplementation showed 
synergistic interaction on 3-NT concentration. A study involved healthy volunteers showed that 
high dietary 𝑁𝑂3
− intake has no significant effect on plasma 3-NT concentrations (Pannala et 
al., 2003). Likewise, inorganic 𝑁𝑂3
− did not significantly change the concentration of platelets 
NT of healthy adults (Richardson et al., 2002). In our previous study (Chapter 4), 
inorganic 𝑁𝑂3
− administration significantly reduced the concentration of 3-NT. However, in 
that study, we included obese participants subjected to acute hyperglycaemia. Therefore, higher 
levels of oxidative stress were expected in their blood than the participants included in the 
current study. Similarly, vitamin C supplementation did not reduce 3-NT concentration 
significantly in healthy volunteers (Wray et al., 2012). However, a significant reduction only 
seen in participants with higher oxidative stress (Ceriello et al., 2013). In contrast, the present 
study showed that both inorganic 𝑁𝑂3
− and vitamin C when administrated together will 
significantly reduce 3-NT concentration in young healthy volunteers. This may signify 
potentiation of the effects of both agents when given together.   
5.4.6 Effects on skin microvascular blood flow  
Marginal improvement in cutaneous microvascular blood flow was observed in younger and 
older participants after inorganic 𝑁𝑂3
− supplementation. Previous study demonstrated that 
supplementation of beetroot for three days to young healthy non-obese individuals significantly 
improved laser Doppler blood flow (Levitt et al., 2015). However, 3 weeks supplementation of 
6 mmol of inorganic 𝑁𝑂3
− in the form of beetroot to older (> 62 years) overweight and obese 
participants did not significantly improved cutaneous microvascular blood flow (Ashor et al., 
2015a). In line with above study, Gilchrist et al. (2013) did not find significant improvement in 
skin microvascular blood flow after 2 weeks of  𝑁𝑂3
−-rich beetroot supplementation of diabetic 
patients. Nevertheless, our findings agree with the results of our meta-analysis testing the 
   
 135 
effects of inorganic  𝑁𝑂3
− on EF which revealed a higher efficacy in healthy non-obese 
participants (Chapter 2).      
5.4.7 Effects on HRV indices  
Inorganic  𝑁𝑂3
− significantly improved HRV indices (SD1 and SD2) in older but not younger 
participants. Low HRV variability is regarded as an important predictor of mortality and 
morbidity in patients with acute myocardial infarction (Huikuri and Stein, 2012). Moreover, 
HRV indices considered to be risk factors for all-cause, cardiac and arrhythmic deaths (Huikuri 
and Stein, 2012). Previous study demonstrated that inorganic  𝑁𝑂3
− significantly increase 
SDNN in healthy African American female adults (Bond et al., 2014). However, recent studies 
did not report a significant improvement of HRV indices after the administration of inorganic 
 𝑁𝑂3
−  (Alsop and Hauton, 2016; Ashor et al., 2016a). The proposed mechanisms of increased 
HRV with inorganic 𝑁𝑂3
− might be related to the ability of NO to enhance parasympathetic and 
reduced sympathetic activities of the heart (Sartori et al., 2005).   
Combined inorganic 𝑁𝑂3
− and vitamin C supplementation demonstrated a synergistic 
interaction in raising RMSSD and pNN50 in older participants. The antioxidant and NO-sparing 
properties of inorganic  𝑁𝑂3
− and vitamin C might be the reason of this improvement in HRV 
(Piccirillo et al., 2003; Monahan et al., 2004; Bond et al., 2014). Previous studies suggest that 
oxidative stress and reduction in NO availability contribute mechanistically to the age-
associated reduction in HRV (Monahan et al., 2004). Moreover, a study in rabbits claimed that 
vitamin C administration in the absence of oxidative stress has no influence on HRV indices 
(Z. Li et al., 1996). Therefore, it seems that inorganic 𝑁𝑂3
− and vitamin C significantly 
improved HRV in older participants by reducing oxidative stress and increasing NO 
availability. Previous study showed that the acute infusion of vitamin C to eight young (23 
years) and seven older (63 years) individuals was associated with a significant improvement in 
HRV in older but not younger participants (Monahan et al., 2004).  
5.4.8 Public health implications  
In older participants, systolic BP was reduced by -4 mmHg following inorganic  𝑁𝑂3
− or 
vitamin C supplementation. It has been suggested that, in moderately hypertensive individuals, 
a 5 mmHg reduction in BP might reduce the incidence of stroke by 22% and CHD by 16% and 
prevent up to 75,000 deaths per year (Vanhatalo et al., 2010). Moreover, we should take into 
consideration that our participants were healthy, well-nourished and with normal BP. 
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Therefore, a reduction of -4 mmHg in systolic BP might have greater benefits in population at 
risk e.g. obese, undernourished or individuals with underlying cardiovascular diseases. 
Inorganic  𝑁𝑂3
− and vitamin C are common in our everyday diet and both have been considered 
to possess beneficial cardiovascular effects. Therefore, studying the possibility of interaction 
of these two dietary agents on cardiovascular markers allow for a better understanding of their 
beneficial roles in our normal diet. In our study, inorganic  𝑁𝑂3
− + vitamin C displayed a 
reduction of -2 m/s in PWV in older participants. Previous meta-analysis of 17 longitudinal 
studies (15,877 subjects, followed-up for a mean of 7.7 years) showed that every 1 m/s increase 
in aortic PWV is associated with 14% increase in the risk of cardiovascular events and 15% 
increase in the risk of CVD mortality (Vlachopoulos et al., 2010).   
5.4.9 Strengths and limitations  
The dietary factors inorganic 𝑁𝑂3
− and vitamin C are abundant in our diet and are frequently 
co-ingested in our meals. In the current study, we have demonstrated for the first time, the 
potential of beneficial synergistic interaction of inorganic 𝑁𝑂3
− and vitamin C on markers of 
CVDs. Moreover, these beneficial effects are further augmented in older population. The 
crossover Latin-square design ensures a strict within-volunteer control of factors that may affect 
the outcomes such as age, body composition and health status. In the current study, we included 
a selected population of healthy normal/overweight population with no diseases or drug 
treatments that may confound our results. Moreover, the presence of two separate age groups 
helped in understanding the modifying effects of age on our interventions. However, there are 
some limitations associated with the study need to be addressed in future clinical trials. We did 
not investigate the possibility of interactions of vitamin C with inorganic 𝑁𝑂3
− in the oral cavity 
(no saliva samples collected), stomach (expelled stomach NO was not collected) and urinary 
system (no urine samples collected). Moreover, we did not use FMD and carotid-femoral PWV; 
these regarded as the gold standard measures of endothelial function (Inaba et al., 2010) and 
arterial stiffness (Ben-Shlomo et al., 2014), respectively.     
5.4.10 Conclusions  
Age was a modifier of the effects of vitamin C and inorganic 𝑁𝑂3
− on markers of CVD risk. 
Furthermore, inorganic 𝑁𝑂3
− and vitamin C co-supplementation yielded greater effects than 
each intervention alone on arterial stiffness and HRV indices and circulatory biomarkers. 
Inorganic 𝑁𝑂3
− qualitatively modified the effects of vitamin C on diastolic BP and HRV. Since 
these micronutrients complement each other by working on different molecular pathway, 
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combined administration of inorganic 𝑁𝑂3
− and vitamin C may have additive or synergistic 
interaction on vascular health. Moreover, to avoid the adverse effects linked to higher doses of 
inorganic 𝑁𝑂3
− and vitamin C, co-supplementation of these micronutrients in lower doses might 
produce greater beneficial effects than each intervention alone. Future studies should focus on 
addressing the mechanisms and the potential sites of interactions of vitamin C and 
inorganic 𝑁𝑂3
−.  
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Chapter 6. General discussion and conclusions    
6.1 Overview  
Cardiovascular mortality varies between countries; relatively low mortality rates are observed 
in Japan and Mediterranean countries in comparison with other high-income countries (Lidder 
and Webb, 2013). Nutritional and life-style factors (i.e., anti-oxidants, essential fatty acids, salt 
intake, physical inactivity, stress) significantly affect the incidence and prevalence of CVD 
(Kapil et al., 2010b). Epidemiological studies have consistently showed that a balanced diet 
rich in fruits and vegetables lowers CVD risk (Crowe et al., 2011). Such foods contain multiple 
bioactive components which can influence a wide range of CVD risk factors including blood 
lipids, insulin sensitivity, oxidative stress, inflammation and ED (Shen et al., 2015). Reduced 
NO availability is one of the primary hallmarks of ED (Hobbs et al., 2013). In addition, the 
discovery of the role of NO in the regulation of EF, angiogenesis and platelet aggregation 
contributed to the deeper understating of the physiological and biomolecular mechanisms 
preceding the development of atherosclerosis and CVD (Nichols et al., 2013). Inorganic 𝑁𝑂3
− 
may represent a key dietary component linked to the health benefits of Japanese and 
Mediterranean diets (Lidder and Webb, 2013) and explained by an increased availability of NO 
derived from the non-enzymatic  𝑁𝑂3
−- 𝑁𝑂2
−-NO pathway (Lundberg et al., 2006). 
Vitamin C is an essential nutrient which has antioxidant roles in the human body (Padayatty et 
al., 2003). It is regarded by some investigators as the most important antioxidant in human 
plasma (Halliwell, 1996). Ascorbic acid (the reduced form of vitamin C) scavenges 
physiologically relevant reactive oxygen and nitrogen species (Carr and Frei, 1999). Evidence 
from observational studies demonstrating associations between higher vitamin C intake (or 
status) and better cardiovascular health (Fletcher et al., 2003). Meta-analysis of data from 9 
cohort studies showed that vitamin C supplementation at doses exceeding 700 mg/day was 
associated with 25% reduction in coronary heart disease risk (Knekt et al., 2004). 
Advanced age is regarded as a major risk factor for CVD (Sindler et al., 2011). Ageing is 
associated with complex structural and functional changes in the vascular system including ED 
and increased arterial stiffness (Jani and Rajkumar, 2006). BH4 and L-arginine, two key 
cofactors in NO production, are reduced in skeletal muscle arterioles with increasing age (Delp 
et al., 2008). Moreover, the low concentration of  𝑁𝑂2
− found in the arteries, heart, and plasma 
of aged mice was successfully reversed by the administration of inorganic 𝑁𝑂2
− (Sindler et al., 
2011). Therefore, development of nutritional strategies to increase NO availability in 
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endothelial cells and so attenuate vascular ageing could positively impact on CVD risk and 
improve the quality of life and life expectancy of older people (El Assar et al., 2012). 
6.2 Inorganic 𝑵𝑶𝟑
− and EF  
In the second chapter of this thesis, I examined published evidence regarding the efficacy of 
inorganic 𝑁𝑂3
− and beetroot supplementation on EF. Additionally, I investigated whether the 
effect of 𝑁𝑂3
− on EF was modified by the participants’ characteristics (age, health status, 
baseline BMI and baseline BP) or study characteristics (design, dose and duration of 
inorganic 𝑁𝑂3
− supplementation). I found that supplementation with inorganic 𝑁𝑂3
− or beetroot 
resulted in significant improvement in FMD and that the improvement in EF tended to be 
greater in younger, non-obese and healthy participants. However, neither PWV nor AIx was 
improved by these interventions. Nevertheless, inorganic 𝑁𝑂3
− or beetroot administration in 
larger doses might be associated with greater reduction in PWV (Figure 2.5, Chapter 2).  
6.3 Vitamin C and EF 
Vitamin C is a powerful antioxidant that may mitigate the earliest stages of atherosclerosis 
through several mechanisms (Aguirre and May, 2008). One of these mechanisms is the ability 
of vitamin C to augment NO availability (May and Harrison, 2013). Vitamin C inactivates 
superoxide free radicals, stabilizes BH4, enhances eNOS activity and preserves L-arginine and 
cGMP (May, 2000). All the above factors are important for endogenous production of NO 
(Forstermann, 2010). Moreover, vitamin C may enhance NO production through the exogenous 
(dietary)  𝑁𝑂3
−- 𝑁𝑂2
−- NO pathway (Hord et al., 2009).  
In the third chapter of my thesis, I conducted an umbrella review which investigated the effects 
of vitamin C supplementation on markers of cardiovascular diseases (i.e. arterial stiffness, 
blood pressure, EF, glycaemic index and lipid profile). My secondary aim was to explore the 
factors that may modify the effects of vitamin C on these cardiovascular markers. The included 
studies revealed little evidence for an overall effect of vitamin C supplementation on markers 
of CVD risk. However, subgroup and meta-regression analyses indicated significant benefits in 
older participants and in those with higher BMI, lower vitamin C status and at higher CVD risk.  
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6.4 Impact of inorganic 𝑵𝑶𝟑
− on adverse cardio-metabolic effects induced by acute 
hyperglycaemia in younger and older obese participants  
Ageing, obesity and hyperglycaemia are major risk factors for CVD (Ahima, 2009). The 
adverse effects of these risk factors may be mediated by oxidative and inflammatory stress 
which causes endothelial dysfunction by decreasing NO availability (El Assar et al., 2012; Mah 
and Bruno, 2012). Reactive oxygen species deplete arginine, oxidise BH4 and enhance ADMA, 
consequently causing eNOS uncoupling which produces free radicals and further reduces NO 
availability (Mah and Bruno, 2012).  
In chapter four of my thesis, I conducted a crossover RCT aimed at testing whether the 
administration of inorganic  𝑁𝑂3
− could ameliorate the acute adverse effects of postprandial 
hyperglycaemia on vascular function in obese participants. I also tested the hypothesis that the 
response to the  𝑁𝑂3
− administration was age-dependent with potentially greater benefits in 
older than in younger participants. Following inorganic 𝑁𝑂3
− supplementation, I observed a 
two-fold higher plasma NOx concentrations in young compared with older participants. 
Moreover, significantly lower concentrations of cGMP and thrombomodulin and higher 
concentration of ICAM-3 were observed in older compared to younger participants. This may 
reflect a state of greater inflammation and oxidative stress in the older participants. 
Supplementation with inorganic 𝑁𝑂3
− produced greater improvements in biomarkers of 
inflammation (IL-6) and oxidative stress (3-NT) in older compared with young participants. 
Conversely, greater improvement in biomarkers of endothelial function (P- and E-selectin) was 
observed in younger rather than older participants. However, no changes in cutaneous 
microvascular blood flow was observed in either age group. Therefore, the findings from this 
study imply that younger and older participants may respond differently to a single dose of 
inorganic 𝑁𝑂3
− in the presence of acute hyperglycaemia. In older participants, oxidative stress 
(increased 3-NT) and inflammation (increased IL-6) elicited by acute hyperglycaemia was 
ameliorated by the co-administration of a single dose of inorganic 𝑁𝑂3
−. In contrast with 3-NT 
and IL-6, in older participants, non-significant changes in E selectin and P selectin 
concentrations were observed after the glucose challenge. These blunted responses might 
reflect the ED in the arteries of older participants and might explain the absence of effects of 
inorganic 𝑁𝑂3
− on these biomarkers.  
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6.5 Effects of inorganic 𝑵𝑶𝟑
− and vitamin C in younger and older participants  
Evidence presented in Chapters 2 and 3 showed that supplementation with either inorganic 
 𝑁𝑂3
− or vitamin C may improve markers of EF in certain circumstances. Both dietary factors 
have the potential to improve NO availability (May, 2000; Hobbs et al., 2013) and both have 
anti-inflammatory and antioxidant functions (Aguirre and May, 2008; Ashor et al., 2016a). 
However, the effects of supplementation with each food component depended on the 
characteristics of the included population. While the effects of vitamin C were greater (or 
detectable only) in older, obese participants and in those with underlying diseases (Ashor et al., 
2014a; Ashor et al., 2015b), the effects of inorganic  𝑁𝑂3
−  were larger in younger, non-obese 
and healthy participants (Lara et al., 2015).    
In Chapter 5, I reported the findings from a 2x2 factorial crossover RCT in healthy non-obese 
young and older adults which was designed to investigate the potential additive or synergistic 
effects of vitamin C and inorganic  𝑁𝑂3
−  on BP, HRV and vascular function. The secondary 
aim was to determine whether age modified the effects of vitamin C and inorganic 𝑁𝑂3
− 
interventions. In contrast with results from studies in obese participants (reported in Chapter 4), 
there was no difference in plasma 𝑁𝑂3
− response to oral supplementation in the non-obese 
participants. I observed significant increase in plasma  𝑁𝑂2
− after inorganic 𝑁𝑂3
− 
supplementation, and this effect was not modified by vitamin C co-administration. However, 
inorganic 𝑁𝑂3
− + vitamin C showed synergistic effects on arterial stiffness, HRV indices and 
circulatory biomarkers. Still, we did not observe similar synergistic effects in BP, skin 
microvascular blood flow and cGMP concentration. Moreover, vitamin C showed different 
effects on BP in young and older participants. Supplementation with this vitamin tended to 
reduce BP in older participants but increase it in younger participants. Similar findings were 
also observed in HRV index (pNN50). However, these unexpected effects of vitamin C 
supplementation on BP in younger participants appeared to be mitigated by the co-
administration of inorganic 𝑁𝑂3
−.  
6.6 Personalized approach to nutritional interventions 
Personalized medicine or precision medicine is the treatments that targeted to the needs of 
individual patients based on genetic, biomarker, phenotypic, or psychosocial characteristics that 
distinguished a given patient from other patients with similar clinical presentation (Jameson 
and Longo, 2015). The aim of personalized medicine is to improve the clinical outcomes for 
individual patients and minimizing unnecessary side effects for those less likely to have a 
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response to a specific treatment (Jameson and Longo, 2015). In the first two chapters, we 
observed that participants’ characteristics such as age, BMI or health status significantly 
modified the effects of inorganic  𝑁𝑂3
− or vitamin C on cardiovascular diseases markers. Meta-
analysis of RCTs (Chapter 2) revealed that inorganic 𝑁𝑂3
− significantly improved EF. 
However, these effects tend to be greater in younger, healthier, non-obese populations. Several 
factors modulate the effects of vitamin C on CVD markers (Chapter 3). Meta-analysis studies 
reported greater improvement of EF in older, obese population (Chapter 3). Moreover, dose, 
duration and health status significantly modified the effects of vitamin C on CVD markers 
(Chapter 3).  
On the other side, in the RCTs reported in chapter 4 and 5 we used age as phenotypic 
characteristic that dictate the personalized approach with our interventions. We noticed that age 
significantly modified the effects of inorganic 𝑁𝑂3
− and vitamin C on cardiovascular outcomes. 
In the inorganic 𝑁𝑂3
− and hyperglycaemia RCT (Chapter 4), significant improvements in 
biomarkers of EF were seen in younger participants only. Moreover, for the first time, this RCT 
showed that inorganic  𝑁𝑂3
− could ameliorate oxidative- and inflammatory stress induced by 
hyperglycaemia in older obese participants. Likewise, in the RCT of inorganic 𝑁𝑂3
− and 
vitamin C (Chapter 5), I observed that age significantly modified the effects of vitamin C on 
BP and HRV indices.  
Results from my thesis emphasized the importance of a personalized approach for increasing 
the efficacy of dietary interventions with vitamin C and inorganic 𝑁𝑂3
−. Furthermore, my 
results may partially explain the failure of antioxidant vitamins to show cardiovascular 
protective effects in large scale interventional studies. Recruiting individuals with diverse 
phenotypic and metabolic profiles may dilute any potential protective effects in subgroups of 
population who may benefit more from these interventions. Therefore, future studies should 
implement a careful selective recruitment strategy, informed by evidence-based literature 
synthesis to maximize the potential benefits of nutritional interventions.    
6.7 Inorganic  𝑵𝑶𝟑
− and vitamin C: looking beyond NO availability   
Inorganic 𝑁𝑂3
− and vitamin C supplementation significantly reduced BP and increased HRV 
indices. However, these changes in BP and HRV were not mirrored with an increase in cGMP 
concentration suggesting that some of the beneficial effects of these dietary agents were cGMP-
independent. Inorganic 𝑁𝑂3
− significantly reduced inflammatory and oxidative stress markers 
in younger and older obese individuals in response to hyperglycaemia (Chapter 4). Moreover, 
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inorganic 𝑁𝑂3
− marginally reduced oxidative stress marker concentrations in younger and older 
non-obese participants (Chapter 5). Therefore, our two RCTs demonstrated that inorganic 𝑁𝑂3
−, 
besides being an exogenous source of NO, may have anti-inflammatory and free radical 
scavenging properties.   
Exploring the mechanisms of action of inorganic 𝑁𝑂3
− and vitamin C is beyond the scope of 
the present study. However, the following are speculations about the proposed mechanism of 
the beneficial effects of both interventions on BP and vascular function. Bryan et al. (2005) 
demonstrated that some of the effects of circulatory 𝑁𝑂2
− are NO-independent. The authors 
showed the ability of  𝑁𝑂2
−  to modulate signaling pathways by enhancing gene expression or 
by post-translational modification of proteins (Bryan et al., 2005). Additionally, previous 
studies have shown that the vascular effects of NO are not completely dependent on cGMP 
production (Bolotina et al., 1994; Jaffrey and Snyder, 2001).   
Previous study showed that pharmacological doses of vitamin C increased hydrogen peroxide 
(H2O2) production (Chen et al., 2007). Furthermore, experimental studies demonstrated that 
H2O2 has vasodilator properties independent of NO pathway (Feletou et al., 2010). The 
mechanisms of the H2O2-induced vascular relaxation involve stimulation of endothelium 
derived hyperpolarizing factors (EDHFs) (Feletou et al., 2010). In an in vitro study of rabbit 
iliac arteries, Garry et al. (2009) showed that vitamin C and BH4 induced relaxation of vessel 
wall by NO-independent, EDHF-dependent mechanisms. Moreover, the relaxation was 
abolished by the addition of H2O2 inhibitor (catalase) (Garry et al., 2009).  
Evidence of negative responses to vitamin C in the younger participants appears to support the 
emerging notion of a potential beneficial role of free radicals in vascular protection. In addition 
to direct vasodilatory properties, free radicals may also play an important role in the 
upregulation of endogenous antioxidant capacity through increased expression of several 
enzymes known to “detoxify” free radicals (Liu et al., 2003; Ristow et al., 2009). Therefore, 
we speculate that, in younger participants, where pro-oxidant and antioxidant forces are 
somewhat balanced, the aggressive reduction in free radical concentration after vitamin C 
administration may have removed or suppressed certain oxidative species that possess some 
beneficial properties in terms of vascular regulation, resulting in the observed increase in BP. 
6.8 Public health implications  
In contrast to the unsatisfactory findings from large-scale clinical trials concerning the 
beneficial effect of chronic antioxidant vitamins administration on cardiovascular health 
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(Honarbakhsh and Schachter, 2009), the present study has identified an acute improvement in 
markers of cardiovascular diseases. However, the difference in design between acute and long-
term interventional studies limits a direct comparison with data from these previous studies. 
Nevertheless, using this short-term, interventional design has allowed us to demonstrate the 
ability of our interventions to reverse the age-associated deterioration in physiological markers 
in older participants without the additional confounding variables associated with longer-term 
treatment studies (Michels and Frei, 2013).  
Findings from my PhD thesis provide important mechanistic and physiological insights 
regarding the link between endothelial dysfunction and oxidative stress in the elderly and 
demonstrate the ability of these single-dose acute interventions to improve cardiovascular 
biomarkers. Moreover, inorganic 𝑁𝑂3
− and vitamin C are abundant in our diet and usually 
consumed together in everyday meals. Therefore, studying the interaction between these 
nutrients is vital to our understanding of the mechanisms of their beneficial effects in diet. After 
all, due to the acute nature of the current studies, we cannot support at this stage the beneficial 
effects of inorganic 𝑁𝑂3
− and vitamin C on cardiovascular health, which awaits confirmation in 
longer-term clinical trials.  
Previously research concentrated on studying the effects of individual components of diet on 
cardiovascular health (e.g. antioxidant vitamins, polyphenols or inorganic 𝑁𝑂3
−) (Hooper et al., 
2008; Myung et al., 2013; Siervo et al., 2013). While it is crucial to study the effects of 
individual components, it is uncertain whether consumption of a single active dietary 
component will have the same beneficial effects as when it is consumed as part of a whole food 
or combination of food (Bondonno et al., 2015a). Combined administration of micronutrients 
may have additive or synergistic interaction due to the fact that these micronutrients 
complement each other by working on different molecular pathway (Bondonno et al., 2015a).  
We detected a -4 mmHg reduction in systolic BP with inorganic 𝑁𝑂3
− or vitamin C 
supplementations. In moderately hypertensive individuals, a 5 mmHg reduction in BP might 
reduce the incidence of stroke by 22% and CHD by 16% and prevent up to 75,000 deaths per 
year (Vanhatalo et al., 2010). Moreover, we should take into consideration that our participants 
were healthy, well-nourished and with normal BP. Therefore, a reduction of -4 mmHg in 
systolic BP might be more augmented in population at risk e.g. obese, undernourished or 
individuals with underlying cardiovascular diseases. Moreover, combined supplementation 
with inorganic 𝑁𝑂3
− and vitamin C determined a reduction of -2 m/s in PWV (Chapter 5). 
Previous meta-analysis of 17 longitudinal studies (15,877 subjects, followed-up for a mean of 
   
 145 
7.7 years) showed that every 1 m/s increase in aortic PWV is associated with 14% increase in 
the risk of cardiovascular events and 15% increase in the risk of CVD mortality (Vlachopoulos 
et al., 2010). Another meta-analysis of 18 longitudinal cohort studies (8169 participants; mean 
follow-up, 3.6 years) showed that every 1 m/s increase in brachial-ankle PWV is associated 
with 12% increase in the risk of cardiovascular events and 13% increase in the risk of CVD 
mortality (Vlachopoulos et al., 2012).  We observed, in older participants, a marked increase in 
HRV indices (SD1 and SD2) after inorganic 𝑁𝑂3
− supplementation (Chapter 5). In a cohort of 
5,272 participants aged 55 years and followed up for 4 years, investigators found that subjects 
in the lowest quartile of SDNN had 80% increase in the risk of cardiac mortality (hazard ratio 
= 1.8, 95% CI: 1 to 3.2) (de Bruyne et al., 1999). Another cohort study involved 605 individuals 
aged between 50 and 75 years followed-up for 9 years revealed that impaired SDNN was 
associated with an approximately 70% increase in the risk of all-cause mortality in 
subpopulation with diabetes (Gerritsen et al., 2001). Therefore, the ability of inorganic 𝑁𝑂3
− to 
improve HRV indices may have a significant impact on cardiovascular health.  
6.9 Strengths and limitations of experimental strategy 
In Chapter 4, we investigated for the first time, the effects of a single dose of inorganic  𝑁𝑂3
−  on 
hyperglycaemia-induced ED in both younger and older participants. The study had a robust 
experimental design (randomised, double-blind and cross-over) and to avoid a carry-over effect, 
we allowed one week wash-out period between each intervention. Previous study demonstrated 
that the concentrations of NO metabolites return to baseline levels after 24 h of consumption 
(James et al., 2015). In Chapter 5, the crossover Latin-square design ensures a strict within-
volunteer control of factors that may affect the outcomes such as age, body composition and 
health status. In that study, we included a selected population of healthy normal/overweight 
population with no diseases or drug treatments that may confound our results. Moreover, the 
presence of two separate age groups helped in understanding the modifying effects of age on 
our interventions. 
However, these crossover RCTs reported in Chapters 4 and 5 have several limitations. Both 
studies were acute studies with small sample size. We do not know whether the effects of 
intervention observed in these studies will last longer in chronic intervention trials. It was 
difficult to compare the concentrations of  𝑁𝑂2
−/ 𝑁𝑂3
− between the two studies due to the 
diverse methods used in handling the blood samples and the diverse method used in laboratory 
analysis. In the work reported in Chapter 4, due to logistic issues, blood samples processing 
were not immediately carried out after collection. Additionally, due to financial issues, we used 
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the available GC-MS method which was not sensitive enough to detect low concentration 
of 𝑁𝑂2
−. However, in the inorganic 𝑁𝑂3
− and vitamin C study we processed the blood directly 
after collection and we used Sievers NO analyser which is regarded as the gold-standard method 
for measuring  𝑁𝑂2
−/ 𝑁𝑂3
− in plasma (Pelletier et al., 2006).   
There are limitations associated with using LDF assessment of EF in our clinical trials. First, is 
the inability to determine the absolute blood flow value with LDF (Turner et al., 2008). LDF 
implements a semi-quantitative assessment of skin blood flow and is thus expressed in arbitrary 
PU (Turner et al., 2008). Second, the contribution of other molecules besides NO to the 
vasodilation associated with LDF. These molecules include prostaglandin I2 and EDHF 
(Kvandal et al., 2003; Holowatz et al., 2005). However, a recently conducted study excludes 
the possibility of contribution of prostaglandins to the vasodilatory response of PORH 
(Hellmann et al., 2015). Lastly, we did not measure NO-independent vasodilation using sodium 
nitroprusside due to a single chamber use. Therefore, we cannot exclude the possibility of 
structural changes in the vessel wall that may cause reduction in the vasodilator capacity of the 
vessels (Turner et al., 2008).  
6.10 Future work  
6.10.1 Long-term effects of inorganic 𝑵𝑶𝟑
− and vitamin C  
In Chapter 2 and 3 of this thesis, most of the studies included in the systematic reviews and 
meta-analyses had a short-duration. For example, the study with the longest duration 
investigating the effects of inorganic 𝑁𝑂3
− on BP and EF was 6 weeks (Velmurugan et al., 
2016). Similarly, the longest studies investigating the effects of vitamin C on BP (Fotherby et 
al., 2000) and EF (Schindler et al., 2003; Magen et al., 2004) were 12 and 8 weeks, respectively. 
However, these studies, together with our two crossover RCTs, cannot verify whether 
inorganic 𝑁𝑂3
− and vitamin C can sustain their efficacy in the long term. Therefore, the next 
step is to investigate the effects of these dietary agents on cardiovascular outcomes in longer-
duration RCTs.  
6.10.2 Effects of inorganic 𝑵𝑶𝟑
− and vitamin C in clinical population  
In our crossover RCTs, our targets were obese and non-obese, healthy younger (18-40 years) 
and older (55-70 years) population. Therefore, it is unknown whether our interventions, 
inorganic 𝑁𝑂3
− and vitamin C, will have similar effects in the elderly (> 70 years) or in 
populations with underlying cardiovascular diseases. Targeting those populations may have 
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much larger public health implications and may contribute to further improvements in quality 
of life.  
6.10.3 Effects of hyperglycaemia on NO metabolites  
We observed that plasma NOx concentration was double at baseline and after inorganic 𝑁𝑂3
− 
supplementation in younger compared with older obese participants subjected to acute 
hyperglycaemia (Chapter 4). In contrast, in the work reported in Chapter 5 which involved non-
obese younger and older participants (with no glucose challenge); there was no significant 
difference in plasma 𝑁𝑂3
− concentrations at baseline and after inorganic 𝑁𝑂3
− supplementation. 
This suggests that adiposity and hyperglycaemia modified plasma 𝑁𝑂3
−/ 𝑁𝑂2
− concentrations in 
older people. It seems that, in older obese individuals, hyperglycaemia may have a detrimental 
effect on NO metabolites. The heightened oxidative stress in older participants observed post-
glucose challenge (Chapter 4) might be the culprit of the reduction in plasma  𝑁𝑂3
− 
concentration. I suggest conducting a study of older obese and non-obese individuals. These 
participants will be subjected to acute hyperglycaemia and supplemented with a single dose of 
inorganic 𝑁𝑂3
−. The aim will be to study the effects of acute hyperglycaemia on NO metabolites 
and oxidative stress markers with and without  𝑁𝑂3
− supplementation. The secondary aim will 
be to investigate whether obesity modify the effects of inorganic 𝑁𝑂3
− supplementation on the 
study outcomes.  
6.10.4  Dose-response relationship of inorganic 𝑵𝑶𝟑
− and vitamin C 
In my vitamin C and inorganic 𝑁𝑂3
− study (Chapter 5), I used fixed doses of inorganic 𝑁𝑂3
− (7 
mg/kg) and vitamin C (20 mg/kg). Previous study of flavanols and inorganic 𝑁𝑂3
− 
supplementation reported a synergistic interaction at lower doses of both dietary factors rather 
than higher doses (Rodriguez-Mateos et al., 2015). Therefore, we recommend an intake-
response study of inorganic 𝑁𝑂3
− and vitamin C. In this study, we will use different doses of 
both inorganic 𝑁𝑂3
− and vitamin C to find out the optimal combinational doses that give the 
most beneficial effects, if any, on BP and EF. Furthermore, in addition to plasma, the 
concentrations of NO metabolites should be investigated in urine, saliva and stomach to verify 
the potential site of interaction of both interventions.    
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6.11 Conclusions  
Data synthesis of RCTs revealed significant improvement of measures of EF after 
supplementation with (often large doses of) inorganic 𝑁𝑂3
− and vitamin C for (usually) short 
time periods. However, participants’ characteristics such as age, BMI and health status 
significantly modified the effects of the above interventions. Inorganic 𝑁𝑂3
− tended to improve 
EF to a greater extent in younger, non-obese and healthy participants. In contrast, vitamin C 
seems to show greater improvement in older, obese and participants with higher CVD risk. 
These results emphasise the importance of a personalised approach to interventions with 
inorganic 𝑁𝑂3
− and vitamin C when attempting to enhance primary or secondary prevention of 
cardiovascular diseases. However, most of the detailed information of effects of inorganic 𝑁𝑂3
− 
or vitamin C supplementation on markers of EF have been derived from studies with small 
sample sizes and of short duration. Researchers should take these limitations in consideration 
when designing future studies.  
As anticipated, an acute glucose challenge increased inflammatory, oxidative stress markers 
and deteriorated NO availability and EF in both younger and older obese individuals. This 
provided a responsive experimental paradigm in which to demonstrate the acute effects of a 
single dose of inorganic 𝑁𝑂3
− in counteracting the adverse effects of hyperglycaemia. Greater 
improvement in biomarkers of EF was observed in younger participants. On other hand, older 
participants showed greater reduction in oxidative stress and inflammatory markers. These 
findings offer novel research questions to be investigated in future studies. Moreover, if 
confirmed in longer interventions, these findings could have important implications for the 
prevention and management of pathological processes associated with post-prandial 
hyperglycaemia. 
There is a potential of additive or synergistic interaction of inorganic 𝑁𝑂3
− and vitamin C on 
markers of CVDs that may have public health implications. The combination of inorganic 𝑁𝑂3
− 
and vitamin C may have greater beneficial effects on cardiovascular outcomes than the 
supplementation of individual agents. The aim of future research is to investigate whether low 
doses of inorganic 𝑁𝑂3
− and vitamin C will achieve greater cardiovascular protection than larger 
doses of these dietary agents given individually. Using low doses of inorganic 𝑁𝑂3
− and vitamin 
C in combination will alleviate the adverse effects associated with larger doses of these dietary 
agents.  
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Appendix A. Ethical approval of the inorganic 𝑵𝑶𝟑
− and hyperglycaemia 
study  
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Appendix B.   𝑵𝑶𝟑
− intake questionnaire  
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Appendix C. Protocols of laboratory analyses of inorganic  𝑵𝑶𝟑
− and 
hyperglycaemia study   
Protocol of 3’, 5’-cyclic guanosine monophosphate (cGMP) assay  
1. Plasma samples were thawed and kits reagent allowed equilibrating with room temperature 
before use.  
2. Wash buffer (WB) prepared by adding 95 ml of deionised water (DW) to 5 ml of wash 
buffer concentrate provided by the kits’ manufacturer.  
3. Assay buffer 2 prepared by adding 50 ml of DW to 50 ml of the concentrated 2X assay 
buffer 2 supplied by the manufacturer. 
4. Assay buffer 2 prepared in step 3 was used to dilute the standard stock provided by the 
manufacture (Table E.1).  
5. Plasma samples diluted 1:10 using assay buffer 2 
Table E.1: Preparation of the standards for cGMP Elisa kits   
Standard Assay buffer 2 in 
µL 
Volume added of standard 
in µL 
cGMP concentration 
(pmol/mL) 
1 900 100 of stock solution 500 
2 800 200 of standard 1 100 
3 800 200 of standard 2 20 
4 800 200 of standard 3 4 
5 800 200 of standard 4 0.8 
 
6. Standards, samples and reagents then added to the plate in the following order (Table E.2) 
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Table E.2: cGMP assay procedure and the addition of the reagents to the wells (volumes 
are in µL) 
 Blank 
A1, B1 
TA 
C1, D1 
NSB 
E1, F1 
Zero SD 
G1, H1 
Standards 
A2-B3 
Samples 
C3-H12 
Assay buffer 2 - - 100 100 - - 
Assay buffer 2 - - 50 - - - 
SD/Samples  - - - - 100 100 
Conjugate  - - 50 50 50 50 
Antibody  - - - 50 50 50 
Seal the plate and incubate for 2 hours at room temperature 
Wash 3 times with WB (200µL) (empty the plate contents in the sink after each 
wash) 
Conjugate  - 5 - - - - 
pNpp substrate  200 200 200 200 200 200 
Incubate for 1 hour 
Stop solution  50 50 50 50 50 50 
Reading the plate with a plate reader at 405 nm optical density   
 
 
Figure E.1: Example standard curve of cGMP analysis 
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Protocol of 3 nitrotyrosine assay  
1. Serum samples and reagents allowed to thaw and equilibrate with room temperature  
2. I prepared 1X Wash Buffer by diluting the 20X WB (25 mL, provided by the 
manufacturer) in DW (475 mL).  
3. I prepared 2X Incubation Buffer by adding 10 mL of 10X Blocking Buffer (provided 
by the manufacturer) to 40 mL of 1X Wash Buffer.   
4. The diluted 2X HRP-Detector antibody prepared by adding 12 µL of the 1000X HRP-
Detector antibody to 6mL of 2X Incubation Buffer (both provided by the manufacturer).  
5. Standard prepared using standard stock and serial dilution was done using 1mL of 1X 
Wash Buffer. The following series of dilution were used to prepare the SDs (Table E.3).  
Table E.3: Preparation of the standards for 3 nitrotyrosine Elisa kits   
Standard SD volume  Wash Buffer 
volume  
Final 
volume  
3 NT concentration 
(ng/mL) 
1 600 µL of 
stock 
0 µL 600 µL 2000 
2 300 µL of 1 600 µL 900 µL 666.66 
3 300 µL of 2 600 µL 900 µL 222.22 
4 300 µL of 3 600 µL 900 µL 74.07 
5 300 µL of 4 600 µL 900 µL 24.69 
6 300 µL of 5 600 µL 900 µL 8.23 
7 300 µL of 6 600 µL 900 µL 2.74 
8 300 µL of 7 600 µL 900 µL 0.91 
   
6. Standards, samples and reagents then added to the plate in the following order (Table 
E.4)  
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Table E.4: 3 nitrotyrosine assay procedure and the addition of the reagents to the wells 
 
 Blank 
B3, B4 
Standards 
A1-A4 
Samples 
C3-H12 
SD/Samples - 50µL 50µL 
HRP Detector antibody  50µL 50µL 50µL 
Cover plate and incubate in room temperature for 2 hours  
Wash the plate 3 times using 300µL of WB, then contents emptied  
HRP Development Solution  100µL 100µL 100µL 
Measure absorbance within 30 minutes using plate reader at 450 nm 
absorbance  
 
Figure E.2: Example standard curve of 3 nitrotyrosine analysis 
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Protocol of Human vascular injury multiplex (P selectin, E selectin, 
intercellular adhesion molecule 3 [ICAM 3] and thrombomodulin) assay  
1. Preparation of Blocker A: adding 20 mL of DW to 1.25 g Blocker A powder. Stir the 
mixture until all protein is suspended then add 5 mL of MSD Phosphate Buffer 
(provided with the kit).  
2. I added 150 L Blocker A to each well of the plate. Sealed the plate and incubated it on 
a plate shaker (600-700 rpm) at room temperature for 1 hour. 
3. Preparation of the washing solution: the washing solution composed of phosphate 
buffered saline with 0.05% Tween-20 (PBS-T). I added 1 PBS tablet to 1 L of deionised 
water. After complete disintegration of the tablet, I added 0.5 mL of Tween-20.  
4. Washing of the plates: after 1 hour incubation with Blocker A, I washed the plate 3 
times with 200 L per well of the PBS-T.  
5. Preparation of standards (Table E.5): to prepare the eight serial dilutions of the 
calibrators (standards), I used the Diluent 10 and a vial of Human Vascular Injury I 
Calibrator Blend (both provided with the kits). I started with Human Vascular Injury I 
Calibrator Blend as the top of the curve (1000 ng/mL). The second standard (250 
ng/mL) composed of 20 L of the stock added to 60 L of Diluent 10. The other five 
standards prepared by doing a 4-fold serial dilution to make calibrator solutions of 63, 
16, 3.9, 0.98 and 0.24 ng/mL. The 8th calibrator is diluent 10 alone (zero calibrator).  
Table E.5: Preparation of the standards for the human vascular injury I Elisa kits   
Standard SD volume  Assay buffer 
volume  
Final 
volume  
Biomarkers 
concentration (ng/mL) 
Stock  N/A N/A N/A 1000 
1 20 µL of 
stock 
60 µL 80 µL 250 
2 20 µL of 1 60 µL 80 µL 63 
3 20 µL of 2 60 µL 80 µL 16 
4 20 µL of 3 60 µL 80 µL 3.9 
5 20 µL of 4 60 µL 80 µL 0.98 
6 20 µL of 5 60 µL 80 µL 0.24 
7 (Blank) N/A 80 µL 80 µL 0 
 
6. After complete washing of the plate, I added 40 L of diluent 10 to each well of the 
plate.  
7. I added 10 L of Calibrator (start with the highest concentration 1000 ng/mL) in 
duplicate to the wells from A1 to H2.  
8. 10 L of samples then added to wells A3 to H12 in duplicates. The plate then incubated 
for 2 hours on shaker (700 rpm) at room temperature.  
9. After 2 hours incubation, I washed the plate three times with 200 L of PBS-T. 
10. Preparation of 1X detection antibody: I added 60 L of 50X SULFO-TAG Detection 
Antibody Blend (provided with kit) to 2.94 mL of Diluent 10.   
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11. I added the 25 L of the detection antibody solution to each well of the plates and 
incubate for another 1 hour at room temperature with shaking at 700 rpm.  
12. Preparation of the read buffer: I added 5 mL of 4X Read Buffer T (provided with kit) to 
15 mL deionised water 
13. One hour later, I washed the plate 3 times again with PBS-T (200 L).  
14. I prepared the MSD reader so the plate can be read immediately after adding the read 
buffer to the plates (150 L).  
 
Figure E.3: Example standard curve of E selectin analysis 
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Figure E.4: Example standard curve of P selectin analysis 
 
Figure E.5: Example standard curve of intercellular adhesion molecule 3 (ICAM-3) analysis 
 
 
Figure E.6: Example standard curve of thrombomodulin analysis 
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Appendix D. Ethical approval of the inorganic 𝑵𝑶𝟑
−  and vitamin C 
study    
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Appendix E. 2-Day Standardized (low vitamin C and low 𝑵𝑶𝟑
−) Diet 
In order to increase the precision and validity of our measurements during the 
study we need to control the amount of vitamin C and nitrate in your diet and you 
should try to follow the dietary guidelines provided below. The dietary plan will be 
thoroughly explained to you and if you have any other questions about the diet 
during the study please let us know and we will be very happy to clarify them for 
you. 
A list of food allowed and food to avoid is shown below together with some 
examples of low nitrate meals.  
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We would also like to remind you that while you are on the study you should try 
to drink and cook with the same water. Different sources of water may contain 
different amount of nitrate and in this way we will ensure that the amount of nitrate 
you will be consuming will be constant during the week. 
 
Drinks 
 Consumption of coffee and tea is allowed during the study. However, we 
will ask to drink the same amount you usually drink and to not change 
these habits during the study.   
 We will ask you to consume alcoholic drinks with moderation and not to 
have more than one alcoholic drink per day. 
 We would like to ask you to consume soft-drinks in moderation and not to 
have more than one can of drinks (330ml) per day. 
 High energy, caffeinated drinks (for example: red bull) are not allowed 
during the study. 
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Some examples of meals that you could have are showed below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Version1, 24 September 
2013 
 
  
Breakfast  
 Tea, coffee 
 Milk with corn flakes or special K 
 Butter on toast 
 Plain croissant, chocolate muffin 
 Plain Yogurt 
 Jam (excluding strawberry, orange, lemon) 
 Scrambled eggs 
Lunch  
 Egg mayo sandwich 
 Chicken sandwich 
 Panini with mozzarella and fresh tomato 
 Chicken fried rice 
 Fresh meat or fish (grilled, steamed or fried) 
 Potatoes (fried, roasted or boiled) 
 Baked pasta with chicken and mozzarella 
 Mushroom and chicken risotto 
 Chocolate bar 
 Chocolate cake, apple crumble  
 Apple, apricot, pear 
Dinner  
 Grilled meat (beef, chicken, pork) with potatoes and mashed peas 
 Pasta with cream cheese, mushrooms and chicken 
 Grilled fresh sausages with mashed potatoes 
 Omelette, mushrooms and potatoes 
 Pizza with fresh tomato and mozzarella 
 Cheeseburger with chips (no ketchup or mayonnaise is allowed) 
 Fish and chips 
 Apple crumble with custard 
 Chocolate cake 
 Apple, apricot, pear 
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Appendix F. Protocols of laboratory analyses of inorganic  𝑵𝑶𝟑
− and 
vitamin C study   
Procedure of the  𝑵𝑶𝟑
− and  𝑵𝑶𝟐
− analyses 
a. Procedure of the analyses:  
1. Deproteinisation of the samples: I added methanol in 1:1 volume (1.25mL of Methanol to 
1.25mL of sample) and vortex directly after mixing. Then, centrifuge the mixture for 10 
minutes (13000RPM). I collected the supernatant and left the precipitants.    
2. I3 solution Preparation: I added 2g of Potassium iodide (KI) to 1.3g Iodine in 40 mL 
Deionised Water (DW), these should be dissolved thoroughly. Then, I added 140 mL of 
acetic acid to the mixture. 10-15mL of I3 product then injected to the purge vessel.  
 Preparation of vanadium chloride: The first step was to prepare 1N/1M HCl by adding 
82.5mL of 36% HCl to 1 litre of DW. The second step adding 0.4g of vanadium (III) 
chloride (MW 157.3) to 50mL of 1 N of HCl to have 50.9mM of vanadium chloride. I mixed 
thoroughly the product in light-protected container then filtered it through filter paper.  
3. I added 200µL of antifoam B emulsion (aqueous-silicone emulsion, Sigma-Aldrich). This 
emulsion contain nitrite, therefore we should wait for few minutes until it return back to 
baseline.  
4. Preparation of NAOH: I added 20g of NAOH to 0.5mL of DW to make 1 Mol of NAOH 
(this NAOH is interposed between the purge vessel and the chemiluminescence analyser; it 
acts as a chemical trap of the acid produced from the reaction in the purge vessel).  
5. Preparation of standards: 
 I added 345mg of Sodium Nitrite into 50mL of DW. This will give 100mM of NaNO2.  
 To prepare 1 mM of NaNO2 (1/100 Dilution). I took 0.5mL of the 100mM stock and added 
it to 49.5mL of DW.  
 Preparing 1uL of stock solution: from 50mL DW, replace 50µL of that DW with 50µL of 
1mM stock.  
 I thoroughly clean the injection syringe before use. Then, I injected 200µL of DW in the 
vessel. The peaks developed by the DW, should be subtracted from the measurements.  
 Standard Curve: I injected serial volumes (50mL, 100mL, 150mL and 200mL) of 1µL 
stocks (in duplicates) to produce  𝑁𝑂3
−/ 𝑁𝑂2
−  standard curves.  
   
 173 
 
Figure F.1:  Example of traces produced from injecting standard well-known concentrations of 
 𝑁𝑂2
− and plasma samples into Sievers gas-phase chemiluminescence nitric oxide analyser. SDs 
represent standards and the 0, 60, 180 represent the selected study time points analysed.     
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Figure F.2:  Example of traces produced from injecting plasma samples into Sievers gas-phase 
chemiluminescence nitric oxide analyser. 0, 60, 180 represent the selected study time points 
analysed.     
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Protocol of vitamin C analysis   
 Protocol of analysis:   
1. Preparation of the Buffer (the mobile phase): I prepared 100 µM of Ammonium Acetate by 
adding 7.708g of Ammonium Acetate (Sigma-Aldrich) to 1L of DW. I stirred the product 
for 5 minutes until complete dissolution of the particles, then I checked the pH of the 
solution (it should be 6.8). Then I took 300 mL of Ammonium Acetate and add them to 700 
mL of acetonitrile (30:70). I filtered the mixture before using in the HPLC.  
2. Preparation of MPA: I added 5g of MPA to 50mL of DW to obtain (10% MPA). 
3. Preparation of standards: Vitamin C stock (0.5mg/mL) prepared by adding 50mg of 
ascorbic acid to 100mL of DW (500mg/L). I took 10mL of ascorbic acid solution and added 
it to 90mL of DW.  
Table F.1: Preparation of the standards for vitamin C analysis. SD: standard; DW: deionised 
water; MPA: meta-phosphoric acid. 
Standards  Concentration  Volume of stock Volume of MPA Volume of DW 
SD1 0.01mg/mL 200µL 250µL 550µL 
SD2 0.008mg/mL 160µL 250µL 590µL 
SD3 0.006mg/mL 120µL 250µL 630µL 
SD4 0.004mg/mL 80µL 250µL 670µL 
SD5 0.002mg/mL 40µL 250µL 710µL 
Blank  0.0mg/mL 0 250µL 750µL 
 
4. Preparation of the samples (deproteinisation): I added 200 µL of plasma sample to 200 µL 
of MPA (10%) and left the product for 5 minutes on ice. I centrifuged the samples for 5 
minutes at 14000rpm. The last step is to dilute 100µL of the supernatant with 100µL of 
DW.  
Assay procedure of dehydroascorbic acid (DHA) 
 Assay procedure:  
1. Samples preparation: I added 100µL of serum sample to 1mL of Assay Buffer (provided by 
the manufacturer) on ice. I centrifuged the product (16000g, 4ºC) for 20 minutes. I took the 
supernatant and kept it on ice for further analysis.  
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2. Standard preparation: first step was to reconstitute the standard stock (10µL) provided by 
the manufacturer with 2.861 mL of DW. Then I added 0.9mL of DW to 0.1mL of the 
reconstituted standard to obtain 100µL of DHA standard.  
3. I added 20µL of standards and samples to the allocated wells. Then, I added Reagent I 
(160µL) and Reagent II (20µL) (provided by manufacturer) to each well. I measured then 
with Plate Reader at 265nm and recorded the absorbance at 10 and 130 seconds.  
4. The following equation then used to calculate the concentration of DHA in serum samples:  
DHA (µmol/mL) = 0.1 × [OD sample (130s) - (OD sample (10s)]/ [OD standard (130s) - (OD 
standard (10s)]/volume of sample  
OD: optical density  
 
Tetrahydrobiopterin assay procedure  
 Assay procedure  
1. Sample preparation: I diluted 10µL of plasma samples  with 385µL sample diluent 
(provided by the manufacturer) OR 
2. Prepare wash buffer: I added 20mL of wash buffer concentrate (provided by the 
manufacturer) to 480mL of DW  
3. Prepare of standards (Table F.2): I centrifuged the standard vial (provided by the 
manufacturer) at 6000-10000rpm for 30s. I reconstituted the standard with 1mL of sample 
diluent (provided by the manufacturer). Figure F.3 showing an example of standard curve 
of BH4 analysis. 
4. Preparation of HRP-conjugate: I centrifuged the stock provide by the manufacturer then 
diluted 10µL of HRP-conjugate with 990µL of HRP-conjugate diluent.  
5. Assay procedure are summarised in Table 5.3 below.   
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Table F.2: Preparation of the standards for tetrahydrobiopterin (BH4) analysis 
Standard Sample diluent Volume of stock added  BH4 concentration 
Pg/mL 
         6         250µL 250µL of stock solution             50 
         5         250µL 250µL of SD6             25 
         4         250µL 250µL of SD5             12.5 
         3         250µL 250µL of SD4             6.25 
         2         250µL 250µL of SD3             3.12 
         1         250µL 250µL of SD2             1.56 
. SD: standard. 
 
Table F.3: Steps followed in tetrahydrobiopterin (BH4) analysis.   
 Blank 
G12-H12 
Standards 
A1-D2 
Samples 
E2-F12 
Standards and 
samples 
 50µL 50µL 
HRP-conjugate  50µL 50µL 
Covered with adhesive film and incubate for 1h at 37ºC 
Wash 5x the plate using 250µL of wash buffer 
substrate 100µL 100µL 100µL 
Incubate for 15-20 min at 37ºC 
Stop solution  50µL 50µL 50µL 
Read the plate at 450nm 
Figure F.3: Example standard curve of tetrahydrobiopterin (BH4) analysis  
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Protocol of 3 nitrotyrosine assay 
a. Protocol of the assay:  
7. Serum samples and reagents allowed to thaw and equilibrate with room temperature  
8. 1X WB prepared by diluting the 10X WB (provided by the manufacturer) in DW.  
9. The diluted anti-nitrotyrosine antibody prepared by adding the anti-nitrotyrosine (HRP-
conjugated) detection antibody concentrate (1:100) to Nitrotyrosine Antibody Diluent 
(both provided by the manufacturer and the dilution factor 1:100).  
10. Standard prepared using standard stock and serial dilution was done using Sample and 
Standard Diluent (both provided by the manufacturer). The following series of dilution 
were used to prepare the SDs (Table 5.4).  
 
Table F.4: Preparation of the standards for 3 nitrotyrosine Elisa kits   
Standard SD volume  Assay 
buffer 
volume  
Final 
volume  
3 NT concentration 
(nmol/mL) 
Stock  N/A N/A N/A 408 µM 
1 10 µL of stock  500 µL 250 µL 8000 
2 250 µL of 1 250 µL 250 µL 4000 
3 250 µL of 2 250 µL 250 µL 2000 
4 250 µL of 3 250 µL 250 µL 1000 
5 250 µL of 4 250 µL 250 µL 500 
6 250 µL of 5 250 µL 250 µL 250 
7 250 µL of 6 250 µL 250 µL 125 
8 250 µL of 7 250 µL 250 µL 62.5 
9 (Blank) N/A 250 µL 250 µL 0 
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11. Standards, samples and reagents then added to the plate in the following order (Table 
F.5). Figure F.4 showing an example of 3 nitrotyrosine standard curve.  
 
Table F.5: 3 nitrotyrosine assay procedure and the addition of the reagents to the wells 
 Blank 
B3, B4 
Standards 
A1-A4 
Samples 
C3-H12 
SD/Samples - 50µL 50µL 
HRP-conjugate antibody  - 50µL 50µL 
Standard and sample diluent  50µL - - 
Antibody diluent   50µL - - 
Cover plate and incubate in room temperature for 1 hour  
Wash the plate 3 times using 300µL of WB, then contents emptied  
TMB substrate  100µL 100µL 100µL 
Cover plate and incubate in the dark, at room temperature, for 30 minutes 
Stop solution  100µL 100µL 100µL 
Measure absorbance within 30 minutes using plate reader at 450 nm absorbance  
Figure F.4: Example of standard curve of 3 nitrotyrosine analysis 
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Appendix G. Chapter 5 supplementary figures  
 
 
Figure 1: Plasma 𝑁𝑂3
− (A) and 𝑁𝑂2
− (B) in younger (n= 10) and older participants (n= 
10) given a single dose of inorganic 𝑁𝑂3
−  (7 mg/kg body weight), vitamin C (20 mg/kg) 
both agents combined or their placebos in a 2×2 factorial crossover design.  Values are 
means ± SEMs. Data were analysed using linear mixed model. Unmatched letters denote 
significantly different from placebo (P < 0.05). AUC: 3 hours area under curve.  
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Figure 2: Plasma vitamin C (A) and dehydroascorbic acid (DHA) (B) in younger (n= 10) 
and older participants (n= 10) given a single dose of inorganic 𝑁𝑂3
− (7 mg/kg body 
weight), vitamin C (20 mg/kg) both agents combined or their placebos in a 2×2 factorial 
crossover design.  Values are means ± SEMs. Data were analysed using linear mixed 
model. Unmatched letters denote significantly different from placebo (P < 0.05). *: P < 
0.05. AUC: 3 hours area under curve.  
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Figure 3: Systolic blood pressure (BP) (A) and the age × vitamin C interaction (B) in 
younger (n= 10) and older participants (n= 10) given a single dose of inorganic 𝑁𝑂3
− (7 
mg/kg body weight), vitamin C (20 mg/kg) both agents combined or their placebos in a 2×2 
factorial crossover design. Values are means ± SEMs. Data were analysed using linear 
mixed model. Unmatched letters denote significantly different from placebo (P < 0.05). **: 
P < 0.01. AUC: 3 hours area under curve. 
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Figure 4: Diastolic blood pressure (BP) (A), the age × vitamin C interaction (B) and inorganic 𝑁𝑂3
− 
× vitamin C interaction (C) in younger (n= 10) and older participants (n= 10) given a single dose of 
inorganic 𝑁𝑂3
− (7 mg/kg body weight), vitamin C (20 mg/kg) both agents combined or their 
placebos in a 2×2 factorial crossover design. Values are means ± SEMs. Data were analysed using 
linear mixed model. Unmatched letters denote significantly different from placebo (P < 0.05). **: 
P < 0.01. AUC: 3 hours area under curve. 
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Figure 5: Mean arterial blood pressure (BP) (A), the age × vitamin C interaction (B) in 
younger (n= 10) and older participants (n= 10) given a single dose of inorganic 𝑁𝑂3
− (7 mg/kg 
body weight), vitamin C (20 mg/kg) both agents combined or their placebos in a 2×2 factorial 
crossover design. Values are means ± SEMs.  Data were analysed using linear mixed model. 
Unmatched letters denote significantly different from placebo (P < 0.05). ***: P < 0.001. 
AUC: 3 hours area under curve. 
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Figure 6: Plasma cyclic guanosine monophosphate (cGMP) (A) tetrahydrobiopterin (BH4) (B) and 3 nitrotyrosine (3-NT) (C) in younger 
(n= 10) and older participants (n= 10) given a single dose of inorganic 𝑁𝑂3
− (7 mg/kg body weight), vitamin C (20 mg/kg) both agents 
combined or their placebos in a 2×2 factorial crossover design.  Values are means ± SEMs. Data were analysed using linear mixed model. 
Unmatched letters denote significantly different from placebo (P < 0.05). AUC: 3 hours area under curve.  
   
 186 
 
References  
Aguirre, R. and May, J. M. (2008) 'Inflammation in the vascular bed: importance of 
vitamin C', Pharmacol Ther, 119(1), pp. 96-103. 
Ahima, R. S. (2009) 'Connecting obesity, aging and diabetes', Nat Med, 15(9), pp. 996-
7. 
Ahmed, T. and Haboubi, N. (2010) 'Assessment and management of nutrition in older 
people and its importance to health', Clin Interv Aging, 5, pp. 207-16. 
Akbaraly, T. N., Hamer, M., Ferrie, J. E., Lowe, G., Batty, G. D., Hagger-Johnson, G., 
Singh-Manoux, A., Shipley, M. J. and Kivimaki, M. (2013) 'Chronic inflammation as a 
determinant of future aging phenotypes', CMAJ, 185(16), pp. E763-70. 
Al Suwaidi, J., Higano, S. T., Holmes, D. R., Jr., Lennon, R. and Lerman, A. (2001) 
'Obesity is independently associated with coronary endothelial dysfunction in patients 
with normal or mildly diseased coronary arteries', J Am Coll Cardiol, 37(6), pp. 1523-8. 
Alp, N. J. and Channon, K. M. (2004) 'Regulation of endothelial nitric oxide synthase 
by tetrahydrobiopterin in vascular disease', Arterioscler Thromb Vasc Biol, 24(3), pp. 
413-20. 
Alsop, P. and Hauton, D. (2016) 'Oral nitrate and citrulline decrease blood pressure 
and increase vascular conductance in young adults: a potential therapy for heart failure', 
Eur J Appl Physiol, 116(9), pp. 1651-61. 
Arcaro, G., Zamboni, M., Rossi, L., Turcato, E., Covi, G., Armellini, F., Bosello, O. 
and Lechi, A. (1999) 'Body fat distribution predicts the degree of endothelial dysfunction 
in uncomplicated obesity', Int J Obes Relat Metab Disord, 23(9), pp. 936-42. 
Aromataris, E., Fernandez, R., Godfrey, C. M., Holly, C., Khalil, H. and Tungpunkom, 
P. (2015) 'Summarizing systematic reviews: methodological development, conduct and 
reporting of an umbrella review approach', Int J Evid Based Healthc, 13(3), pp. 132-40. 
Ashor, A. W., Chowdhury, S., Oggioni, C., Qadir, O., Brandt, K., Ishaq, A., Mathers, 
J. C., Saretzki, G. and Siervo, M. (2016a) 'Inorganic Nitrate Supplementation in Young 
   
 187 
and Old Obese Adults Does Not Affect Acute Glucose and Insulin Responses but Lowers 
Oxidative Stress', J Nutr, 146(11), pp. 2224-2232. 
Ashor, A. W., Jajja, A., Sutyarjoko, A., Brandt, K., Qadir, O., Lara, J. and Siervo, M. 
(2015a) 'Effects of beetroot juice supplementation on microvascular blood flow in older 
overweight and obese subjects: a pilot randomised controlled study', J Hum Hypertens, 
29(8), pp. 511-3. 
Ashor, A. W., Lara, J., Mathers, J. C. and Siervo, M. (2014a) 'Effect of vitamin C on 
endothelial function in health and disease: a systematic review and meta-analysis of 
randomised controlled trials', Atherosclerosis, 235(1), pp. 9-20. 
Ashor, A. W., Siervo, M., Lara, J., Oggioni, C., Afshar, S. and Mathers, J. C. (2015b) 
'Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic 
review and meta-analysis of randomised controlled trials', Br J Nutr, 113(8), pp. 1182-
94. 
Ashor, A. W., Siervo, M., Lara, J., Oggioni, C. and Mathers, J. C. (2014b) 'Antioxidant 
vitamin supplementation reduces arterial stiffness in adults: a systematic review and 
meta-analysis of randomized controlled trials', J Nutr, 144(10), pp. 1594-602. 
Ashor, A. W., Siervo, M. and Mathers, J. C. (2016b) 'Chapter 43 - Vitamin C, 
Antioxidant Status, and Cardiovascular Aging A2 - Malavolta, Marco', in Mocchegiani, 
E. (ed.) Molecular Basis of Nutrition and Aging. San Diego: Academic Press,  pp. 609-
619. 
Ashor, A. W., Siervo, M., van der Velde, F., Willis, N. D. and Mathers, J. C. (2016c) 
'Systematic review and meta-analysis of randomised controlled trials testing the effects 
of vitamin C supplementation on blood lipids', Clin Nutr, 35(3), pp. 626-37. 
Ashor, A. W., Werner, A. D., Lara, J., Willis, N. D., Mathers, J. C. and Siervo, M. 
(2017) 'Effects of vitamin C supplementation on glycaemic control: a systematic review 
and meta-analysis of randomised controlled trials', Eur J Clin Nutr. 
Asleh, R. and Levy, A. P. (2010) 'Divergent effects of alpha-tocopherol and vitamin C 
on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 
genotype', Antioxid Redox Signal, 12(2), pp. 209-17. 
   
 188 
Aviv, H., Khan, M. Y., Skurnick, J., Okuda, K., Kimura, M., Gardner, J., Priolo, L. 
and Aviv, A. (2001) 'Age dependent aneuploidy and telomere length of the human 
vascular endothelium', Atherosclerosis, 159(2), pp. 281-7. 
Avogaro, A. and de Kreutzenberg, S. V. (2005) 'Mechanisms of endothelial 
dysfunction in obesity', Clin Chim Acta, 360(1-2), pp. 9-26. 
Bahadoran, Z., Mirmiran, P., Ghasemi, A., Carlstrom, M., Azizi, F. and Hadaegh, F. 
(2017) 'Vitamin C intake modify the impact of dietary nitrite on the incidence of type 2 
diabetes: A 6-year follow-up in Tehran Lipid and Glucose Study', Nitric Oxide, 62, pp. 
24-31. 
Bahra, M., Kapil, V., Pearl, V., Ghosh, S. and Ahluwalia, A. (2012) 'Inorganic nitrate 
ingestion improves vascular compliance but does not alter flow-mediated dilatation in 
healthy volunteers', Nitric Oxide, 26(4), pp. 197-202. 
Bai, Y., Sun, L., Yang, T., Sun, K., Chen, J. and Hui, R. (2009) 'Increase in fasting 
vascular endothelial function after short-term oral L-arginine is effective when baseline 
flow-mediated dilation is low: a meta-analysis of randomized controlled trials', Am J Clin 
Nutr, 89(1), pp. 77-84. 
Baiao Ddos, S., Conte-Junior, C. A., Paschoalin, V. M. and Alvares, T. S. (2016) 
'Beetroot juice increase nitric oxide metabolites in both men and women regardless of 
body mass', Int J Food Sci Nutr, 67(1), pp. 40-6. 
Bailey, J. C., Feelisch, M., Horowitz, J. D., Frenneaux, M. P. and Madhani, M. (2014) 
'Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation', 
Pharmacol Ther, 144(3), pp. 303-20. 
Bakker, W., Eringa, E. C., Sipkema, P. and van Hinsbergh, V. W. (2009) 'Endothelial 
dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity', 
Cell Tissue Res, 335(1), pp. 165-89. 
Bartsch, H., Ohshima, H. and Pignatelli, B. (1988) 'Inhibitors of endogenous 
nitrosation. Mechanisms and implications in human cancer prevention', Mutat Res, 
202(2), pp. 307-24. 
   
 189 
Bastien, M., Poirier, P., Lemieux, I. and Despres, J. P. (2014) 'Overview of 
epidemiology and contribution of obesity to cardiovascular disease', Prog Cardiovasc 
Dis, 56(4), pp. 369-81. 
Bednar, C. and Kies, C. (1994) 'Nitrate and vitamin C from fruits and vegetables: 
impact of intake variations on nitrate and nitrite excretions of humans', Plant Foods Hum 
Nutr, 45(1), pp. 71-80. 
Ben-Shlomo, Y., Spears, M., Boustred, C., May, M., Anderson, S. G., Benjamin, E. J., 
Boutouyrie, P., Cameron, J., Chen, C. H., Cruickshank, J. K., Hwang, S. J., Lakatta, E. 
G., Laurent, S., Maldonado, J., Mitchell, G. F., Najjar, S. S., Newman, A. B., Ohishi, M., 
Pannier, B., Pereira, T., Vasan, R. S., Shokawa, T., Sutton-Tyrell, K., Verbeke, F., Wang, 
K. L., Webb, D. J., Willum Hansen, T., Zoungas, S., McEniery, C. M., Cockcroft, J. R. 
and Wilkinson, I. B. (2014) 'Aortic pulse wave velocity improves cardiovascular event 
prediction: an individual participant meta-analysis of prospective observational data from 
17,635 subjects', J Am Coll Cardiol, 63(7), pp. 636-46. 
Bendall, J. K., Douglas, G., McNeill, E., Channon, K. M. and Crabtree, M. J. (2014) 
'Tetrahydrobiopterin in cardiovascular health and disease', Antioxid Redox Signal, 20(18), 
pp. 3040-77. 
Benjamin, N., O'Driscoll, F., Dougall, H., Duncan, C., Smith, L., Golden, M. and 
McKenzie, H. (1994) 'Stomach NO synthesis', Nature, 368(6471), p. 502. 
Coronary Heart Disease Statistics (2012) Directed by BHF. London British Heart 
Foundation. Available at: http://www.bhf.org.uk/publications/view-
publication.aspx?ps=1002097. 
Bitar, M. S., Wahid, S., Mustafa, S., Al-Saleh, E., Dhaunsi, G. S. and Al-Mulla, F. 
(2005) 'Nitric oxide dynamics and endothelial dysfunction in type II model of genetic 
diabetes', Eur J Pharmacol, 511(1), pp. 53-64. 
Blankenberg, S., Barbaux, S. and Tiret, L. (2003) 'Adhesion molecules and 
atherosclerosis', Atherosclerosis, 170(2), pp. 191-203. 
Block, G., Mangels, A. R., Norkus, E. P., Patterson, B. H., Levander, O. A. and Taylor, 
P. R. (2001) 'Ascorbic acid status and subsequent diastolic and systolic blood pressure', 
Hypertension, 37(2), pp. 261-7. 
   
 190 
Boekholdt, S. M., Meuwese, M. C., Day, N. E., Luben, R., Welch, A., Wareham, N. J. 
and Khaw, K. T. (2006) 'Plasma concentrations of ascorbic acid and C-reactive protein, 
and risk of future coronary artery disease, in apparently healthy men and women: the 
EPIC-Norfolk prospective population study', Br J Nutr, 96(3), pp. 516-22. 
Bolotina, V. M., Najibi, S., Palacino, J. J., Pagano, P. J. and Cohen, R. A. (1994) 'Nitric 
oxide directly activates calcium-dependent potassium channels in vascular smooth 
muscle', Nature, 368(6474), pp. 850-3. 
Bond, V., Curry, B. H., Adams, R. G., Asadi, M. S., Stancil, K. A., Millis, R. M. and 
Haddad, G. E. (2014) 'Effects of Nitrate Supplementation on Cardiovascular and 
Autonomic Reactivity in African-American Females', ISRN Physiol, 2014. 
Bondonno, C. P., Croft, K. D., Ward, N., Considine, M. J. and Hodgson, J. M. (2015a) 
'Dietary flavonoids and nitrate: effects on nitric oxide and vascular function', Nutr Rev, 
73(4), pp. 216-35. 
Bondonno, C. P., Liu, A. H., Croft, K. D., Ward, N. C., Shinde, S., Moodley, Y., 
Lundberg, J. O., Puddey, I. B., Woodman, R. J. and Hodgson, J. M. (2015b) 'Absence of 
an effect of high nitrate intake from beetroot juice on blood pressure in treated 
hypertensive individuals: a randomized controlled trial', Am J Clin Nutr, 102(2), pp. 368-
75. 
Bondonno, C. P., Yang, X., Croft, K. D., Considine, M. J., Ward, N. C., Rich, L., 
Puddey, I. B., Swinny, E., Mubarak, A. and Hodgson, J. M. (2012) 'Flavonoid-rich apples 
and nitrate-rich spinach augment nitric oxide status and improve endothelial function in 
healthy men and women: a randomized controlled trial', Free Radic Biol Med, 52(1), pp. 
95-102. 
Britton, E. and McLaughlin, J. T. (2013) 'Ageing and the gut', Proc Nutr Soc, 72(1), 
pp. 173-7. 
Brown, B. G., Zhao, X. Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., 
Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., Frohlich, J. and Albers, J. J. 
(2001) 'Simvastatin and niacin, antioxidant vitamins, or the combination for the 
prevention of coronary disease', N Engl J Med, 345(22), pp. 1583-92. 
   
 191 
Brownie, S. (2006) 'Why are elderly individuals at risk of nutritional deficiency?', Int 
J Nurs Pract, 12(2), pp. 110-8. 
Brubacher, D., Moser, U. and Jordan, P. (2000) 'Vitamin C concentrations in plasma 
as a function of intake: a meta-analysis', Int J Vitam Nutr Res, 70(5), pp. 226-37. 
Bryan, N. S., Fernandez, B. O., Bauer, S. M., Garcia-Saura, M. F., Milsom, A. B., 
Rassaf, T., Maloney, R. E., Bharti, A., Rodriguez, J. and Feelisch, M. (2005) 'Nitrite is a 
signaling molecule and regulator of gene expression in mammalian tissues', Nat Chem 
Biol, 1(5), pp. 290-7. 
Bryan, N. S. and Grisham, M. B. (2007) 'Methods to detect nitric oxide and its 
metabolites in biological samples', Free Radic Biol Med, 43(5), pp. 645-57. 
Bryan, N. S. and Ivy, J. L. (2015) 'Inorganic nitrite and nitrate: evidence to support 
consideration as dietary nutrients', Nutr Res, 35(8), pp. 643-54. 
Burzle, M. and Hediger, M. A. (2012) 'Functional and physiological role of vitamin C 
transporters', Curr Top Membr, 70, pp. 357-75. 
Butler, A. R. and Feelisch, M. (2008) 'Therapeutic uses of inorganic nitrite and nitrate: 
from the past to the future', Circulation, 117(16), pp. 2151-9. 
Caprio, M., Mammi, C. and Rosano, G. M. (2012) 'Vitamin D: a novel player in 
endothelial function and dysfunction', Arch Med Sci, 8(1), pp. 4-5. 
Carlsson, S., Wiklund, N. P., Engstrand, L., Weitzberg, E. and Lundberg, J. O. (2001) 
'Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and 
bacterial growth in urine', Nitric Oxide, 5(6), pp. 580-6. 
Carlstrom, M., Larsen, F. J., Nystrom, T., Hezel, M., Borniquel, S., Weitzberg, E. and 
Lundberg, J. O. (2010) 'Dietary inorganic nitrate reverses features of metabolic syndrome 
in endothelial nitric oxide synthase-deficient mice', Proc Natl Acad Sci U S A, 107(41), 
pp. 17716-20. 
Carlstrom, M., Persson, A. E., Larsson, E., Hezel, M., Scheffer, P. G., Teerlink, T., 
Weitzberg, E. and Lundberg, J. O. (2011) 'Dietary nitrate attenuates oxidative stress, 
prevents cardiac and renal injuries, and reduces blood pressure in salt-induced 
hypertension', Cardiovasc Res, 89(3), pp. 574-85. 
   
 192 
Carr, A. and Frei, B. (1999) 'Does vitamin C act as a pro-oxidant under physiological 
conditions?', FASEB J, 13(9), pp. 1007-24. 
Carter, P., Gray, L. J., Troughton, J., Khunti, K. and Davies, M. J. (2010) 'Fruit and 
vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-
analysis', BMJ, 341, p. c4229. 
Cau, S. B., Carneiro, F. S. and Tostes, R. C. (2012) 'Differential modulation of nitric 
oxide synthases in aging: therapeutic opportunities', Front Physiol, 3, p. 218. 
Cavalcante, J. L., Lima, J. A., Redheuil, A. and Al-Mallah, M. H. (2011) 'Aortic 
stiffness: current understanding and future directions', J Am Coll Cardiol, 57(14), pp. 
1511-22. 
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Bucciarelli, 
L., Rondinelli, M. and Genovese, S. (2013) 'Vitamin C further improves the protective 
effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, 
inflammation, and endothelial dysfunction in type 1 diabetes', Diabetes Care, 36(12), pp. 
4104-8. 
Ceriello, A., Quagliaro, L., Piconi, L., Assaloni, R., Da Ros, R., Maier, A., Esposito, 
K. and Giugliano, D. (2004) 'Effect of postprandial hypertriglyceridemia and 
hyperglycemia on circulating adhesion molecules and oxidative stress generation and the 
possible role of simvastatin treatment', Diabetes, 53(3), pp. 701-10. 
Ceriello, A., Taboga, C., Tonutti, L., Quagliaro, L., Piconi, L., Bais, B., Da Ros, R. 
and Motz, E. (2002) 'Evidence for an independent and cumulative effect of postprandial 
hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress 
generation: effects of short- and long-term simvastatin treatment', Circulation, 106(10), 
pp. 1211-8. 
Cermak, N. M., Hansen, D., Kouw, I. W., van Dijk, J. W., Blackwell, J. R., Jones, A. 
M., Gibala, M. J. and van Loon, L. J. (2015) 'A single dose of sodium nitrate does not 
improve oral glucose tolerance in patients with type 2 diabetes mellitus', Nutr Res, 35(8), 
pp. 674-80. 
   
 193 
Cesari, M., Cerullo, F., Demougeot, L., Zamboni, V., Gambassi, G. and Vellas, B. 
(2014) 'Antioxidant Supplementation in Older Persons', in Laher, I. (ed.) Systems Biology 
of Free Radicals and Antioxidants. Springer Berlin Heidelberg,  pp. 3899-3927. 
Chambers, J. C., Ueland, P. M., Obeid, O. A., Wrigley, J., Refsum, H. and Kooner, J. 
S. (2000) 'Improved vascular endothelial function after oral B vitamins: An effect 
mediated through reduced concentrations of free plasma homocysteine', Circulation, 
102(20), pp. 2479-83. 
Chambial, S., Dwivedi, S., Shukla, K. K., John, P. J. and Sharma, P. (2013) 'Vitamin 
C in disease prevention and cure: an overview', Indian J Clin Biochem, 28(4), pp. 314-
28. 
Channon, K. M. (2006) 'The endothelium and the pathogenesis of atherosclerosis', 
Medicine, 34(5), pp. 173-177. 
Charakida, M., Masi, S., Luscher, T. F., Kastelein, J. J. and Deanfield, J. E. (2010) 
'Assessment of atherosclerosis: the role of flow-mediated dilatation', Eur Heart J, 31(23), 
pp. 2854-61. 
Chen, Q., Espey, M. G., Sun, A. Y., Lee, J. H., Krishna, M. C., Shacter, E., Choyke, 
P. L., Pooput, C., Kirk, K. L., Buettner, G. R. and Levine, M. (2007) 'Ascorbate in 
pharmacologic concentrations selectively generates ascorbate radical and hydrogen 
peroxide in extracellular fluid in vivo', Proc Natl Acad Sci U S A, 104(21), pp. 8749-54. 
Chung, H. Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A. Y., Carter, 
C., Yu, B. P. and Leeuwenburgh, C. (2009) 'Molecular inflammation: underpinnings of 
aging and age-related diseases', Ageing Res Rev, 8(1), pp. 18-30. 
Claesson, M. J., Jeffery, I. B., Conde, S., Power, S. E., O/'Connor, E. M., Cusack, S., 
Harris, H. M. B., Coakley, M., Lakshminarayanan, B., O/'Sullivan, O., Fitzgerald, G. F., 
Deane, J., O/'Connor, M., Harnedy, N., O/'Connor, K., O/'Mahony, D., van Sinderen, D., 
Wallace, M., Brennan, L., Stanton, C., Marchesi, J. R., Fitzgerald, A. P., Shanahan, F., 
Hill, C., Ross, R. P. and O/'Toole, P. W. (2012) 'Gut microbiota composition correlates 
with diet and health in the elderly', Nature, 488(7410), pp. 178-184. 
Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N. H., Eberlein, K. A., 
Godwin, J., Qizilbash, N., Taylor, J. O. and Hennekens, C. H. (1990) 'Blood pressure, 
   
 194 
stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: 
overview of randomised drug trials in their epidemiological context', Lancet, 335(8693), 
pp. 827-38. 
Constans, J. and Conri, C. (2006) 'Circulating markers of endothelial function in 
cardiovascular disease', Clin Chim Acta, 368(1-2), pp. 33-47. 
Cook, N. R., Albert, C. M., Gaziano, J. M., Zaharris, E., MacFadyen, J., Danielson, 
E., Buring, J. E. and Manson, J. E. (2007) 'A randomized factorial trial of vitamins C and 
E and beta carotene in the secondary prevention of cardiovascular events in women: 
results from the Women's Antioxidant Cardiovascular Study', Arch Intern Med, 167(15), 
pp. 1610-8. 
Cooke, M. S., Evans, M. D., Podmore, I. D., Herbert, K. E., Mistry, N., Mistry, P., 
Hickenbotham, P. T., Hussieni, A., Griffiths, H. R. and Lunec, J. (1998) 'Novel repair 
action of vitamin C upon in vivo oxidative DNA damage', FEBS Lett, 439(3), pp. 363-7. 
Cordero, Z., Drogan, D., Weikert, C. and Boeing, H. (2010) 'Vitamin E and risk of 
cardiovascular diseases: a review of epidemiologic and clinical trial studies', Crit Rev 
Food Sci Nutr, 50(5), pp. 420-40. 
Correia, M. L. and Haynes, W. G. (2007) 'Arterial compliance and endothelial 
function', Curr Diab Rep, 7(4), pp. 269-75. 
Corretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D., Charbonneau, F., 
Creager, M. A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., 
Vallance, P., Vita, J. and Vogel, R. (2002) 'Guidelines for the ultrasound assessment of 
endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the 
International Brachial Artery Reactivity Task Force', J Am Coll Cardiol, 39(2), pp. 257-
65. 
Cracowski, J. L., Minson, C. T., Salvat-Melis, M. and Halliwill, J. R. (2006) 
'Methodological issues in the assessment of skin microvascular endothelial function in 
humans', Trends Pharmacol Sci, 27(9), pp. 503-8. 
Crowe, F. L., Roddam, A. W., Key, T. J., Appleby, P. N., Overvad, K., Jakobsen, M. 
U., Tjonneland, A., Hansen, L., Boeing, H., Weikert, C., Linseisen, J., Kaaks, R., 
Trichopoulou, A., Misirli, G., Lagiou, P., Sacerdote, C., Pala, V., Palli, D., Tumino, R., 
   
 195 
Panico, S., Bueno-de-Mesquita, H. B., Boer, J., van Gils, C. H., Beulens, J. W., Barricarte, 
A., Rodriguez, L., Larranaga, N., Sanchez, M. J., Tormo, M. J., Buckland, G., Lund, E., 
Hedblad, B., Melander, O., Jansson, J. H., Wennberg, P., Wareham, N. J., Slimani, N., 
Romieu, I., Jenab, M., Danesh, J., Gallo, V., Norat, T. and Riboli, E. (2011) 'Fruit and 
vegetable intake and mortality from ischaemic heart disease: results from the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study', Eur Heart J, 
32(10), pp. 1235-43. 
Cullen, P., Rauterberg, J. and Lorkowski, S. (2005) 'The Pathogenesis of 
Atherosclerosis', in Eckardstein, A. v. (ed.) Atherosclerosis: Diet and Drugs. Springer-
Verlag. 
Cunnington, C., Van Assche, T., Shirodaria, C., Kylintireas, I., Lindsay, A. C., Lee, J. 
M., Antoniades, C., Margaritis, M., Lee, R., Cerrato, R., Crabtree, M. J., Francis, J. M., 
Sayeed, R., Ratnatunga, C., Pillai, R., Choudhury, R. P., Neubauer, S. and Channon, K. 
M. (2012) 'Systemic and Vascular Oxidation Limits the Efficacy of Oral 
Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease', Circulation, 
125(11), pp. 1356-1366. 
d'Uscio, L. V., Milstien, S., Richardson, D., Smith, L. and Katusic, Z. S. (2003) 'Long-
term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide 
synthase activity', Circ Res, 92(1), pp. 88-95. 
Dahlof, B. (2010) 'Cardiovascular disease risk factors: epidemiology and risk 
assessment', Am J Cardiol, 105(1 Suppl), pp. 3A-9A. 
Dayal, S. and Lentz, S. R. (2005) 'ADMA and hyperhomocysteinemia', Vasc Med, 10 
Suppl 1, pp. S27-33. 
de Bree, A., van Mierlo, L. A. and Draijer, R. (2007) 'Folic acid improves vascular 
reactivity in humans: a meta-analysis of randomized controlled trials', Am J Clin Nutr, 
86(3), pp. 610-7. 
de Bruyne, M. C., Kors, J. A., Hoes, A. W., Klootwijk, P., Dekker, J. M., Hofman, A., 
van Bemmel, J. H. and Grobbee, D. E. (1999) 'Both decreased and increased heart rate 
variability on the standard 10-second electrocardiogram predict cardiac mortality in the 
elderly: the Rotterdam Study', Am J Epidemiol, 150(12), pp. 1282-8. 
   
 196 
De Caterina, R., Zampolli, A., Del Turco, S., Madonna, R. and Massaro, M. (2006) 
'Nutritional mechanisms that influence cardiovascular disease', Am J Clin Nutr, 83(2), pp. 
421S-426S. 
Deanfield, J. E., Halcox, J. P. and Rabelink, T. J. (2007) 'Endothelial function and 
dysfunction: testing and clinical relevance', Circulation, 115(10), pp. 1285-95. 
Dellavalle, C. T., Xiao, Q., Yang, G., Shu, X. O., Aschebrook-Kilfoy, B., Zheng, W., 
Lan Li, H., Ji, B. T., Rothman, N., Chow, W. H., Gao, Y. T. and Ward, M. H. (2014) 
'Dietary nitrate and nitrite intake and risk of colorectal cancer in the Shanghai Women's 
Health Study', Int J Cancer, 134(12), pp. 2917-26. 
Delp, M. D., Behnke, B. J., Spier, S. A., Wu, G. and Muller-Delp, J. M. (2008) 'Ageing 
diminishes endothelium-dependent vasodilatation and tetrahydrobiopterin content in rat 
skeletal muscle arterioles', J Physiol, 586(4), pp. 1161-8. 
Dietrich, M., Block, G., Hudes, M., Morrow, J. D., Norkus, E. P., Traber, M. G., Cross, 
C. E. and Packer, L. (2002) 'Antioxidant supplementation decreases lipid peroxidation 
biomarker F(2)-isoprostanes in plasma of smokers', Cancer Epidemiol Biomarkers Prev, 
11(1), pp. 7-13. 
Dobrovic, A. and Kristensen, L. S. (2009) 'DNA methylation, epimutations and cancer 
predisposition', Int J Biochem Cell Biol, 41(1), pp. 34-9. 
Dobson, H. M., Muir, M. M. and Hume, R. (1984) 'The effect of ascorbic acid on the 
seasonal variations in serum cholesterol levels', Scott Med J, 29(3), pp. 176-82. 
Dong, J. Y., Qin, L. Q., Zhang, Z., Zhao, Y., Wang, J., Arigoni, F. and Zhang, W. 
(2011) 'Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of 
randomized, double-blind, placebo-controlled trials', Am Heart J, 162(6), pp. 959-65. 
Dong, Z. M., Chapman, S. M., Brown, A. A., Frenette, P. S., Hynes, R. O. and Wagner, 
D. D. (1998) 'The combined role of P- and E-selectins in atherosclerosis', J Clin Invest, 
102(1), pp. 145-52. 
Duarte, T. L. and Lunec, J. (2005) 'Review: When is an antioxidant not an antioxidant? 
A review of novel actions and reactions of vitamin C', Free Radic Res, 39(7), pp. 671-86. 
   
 197 
Duconge, J., Miranda-Massari, J. R., Gonzalez, M. J., Jackson, J. A., Warnock, W. and 
Riordan, N. H. (2008) 'Pharmacokinetics of vitamin C: insights into the oral and 
intravenous administration of ascorbate', P R Health Sci J, 27(1), pp. 7-19. 
Duncan, C., Dougall, H., Johnston, P., Green, S., Brogan, R., Leifert, C., Smith, L., 
Golden, M. and Benjamin, N. (1995) 'Chemical generation of nitric oxide in the mouth 
from the enterosalivary circulation of dietary nitrate', Nat Med, 1(6), pp. 546-51. 
Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) 'Bias in meta-
analysis detected by a simple, graphical test', BMJ, 315(7109), pp. 629-34. 
El Assar, M., Angulo, J., Vallejo, S., Peiro, C., Sanchez-Ferrer, C. F. and Rodriguez-
Manas, L. (2012) 'Mechanisms involved in the aging-induced vascular dysfunction', 
Front Physiol, 3, p. 132. 
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V. and Vail, 
A. (2002) 'Meta-analyses involving cross-over trials: methodological issues', Int J 
Epidemiol, 31(1), pp. 140-9. 
Enstrom, J. E., Kanim, L. E. and Klein, M. A. (1992) 'Vitamin C intake and mortality 
among a sample of the United States population', Epidemiology, 3(3), pp. 194-202. 
Erusalimsky, J. D. (2009) 'Vascular endothelial senescence: from mechanisms to 
pathophysiology', J Appl Physiol (1985), 106(1), pp. 326-32. 
Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I., Corella, D., Aros, F., Gomez-
Gracia, E., Ruiz-Gutierrez, V., Fiol, M., Lapetra, J., Lamuela-Raventos, R. M., Serra-
Majem, L., Pinto, X., Basora, J., Munoz, M. A., Sorli, J. V., Martinez, J. A. and Martinez-
Gonzalez, M. A. (2013) 'Primary prevention of cardiovascular disease with a 
Mediterranean diet', N Engl J Med, 368(14), pp. 1279-90. 
Farsetti, A., Grasselli, A., Bacchetti, S., Gaetano, C. and Capogrossi, M. C. (2009) 
'The telomerase tale in vascular aging: regulation by estrogens and nitric oxide signaling', 
J Appl Physiol (1985), 106(1), pp. 333-7. 
Feletou, M., Kohler, R. and Vanhoutte, P. M. (2010) 'Endothelium-derived vasoactive 
factors and hypertension: possible roles in pathogenesis and as treatment targets', Curr 
Hypertens Rep, 12(4), pp. 267-75. 
   
 198 
Festa, A., D'Agostino, R., Jr., Tracy, R. P. and Haffner, S. M. (2002) 'C-reactive 
protein is more strongly related to post-glucose load glucose than to fasting glucose in 
non-diabetic subjects; the Insulin Resistance Atherosclerosis Study', Diabet Med, 19(11), 
pp. 939-43. 
Fleming, R. M. (2000) 'The effect of high-protein diets on coronary blood flow', 
Angiology, 51(10), pp. 817-26. 
Fletcher, A. E., Breeze, E. and Shetty, P. S. (2003) 'Antioxidant vitamins and mortality 
in older persons: findings from the nutrition add-on study to the Medical Research 
Council Trial of Assessment and Management of Older People in the Community', Am J 
Clin Nutr, 78(5), pp. 999-1010. 
Fontana, L., Meyer, T. E., Klein, S. and Holloszy, J. O. (2004) 'Long-term calorie 
restriction is highly effective in reducing the risk for atherosclerosis in humans', Proc Natl 
Acad Sci U S A, 101(17), pp. 6659-63. 
Foo, S. Y., Heller, E. R., Wykrzykowska, J., Sullivan, C. J., Manning-Tobin, J. J., 
Moore, K. J., Gerszten, R. E. and Rosenzweig, A. (2009) 'Vascular effects of a low-
carbohydrate high-protein diet', Proc Natl Acad Sci U S A, 106(36), pp. 15418-23. 
Forstermann, U. (2010) 'Nitric oxide and oxidative stress in vascular disease', Pflugers 
Arch, 459(6), pp. 923-39. 
Forstermann, U. and Sessa, W. C. (2012) 'Nitric oxide synthases: regulation and 
function', Eur Heart J, 33(7), pp. 829-37, 837a-837d. 
Fotherby, M. D., Williams, J. C., Forster, L. A., Craner, P. and Ferns, G. A. (2000) 
'Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons', J 
Hypertens, 18(4), pp. 411-5. 
Frayn, K. N. and Stanner, S. (eds.) (2005) Cardiovascular disease : diet, nutrition and 
emerging risk factors : the report of a British Nutrition Foundation task force. Oxford: 
Blackwell Pub. 
Frei, B. (1999) 'On the role of vitamin C and other antioxidants in atherogenesis and 
vascular dysfunction', Proc Soc Exp Biol Med, 222(3), pp. 196-204. 
   
 199 
Frei, B., Birlouez-Aragon, I. and Lykkesfeldt, J. (2012) 'Authors' perspective: What is 
the optimum intake of vitamin C in humans?', Crit Rev Food Sci Nutr, 52(9), pp. 815-29. 
Fujisawa, S., Ishihara, M., Atsumi, T. and Kadoma, Y. (2006) 'A quantitative approach 
to the free radical interaction between alpha-tocopherol or ascorbate and flavonoids', In 
Vivo, 20(4), pp. 445-52. 
Fusco, D., Colloca, G., Lo Monaco, M. R. and Cesari, M. (2007) 'Effects of antioxidant 
supplementation on the aging process', Clin Interv Aging, 2(3), pp. 377-87. 
Fyhrquist, F. and Saijonmaa, O. (2012) 'Telomere length and cardiovascular aging', 
Ann Med, 44 Suppl 1, pp. S138-42. 
Gao, X., Yang, T., Liu, M., Peleli, M., Zollbrecht, C., Weitzberg, E., Lundberg, J. O., 
Persson, A. E. and Carlstrom, M. (2015) 'NADPH oxidase in the renal microvasculature 
is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite', 
Hypertension, 65(1), pp. 161-70. 
Garcia-Saura, M. F., Saijo, F., Bryan, N. S., Bauer, S., Rodriguez, J. and Feelisch, M. 
(2012) 'Nitroso-redox status and vascular function in marginal and severe ascorbate 
deficiency', Antioxid Redox Signal, 17(7), pp. 937-50. 
Garry, A., Edwards, D. H., Fallis, I. F., Jenkins, R. L. and Griffith, T. M. (2009) 
'Ascorbic acid and tetrahydrobiopterin potentiate the EDHF phenomenon by generating 
hydrogen peroxide', Cardiovasc Res, 84(2), pp. 218-26. 
Gaziano, J. M. (2007) 'Global Burden of Cardiovascular Disease', in Libby, P., Bonow, 
R. O., Mann, D. L. and Zipes, D. P. (eds.) Braunwald's heart disease : a textbook of 
cardiovascular medicine. Elsevier Saunders. 
Geleijnse, J. M., Kok, F. J. and Grobbee, D. E. (2003) 'Blood pressure response to 
changes in sodium and potassium intake: a metaregression analysis of randomised trials', 
J Hum Hypertens, 17(7), pp. 471-80. 
George, S. J. and Lyon, C. (2010) 'Pathogenesis of Atherosclerosis', in George, S. J. 
and Johnson, J. (eds.) Atherosclerosis: Molecular and Cellular Mechanisms. WILEY-
VCH Verlag. 
   
 200 
Gerritsen, J., Dekker, J. M., TenVoorde, B. J., Kostense, P. J., Heine, R. J., Bouter, L. 
M., Heethaar, R. M. and Stehouwer, C. D. (2001) 'Impaired autonomic function is 
associated with increased mortality, especially in subjects with diabetes, hypertension, or 
a history of cardiovascular disease: the Hoorn Study', Diabetes Care, 24(10), pp. 1793-8. 
Gilchrist, M., Winyard, P. G., Aizawa, K., Anning, C., Shore, A. and Benjamin, N. 
(2013) 'Effect of dietary nitrate on blood pressure, endothelial function, and insulin 
sensitivity in type 2 diabetes', Free Radic Biol Med, 60, pp. 89-97. 
Giles, T. D. (2006) 'Aspects of nitric oxide in health and disease: a focus on 
hypertension and cardiovascular disease', J Clin Hypertens (Greenwich), 8(12 Suppl 4), 
pp. 2-16. 
Gladwin, M. T., Schechter, A. N., Kim-Shapiro, D. B., Patel, R. P., Hogg, N., Shiva, 
S., Cannon, R. O., Kelm, M., Wink, D. A., Espey, M. G., Oldfield, E. H., Pluta, R. M., 
Freeman, B. A., Lancaster, J. R., Feelisch, M. and Lundberg, J. O. (2005) 'The emerging 
biology of the nitrite anion', Nat Chem Biol, 1(6), pp. 308-314. 
Gornik, H. L. and Creager, M. A. (2004) 'Arginine and endothelial and vascular health', 
J Nutr, 134(10 Suppl), pp. 2880S-2887S; discussion 2895S. 
Govoni, M., Jansson, E. A., Weitzberg, E. and Lundberg, J. O. (2008) 'The increase in 
plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial 
mouthwash', Nitric Oxide, 19(4), pp. 333-7. 
Hall, W. L. (2009) 'Dietary saturated and unsaturated fats as determinants of blood 
pressure and vascular function', Nutrition Research Reviews, 22(01), pp. 18-38. 
Halliwell, B. (1996) 'Vitamin C: antioxidant or pro-oxidant in vivo?', Free Radic Res, 
25(5), pp. 439-54. 
Hamdy, O., Ledbury, S., Mullooly, C., Jarema, C., Porter, S., Ovalle, K., Moussa, A., 
Caselli, A., Caballero, A. E., Economides, P. A., Veves, A. and Horton, E. S. (2003) 
'Lifestyle modification improves endothelial function in obese subjects with the insulin 
resistance syndrome', Diabetes Care, 26(7), pp. 2119-25. 
Hansson, G. K. (2005) 'Inflammation, atherosclerosis, and coronary artery disease', N 
Engl J Med, 352(16), pp. 1685-95. 
   
 201 
Hansson, G. K., Robertson, A. K. and Soderberg-Naucler, C. (2006) 'Inflammation 
and atherosclerosis', Annu Rev Pathol, 1, pp. 297-329. 
Harris, R. A., Nishiyama, S. K., Wray, D. W. and Richardson, R. S. (2010) 'Ultrasound 
assessment of flow-mediated dilation', Hypertension, 55(5), pp. 1075-85. 
Haslam, D. W. and James, W. P. (2005) 'Obesity', Lancet, 366(9492), pp. 1197-209. 
Hellmann, M., Gaillard-Bigot, F., Roustit, M. and Cracowski, J. L. (2015) 'Prostanoids 
are not involved in postocclusive reactive hyperaemia in human skin', Fundam Clin 
Pharmacol, 29(5), pp. 510-6. 
Hennig, B. and Toborek, M. (2001) 'Nutrition and endothelial cell function: 
implications in atherosclerosis', Nutrition research (New York, N.Y.), 21(1), pp. 279-293. 
Hercberg, S., Galan, P., Preziosi, P., Bertrais, S., Mennen, L., Malvy, D., Roussel, A. 
M., Favier, A. and Briancon, S. (2004) 'The SU.VI.MAX Study: a randomized, placebo-
controlled trial of the health effects of antioxidant vitamins and minerals', Arch Intern 
Med, 164(21), pp. 2335-42. 
Herrera, M. D., Mingorance, C., Rodriguez-Rodriguez, R. and Alvarez de Sotomayor, 
M. (2010) 'Endothelial dysfunction and aging: an update', Ageing Res Rev, 9(2), pp. 142-
52. 
Higashi, Y. (2015) 'Assessment of endothelial function. History, methodological 
aspects, and clinical perspectives', Int Heart J, 56(2), pp. 125-34. 
Higgins, J. P., Thompson, S. G., Deeks, J. J. and Altman, D. G. (2003) 'Measuring 
inconsistency in meta-analyses', BMJ, 327(7414), pp. 557-60. 
Higgins, J. P. T. and Green, S. (2008) 'Guide to the Contents of a Cochrane Protocol 
and Review', in  Cochrane Handbook for Systematic Reviews of Interventions. John Wiley 
& Sons, Ltd,  pp. 51-79. 
Ho, F. M., Lin, W. W., Chen, B. C., Chao, C. M., Yang, C. R., Lin, L. Y., Lai, C. C., 
Liu, S. H. and Liau, C. S. (2006) 'High glucose-induced apoptosis in human vascular 
endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway 
and prevented by PI3K/Akt/eNOS pathway', Cell Signal, 18(3), pp. 391-9. 
   
 202 
Hobbs, D. A., George, T. W. and Lovegrove, J. A. (2013) 'The effects of dietary nitrate 
on blood pressure and endothelial function: a review of human intervention studies', Nutr 
Res Rev, 26(2), pp. 210-22. 
Holewijn, S., den Heijer, M., Stalenhoef, A. F. and de Graaf, J. (2010) 'Non-invasive 
measurements of atherosclerosis (NIMA): current evidence and future perspectives', Neth 
J Med, 68(12), pp. 388-99. 
Holowatz, L. A. (2011) 'Ascorbic acid: what do we really no?', J Appl Physiol (1985), 
111(6), pp. 1542-3. 
Holowatz, L. A., Thompson-Torgerson, C. S. and Kenney, W. L. (2008) 'The human 
cutaneous circulation as a model of generalized microvascular function', J Appl Physiol 
(1985), 105(1), pp. 370-2. 
Holowatz, L. A., Thompson, C. S., Minson, C. T. and Kenney, W. L. (2005) 
'Mechanisms of acetylcholine-mediated vasodilatation in young and aged human skin', J 
Physiol, 563(Pt 3), pp. 965-73. 
Honarbakhsh, S. and Schachter, M. (2009) 'Vitamins and cardiovascular disease', Br J 
Nutr, 101(8), pp. 1113-31. 
Hoon, M. W., Johnson, N. A., Chapman, P. G. and Burke, L. M. (2013) 'The effect of 
nitrate supplementation on exercise performance in healthy individuals: a systematic 
review and meta-analysis', Int J Sport Nutr Exerc Metab, 23(5), pp. 522-32. 
Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S., Harvey, I., Le Cornu, K. A., Ryder, 
J. J., Hall, W. L. and Cassidy, A. (2008) 'Flavonoids, flavonoid-rich foods, and 
cardiovascular risk: a meta-analysis of randomized controlled trials', Am J Clin Nutr, 
88(1), pp. 38-50. 
Hord, N. G. (2011) 'Dietary Nitrates, Nitrites, and Cardiovascular Disease', Current 
Atherosclerosis Reports, 13(6), pp. 484-492. 
Hord, N. G., Tang, Y. and Bryan, N. S. (2009) 'Food sources of nitrates and nitrites: 
the physiologic context for potential health benefits', Am J Clin Nutr, 90(1), pp. 1-10. 
   
 203 
Hoshi, R. A., Pastre, C. M., Vanderlei, L. C. and Godoy, M. F. (2013) 'Poincare plot 
indexes of heart rate variability: relationships with other nonlinear variables', Auton 
Neurosci, 177(2), pp. 271-4. 
Hughes, W. E., Ueda, K., Treichler, D. P. and Casey, D. P. (2016) 'Effects of acute 
dietary nitrate supplementation on aortic blood pressure and aortic augmentation index in 
young and older adults', Nitric Oxide, 59, pp. 21-7. 
Huikuri, H. V. and Stein, P. K. (2012) 'Clinical application of heart rate variability 
after acute myocardial infarction', Front Physiol, 3, p. 41. 
Hussin AM, Ashor AW, Schoenmakers I, Hill T, Mathers JC and M., S. (2015) 'Effects 
of vitamin D supplementation on endothelial function: a systematic review and meta-
analysis of randomised controlled trials', Eur J Nutr, Under review. 
Inaba, Y., Chen, J. A. and Bergmann, S. R. (2010) 'Prediction of future cardiovascular 
outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis', Int J 
Cardiovasc Imaging, 26(6), pp. 631-40. 
Ingram, T. E., Fraser, A. G., Bleasdale, R. A., Ellins, E. A., Margulescu, A. D., Halcox, 
J. P. and James, P. E. (2013) 'Low-dose sodium nitrite attenuates myocardial ischemia 
and vascular ischemia-reperfusion injury in human models', J Am Coll Cardiol, 61(25), 
pp. 2534-41. 
Ischiropoulos, H. (2009) 'Protein tyrosine nitration--an update', Arch Biochem 
Biophys, 484(2), pp. 117-21. 
Jablonski, K. L., Racine, M. L., Geolfos, C. J., Gates, P. E., Chonchol, M., McQueen, 
M. B. and Seals, D. R. (2013) 'Dietary Sodium Restriction Reverses Vascular Endothelial 
Dysfunction in Middle-Aged/Older Adults With Moderately Elevated Systolic Blood 
Pressure', Journal of the American College of Cardiology, 61(3), pp. 335-343. 
Jackson, T. S., Xu, A., Vita, J. A. and Keaney, J. F., Jr. (1998) 'Ascorbate prevents the 
interaction of superoxide and nitric oxide only at very high physiological concentrations', 
Circ Res, 83(9), pp. 916-22. 
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. 
J. and McQuay, H. J. (1996) 'Assessing the quality of reports of randomized clinical trials: 
is blinding necessary?', Control Clin Trials, 17(1), pp. 1-12. 
   
 204 
Jaffrey, S. R. and Snyder, S. H. (2001) 'The biotin switch method for the detection of 
S-nitrosylated proteins', Sci STKE, 2001(86), p. pl1. 
Jajja, A., Sutyarjoko, A., Lara, J., Rennie, K., Brandt, K., Qadir, O. and Siervo, M. 
(2014) 'Beetroot supplementation lowers daily systolic blood pressure in older, 
overweight subjects', Nutr Res, 34(10), pp. 868-75. 
James, P. E., Willis, G. R., Allen, J. D., Winyard, P. G. and Jones, A. M. (2015) 'Nitrate 
pharmacokinetics: Taking note of the difference', Nitric Oxide, 48, pp. 44-50. 
Jameson, J. L. and Longo, D. L. (2015) 'Precision medicine--personalized, 
problematic, and promising', N Engl J Med, 372(23), pp. 2229-34. 
Jani, B. and Rajkumar, C. (2006) 'Ageing and vascular ageing', Postgrad Med J, 
82(968), pp. 357-62. 
Jiang, H., Torregrossa, A. C., Potts, A., Pierini, D., Aranke, M., Garg, H. K. and Bryan, 
N. S. (2014) 'Dietary nitrite improves insulin signaling through GLUT4 translocation', 
Free Radic Biol Med, 67, pp. 51-7. 
Jones, A. M. (2014) 'Dietary nitrate supplementation and exercise performance', Sports 
Med, 44 Suppl 1, pp. S35-45. 
Joshipura, K. J., Hu, F. B., Manson, J. E., Stampfer, M. J., Rimm, E. B., Speizer, F. 
E., Colditz, G., Ascherio, A., Rosner, B., Spiegelman, D. and Willett, W. C. (2001) 'The 
effect of fruit and vegetable intake on risk for coronary heart disease', Ann Intern Med, 
134(12), pp. 1106-14. 
Juraschek, S. P., Guallar, E., Appel, L. J. and Miller, E. R., 3rd (2012) 'Effects of 
vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled 
trials', Am J Clin Nutr, 95(5), pp. 1079-88. 
Jurk, D., Wilson, C., Passos, J. F., Oakley, F., Correia-Melo, C., Greaves, L., Saretzki, 
G., Fox, C., Lawless, C., Anderson, R., Hewitt, G., Pender, S. L., Fullard, N., Nelson, G., 
Mann, J., van de Sluis, B., Mann, D. A. and von Zglinicki, T. (2014) 'Chronic 
inflammation induces telomere dysfunction and accelerates ageing in mice', Nat 
Commun, 2, p. 4172. 
   
 205 
Kadoma, Y., Ishihara, M. and Fujisawa, S. (2006a) 'A quantitative approach to the free 
radical interaction between alpha-tocopherol and the coantioxidants eugenol, resveratrol 
or ascorbate', In Vivo, 20(1), pp. 61-7. 
Kadoma, Y., Ishihara, M., Okada, N. and Fujisawa, S. (2006b) 'Free radical interaction 
between vitamin E (alpha-, beta-, gamma- and delta-tocopherol), ascorbate and 
flavonoids', In Vivo, 20(6B), pp. 823-7. 
Kapil, V., Milsom, A. B., Okorie, M., Maleki-Toyserkani, S., Akram, F., Rehman, F., 
Arghandawi, S., Pearl, V., Benjamin, N., Loukogeorgakis, S., Macallister, R., Hobbs, A. 
J., Webb, A. J. and Ahluwalia, A. (2010a) 'Inorganic nitrate supplementation lowers 
blood pressure in humans: role for nitrite-derived NO', Hypertension, 56(2), pp. 274-81. 
Kapil, V., Webb, A. J. and Ahluwalia, A. (2010b) 'Inorganic nitrate and the 
cardiovascular system', Heart, 96(21), pp. 1703-9. 
Kapil, V., Weitzberg, E., Lundberg, J. O. and Ahluwalia, A. (2014) 'Clinical evidence 
demonstrating the utility of inorganic nitrate in cardiovascular health', Nitric Oxide, 38, 
pp. 45-57. 
Kelly, J., Fulford, J., Vanhatalo, A., Blackwell, J. R., French, O., Bailey, S. J., 
Gilchrist, M., Winyard, P. G. and Jones, A. M. (2013) 'Effects of short-term dietary nitrate 
supplementation on blood pressure, O2 uptake kinetics, and muscle and cognitive 
function in older adults', Am J Physiol Regul Integr Comp Physiol, 304(2), pp. R73-83. 
Kevil, C. G., Kolluru, G. K., Pattillo, C. B. and Giordano, T. (2011) 'Inorganic nitrite 
therapy: historical perspective and future directions', Free Radic Biol Med, 51(3), pp. 576-
93. 
Khalifi, S., Rahimipour, A., Jeddi, S., Ghanbari, M., Kazerouni, F. and Ghasemi, A. 
(2015) 'Dietary nitrate improves glucose tolerance and lipid profile in an animal model of 
hyperglycemia', Nitric Oxide, 44, pp. 24-30. 
Khaw, K. T., Bingham, S., Welch, A., Luben, R., Wareham, N., Oakes, S. and Day, 
N. (2001) 'Relation between plasma ascorbic acid and mortality in men and women in 
EPIC-Norfolk prospective study: a prospective population study. European Prospective 
Investigation into Cancer and Nutrition', Lancet, 357(9257), pp. 657-63. 
   
 206 
Khazaei, M., Moien-Afshari, F. and Laher, I. (2008) 'Vascular endothelial function in 
health and diseases', Pathophysiology, 15(1), pp. 49-67. 
Khodaeian, M., Tabatabaei-Malazy, O., Qorbani, M., Farzadfar, F., Amini, P. and 
Larijani, B. (2015) 'Effect of vitamins C and E on insulin resistance in diabetes: a meta-
analysis study', Eur J Clin Invest, 45(11), pp. 1161-74. 
Kim-Shapiro, D. B. and Gladwin, M. T. (2014) 'Mechanisms of nitrite bioactivation', 
Nitric Oxide, 38, pp. 58-68. 
Klingenberg, R., Hasun, M., Corti, R. and Luscher, T. F. (2012) 'Clinical 
Manifestations of Atherosclerosis', in Wick, G. and Grundtman, C. (eds.) Inflammation 
and Atherosclerosis. Springer-Verlag. 
Knekt, P., Ritz, J., Pereira, M. A., O'Reilly, E. J., Augustsson, K., Fraser, G. E., 
Goldbourt, U., Heitmann, B. L., Hallmans, G., Liu, S., Pietinen, P., Spiegelman, D., 
Stevens, J., Virtamo, J., Willett, W. C., Rimm, E. B. and Ascherio, A. (2004) 'Antioxidant 
vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts', Am J Clin Nutr, 
80(6), pp. 1508-20. 
Konukoglu, D., Firtina, S. and Serin, O. (2008) 'The relationship between plasma 
asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in 
subjects with normal, impaired, and diabetic glucose tolerance', Metabolism, 57(1), pp. 
110-5. 
Korantzopoulos, P. and Galaris, D. (2003) 'The protective role of vitamin C on 
endothelial dysfunction', Journal of Clinical and Basic Cardiology, 6(1), pp. 3-6. 
Kris-Etherton, P. M., Harris, W. S. and Appel, L. J. (2002) 'Fish consumption, fish oil, 
omega-3 fatty acids, and cardiovascular disease', Circulation, 106(21), pp. 2747-57. 
Kurz, D. J., Decary, S., Hong, Y., Trivier, E., Akhmedov, A. and Erusalimsky, J. D. 
(2004) 'Chronic oxidative stress compromises telomere integrity and accelerates the onset 
of senescence in human endothelial cells', J Cell Sci, 117(Pt 11), pp. 2417-26. 
Kvandal, P., Stefanovska, A., Veber, M., Kvernmo, H. D. and Kirkeboen, K. A. (2003) 
'Regulation of human cutaneous circulation evaluated by laser Doppler flowmetry, 
iontophoresis, and spectral analysis: importance of nitric oxide and prostaglandines', 
Microvasc Res, 65(3), pp. 160-71. 
   
 207 
Langie, S. A., Kowalczyk, P., Tomaszewski, B., Vasilaki, A., Maas, L. M., Moonen, 
E. J., Palagani, A., Godschalk, R. W., Tudek, B., van Schooten, F. J., Berghe, W. V., 
Zabielski, R. and Mathers, J. C. (2014) 'Redox and epigenetic regulation of the APE1 
gene in the hippocampus of piglets: The effect of early life exposures', DNA Repair 
(Amst), 18, pp. 52-62. 
Lara, J., Ashor, A. W., Oggioni, C., Ahluwalia, A., Mathers, J. C. and Siervo, M. 
(2015) 'Effects of inorganic nitrate and beetroot supplementation on endothelial function: 
a systematic review and meta-analysis', Eur J Nutr, 55(2), p. 9. 
Larsen, F. J., Ekblom, B., Sahlin, K., Lundberg, J. O. and Weitzberg, E. (2006) 'Effects 
of dietary nitrate on blood pressure in healthy volunteers', N Engl J Med, 355(26), pp. 
2792-3. 
Larsen, F. J., Schiffer, T. A., Borniquel, S., Sahlin, K., Ekblom, B., Lundberg, J. O. 
and Weitzberg, E. (2011) 'Dietary inorganic nitrate improves mitochondrial efficiency in 
humans', Cell Metab, 13(2), pp. 149-59. 
Larsen, F. J., Schiffer, T. A., Ekblom, B., Mattsson, M. P., Checa, A., Wheelock, C. 
E., Nystrom, T., Lundberg, J. O. and Weitzberg, E. (2014) 'Dietary nitrate reduces resting 
metabolic rate: a randomized, crossover study in humans', Am J Clin Nutr, 99(4), pp. 843-
50. 
Larsen, F. J., Weitzberg, E., Lundberg, J. O. and Ekblom, B. (2007) 'Effects of dietary 
nitrate on oxygen cost during exercise', Acta Physiol (Oxf), 191(1), pp. 59-66. 
Lau, J., Ioannidis, J. P., Terrin, N., Schmid, C. H. and Olkin, I. (2006) 'The case of the 
misleading funnel plot', BMJ, 333(7568), pp. 597-600. 
Laurent, S. and Boutouyrie, P. (2007) 'Arterial stiffness: a new surrogate end point for 
cardiovascular disease?', J Nephrol, 20 Suppl 12, pp. S45-50. 
Lee, J. S., Stebbins, C. L., Jung, E., Nho, H., Kim, J. K., Chang, M. J. and Choi, H. M. 
(2015) 'Effects of chronic dietary nitrate supplementation on the hemodynamic response 
to dynamic exercise', Am J Physiol Regul Integr Comp Physiol, 309(5), pp. R459-66. 
Lehr, H. A., Germann, G., McGregor, G. P., Migeod, F., Roesen, P., Tanaka, H., Uhlig, 
C. and Biesalski, H. K. (2006) 'Consensus meeting on "Relevance of parenteral vitamin 
   
 208 
C in acute endothelial dependent pathophysiological conditions (EDPC)"', Eur J Med Res, 
11(12), pp. 516-26. 
Lei, J., Vodovotz, Y., Tzeng, E. and Billiar, T. R. (2013) 'Nitric oxide, a protective 
molecule in the cardiovascular system', Nitric Oxide, 35C, pp. 175-185. 
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, 
K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J. and Cantilena, L. R. (1996) 
'Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary 
allowance', Proc Natl Acad Sci U S A, 93(8), pp. 3704-9. 
Levine, M., Wang, Y., Padayatty, S. J. and Morrow, J. (2001) 'A new recommended 
dietary allowance of vitamin C for healthy young women', Proc Natl Acad Sci U S A, 
98(17), pp. 9842-6. 
Levitt, E. L., Keen, J. T. and Wong, B. J. (2015) 'Augmented reflex cutaneous 
vasodilatation following short-term dietary nitrate supplementation in humans', Exp 
Physiol, 100(6), pp. 708-18. 
Li, Y. and Schellhorn, H. E. (2007) 'New developments and novel therapeutic 
perspectives for vitamin C', J Nutr, 137(10), pp. 2171-84. 
Li, Z., Mao, H. Z., Abboud, F. M. and Chapleau, M. W. (1996) 'Oxygen-derived free 
radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits', Circ Res, 79(4), 
pp. 802-11. 
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P., 
Clarke, M., Devereaux, P. J., Kleijnen, J. and Moher, D. (2009) 'The PRISMA statement 
for reporting systematic reviews and meta-analyses of studies that evaluate healthcare 
interventions: explanation and elaboration', BMJ, 339, p. b2700. 
Lidder, S. and Webb, A. J. (2013) 'Vascular effects of dietary nitrate (as found in green 
leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway', Br J Clin 
Pharmacol, 75(3), pp. 677-96. 
Lind, L. (2003) 'Circulating markers of inflammation and atherosclerosis', 
Atherosclerosis, 169(2), pp. 203-14. 
   
 209 
Linder, L., Kiowski, W., Buhler, F. R. and Luscher, T. F. (1990) 'Indirect evidence for 
release of endothelium-derived relaxing factor in human forearm circulation in vivo. 
Blunted response in essential hypertension', Circulation, 81(6), pp. 1762-7. 
Liu, A. H., Bondonno, C. P., Croft, K. D., Puddey, I. B., Woodman, R. J., Rich, L., 
Ward, N. C., Vita, J. A. and Hodgson, J. M. (2013) 'Effects of a nitrate-rich meal on 
arterial stiffness and blood pressure in healthy volunteers', Nitric Oxide, 35, pp. 123-30. 
Liu, Y., Zhao, H., Li, H., Kalyanaraman, B., Nicolosi, A. C. and Gutterman, D. D. 
(2003) 'Mitochondrial sources of H2O2 generation play a key role in flow-mediated 
dilation in human coronary resistance arteries', Circ Res, 93(6), pp. 573-80. 
Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. and Kroemer, G. (2013) 'The 
hallmarks of aging', Cell, 153(6), pp. 1194-217. 
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M. and Sitzer, M. (2007) 
'Prediction of clinical cardiovascular events with carotid intima-media thickness: a 
systematic review and meta-analysis', Circulation, 115(4), pp. 459-67. 
Loria, C. M., Klag, M. J., Caulfield, L. E. and Whelton, P. K. (2000) 'Vitamin C status 
and mortality in US adults', Am J Clin Nutr, 72(1), pp. 139-45. 
Lovegrove, J. A. and Griffin, B. A. (2013) 'The acute and long-term effects of dietary 
fatty acids on vascular function in health and disease', Current Opinion in Clinical 
Nutrition & Metabolic Care, 16(2), pp. 162-167 10.1097/MCO.0b013e32835c5f29. 
Luiking, Y. C., Ten Have, G. A., Wolfe, R. R. and Deutz, N. E. (2012) 'Arginine de 
novo and nitric oxide production in disease states', Am J Physiol Endocrinol Metab, 
303(10), pp. E1177-89. 
Lundberg, J. O., Carlsson, S., Engstrand, L., Morcos, E., Wiklund, N. P. and 
Weitzberg, E. (1997) 'Urinary nitrite: more than a marker of infection', Urology, 50(2), 
pp. 189-91. 
Lundberg, J. O., Carlstrom, M., Larsen, F. J. and Weitzberg, E. (2011) 'Roles of dietary 
inorganic nitrate in cardiovascular health and disease', Cardiovasc Res, 89(3), pp. 525-
32. 
   
 210 
Lundberg, J. O., Feelisch, M., Bjorne, H., Jansson, E. A. and Weitzberg, E. (2006) 
'Cardioprotective effects of vegetables: is nitrate the answer?', Nitric Oxide, 15(4), pp. 
359-62. 
Lundberg, J. O., Gladwin, M. T., Ahluwalia, A., Benjamin, N., Bryan, N. S., Butler, 
A., Cabrales, P., Fago, A., Feelisch, M., Ford, P. C., Freeman, B. A., Frenneaux, M., 
Friedman, J., Kelm, M., Kevil, C. G., Kim-Shapiro, D. B., Kozlov, A. V., Lancaster Jr, J. 
R., Lefer, D. J., McColl, K., McCurry, K., Patel, R. P., Petersson, J., Rassaf, T., Reutov, 
V. P., Richter-Addo, G. B., Schechter, A., Shiva, S., Tsuchiya, K., Van Faassen, E. E., 
Webb, A. J., Zuckerbraun, B. S., Zweier, J. L. and Weitzberg, E. (2009) 'Nitrate and nitrite 
in biology, nutrition and therapeutics', Nat Chem Biol, 5(12), pp. 865-869. 
Lundberg, J. O., Weitzberg, E. and Gladwin, M. T. (2008) 'The nitrate-nitrite-nitric 
oxide pathway in physiology and therapeutics', Nat Rev Drug Discov, 7(2), pp. 156-67. 
Lundberg, J. O., Weitzberg, E., Lundberg, J. M. and Alving, K. (1994) 'Intragastric 
nitric oxide production in humans: measurements in expelled air', Gut, 35(11), pp. 1543-
6. 
Lykkesfeldt, J. (2007) 'Ascorbate and dehydroascorbic acid as reliable biomarkers of 
oxidative stress: analytical reproducibility and long-term stability of plasma samples 
subjected to acidic deproteinization', Cancer Epidemiol Biomarkers Prev, 16(11), pp. 
2513-6. 
Lykkesfeldt, J., Hagen, T. M., Vinarsky, V. and Ames, B. N. (1998) 'Age-associated 
decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes--
reversal with (R)-alpha-lipoic acid supplementation', Faseb j, 12(12), pp. 1183-9. 
Lykkesfeldt, J., Michels, A. J. and Frei, B. (2014) 'Vitamin C', Adv Nutr, 5(1), pp. 16-
8. 
Lykkesfeldt, J. and Poulsen, H. E. (2010) 'Is vitamin C supplementation beneficial? 
Lessons learned from randomised controlled trials', Br J Nutr, 103(9), pp. 1251-9. 
Lyons, D., Roy, S., Patel, M., Benjamin, N. and Swift, C. G. (1997) 'Impaired nitric 
oxide-mediated vasodilatation and total body nitric oxide production in healthy old age', 
Clin Sci (Lond), 93(6), pp. 519-25. 
   
 211 
Machha, A. and Schechter, A. N. (2012) 'Inorganic nitrate: a major player in the 
cardiovascular health benefits of vegetables?', Nutr Rev, 70(6), pp. 367-72. 
Magen, E., Viskoper, R., Mishal, J., Priluk, R., Berezovsky, A., Laszt, A., London, D. 
and Yosefy, C. (2004) 'Resistant arterial hypertension and hyperlipidemia: atorvastatin, 
not vitamin C, for blood pressure control', Isr Med Assoc J, 6(12), pp. 742-6. 
Mah, E. and Bruno, R. S. (2012) 'Postprandial hyperglycemia on vascular endothelial 
function: mechanisms and consequences', Nutr Res, 32(10), pp. 727-40. 
Mah, E., Noh, S. K., Ballard, K. D., Matos, M. E., Volek, J. S. and Bruno, R. S. (2011) 
'Postprandial hyperglycemia impairs vascular endothelial function in healthy men by 
inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine', J 
Nutr, 141(11), pp. 1961-8. 
Mangoni, A. A. and Jackson, S. H. (2004) 'Age-related changes in pharmacokinetics 
and pharmacodynamics: basic principles and practical applications', Br J Clin Pharmacol, 
57(1), pp. 6-14. 
Mark, S. D., Wang, W., Fraumeni, J. F., Jr., Li, J. Y., Taylor, P. R., Wang, G. Q., Guo, 
W., Dawsey, S. M., Li, B. and Blot, W. J. (1996) 'Lowered risks of hypertension and 
cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition 
Intervention Trial', Am J Epidemiol, 143(7), pp. 658-64. 
Martínez-González, M. A., García-López, M., Bes-Rastrollo, M., Toledo, E., 
Martínez-Lapiscina, E. H., Delgado-Rodriguez, M., Vazquez, Z., Benito, S. and Beunza, 
J. J. (2011) 'Mediterranean diet and the incidence of cardiovascular disease: A Spanish 
cohort', Nutrition, Metabolism and Cardiovascular Diseases, 21(4), pp. 237-244. 
Martyn, J. A., Kaneki, M. and Yasuhara, S. (2008) 'Obesity-induced insulin resistance 
and hyperglycemia: etiologic factors and molecular mechanisms', Anesthesiology, 109(1), 
pp. 137-48. 
Mathers, J. C. (2015) 'Impact of nutrition on the ageing process', Br J Nutr, 113 Suppl, 
pp. S18-22. 
May, J. M. (2000) 'How does ascorbic acid prevent endothelial dysfunction?', Free 
Radic Biol Med, 28(9), pp. 1421-9. 
   
 212 
May, J. M. and Harrison, F. E. (2013) 'Role of Vitamin C in the Function of the 
Vascular Endothelium', Antioxid Redox Signal. 
McRae, M. P. (2008) 'Vitamin C supplementation lowers serum low-density 
lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled 
trials', J Chiropr Med, 7(2), pp. 48-58. 
Mensah, G. A. (2007) 'Healthy endothelium: the scientific basis for cardiovascular 
health promotion and chronic disease prevention', Vascul Pharmacol, 46(5), pp. 310-4. 
Michels, A. J. and Frei, B. (2013) 'Myths, artifacts, and fatal flaws: identifying 
limitations and opportunities in vitamin C research', Nutrients, 5(12), pp. 5161-92. 
Michels, A. J., Hagen, T. M. and Frei, B. (2013) 'Human genetic variation influences 
vitamin C homeostasis by altering vitamin C transport and antioxidant enzyme function', 
Annu Rev Nutr, 33, pp. 45-70. 
Michiels, C. (2003) 'Endothelial cell functions', J Cell Physiol, 196(3), pp. 430-43. 
Miller, G. D., Marsh, A. P., Dove, R. W., Beavers, D., Presley, T., Helms, C., Bechtold, 
E., King, S. B. and Kim-Shapiro, D. (2012) 'Plasma nitrate and nitrite are increased by a 
high nitrate supplement, but not by high nitrate foods in older adults', Nutrition Research 
(New York, N.y.), 32(3), pp. 160-168. 
Minamino, T. and Komuro, I. (2007) 'Vascular cell senescence: contribution to 
atherosclerosis', Circ Res, 100(1), pp. 15-26. 
Minamino, T., Miyauchi, H., Yoshida, T., Ishida, Y., Yoshida, H. and Komuro, I. 
(2002) 'Endothelial cell senescence in human atherosclerosis: role of telomere in 
endothelial dysfunction', Circulation, 105(13), pp. 1541-4. 
Mitchell, G. F., Parise, H., Benjamin, E. J., Larson, M. G., Keyes, M. J., Vita, J. A., 
Vasan, R. S. and Levy, D. (2004) 'Changes in arterial stiffness and wave reflection with 
advancing age in healthy men and women: the Framingham Heart Study', Hypertension, 
43(6), pp. 1239-45. 
Monahan, K. D., Eskurza, I. and Seals, D. R. (2004) 'Ascorbic acid increases 
cardiovagal baroreflex sensitivity in healthy older men', Am J Physiol Heart Circ Physiol, 
286(6), pp. H2113-7. 
   
 213 
Montenegro, M. F., Amaral, J. H., Pinheiro, L. C., Sakamoto, E. K., Ferreira, G. C., 
Reis, R. I., Marcal, D. M., Pereira, R. P. and Tanus-Santos, J. E. (2011) 'Sodium nitrite 
downregulates vascular NADPH oxidase and exerts antihypertensive effects in 
hypertension', Free Radic Biol Med, 51(1), pp. 144-52. 
Montero, D., Pierce, G. L., Stehouwer, C. D., Padilla, J. and Thijssen, D. H. (2015) 
'The impact of age on vascular smooth muscle function in humans', J Hypertens, 33(3), 
pp. 445-53; discussion 453. 
Montero, D., Walther, G., Stehouwer, C. D., Houben, A. J., Beckman, J. A. and Vinet, 
A. (2014) 'Effect of antioxidant vitamin supplementation on endothelial function in type 
2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled 
trials', Obes Rev, 15(2), pp. 107-16. 
Mortensen, A. and Lykkesfeldt, J. (2014) 'Does vitamin C enhance nitric oxide 
bioavailability in a tetrahydrobiopterin-dependent manner? In vitro, in vivo and clinical 
studies', Nitric Oxide, 36, pp. 51-7. 
Mosca, L., Appel, L. J., Benjamin, E. J., Berra, K., Chandra-Strobos, N., Fabunmi, R. 
P., Grady, D., Haan, C. K., Hayes, S. N., Judelson, D. R., Keenan, N. L., McBride, P., 
Oparil, S., Ouyang, P., Oz, M. C., Mendelsohn, M. E., Pasternak, R. C., Pinn, V. W., 
Robertson, R. M., Schenck-Gustafsson, K., Sila, C. A., Smith, S. C., Jr., Sopko, G., 
Taylor, A. L., Walsh, B. W., Wenger, N. K. and Williams, C. L. (2004) 'Evidence-based 
guidelines for cardiovascular disease prevention in women', J Am Coll Cardiol, 43(5), pp. 
900-21. 
Mosdol, A., Erens, B. and Brunner, E. J. (2008) 'Estimated prevalence and predictors 
of vitamin C deficiency within UK's low-income population', J Public Health (Oxf), 
30(4), pp. 456-60. 
Moser, M. A. and Chun, O. K. (2016) 'Vitamin C and Heart Health: A Review Based 
on Findings from Epidemiologic Studies', Int J Mol Sci, 17(8). 
Mowat, C., Carswell, A., Wirz, A. and McColl, K. E. (1999) 'Omeprazole and dietary 
nitrate independently affect levels of vitamin C and nitrite in gastric juice', 
Gastroenterology, 116(4), pp. 813-22. 
   
 214 
Mowat, C. and McColl, K. E. (2001) 'Alterations in intragastric nitrite and vitamin C 
levels during acid inhibitory therapy', Best Pract Res Clin Gastroenterol, 15(3), pp. 523-
37. 
MRC/BHF (2002) 'MRC/BHF Heart Protection Study of antioxidant vitamin 
supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial', 
Lancet, 360(9326), pp. 23-33. 
Munoz-Espin, D. and Serrano, M. (2014) 'Cellular senescence: from physiology to 
pathology', Nat Rev Mol Cell Biol, 15(7), pp. 482-96. 
Munzel, T., Gori, T., Bruno, R. M. and Taddei, S. (2010) 'Is oxidative stress a 
therapeutic target in cardiovascular disease?', Eur Heart J, 31(22), pp. 2741-8. 
Murad, F. (1986) 'Cyclic guanosine monophosphate as a mediator of vasodilation', J 
Clin Invest, 78(1), pp. 1-5. 
Murphy, M. P. (2009) 'How mitochondria produce reactive oxygen species', Biochem 
J, 417(1), pp. 1-13. 
Murray, C. J., Richards, M. A., Newton, J. N., Fenton, K. A., Anderson, H. R., 
Atkinson, C., Bennett, D., Bernabe, E., Blencowe, H., Bourne, R., Braithwaite, T., 
Brayne, C., Bruce, N. G., Brugha, T. S., Burney, P., Dherani, M., Dolk, H., Edmond, K., 
Ezzati, M., Flaxman, A. D., Fleming, T. D., Freedman, G., Gunnell, D., Hay, R. J., 
Hutchings, S. J., Ohno, S. L., Lozano, R., Lyons, R. A., Marcenes, W., Naghavi, M., 
Newton, C. R., Pearce, N., Pope, D., Rushton, L., Salomon, J. A., Shibuya, K., Vos, T., 
Wang, H., Williams, H. C., Woolf, A. D., Lopez, A. D. and Davis, A. (2013) 'UK health 
performance: findings of the Global Burden of Disease Study 2010', Lancet, 381(9871), 
pp. 997-1020. 
Myint, P. K., Luben, R. N., Wareham, N. J. and Khaw, K. T. (2011) 'Association 
between plasma vitamin C concentrations and blood pressure in the European prospective 
investigation into cancer-Norfolk population-based study', Hypertension, 58(3), pp. 372-
9. 
Myung, S. K., Ju, W., Cho, B., Oh, S. W., Park, S. M., Koo, B. K. and Park, B. J. 
(2013) 'Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular 
   
 215 
disease: systematic review and meta-analysis of randomised controlled trials', BMJ, 346, 
p. f10. 
Namikoshi, T., Tomita, N., Satoh, M., Sakuta, T., Kuwabara, A., Nagasu, H., 
Yorimitsu, D., Sasaki, T. and Kashihara, N. (2009) 'High dietary protein intake induces 
endothelial dysfunction in uninephrectomized rats', Mol Med Rep, 2(3), pp. 429-34. 
Nawrot, T. S., Staessen, J. A., Holvoet, P., Struijker-Boudier, H. A., Schiffers, P., Van 
Bortel, L. M., Fagard, R. H., Gardner, J. P., Kimura, M. and Aviv, A. (2010) 'Telomere 
length and its associations with oxidized-LDL, carotid artery distensibility and smoking', 
Front Biosci (Elite Ed), 2, pp. 1164-8. 
Newton, D. J., Khan, F. and Belch, J. J. (2001) 'Assessment of microvascular 
endothelial function in human skin', Clin Sci (Lond), 101(6), pp. 567-72. 
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, 
E. C., Biryukov, S., Abbafati, C., Abera, S. F., Abraham, J. P., Abu-Rmeileh, N. M., 
Achoki, T., AlBuhairan, F. S., Alemu, Z. A., Alfonso, R., Ali, M. K., Ali, R., Guzman, 
N. A., Ammar, W., Anwari, P., Banerjee, A., Barquera, S., Basu, S., Bennett, D. A., 
Bhutta, Z., Blore, J., Cabral, N., Nonato, I. C., Chang, J. C., Chowdhury, R., Courville, 
K. J., Criqui, M. H., Cundiff, D. K., Dabhadkar, K. C., Dandona, L., Davis, A., Dayama, 
A., Dharmaratne, S. D., Ding, E. L., Durrani, A. M., Esteghamati, A., Farzadfar, F., Fay, 
D. F., Feigin, V. L., Flaxman, A., Forouzanfar, M. H., Goto, A., Green, M. A., Gupta, R., 
Hafezi-Nejad, N., Hankey, G. J., Harewood, H. C., Havmoeller, R., Hay, S., Hernandez, 
L., Husseini, A., Idrisov, B. T., Ikeda, N., Islami, F., Jahangir, E., Jassal, S. K., Jee, S. H., 
Jeffreys, M., Jonas, J. B., Kabagambe, E. K., Khalifa, S. E., Kengne, A. P., Khader, Y. 
S., Khang, Y. H., Kim, D., Kimokoti, R. W., Kinge, J. M., Kokubo, Y., Kosen, S., Kwan, 
G., Lai, T., Leinsalu, M., Li, Y., Liang, X., Liu, S., Logroscino, G., Lotufo, P. A., Lu, Y., 
Ma, J., Mainoo, N. K., Mensah, G. A., Merriman, T. R., Mokdad, A. H., Moschandreas, 
J., Naghavi, M., Naheed, A., Nand, D., Narayan, K. M., Nelson, E. L., Neuhouser, M. L., 
Nisar, M. I., Ohkubo, T., Oti, S. O., Pedroza, A., et al. (2014) 'Global, regional, and 
national prevalence of overweight and obesity in children and adults during 1980-2013: 
a systematic analysis for the Global Burden of Disease Study 2013', Lancet, 384(9945), 
pp. 766-81. 
Nguyen, T. and Lau, D. C. (2012) 'The obesity epidemic and its impact on 
hypertension', Can J Cardiol, 28(3), pp. 326-33. 
   
 216 
Nichols, W. W., Harripersaud, K. and Petersen, J. W. (2013) 'Nitrates and Arterial 
Function', Current Cardiovascular Risk Reports, 7(3), pp. 224-232. 
North, B. J. and Sinclair, D. A. (2012) 'The intersection between aging and 
cardiovascular disease', Circ Res, 110(8), pp. 1097-108. 
Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A. W., Tschannen, B., Altman, D. G., 
Egger, M. and Juni, P. (2010) 'Small study effects in meta-analyses of osteoarthritis trials: 
meta-epidemiological study', BMJ, 341, p. c3515. 
Nyyssonen, K., Parviainen, M. T., Salonen, R., Tuomilehto, J. and Salonen, J. T. 
(1997) 'Vitamin C deficiency and risk of myocardial infarction: prospective population 
study of men from eastern Finland', BMJ, 314(7081), pp. 634-8. 
Ogami, M., Ikura, Y., Ohsawa, M., Matsuo, T., Kayo, S., Yoshimi, N., Hai, E., Shirai, 
N., Ehara, S., Komatsu, R., Naruko, T. and Ueda, M. (2004) 'Telomere shortening in 
human coronary artery diseases', Arterioscler Thromb Vasc Biol, 24(3), pp. 546-50. 
Omar, S. A., Webb, A. J., Lundberg, J. O. and Weitzberg, E. (2015) 'Therapeutic 
effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases', J Intern 
Med. 
Ong, P. J., Dean, T. S., Hayward, C. S., Della Monica, P. L., Sanders, T. A. and Collins, 
P. (1999) 'Effect of fat and carbohydrate consumption on endothelial function', Lancet, 
354(9196), p. 2134. 
Osganian, S. K., Stampfer, M. J., Rimm, E., Spiegelman, D., Hu, F. B., Manson, J. E. 
and Willett, W. C. (2003) 'Vitamin C and risk of coronary heart disease in women', J Am 
Coll Cardiol, 42(2), pp. 246-52. 
Oxman, A. D. and Guyatt, G. H. (1991) 'Validation of an index of the quality of review 
articles', J Clin Epidemiol, 44(11), pp. 1271-8. 
Packer, L. (2005) 'Oxidants and Antioxidants: Mechanism of Action and Regulation 
of Gene Expression by Bioflavonoids', in Surh, Y.-J. and Packer, L. (eds.) Oxidative 
Stress Inflammation and Health. Taylor and Francis. 
   
 217 
Padayatty, S. J., Katz, A., Wang, Y., Eck, P., Kwon, O., Lee, J. H., Chen, S., Corpe, 
C., Dutta, A., Dutta, S. K. and Levine, M. (2003) 'Vitamin C as an antioxidant: evaluation 
of its role in disease prevention', J Am Coll Nutr, 22(1), pp. 18-35. 
Padayatty, S. J. and Levine, M. (2016) 'Vitamin C: the known and the unknown and 
Goldilocks', Oral Dis, 22(6), pp. 463-93. 
Pannala, A. S., Mani, A. R., Spencer, J. P., Skinner, V., Bruckdorfer, K. R., Moore, K. 
P. and Rice-Evans, C. A. (2003) 'The effect of dietary nitrate on salivary, plasma, and 
urinary nitrate metabolism in humans', Free Radic Biol Med, 34(5), pp. 576-84. 
Panza, J. A., Casino, P. R., Kilcoyne, C. M. and Quyyumi, A. A. (1993) 'Role of 
endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular 
relaxation of patients with essential hypertension', Circulation, 87(5), pp. 1468-74. 
Panza, J. A., Quyyumi, A. A., Brush, J. E., Jr. and Epstein, S. E. (1990) 'Abnormal 
endothelium-dependent vascular relaxation in patients with essential hypertension', N 
Engl J Med, 323(1), pp. 22-7. 
Park, J. W., Piknova, B., Huang, P. L., Noguchi, C. T. and Schechter, A. N. (2013) 
'Effect of blood nitrite and nitrate levels on murine platelet function', PLoS One, 8(2), p. 
e55699. 
Park, S. and Lakatta, E. G. (2012) 'Role of inflammation in the pathogenesis of arterial 
stiffness', Yonsei Med J, 53(2), pp. 258-61. 
Pashkow, F. J. (2011) 'Oxidative Stress and Inflammation in Heart Disease: Do 
Antioxidants Have a Role in Treatment and/or Prevention?', Int J Inflam, 2011, p. 514623. 
Patel, R. S., Al Mheid, I., Morris, A. A., Ahmed, Y., Kavtaradze, N., Ali, S., 
Dabhadkar, K., Brigham, K., Hooper, W. C., Alexander, R. W., Jones, D. P. and 
Quyyumi, A. A. (2011) 'Oxidative stress is associated with impaired arterial elasticity', 
Atherosclerosis, 218(1), pp. 90-5. 
Peleli, M., Hezel, M., Zollbrecht, C., Persson, A. E., Lundberg, J. O., Weitzberg, E., 
Fredholm, B. B. and Carlstrom, M. (2015) 'In adenosine A2B knockouts acute treatment 
with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling 
in the liver', Front Physiol, 6, p. 222. 
   
 218 
Pelletier, M. M., Kleinbongard, P., Ringwood, L., Hito, R., Hunter, C. J., Schechter, 
A. N., Gladwin, M. T. and Dejam, A. (2006) 'The measurement of blood and plasma 
nitrite by chemiluminescence: pitfalls and solutions', Free Radic Biol Med, 41(4), pp. 
541-8. 
Percival, R. S., Challacombe, S. J. and Marsh, P. D. (1991) 'Age-related 
microbiological changes in the salivary and plaque microflora of healthy adults', J Med 
Microbiol, 35(1), pp. 5-11. 
Piccirillo, G., Nocco, M., Moise, A., Lionetti, M., Naso, C., di Carlo, S. and 
Marigliano, V. (2003) 'Influence of vitamin C on baroreflex sensitivity in chronic heart 
failure', Hypertension, 41(6), pp. 1240-5. 
Piconi, L., Quagliaro, L., Da Ros, R., Assaloni, R., Giugliano, D., Esposito, K., Szabo, 
C. and Ceriello, A. (2004) 'Intermittent high glucose enhances ICAM-1, VCAM-1, E-
selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the 
role of poly(ADP-ribose) polymerase', J Thromb Haemost, 2(8), pp. 1453-9. 
Pierce, G. L., Lesniewski, L. A., Lawson, B. R., Beske, S. D. and Seals, D. R. (2009) 
'Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via 
oxidative stress in overweight/obese middle-aged and older humans', Circulation, 119(9), 
pp. 1284-92. 
Pludowski, P., Holick, M. F., Pilz, S., Wagner, C. L., Hollis, B. W., Grant, W. B., 
Shoenfeld, Y., Lerchbaum, E., Llewellyn, D. J., Kienreich, K. and Soni, M. (2013) 
'Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular 
disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence', 
Autoimmun Rev, 12(10), pp. 976-89. 
Pober, J. S., Min, W. and Bradley, J. R. (2009) 'Mechanisms of endothelial 
dysfunction, injury, and death', Annu Rev Pathol, 4, pp. 71-95. 
Podmore, I. D., Griffiths, H. R., Herbert, K. E., Mistry, N., Mistry, P. and Lunec, J. 
(1998) 'Vitamin C exhibits pro-oxidant properties', Nature, 392(6676), p. 559. 
Porter, W. L. (1993) 'Paradoxical behavior of antioxidants in food and biological 
systems', Toxicol Ind Health, 9(1-2), pp. 93-122. 
   
 219 
Puca, A. A., Carrizzo, A., Villa, F., Ferrario, A., Casaburo, M., Maciag, A. and 
Vecchione, C. (2013) 'Vascular ageing: the role of oxidative stress', Int J Biochem Cell 
Biol, 45(3), pp. 556-9. 
Qadir, O. K., Teh, J., Siervo, M., Seal, C. J. and Brandt, K. (2013) 'Method using gas 
chromatography mass spectrometry (GC-MS) for analysis of nitrate and nitrite in 
vegetables', NUTRIHORT : Nutrient management, innovative techniques and nutrient 
legislation in intensive horticulture for an improved water quality. Ghent, Belgium. 
Institute for Agricultural and Fisheries Research. 
Qiao, Q., Jousilahti, P., Eriksson, J. and Tuomilehto, J. (2003) 'Predictive properties 
of impaired glucose tolerance for cardiovascular risk are not explained by the 
development of overt diabetes during follow-up', Diabetes Care, 26(10), pp. 2910-4. 
Radi, R. (2004) 'Nitric oxide, oxidants, and protein tyrosine nitration', Proc Natl Acad 
Sci U S A, 101(12), pp. 4003-8. 
Raitakari, M., Ilvonen, T., Ahotupa, M., Lehtimaki, T., Harmoinen, A., Suominen, P., 
Elo, J., Hartiala, J. and Raitakari, O. T. (2004) 'Weight reduction with very-low-caloric 
diet and endothelial function in overweight adults: role of plasma glucose', Arterioscler 
Thromb Vasc Biol, 24(1), pp. 124-8. 
Rallidis, L. S., Lekakis, J., Kolomvotsou, A., Zampelas, A., Vamvakou, G., Efstathiou, 
S., Dimitriadis, G., Raptis, S. A. and Kremastinos, D. T. (2009) 'Close adherence to a 
Mediterranean diet improves endothelial function in subjects with abdominal obesity', Am 
J Clin Nutr, 90(2), pp. 263-8. 
Rammos, C., Hendgen-Cotta, U. B., Sobierajski, J., Bernard, A., Kelm, M. and Rassaf, 
T. (2014) 'Dietary nitrate reverses vascular dysfunction in older adults with moderately 
increased cardiovascular risk', J Am Coll Cardiol, 63(15), pp. 1584-5. 
Rassaf, T., Feelisch, M. and Kelm, M. (2004) 'Circulating NO pool: assessment of 
nitrite and nitroso species in blood and tissues', Free Radic Biol Med, 36(4), pp. 413-22. 
Rehman, A., Collis, C. S., Yang, M., Kelly, M., Diplock, A. T., Halliwell, B. and Rice-
Evans, C. (1998) 'The effects of iron and vitamin C co-supplementation on oxidative 
damage to DNA in healthy volunteers', Biochem Biophys Res Commun, 246(1), pp. 293-
8. 
   
 220 
Richardson, G., Hicks, S. L., O'Byrne, S., Frost, M. T., Moore, K., Benjamin, N. and 
McKnight, G. M. (2002) 'The ingestion of inorganic nitrate increases gastric S-
nitrosothiol levels and inhibits platelet function in humans', Nitric Oxide, 7(1), pp. 24-9. 
Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., 
Hennekens, C. H. and Buring, J. E. (2005) 'A randomized trial of low-dose aspirin in the 
primary prevention of cardiovascular disease in women', N Engl J Med, 352(13), pp. 
1293-304. 
Rietjens, I. M., Boersma, M. G., Haan, L., Spenkelink, B., Awad, H. M., Cnubben, N. 
H., van Zanden, J. J., Woude, H., Alink, G. M. and Koeman, J. H. (2002) 'The pro-oxidant 
chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids', 
Environ Toxicol Pharmacol, 11(3-4), pp. 321-33. 
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E., Colditz, G. A. and 
Willett, W. C. (1993) 'Vitamin E consumption and the risk of coronary heart disease in 
men', N Engl J Med, 328(20), pp. 1450-6. 
Ristow, M., Zarse, K., Oberbach, A., Kloting, N., Birringer, M., Kiehntopf, M., 
Stumvoll, M., Kahn, C. R. and Bluher, M. (2009) 'Antioxidants prevent health-promoting 
effects of physical exercise in humans', Proc Natl Acad Sci U S A, 106(21), pp. 8665-70. 
Ritz, E. (2007) 'Total cardiovascular risk management', Am J Cardiol, 100(3A), pp. 
53J-60J. 
Rodrigues, A. N., de Abreu, G. R. and Gouvêa, S. A. (2012) 'Cardiovascular Risk 
Investigation: When Should It Start?', in Gasparyan, A. Y. (ed.) Cardiovascular Risk 
Factors. Croatia: InTech. 
Rodriguez-Mateos, A., Hezel, M., Aydin, H., Kelm, M., Lundberg, J. O., Weitzberg, 
E., Spencer, J. P. and Heiss, C. (2015) 'Interactions between cocoa flavanols and inorganic 
nitrate: additive effects on endothelial function at achievable dietary amounts', Free Radic 
Biol Med, 80, pp. 121-8. 
Rosenfeld, M. E. (2013) 'Inflammation and atherosclerosis: direct versus indirect 
mechanisms', Curr Opin Pharmacol, 13(2), pp. 154-60. 
   
 221 
Rossi, R., Chiurlia, E., Nuzzo, A., Cioni, E., Origliani, G. and Modena, M. G. (2004) 
'Flow-mediated vasodilation and the risk of developing hypertension in healthy 
postmenopausal women', J Am Coll Cardiol, 44(8), pp. 1636-40. 
Roustit, M. and Cracowski, J. L. (2012) 'Non-invasive assessment of skin 
microvascular function in humans: an insight into methods', Microcirculation, 19(1), pp. 
47-64. 
Roustit, M. and Cracowski, J. L. (2013) 'Assessment of endothelial and neurovascular 
function in human skin microcirculation', Trends Pharmacol Sci, 34(7), pp. 373-84. 
Safar, M. E., Blacher, J. and Jankowski, P. (2011) 'Arterial stiffness, pulse pressure, 
and cardiovascular disease-is it possible to break the vicious circle?', Atherosclerosis, 
218(2), pp. 263-71. 
Sakuragi, S. and Abhayaratna, W. P. (2010) 'Arterial stiffness: methods of 
measurement, physiologic determinants and prediction of cardiovascular outcomes', Int J 
Cardiol, 138(2), pp. 112-8. 
Sargeant, L. A., Wareham, N. J., Bingham, S., Day, N. E., Luben, R. N., Oakes, S., 
Welch, A. and Khaw, K. T. (2000) 'Vitamin C and hyperglycemia in the European 
Prospective Investigation into Cancer--Norfolk (EPIC-Norfolk) study: a population-
based study', Diabetes Care, 23(6), pp. 726-32. 
Sartori, C., Lepori, M. and Scherrer, U. (2005) 'Interaction between nitric oxide and 
the cholinergic and sympathetic nervous system in cardiovascular control in humans', 
Pharmacol Ther, 106(2), pp. 209-20. 
Schindler, T. H., Nitzsche, E. U., Munzel, T., Olschewski, M., Brink, I., Jeserich, M., 
Mix, M., Buser, P. T., Pfisterer, M., Solzbach, U. and Just, H. (2003) 'Coronary 
vasoregulation in patients with various risk factors in response to cold pressor testing: 
contrasting myocardial blood flow responses to short- and long-term vitamin C 
administration', J Am Coll Cardiol, 42(5), pp. 814-22. 
Schini-Kerth, V. B., Auger, C., Kim, J. H., Etienne-Selloum, N. and Chataigneau, T. 
(2010) 'Nutritional improvement of the endothelial control of vascular tone by 
polyphenols: role of NO and EDHF', Pflugers Arch, 459(6), pp. 853-62. 
   
 222 
Schleicher, R. L., Carroll, M. D., Ford, E. S. and Lacher, D. A. (2009) 'Serum vitamin 
C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National 
Health and Nutrition Examination Survey (NHANES)', Am J Clin Nutr, 90(5), pp. 1252-
63. 
Schmidt, T. S. and Alp, N. J. (2007) 'Mechanisms for the role of tetrahydrobiopterin 
in endothelial function and vascular disease', Clin Sci (Lond), 113(2), pp. 47-63. 
Schultz, D. S., Deen, W. M., Karel, S. F., Wagner, D. A. and Tannenbaum, S. R. (1985) 
'Pharmacokinetics of nitrate in humans: role of gastrointestinal absorption and 
metabolism', Carcinogenesis, 6(6), pp. 847-852. 
Scorza, G., Pietraforte, D. and Minetti, M. (1997) 'Role of ascorbate and protein thiols 
in the release of nitric oxide from S-nitroso-albumin and S-nitroso-glutathione in human 
plasma', Free Radic Biol Med, 22(4), pp. 633-42. 
Seals, D. R., Jablonski, K. L. and Donato, A. J. (2011) 'Aging and vascular endothelial 
function in humans', Clin Sci (Lond), 120(9), pp. 357-75. 
Seals, D. R., Kaplon, R. E., Gioscia-Ryan, R. A. and LaRocca, T. J. (2014) 'You're 
only as old as your arteries: translational strategies for preserving vascular endothelial 
function with aging', Physiology (Bethesda), 29(4), pp. 250-64. 
Sena, C. M., Pereira, A. M. and Seica, R. (2013) 'Endothelial dysfunction - A major 
mediator of diabetic vascular disease', Biochim Biophys Acta, 1832(12), pp. 2216-31. 
Sesso, H. D., Buring, J. E., Christen, W. G., Kurth, T., Belanger, C., MacFadyen, J., 
Bubes, V., Manson, J. E., Glynn, R. J. and Gaziano, J. M. (2008) 'Vitamins E and C in 
the prevention of cardiovascular disease in men: the Physicians' Health Study II 
randomized controlled trial', JAMA, 300(18), pp. 2123-33. 
Shen, J., Wilmot, K. A., Ghasemzadeh, N., Molloy, D. L., Burkman, G., Mekonnen, 
G., Gongora, M. C., Quyyumi, A. A. and Sperling, L. S. (2015) 'Mediterranean Dietary 
Patterns and Cardiovascular Health', Annu Rev Nutr, 35, pp. 425-49. 
Shepherd, A. I., Gilchrist, M., Winyard, P. G., Jones, A. M., Hallmann, E., 
Kazimierczak, R., Rembialkowska, E., Benjamin, N., Shore, A. C. and Wilkerson, D. P. 
(2015) 'Effects of dietary nitrate supplementation on the oxygen cost of exercise and 
   
 223 
walking performance in individuals with type 2 diabetes: a randomized, double-blind, 
placebo-controlled crossover trial', Free Radic Biol Med, 86, pp. 200-8. 
Shirwany, N. A. and Zou, M. H. (2010) 'Arterial stiffness: a brief review', Acta 
Pharmacol Sin, 31(10), pp. 1267-76. 
Shishehbor, M. H., Aviles, R. J., Brennan, M. L., Fu, X., Goormastic, M., Pearce, G. 
L., Gokce, N., Keaney, J. F., Jr., Penn, M. S., Sprecher, D. L., Vita, J. A. and Hazen, S. 
L. (2003) 'Association of nitrotyrosine levels with cardiovascular disease and modulation 
by statin therapy', JAMA, 289(13), pp. 1675-80. 
Sibal, L., Agarwal, S. C., Home, P. D. and Boger, R. H. (2010) 'The Role of 
Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular 
Disease', Curr Cardiol Rev, 6(2), pp. 82-90. 
Sibmooh, N., Piknova, B., Rizzatti, F. and Schechter, A. N. (2008) 'Oxidation of iron-
nitrosyl-hemoglobin by dehydroascorbic acid releases nitric oxide to form nitrite in 
human erythrocytes', Biochemistry, 47(9), pp. 2989-96. 
Siervo, M., Corander, M., Stranges, S. and Bluck, L. (2011a) 'Post-challenge 
hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of 
asymmetric dimethylarginine (ADMA)', Nutr Metab Cardiovasc Dis, 21(1), pp. 1-10. 
Siervo, M., Lara, J., Jajja, A., Sutyarjoko, A., Ashor, A. W., Brandt, K., Qadir, O., 
Mathers, J. C., Benjamin, N., Winyard, P. G., Anning, C., Shore, A. and Gilchrist, M. 
(2015) 'Ageing modifies the effects of beetroot juice supplementation on 24-hour blood 
pressure variability: An individual participant meta-analysis', Nitric Oxide, 47, pp. 97-
105. 
Siervo, M., Lara, J., Ogbonmwan, I. and Mathers, J. C. (2013) 'Inorganic nitrate and 
beetroot juice supplementation reduces blood pressure in adults: a systematic review and 
meta-analysis', J Nutr, 143(6), pp. 818-26. 
Siervo, M., Stephan, B. C., Feelisch, M. and Bluck, L. J. (2011b) 'Measurement of in 
vivo nitric oxide synthesis in humans using stable isotopic methods: a systematic review', 
Free Radic Biol Med, 51(4), pp. 795-804. 
Sindler, A. L., Devan, A. E., Fleenor, B. S. and Seals, D. R. (2014) 'Inorganic nitrite 
supplementation for healthy arterial aging', J Appl Physiol (1985), 116(5), pp. 463-77. 
   
 224 
Sindler, A. L., Fleenor, B. S., Calvert, J. W., Marshall, K. D., Zigler, M. L., Lefer, D. 
J. and Seals, D. R. (2011) 'Nitrite supplementation reverses vascular endothelial 
dysfunction and large elastic artery stiffness with aging', Aging Cell, 10(3), pp. 429-37. 
Singhal, A. (2005) 'Endothelial dysfunction: role in obesity-related disorders and the 
early origins of CVD', Proc Nutr Soc, 64(1), pp. 15-22. 
Stoclet, J. C., Chataigneau, T., Ndiaye, M., Oak, M. H., El Bedoui, J., Chataigneau, 
M. and Schini-Kerth, V. B. (2004) 'Vascular protection by dietary polyphenols', Eur J 
Pharmacol, 500(1-3), pp. 299-313. 
Stokes, K. Y., Dugas, T. R., Tang, Y., Garg, H., Guidry, E. and Bryan, N. S. (2009) 
'Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses 
endothelial dysfunction', Am J Physiol Heart Circ Physiol, 296(5), pp. H1281-8. 
Stylianou, I. M., Bauer, R. C., Reilly, M. P. and Rader, D. J. (2012) 'Genetic basis of 
atherosclerosis: insights from mice and humans', Circ Res, 110(2), pp. 337-55. 
Sugamura, K. and Keaney, J. F., Jr. (2011) 'Reactive oxygen species in cardiovascular 
disease', Free Radic Biol Med, 51(5), pp. 978-92. 
Sumpio, B. E., Riley, J. T. and Dardik, A. (2002) 'Cells in focus: endothelial cell', Int 
J Biochem Cell Biol, 34(12), pp. 1508-12. 
Tabatabaei-Malazy, O., Nikfar, S., Larijani, B. and Abdollahi, M. (2014) 'Influence of 
ascorbic acid supplementation on type 2 diabetes mellitus in observational and 
randomized controlled trials; a systematic review with meta-analysis', J Pharm Pharm 
Sci, 17(4), pp. 554-82. 
Taddei, S., Virdis, A., Ghiadoni, L., Salvetti, G., Bernini, G., Magagna, A. and Salvetti, 
A. (2001) 'Age-related reduction of NO availability and oxidative stress in humans', 
Hypertension, 38(2), pp. 274-9. 
Takahama, U., Tanaka, M. and Hirota, S. (2008) 'Interaction between ascorbic acid 
and chlorogenic acid during the formation of nitric oxide in acidified saliva', J Agric Food 
Chem, 56(21), pp. 10406-13. 
Takano, S., Kimura, S., Ohdama, S. and Aoki, N. (1990) 'Plasma thrombomodulin in 
health and diseases', Blood, 76(10), pp. 2024-9. 
   
 225 
Tallarida, R. J. (2001) 'Drug synergism: its detection and applications', J Pharmacol 
Exp Ther, 298(3), pp. 865-72. 
Tallarida, R. J. (2011) 'Quantitative methods for assessing drug synergism', Genes 
Cancer, 2(11), pp. 1003-8. 
Tang, E. H. and Vanhoutte, P. M. (2010) 'Endothelial dysfunction: a strategic target in 
the treatment of hypertension?', Pflugers Arch, 459(6), pp. 995-1004. 
Teixeira, D., Fernandes, R., Prudencio, C. and Vieira, M. (2016) '3-Nitrotyrosine 
quantification methods: Current concepts and future challenges', Biochimie, 125, pp. 1-
11. 
Thom, N. J., Early, A. R., Hunt, B. E., Harris, R. A. and Herring, M. P. (2016) 'Eating 
and arterial endothelial function: a meta-analysis of the acute effects of meal consumption 
on flow-mediated dilation', Obes Rev, 17(11), pp. 1080-1090. 
Thomas, D. R. (2006) 'Vitamins in aging, health, and longevity', Clin Interv Aging, 
1(1), pp. 81-91. 
Title, L. M., Cummings, P. M., Giddens, K., Genest, J. J., Jr. and Nassar, B. A. (2000) 
'Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with 
coronary artery disease', J Am Coll Cardiol, 36(3), pp. 758-65. 
Toda, N. and Okamura, T. (2013) 'Obesity impairs vasodilatation and blood flow 
increase mediated by endothelial nitric oxide: An overview', J Clin Pharmacol, 53(12), 
pp. 1228-39. 
Toda, N. and Toda, H. (2010) 'Nitric oxide-mediated blood flow regulation as affected 
by smoking and nicotine', Eur J Pharmacol, 649(1-3), pp. 1-13. 
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T. and Sekikawa, A. (1999) 
'Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired 
fasting glucose. The Funagata Diabetes Study', Diabetes Care, 22(6), pp. 920-4. 
Tounian, P., Aggoun, Y., Dubern, B., Varille, V., Guy-Grand, B., Sidi, D., Girardet, J. 
P. and Bonnet, D. (2001) 'Presence of increased stiffness of the common carotid artery 
and endothelial dysfunction in severely obese children: a prospective study', Lancet, 
358(9291), pp. 1400-4. 
   
 226 
Tousoulis, D., Antoniades, C. and Stefanadis, C. (2005) 'Evaluating endothelial 
function in humans: a guide to invasive and non-invasive techniques', Heart, 91(4), pp. 
553-8. 
Tousoulis, D., Tentolouris, C., Crake, T., Toutouzas, P. and Davies, G. (1997) 'Basal 
and flow-mediated nitric oxide production by atheromatous coronary arteries', J Am Coll 
Cardiol, 29(6), pp. 1256-62. 
Traber, M. G. and Stevens, J. F. (2011) 'Vitamins C and E: beneficial effects from a 
mechanistic perspective', Free Radic Biol Med, 51(5), pp. 1000-13. 
Turner, J., Belch, J. J. and Khan, F. (2008) 'Current concepts in assessment of 
microvascular endothelial function using laser Doppler imaging and iontophoresis', 
Trends Cardiovasc Med, 18(4), pp. 109-16. 
Tyson, J. and Mathers, J. C. (2007) 'Dietary and genetic modulation of DNA repair in 
healthy human adults', Proc Nutr Soc, 66(1), pp. 42-51. 
Ungvari, Z., Kaley, G., de Cabo, R., Sonntag, W. E. and Csiszar, A. (2010) 
'Mechanisms of vascular aging: new perspectives', J Gerontol A Biol Sci Med Sci, 65(10), 
pp. 1028-41. 
van Deursen, J. M. (2014) 'The role of senescent cells in ageing', Nature, 509(7501), 
pp. 439-46. 
van Hinsbergh, V. W. (2012) 'Endothelium--role in regulation of coagulation and 
inflammation', Semin Immunopathol, 34(1), pp. 93-106. 
van Sloten, T. T., Henry, R. M., Dekker, J. M., Nijpels, G., Unger, T., Schram, M. T. 
and Stehouwer, C. D. (2014) 'Endothelial dysfunction plays a key role in increasing 
cardiovascular risk in type 2 diabetes: the Hoorn study', Hypertension, 64(6), pp. 1299-
305. 
Vanderlei, L. C., Pastre, C. M., Hoshi, R. A., Carvalho, T. D. and Godoy, M. F. (2009) 
'Basic notions of heart rate variability and its clinical applicability', Rev Bras Cir 
Cardiovasc, 24(2), pp. 205-17. 
Vanhatalo, A., Bailey, S. J., Blackwell, J. R., DiMenna, F. J., Pavey, T. G., Wilkerson, 
D. P., Benjamin, N., Winyard, P. G. and Jones, A. M. (2010) 'Acute and chronic effects 
   
 227 
of dietary nitrate supplementation on blood pressure and the physiological responses to 
moderate-intensity and incremental exercise', Am J Physiol Regul Integr Comp Physiol, 
299(4), pp. R1121-31. 
Vanhoutte, P. M., Shimokawa, H., Tang, E. H. and Feletou, M. (2009) 'Endothelial 
dysfunction and vascular disease', Acta Physiol (Oxf), 196(2), pp. 193-222. 
Velmurugan, S., Gan, J. M., Rathod, K. S., Khambata, R. S., Ghosh, S. M., Hartley, 
A., Van Eijl, S., Sagi-Kiss, V., Chowdhury, T. A., Curtis, M., Kuhnle, G. G., Wade, W. 
G. and Ahluwalia, A. (2016) 'Dietary nitrate improves vascular function in patients with 
hypercholesterolemia: a randomized, double-blind, placebo-controlled study', Am J Clin 
Nutr, 103(1), pp. 25-38. 
Velmurugan, S., Kapil, V., Ghosh, S. M., Davies, S., McKnight, A., Aboud, Z., 
Khambata, R. S., Webb, A. J., Poole, A. and Ahluwalia, A. (2013) 'Antiplatelet effects of 
dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex', Free 
Radic Biol Med, 65, pp. 1521-32. 
Versari, D., Daghini, E., Virdis, A., Ghiadoni, L. and Taddei, S. (2009) 'Endothelial 
dysfunction as a target for prevention of cardiovascular disease', Diabetes Care, 32 Suppl 
2, pp. S314-21. 
Verschuren, W. M. (2012) 'Diet and cardiovascular disease', Curr Cardiol Rep, 14(6), 
pp. 701-8. 
Vijg, J. and Suh, Y. (2013) 'Genome instability and aging', Annu Rev Physiol, 75, pp. 
645-68. 
Virdis, A., Ghiadoni, L., Giannarelli, C. and Taddei, S. (2010) 'Endothelial dysfunction 
and vascular disease in later life', Maturitas, 67(1), pp. 20-4. 
Visioli, F. and Hagen, T. M. (2007) 'Nutritional strategies for healthy cardiovascular 
aging: focus on micronutrients', Pharmacol Res, 55(3), pp. 199-206. 
Vita, J. A., Keaney, J. F., Jr., Larson, M. G., Keyes, M. J., Massaro, J. M., Lipinska, 
I., Lehman, B. T., Fan, S., Osypiuk, E., Wilson, P. W., Vasan, R. S., Mitchell, G. F. and 
Benjamin, E. J. (2004) 'Brachial artery vasodilator function and systemic inflammation 
in the Framingham Offspring Study', Circulation, 110(23), pp. 3604-9. 
   
 228 
Vlachopoulos, C., Aznaouridis, K. and Stefanadis, C. (2010) 'Prediction of 
cardiovascular events and all-cause mortality with arterial stiffness: a systematic review 
and meta-analysis', J Am Coll Cardiol, 55(13), pp. 1318-27. 
Vlachopoulos, C., Aznaouridis, K., Terentes-Printzios, D., Ioakeimidis, N. and 
Stefanadis, C. (2012) 'Prediction of cardiovascular events and all-cause mortality with 
brachial-ankle elasticity index: a systematic review and meta-analysis', Hypertension, 
60(2), pp. 556-62. 
Wang, Q., Liang, X., Wang, L., Lu, X., Huang, J., Cao, J., Li, H. and Gu, D. (2012) 
'Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis 
of randomized controlled trials', Atherosclerosis, 221(2), pp. 536-43. 
Wang, Q., Yang, M., Xu, H. and Yu, J. (2014) 'Tetrahydrobiopterin improves 
endothelial function in cardiovascular disease: a systematic review', Evid Based 
Complement Alternat Med, 2014, p. 850312. 
Ward, N. C., Hodgson, J. M., Croft, K. D., Burke, V., Beilin, L. J. and Puddey, I. B. 
(2005) 'The combination of vitamin C and grape-seed polyphenols increases blood 
pressure: a randomized, double-blind, placebo-controlled trial', J Hypertens, 23(2), pp. 
427-34. 
Waters, D. D., Alderman, E. L., Hsia, J., Howard, B. V., Cobb, F. R., Rogers, W. J., 
Ouyang, P., Thompson, P., Tardif, J. C., Higginson, L., Bittner, V., Steffes, M., Gordon, 
D. J., Proschan, M., Younes, N. and Verter, J. I. (2002) 'Effects of hormone replacement 
therapy and antioxidant vitamin supplements on coronary atherosclerosis in 
postmenopausal women: a randomized controlled trial', JAMA, 288(19), pp. 2432-40. 
Webb, A. J., Patel, N., Loukogeorgakis, S., Okorie, M., Aboud, Z., Misra, S., Rashid, 
R., Miall, P., Deanfield, J., Benjamin, N., MacAllister, R., Hobbs, A. J. and Ahluwalia, 
A. (2008) 'Acute blood pressure lowering, vasoprotective, and antiplatelet properties of 
dietary nitrate via bioconversion to nitrite', Hypertension, 51(3), pp. 784-90. 
Weber, C. and Noels, H. (2011) 'Atherosclerosis: current pathogenesis and therapeutic 
options', Nat Med, 17(11), pp. 1410-22. 
   
 229 
Weck, M. N., Stegmaier, C., Rothenbacher, D. and Brenner, H. (2007) 'Epidemiology 
of chronic atrophic gastritis: population-based study among 9444 older adults from 
Germany', Aliment Pharmacol Ther, 26(6), pp. 879-87. 
WHO (2013) Cardiovascular diseases (CVDs) fact sheets. Available at: 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html. 
Wilkinson, I. B. and Webb, D. J. (2001) 'Venous occlusion plethysmography in 
cardiovascular research: methodology and clinical applications', Br J Clin Pharmacol, 
52(6), pp. 631-46. 
Wilson, P. W. F. (2004) 'The epidemiology of atherosclerotic disease', in Loscalzo, J. 
(ed.) Molecular Mechanisms of Atherosclerosis. London: Taylor & Francis. 
Wolff, I. A. and Wasserman, A. E. (1972) 'Nitrates, nitrites, and nitrosamines', Science, 
177(4043), pp. 15-9. 
Wray, D. W., Nishiyama, S. K., Harris, R. A., Zhao, J., McDaniel, J., Fjeldstad, A. S., 
Witman, M. A., Ives, S. J., Barrett-O'Keefe, Z. and Richardson, R. S. (2012) 'Acute 
reversal of endothelial dysfunction in the elderly after antioxidant consumption', 
Hypertension, 59(4), pp. 818-24. 
Wrieden, W. L., Hannah, M. K., Bolton-Smith, C., Tavendale, R., Morrison, C. and 
Tunstall-Pedoe, H. (2000) 'Plasma vitamin C and food choice in the third Glasgow 
MONICA population survey', J Epidemiol Community Health, 54(5), pp. 355-60. 
Xin, W., Wei, W. and Li, X. (2012) 'Effect of fish oil supplementation on fasting 
vascular endothelial function in humans: a meta-analysis of randomized controlled trials', 
PLoS One, 7(9), p. e46028. 
Yang, T., Peleli, M., Zollbrecht, C., Giulietti, A., Terrando, N., Lundberg, J. O., 
Weitzberg, E. and Carlstrom, M. (2015) 'Inorganic nitrite attenuates NADPH oxidase-
derived superoxide generation in activated macrophages via a nitric oxide-dependent 
mechanism', Free Radic Biol Med, 83, pp. 159-66. 
Yasmin and Brown, M. J. (1999) 'Similarities and differences between augmentation 
index and pulse wave velocity in the assessment of arterial stiffness', QJM, 92(10), pp. 
595-600. 
   
 230 
Ye, Z. and Song, H. (2008) 'Antioxidant vitamins intake and the risk of coronary heart 
disease: meta-analysis of cohort studies', Eur J Cardiovasc Prev Rehabil, 15(1), pp. 26-
34. 
Yetik-Anacak, G. and Catravas, J. D. (2006) 'Nitric oxide and the endothelium: History 
and impact on cardiovascular disease', Vascular Pharmacology, 45(5), pp. 268-276. 
Yochum, L. A., Folsom, A. R. and Kushi, L. H. (2000) 'Intake of antioxidant vitamins 
and risk of death from stroke in postmenopausal women', Am J Clin Nutr, 72(2), pp. 476-
83. 
You, W. C., Chang, Y. S., Heinrich, J., Ma, J. L., Liu, W. D., Zhang, L., Brown, L. 
M., Yang, C. S., Gail, M. H., Fraumeni, J. F., Jr. and Xu, G. W. (2001) 'An intervention 
trial to inhibit the progression of precancerous gastric lesions: compliance, serum 
micronutrients and S-allyl cysteine levels, and toxicity', Eur J Cancer Prev, 10(3), pp. 
257-63. 
Zheng, D. and Murray, A. (2011) 'Peripheral arterial volume distensibility: significant 
differences with age and blood pressure measured using an applied external pressure', 
Physiol Meas, 32(5), pp. 499-512. 
Zieman, S. J., Melenovsky, V. and Kass, D. A. (2005) 'Mechanisms, pathophysiology, 
and therapy of arterial stiffness', Arterioscler Thromb Vasc Biol, 25(5), pp. 932-43. 
Zietzer, A. and Hillmeister, P. (2014) 'Leucocyte telomere length as marker for 
cardiovascular ageing', Acta Physiol (Oxf), 211(2), pp. 251-6. 
Zoungas, S. and Asmar, R. P. (2007) 'Arterial stiffness and cardiovascular outcome', 
Clin Exp Pharmacol Physiol, 34(7), pp. 647-51. 
Zweier, J. L., Li, H., Samouilov, A. and Liu, X. (2010) 'Mechanisms of nitrite 
reduction to nitric oxide in the heart and vessel wall', Nitric Oxide, 22(2), pp. 83-90. 
Zweier, J. L., Samouilov, A. and Kuppusamy, P. (1999) 'Non-enzymatic nitric oxide 
synthesis in biological systems', Biochim Biophys Acta, 1411(2-3), pp. 250-62. 
Zweier, J. L., Wang, P., Samouilov, A. and Kuppusamy, P. (1995) 'Enzyme-
independent formation of nitric oxide in biological tissues', Nat Med, 1(8), pp. 804-9. 
 
